<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-12-22 09:21:28 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>94</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48deb9a97772c3939779b0a727ea3595d2e4a10f" target='_blank'>
              PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
              </a>
            </td>
          <td>
            Teresa Dinter, Sebastian Mackowiak, Zachary J. Rogers, Vidit Bhandarkar, Molly Carney, Yiming J. Zhang, D. Morgan, Lorelai Pop, Fiona Chatterjee, E. Lutz, Yajit Jain, Adityanarayanan Radhakrishnan, Eric Lander, K. Dane Wittrup, J. C. Love, Alexander Meissner, Stefani Spranger
          </td>
          <td>2025-11-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Tumor-specific CD8+ T lymphocytes play a critical role in anticancer immunity but frequently become dysfunctional and exhausted within the immunosuppressive tumor microenvironment. Although immune checkpoint inhibitors can restore T-cell activity, resistance to these treatments remains a significant challenge. Therefore, understanding the transcriptional and regulatory mechanisms underlying CD8+ T-cell exhaustion is crucial for the development of effective therapies. We developed two murine models of acquired immune checkpoint inhibitor resistance through prolonged anti-PD1 treatment. To gain insight into CD8+ T-cell exhaustion, we performed single-cell multiomics analysis, including both scRNA-seq and scATAC-seq, to capture gene expression profiles and chromatin accessibility. Moreover, we collected three external datasets to validate the results in silico. We further assessed the therapeutic potential of Runx2 through marker expression and cytotoxicity assays. Our single-cell analysis revealed distinct T-cell subsets, including early and terminally exhausted populations, along with their exhaustion trajectories. Runx2 was identified as a key transcription factor associated with CD8+ T-cell exhaustion in both models and correlated with immunotherapy response in clinical data. Additionally, functional marker expression and cytotoxicity assays demonstrated that inhibiting Runx2 improved CD8+ T-cell cytotoxicity. These findings highlight the role of Runx2 as a crucial regulator of CD8+ T-cell exhaustion in the context of prolonged immune checkpoint inhibitor treatment. Targeting Runx2 may provide a novel strategy to overcome immune checkpoint inhibitor resistance and enhance therapeutic efficacy, offering promising avenues for combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4efed637bde0b584b5806d223ee2a3f6b51d5e91" target='_blank'>
              Transcriptional dynamics of CD8+ T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution
              </a>
            </td>
          <td>
            Tzu-Yang Tseng, , Hsuan-Cheng Huang, Yu-Ching Wu, Chiun Hsu, Chia-Lang Hsu, D. Ou, Hsueh‐Fen Juan
          </td>
          <td>2025-12-01</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/79fbb4abcb1eeb6127549b886296b47a4c3b2fa0" target='_blank'>
              Temporal single-cell analysis reveals age-associated delay in immune resolution after respiratory viral infection
              </a>
            </td>
          <td>
            Yue Wu, Chaofan Li, Jinyi Tang, Xiaochen Gao, I. Cheon, Bibo Zhu, Ruixuan Zhang, C. Fain, Shengen Shawn Hu, H. Narasimhan, Gislane de Almeida Santos, K. Ayasoufi, , Hui Zong, Chongzhi Zang, Haidong Dong, Jie Sun
          </td>
          <td>2025-12-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Background Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, an immunomodulatory drug (IMiD), demonstrates clinical synergy with CAR-T therapy, yet the underlying mechanisms driving this potentiation remain poorly defined. This study aimed to elucidate how pomalidomide enhances CAR-T cell function and remodels the immune microenvironment to overcome therapeutic limitations. Methods In vitro assays (CCK-8, LDH, qPCR, ELISA, flow cytometry) and bulk RNA-seq assessed pomalidomide’s effects on human CAR-T cells. In vivo efficacy was evaluated in myeloma xenograft models. Single-cell RNA sequencing (scRNA-seq) of PBMCs from a lymphoma patient post-CAR-T/pomalidomide assessed immune microenvironment remodeling. Results Pomalidomide significantly enhanced CAR-T cell proliferation and cytotoxicity in an activation-dependent manner. It upregulated effector molecules (IL-2, IFN-γ) and chemokines (CXCL9-CXCL11), promoted central memory T cells (Tcm), and induced metabolic reprogramming while reducing exhaustion markers. In xenografts, combination therapy induced tumor regression and extended survival vs. CAR-T alone. scRNA-seq revealed pomalidomide-driven remodeling, characterized by increased T/NK cell proportions/activity and reduced myeloid-derived suppressor cell (MDSC) signatures. Conclusions Pomalidomide synergizes with CAR-T by directly enhancing CAR-T function (memory, cytokine/chemokine production, metabolic fitness, and reduced exhaustion) and remodeling the suppressive immune microenvironment (increased cytotoxic effectors, diminished MDSC activity). These findings provide a crucial mechanistic rationale for optimizing pomalidomide-CAR-T combinations in refractory lymphoid malignancies. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04247-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6abcb94332697bc83ab93d4c224183daa93951d7" target='_blank'>
              Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies
              </a>
            </td>
          <td>
            Yi Zhou, Yan Yu, Linzhi Xie, Liwen Wang, Yuhan Yan, Qian Cheng, Jing Liu, Chang Zhang, Xin Li
          </td>
          <td>2025-12-18</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/275812dc3294ac678dbefad1e9f5e6d112d20c5e" target='_blank'>
              SP140 limits type I interferon–driven pathology, preserving T cell motility and promoting resistance in tuberculosis
              </a>
            </td>
          <td>
            Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Serge Mazères, Yaël Duvergé, Yohan Lorreyte, Emmanuelle Näser, S. Behar, Emma Lefrançais, O. Neyrolles, Denis Hudrisier
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="ABSTRACT The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dbc5d5398d9317cc8645ea9323e07cb973e30cab" target='_blank'>
              cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
              </a>
            </td>
          <td>
            Meiqi Ren, Zhichao Eric Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong C. Shen, Xiangyu Yao, Zhipeng Yan
          </td>
          <td>2025-11-30</td>
          <td>Cancer Biology & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0f99bb18019cd4b39bd05d6d11bec440e5d21593" target='_blank'>
              B cell transcriptomics reveals lasting dysregulation and rapid decline of protective immune memory after chronic hepatitis C cure
              </a>
            </td>
          <td>
            Fang Chen, E. Giang, Padmaja Natarajan, Tony S. Mondala, Steven R. Head, Sing Chau Lau, Aishwarya Sundaresan, Liudmila Kulakova, Xiaohe Lin, Jasneet Aneja, R. Andrabi, Yun Zhang, Richard H. Scheuermann, Eric A. Toth, Thomas R. Fuerst, Lia Lewis-Ximenez, Arthur Y Kim, Paul Pockros, Georg M Lauer, M. Law
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e088dcd4f395d6c7df482c6c35fcef0137dc41" target='_blank'>
              An epigenetic switch in vascular phenotype augments anti-tumor immunity
              </a>
            </td>
          <td>
            Dae Joong Kim, Mitchell T McGinty, S. Anandh, C. Riedstra, Yuvraj Sethi, Melanie R. Rutkowski, A. C. Dudley
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fab0829fa668d3f68087f51374ae0be2ba943151" target='_blank'>
              Perturbational single-cell profiling of patient tumors defines lineage- and context-specific programs of innate immune resistance
              </a>
            </td>
          <td>
            C. Perry, A. Frey, Y. Fei, J. Wang, P. Costa, H. N. Amin, S. Ghadermarzi, D. Levine, W. Tong, A. Koda, M. Mackie, , Y. Nie, K. Clulo, F. Ouerghi, J. Wei, T. Cordero Dumit, M. Yaskolko, , A. Caldera, O. Kyrysyuk, L. Lum, J. W. Allen, W. Guo, A. Naqash, A. Elliot, A. Vanderwalde, M. Capelletti, T. Adeyelu, S. Barry, M. Hugaboom, A. Bacchiocchi, H. Kluger, M. Bosenberg, A. Iwasaki, D. Braun, J. Clune, D. van Dijk, K. Olino, J. Ishizuka
          </td>
          <td>2025-12-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/49cdf4d2b06dc0c77173ce97caf0d6a3fa0e9a28" target='_blank'>
              Single-Cell Immune Profiling Reveals Non-classical Monocyte-Driven Immunodepression in Tuberculosis Treatment Non-Responders
              </a>
            </td>
          <td>
            Yang Che, Yiqun Xiong, Dongliang Zhang, Yahong Qu, Hao Shen, Weixin Wang, Junshun Gao, ZhenBo Wang, Yi Chen, Zhihong Shen
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, Na-Young Kim, Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Abstract Objectives Immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, represent a pivotal approach in the treatment of multiple myeloma (MM). However, the complex immunosuppressive tumor microenvironment (TME) poses significant challenges to their efficacy. Among the immunosuppressive cells in the MM TME, granulocytic myeloid-derived suppressor cells (G-MDSCs) are predominant, yet their functions remain incompletely understood. This study aimed to comprehensively analyze the role of G-MDSCs in MM patients undergoing CAR-T therapy. Methods Single-cell transcriptomic data from seven MM patients before and after CAR-T therapy were analyzed to characterize G-MDSCs. Functional enrichment and gene set enrichment analysis (GSEA) were performed to identify signaling pathways. A risk prediction model was constructed using RNA-seq and survival data from 713 MM patients, and validated by Kaplan–Meier analysis. In vitro experiments were conducted to assess the immunosuppressive functions of G-MDSCs. Results The findings, though exploratory due to limited sample size and inter-patient heterogeneity, suggested pathological activation and immunosuppressive roles of G-MDSCs potentially linked to patient prognosis. G-MDSCs were identified as key modulators of immune responses within the TME, with GSEA indicating regulation via IFN-α/γ signaling. They may facilitate immune evasion of MM cells by promoting proliferation through the IGF1–IGF1R axis and inhibiting T cells and other immune cells via the SIRPA–CD47 pathway. The risk prediction model based on G-MDSC gene signatures demonstrated high prognostic accuracy (AUC = 0.94). PTGS1 was identified as a key marker associated with high-risk groups, and functional assays confirmed its role in mediating G-MDSC immunosuppressive activity. Conclusions This study provides preliminary insights into the functional role of G-MDSCs in the MM TME and highlights their impact on CAR-T therapy outcomes. The findings suggest potential therapeutic strategies, including targeting PTGS1, to enhance CAR-T efficacy. Larger and more diverse cohorts are required to substantiate these observations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e8ff33894cad405d661ae879b8aae448cec342e" target='_blank'>
              Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: insights from single-cell RNA sequencing in multiple myeloma
              </a>
            </td>
          <td>
            Chaoyu Zhang, Fang An
          </td>
          <td>2025-11-02</td>
          <td>Immunopharmacology and Immunotoxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Immunization strategies are central to pathogen control, where efficacy relies on antigen uptake, distribution, persistence, and inflammatory context. We recently demonstrated that dermal lymphatic capillaries regulate antigen presentation in lymph nodes (LN) by restraining fluid and virion transport following vaccinia virus (VACV) infection by skin scarification. Concurrently, a perifollicular, LN lymphangiogenic response encapsulates expanding B cell follicles. Given the important role of antigen transport and uptake on humoral immunity, we tested the hypothesis that lymphatic remodeling in the skin and LNs regulates germinal center (GC)–dependent antibody responses during infection. Using a model of lymphatic-specific VEGFR2 inhibition, we found that inhibiting viral-induced lymphatic remodeling in skin and LNs prompted significant GC expansion but paradoxically decreases protective VACV-specific class-switched antibodies. While the larger GC responses appeared structurally normal, they failed to support a proliferative burst consistent with clonal selection. Mathematical modeling revealed that this disconnect between GC size and function arises from impaired productive T follicular cell interactions in larger GC volumes and consistent with this finding, the optimal GC size was evolutionarily conserved across diverse mammals. Finally, we found that the presence of virus in the LN initiates these changes in GC function, inhibits LN lymphangiogenesis, increases B cell follicle size, and reduces selection efficiency. Therefore, protecting LN lymphatic vessels from virus-induced interferons rescues perifollicular lymphatic growth and follicle size, indicating that LN lymphangiogenesis directly constrains the follicular response. In summary, this study underscores the central role of lymphatic remodeling in compartmentalizing antigen and inflammatory signals to optimize GC fitness and protective antibody responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18897f02b6b8cf5b9015d6f4b3a2227528f3f4f2" target='_blank'>
              Lymphatic constraint of germinal centers optimizes protective antibody responses
              </a>
            </td>
          <td>
            Tenny Mudianto, Gabrielle R. Berman, Kimberly Zaldaña, Luan Firmino Cruz, M. Schips, Niklas Schwan, Ochapa Ibrahim, Vanessa Cristaldi, , Lina Fikri, Sabrina M. Solis, Han M. Chen, Michael Cammer, R. Herati, S. Koralov, Andrew David Miller, Michael Meyer-Hermann, Carla R Nowosad, Amanda W. Lund
          </td>
          <td>2025-11-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood. Methods To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses. Results We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models. Conclusion Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b3ad6676052a006d7f44e56422f87b86b5aaedd5" target='_blank'>
              Oncolytic virus-induced IL-1β+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
              </a>
            </td>
          <td>
            Fan Li, Jingru Chen, Yuanke Li, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang, Jufeng Yu, Zhen Zhao, Li Deng, Shiyu Liu, Yajuan Wan, Zhigang Zhao, Song‐Tao Xu, Jiangmei Li, Youjia Cao, Hongkai Zhang
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6015d74c03081f1756895ea39d8fb38a3dc11ac" target='_blank'>
              Tissue-embedded CD4⁺ plasticity defines mucosal immunity in Inflammatory Bowel Disease
              </a>
            </td>
          <td>
            Q. Jiang, V. Merkus, C. Lindelauf, Nannan Guo, L. Ouboter, T. Höllt, P. Voorneveld, C. Meijer-Boekel, F. Koning, A.E. van der Meulen-de Jong, M. F. Pascutti, Vincent van Unen
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Abstract Despite advances in targeted therapies, treatment of chronic lymphocytic leukemia (CLL) remains challenging, highlighting the urgent need for effective new therapeutic strategies. Although chimeric antigen receptor (CAR) T‐cell therapy dramatically improved outcomes in acute lymphoblastic leukemia (ALL), its efficacy in CLL is limited. We hypothesize that this disparity results from pronounced CAR T‐cell exhaustion and the immunosuppressive tumor microenvironment (TME) in CLL. We utilized an autologous 3D TME co‐culture model to investigate the functionality of CAR T cells derived from CLL and ALL patients within physiologically relevant conditions. Our results revealed increased exhaustion levels and diminished cytotoxicity of CAR T cells from CLL patients compared to those from ALL patients. Importantly, combining CAR T‐cell treatment with interleukin‐10 (IL‐10) or CXCR4 blockade effectively improved cytotoxicity against CLL cells, even in stromal‐protected regions within the 3D model. These findings offer insights into CAR T‐cell dysfunction in CLL and support novel TME‐targeted combination strategies to improve clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1aec597c65d49a8cbf32e49d8a9716856ac9762a" target='_blank'>
              Functional differences between CLL‐ and ALL‐derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL‐10 as potential modulatory targets
              </a>
            </td>
          <td>
            J. Dingfelder, M. Aigner, Jana Lindacher, Pascal Lukas, C. Flamann, Gina Nusser, Katharina Zimmermann, Axel Schambach, Frederik Graw, Simon Völkl, Heiko Bruns, Manuela Krumbholz, Martina Haibach, Jochen Wilke, Andreas Mackensen, G. Lutzny-Geier
          </td>
          <td>2025-12-01</td>
          <td>HemaSphere</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized the treatment of advanced malignancies such as melanoma. However, a significant proportion of patients fail to respond, owing to mechanisms that remain poorly understood. Here, we developed murine melanoma cell lines (R1 and R2) derived from MO4 tumors and that are resistant to anti-PD−1 therapy. These resistant cells exhibited increased tumor initiation capacity in vivo correlating with enhanced spheroid formation in vitro, and greater invasiveness and metastatic potential in a lung macrometastasis model. Mechanistically, both R1- and R2- derived tumors showed enrichment of a cancer stem cell (CSC)-like population overexpressing Wnt3a, which correlated with reduced infiltration and impaired function of CD8+ tissue-resident memory (TRMs) T cells. This suggested a functional link between Wnt-driven cancer stemness and TRMs dysfunction. Pharmacological inhibition of Wnt/β-catenin signaling in vitro enhanced CD8+ T cell proliferation and expression of functional markers. Notably, Wnt/β-catenin inhibition in vivo reversed anti-PD−1 resistance in resistant tumors, coinciding with reduced OCT4+Wnt3a+ CSC-like cells and restoration of TNFα+CD8+ TRMs. Finally, transcriptomic analysis of publicly available melanoma cohorts showed that enrichment of the Wnt pathway correlates with poor prognosis and ICB resistance, highlighting this pathway as a potential druggable negative regulator of ICB efficacy in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f77e7d52138792d22d71c5dbfbe6f13abb61e07" target='_blank'>
              Wnt3a-expressing cancer stem cells impair CD8+ TRM function, contributing to immunotherapy resistance in Melanoma
              </a>
            </td>
          <td>
            Julian A. Gajón, Ángel Juárez-Flores, Fatima Mendoza-Roldan, J. Hernández-Aceves, Samira Muñoz-Cruz, Armando Pérez-Torres, E. Fuentes-Pananá, L. C. Bonifaz
          </td>
          <td>2025-12-03</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 antibodies are used to induce an immune response against many types of tumors. However, ICIs often also induce autoimmune responses, referred to as immune-related adverse events (irAEs), which occur unpredictably and at varying levels of severity in ICI-treated patients. The immunologic factors that predispose patients to the development of severe irAE are largely unclear. Here, we utilized high dimensional mass cytometry immunophenotyping of longitudinal blood samples from patients with metastatic melanoma treated with combination anti-PD-1/CTLA4 ICI therapy in the context of a clinical trial to characterize alterations in immune profiles induced by combination ICI therapy and to identify immune features associated with development of severe irAEs. Deep T cell profiling highlighted that ICI therapy induces prominent expansions of activated, CD38hi CD4+ and CD8+ T cells, which are frequently bound by the therapeutic anti-PD-1 antibody, as well as substantial changes in regulatory T cell phenotypes. However, neither the baseline frequency nor the extent of expansion of these cell populations was associated with development of severe irAEs. Rather, single cell-association testing revealed naïve CD4+ T cell abundance pre-treatment as significantly associated with the development of severe irAEs. Biaxial gating of naïve CD4+ T cells confirmed a significant positive association of naïve CD4+ T cell proportion and development of a severe irAE and with the number of irAEs developed in this cohort. Results from this broad profiling study indicate the abundance of naïve CD4+ T cells as a predictive feature for the development of severe irAEs following combination anti-PD-1/CTLA4 ICI therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b62cfec8fd4211059f5e6293956cd71228dc3135" target='_blank'>
              Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma.
              </a>
            </td>
          <td>
            K. Marks, Alice Horisberger, M. Elahee, I. Adejoorin, Nilasha Ghosh, M. Postow, L. Donlin, Anne R Bass, Deepak A. Rao
          </td>
          <td>2025-11-25</td>
          <td>JCI insight</td>
          <td>0</td>
          <td>94</td>
        </tr>

        <tr id="Stem-like T cells (TSL) represent a distinct subset of CD4+ and CD8+ T cells characterized by self-renewal, multipotent differentiation, and long-term persistence, and have emerged as pivotal regulators of immune responses in chronic disease contexts. Despite growing interest, the developmental programs, molecular signatures, and clinical relevance of TSL remain incompletely understood, limiting their translational potential. Recent evidence highlights the central role of key transcription factors such as TCF-1 and BCL6, metabolic circuits including the Wnt-β-catenin and STAT3 pathways, and microenvironmental signals in sustaining the identity and function of TSL subsets. In various pathologies—including chronic infections, cancer, autoimmunity, and transplant rejection—TSL cells contribute to both immune persistence and pathogenic activation through their capacity to replenish exhausted effectors or differentiate into inflammatory subtypes. These cells not only shape immune trajectory but also hold promise as dynamic biomarkers and therapeutic targets. Targeted modulation of TSL via cytokine supplementation, immune checkpoint blockade, adoptive transfer, or niche interference is under investigation, with encouraging results in preclinical and early translational studies. This review outlines the molecular regulation and functional diversity of stem-like CD4+ and CD8+ T cells, evaluates their disease-specific roles, and discusses strategies to harness or inhibit these populations for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/957ce990207260aaa43e17d3f30590a154a82c00" target='_blank'>
              Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases
              </a>
            </td>
          <td>
            Wang Zhan, Longyong Lai, Shuan Ran, Yuan Li, Jiulu Zhao, Jie Wu, Chao Guo, Jikai Cui, Jiahong Xia
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Abstract Introduction Synovial natural killer (NK) cells contribute to inflammation in arthritis by secreting cytokines and modulating synovial fibroblast activation. The aim of this study was to describe systemic versus local inflammatory changes of NK cell subsets as well as their physical cell-cell interactions in arthritis patients. Methods Spectral flow cytometry was used to compare paired peripheral blood (PB) and synovial fluid (SF) immune cells from patients with active inflammatory arthritis and healthy controls. Physical cell-cell interactions within tissues were studied by applying a recently developed cellular interaction mapping framework. Results Our paired approach revealed significant local enrichment of immature and activated NK cells in SF, characterized by elevated markers of early differentiation, immune-checkpoint regulation, and tissue-residency, highlighting tightly controlled immune activation at inflamed sites. Single-cell analysis confirmed heterogeneity within SF-NK cells, suggesting multiple co-existing activation states and developmental stages. PB-NK cells from patients differed profoundly compared to healthy controls, showing less immature NK cell subsets and an enrichment of mature, pro-inflammatory subsets indicative of systemic immune activation. Cellular interaction mapping revealed mainly NK/neutrophil interactions of patients’ NK cells, while interactions with B-cells, T-cells, or monocytes were negligible. T-cells also displayed profound local and systemic alterations. Cellular interaction mapping revealed that next to NK/neutrophil interactions, interactions between B-cells with monocytes and T-cells with neutrophils characterize joint inflammation. Conclusion This paired high-dimensional analysis revealed systemic and local alterations in NK cell subsets shaped by co-existing developmental stages and immune regulatory mechanisms. Cellular interaction mapping indicated that neutrophils are a main interaction-partner of NK cells in inflamed joints.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33e0fc210c968311a194a2ca7566f89ed217a080" target='_blank'>
              Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis
              </a>
            </td>
          <td>
            F. Deicher, T. Exner, Maren Claus, S. Yousefian, Lea Rodon, Sophie Elisabeth Leonhardt, J. H. Distler, Carsten Watzl, Hanns-Martin Lorenz, Simon Haas, Daniel Hübschmann, Wolfgang Merkt
          </td>
          <td>2025-10-31</td>
          <td>Journal of Innate Immunity</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/07c7ce9a407bf29f4b537e0cbead424db44e5f61" target='_blank'>
              Targeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL
              </a>
            </td>
          <td>
            J. Bigot, Mathieu Bouttier, Vincent Fregona, Clémence Rouzier, Manon Bayet, Sylvie Hebrard, N. Prade, Stéphanie Lagarde, Christine Didier, Laetitia Largeaud, F. Vergez, A. Quillet-Mary, Loic Ysebaert, C. Broccardo, André Baruchel, Marion Strullu, E. Clappier, Marlène Pasquet, Elodie Lainey, Eric Delabesse, Bastien Gerby
          </td>
          <td>2025-12-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="ABSTRACT Chronic antigen exposure drives CD4⁺ T cell senescence, yet how autoimmunity and persistent viral infections differentially shape T cell differentiation and function remains unclear. Using cytomegalovirus (CMV) and rheumatoid arthritis (RA) as models of chronic immune activation, we performed high‐dimensional mass cytometry and functional assays to define their impact on CD4⁺ T cells. In CMV‐seropositive individuals, CD27−CD28− CD4⁺ T cells were abundant and exhibited a predominantly cytotoxic, nonproliferative phenotype. Only a minor fraction was CMV‐reactive, suggesting that bystander‐driven differentiation contributes to this subset. In the absence of CMV, senescent CD4⁺ T cells were infrequent and phenotypically distinct, though they still exhibited low proliferative capacity. EBV and HSV did not independently increase CD27−CD28− CD4⁺ T cell frequency. Similarly, RA had little effect on their abundance but instead tuned the functional quality of senescent cells. In CMV‐seropositive RA patients, senescent CD4⁺ T cells produced less pro‐inflammatory cytokines and showed impaired cytotoxic degranulation. Central memory CD4⁺ and CD27−CD28− CD8⁺ T cell functions were preserved, with no evidence for CMV reactivation, suggesting maintained viral control by unaffected T cell responses. These findings highlight distinct, nonredundant effects of CMV and RA on CD4⁺ T cell senescence and reveal RA‐specific functional defects in senescent CD4⁺ T cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3441dc9dbc45e96d9b0a98bad7c5d0ce97797b4d" target='_blank'>
              Divergent Effects of Cytomegalovirus and Rheumatoid Arthritis on Senescent CD4+ T Cells
              </a>
            </td>
          <td>
            Lea Williams, Ali O Saber, Silina Awad, Xi Su, Asgar Ansari, Ruozhang Xu, Hannah Jung, Anupama Shahane, Joshua F. Baker, Laura F. Su
          </td>
          <td>2025-11-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) can switch between immune-activating and cancer-promoting states; yet, the stress pathways that lock them into procancerous states remain obscure. Here we defined the role of transcription factor NRF2 as a mediator of procancerous macrophages. Methods We combined spatial transcriptomics, single-cell RNA sequencing, three-dimensional (3D) cell culture and in vivo tumor models to explore how NRF2 activation status in tumor-associated macrophages modifies responses to immunotherapy. Results In MC38 colon tumors, repeated anti-CD40 or radiotherapy created necrosis that split TAMs into peripheral Cxcl9+ and peri-necrotic Spp1+ subsets. Spatial transcriptomics, single-cell RNA sequencing, and Keap1-deficient mice showed that the latter are NRF2-imprinted “stress-TAMs”, with immunosuppressive and tumor-promoting activity. The same NRF2 activation gradient separates pro-inflammatory CXCL9+ and anti-inflammatory SPP1+TAMs across diverse human cancers. NRF2-imprinted TAMs silence IFN-STAT1 programs, lose major histocompatibility complex-II and chemokine expression, fail to expand T cells, drive tumor cell invasion in 3D co-cultures, and foster metastasis. Constitutive hematopoietic NRF2 activation accelerated the growth of therapy-naïve MMTV-PyMT breast tumors and markedly impaired the efficacy of agonistic anti-CD40 antibody therapy in MC38 subcutaneous and lung-metastasis models. Conversely, macrophage-specific Nrf2 deletion restored immunogenic TAMs and potentiated anti-CD40 and anti-programmed cell death protein-1 treatments. Conclusions Our data pinpoint a previously underappreciated cytoprotective mechanism, which inadvertently sustains immunosuppressive macrophages and confers therapy resistance. These results define stress-induced TAMs as an untapped driver of macrophage-based immune evasion. Inhibiting NRF2 activity alongside standard immunotherapies could restore a pro-inflammatory macrophage–T-cell amplification loop, potentially improving patient responses to T-cell—and macrophage-directed immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3b564268f908e2668ba03acbe4a747ca42980a5" target='_blank'>
              Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy
              </a>
            </td>
          <td>
            Dominik J. Schaer, Nadja Schulthess-Lutz, Livio Baselgia, Kahrisan Kunasingam, R. Humar, K. Hansen, Melanie Eschment, Elena Duerst, F. Vallelian
          </td>
          <td>2025-10-31</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="B lymphocytes exhibit a multifaceted and context-dependent role in tumor biology, acting as both promoters and suppressors of malignancy through dynamic interactions within the tumor microenvironment (TME). This review synthesizes current evidence on the dual functions of B cells in tumor immunity, highlighting their capacity to orchestrate antitumor responses via antigen presentation, antibody-dependent cytotoxicity, and tertiary lymphoid structure (TLS)-mediated T cell activation, while paradoxically driving immunosuppression through regulatory B cells (Bregs), pro-angiogenic signaling, and immune checkpoint modulation. Key mechanisms include TLS formation, which enhances cytotoxic T cell priming and correlates with improved immunotherapy outcomes, and Breg-mediated secretion of IL-10/TGF-β, which fosters T cell exhaustion and myeloid-derived suppressor cell recruitment. Tumor-type specificity is evident: TLS-rich malignancies like melanoma and Non-Small Cell Lung Cancer (NSCLC) show B cell-driven immune activation, whereas pancreatic and hepatocellular carcinomas demonstrate B cell functional plasticity influenced by metabolic and epigenetic reprogramming. Therapeutically, B cell-targeted strategies—including CD20 antibodies, CAR-T cells, and B cell epitope vaccines—demonstrate efficacy in hematologic and solid tumors, yet face challenges due to subset heterogeneity and sex-specific response disparities. Emerging approaches combine immune checkpoint inhibitors (ICBs) with TLS-inducing agents or exploit B cell-derived biomarkers for personalized therapy. Future directions emphasize deciphering B cell metabolic-niche crosstalk, optimizing combinatorial regimens, and leveraging spatial multiomics to resolve functional heterogeneity. By bridging mechanistic insights with clinical translation, this work underscores B cells as pivotal regulators of tumor immunity and advocates for precision strategies to harness their antitumor potential while mitigating pro-tumor plasticity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ebd579b54f9dae49f949806c09388f29afa2ecc8" target='_blank'>
              The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications
              </a>
            </td>
          <td>
            Zhuangwei Lv, Ruohao Yang, Kai Zhang, Ruihan Wang, Xiaoyu Shi, Jinhua Wu, Lulu Liu, J. Jiao
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Sepsis remains a leading global cause of death, with immune heterogeneity’s molecular mechanisms poorly understood. This study analyzed 1,862 human peripheral blood samples, constructing a molecular interaction disturbance network that first revealed the network biology underlying sepsis immune heterogeneity. We identified 3 sepsis subtypes with marked different prognostic characteristics, with the C1 subtype showing the worst prognosis characterized by severe CD4+ T cell exhaustion—validated across 10 independent cohorts. Integrating single-cell transcriptomics from over 450,000 cells, proteomics, and functional validation, we identified monocyte-derived matrix metalloproteinase-9 (MMP9) as a key regulator driving CD4+ T cell dysfunction. Mechanistically, MMP9 modulates T cell exhaustion through dual mechanisms: promoting leukocyte-associated immunoglobulin-like receptor-1 (Lair-1) aggregation on T cell membranes, directly inhibiting zeta chain of T cell receptor associated protein kinase 70 (ZAP70) phosphorylation in T cell receptor signaling, while impairing Ca2+-release-activated Ca2+ channel function and intracellular calcium clearance, causing calcium dysregulation that blocks nuclear factor of activated T cells (NFAT) activation and nuclear translocation. The selective MMP9 inhibitor MMP9-in-1 effectively reversed T cell dysfunction, restored calcium homeostasis and NFAT nuclear translocation, markedly enhanced CD4+ T cell interleukin-2 and interferon-γ production, and reduced programmed cell death protein 1 expression. This work establishes a comprehensive translational framework from molecular network disturbances to clinical phenotypes, advancing sepsis immunopathophysiology understanding and providing effective targets for the treatment of sepsis patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/669347da1bb81250d0a1cfa9e2302d53bc332296" target='_blank'>
              Targeting Matrix Metalloproteinase-9 to Alleviate T Cell Exhaustion and Improve Sepsis Prognosis
              </a>
            </td>
          <td>
            Xuan Wang, Jingyuan Ning, Liang Zhou, Hongru Li, Jinlei Cui, Jiachao Wang, Xiangyang Liang, Jinquan Li, Miao Li, Xue Gao, Wen-jian Li, Xing Chen, Fei Yu, Lin Wei, Cuiqing Ma
          </td>
          <td>2025-11-02</td>
          <td>Research</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Effective anti-tumor immunity critically depends on functional CD8+ T cells, yet in almost all solid tumors, these cells become dysfunctional, exhausted, or spatially excluded. This breakdown of immune surveillance arises not only from cell-intrinsic T cell exhaustion but also from multimodal communication among tumor, stromal, and immune cells within the tumor microenvironment (TME). This communication is mediated not only through direct receptor-ligand interactions but also through a suite of indirect mechanisms, such as metabolic competition, secretion of immunosuppressive metabolites and cytokines, extracellular vesicle exchange, and even mitochondrial transfer via tunneling nanotubes or membrane transfer through T cell trogocytosis. Together, these suppressive interactions impair CD8+ T cell metabolism, effector function, and persistence, thereby enabling tumor immune evasion. In this review, we summarize current understanding of how multimodal cell-cell communication, including immune checkpoints, metabolic reprogramming, and stromal crosstalk, cooperatively drive CD8+ T cell dysfunction. We also highlight emerging therapeutic strategies aimed at rewiring these suppressive networks, with emphasis on translational potential. A deeper understanding of the spatial, molecular, and metabolic context of CD8+ T cell suppression offers new avenues to enhance the efficacy of cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5ae6993d7bfa10b0ab3f27994a45882bb6514da" target='_blank'>
              Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion
              </a>
            </td>
          <td>
            Liping Chen, Qianping Huang, Peipei Zhou
          </td>
          <td>2025-11-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract SLAMF8 is predominantly expressed in macrophages and plays an important role in autoimmune diseases and inflammation. Our previous studies have focused on SLAMF8, however, the potential of SLAMF8 as an immunotherapeutic target and its role in regulating the tumor immune microenvironment remain to be elucidated. This study demonstrated that macrophage-specific SLAMF8 is significantly associated with a poor prognosis for colorectal cancer (CRC). Additionally, M2 macrophage and tumor-associated macrophages (TAMs) models were used to verify that SLAMF8 induces an immunosuppressive phenotype in macrophages and regulates antitumor immunity by inhibiting the activation and function of CD8+ T cells. In vivo, we confirmed that SLAMF8 inhibition promoted remodeling of the immunosuppressive microenvironment and augmented immunotherapy sensitivity in CRC. Mechanistically, we demonstrated that SLAMF8 promotes the polarization of macrophages toward the M2 phenotype via the PI3K/AKT and JAK/STAT3 signaling pathways. In summary, this study confirmed that inhibiting SLAMF8 exerts an antitumor effect by reversing the immunosuppressive tumor microenvironment in CRC, providing new therapeutic targets and strategies for combined immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0eb7d8ffd5d61d0e44a547a2d1181cb708517e0e" target='_blank'>
              Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer
              </a>
            </td>
          <td>
            Xingzhi Han, Xueying Bai, Ning Wang, Yuexin Sun, Jing Hu, Li Li, Zhihao Liu, Yaping Zhang, Zixin Liang, Liuqi Sang, Lu Han, Qun Zhang, Xiaoping Qian
          </td>
          <td>2025-11-10</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitors (ICIs) have been proven to be one of the most promising and effective immunotherapies; however, their efficacy in colorectal cancer (CRC) remains significantly limited. Therefore, understanding the mechanism of resistance to ICIs therapy in CRC patients is of great significance for the development of new anti-tumor immunotherapy targets. Methods Ccl7 myeloid cell-specific knockout mice and MC38 tumor-bearing mouse models were established to investigate the role of Ccl7 during CRC progression. Proteomic analysis, RNA-seq, and flow cytometry analysis were used to determine the role of Ccl7 in the tumor immune microenvironment. Results Herein, we found that elevated CCL7+ tumor-associated macrophages (TAMs) in tumors correlated with tolerance to ICIs blockage therapy in patients with CRC. Deletion of CCL7 in myeloid cells resulted in reduced accumulation of immunosuppressive TAMs and increased infiltration of activated CD8+ T cells within the tumor. Mechanistically, CCL7 modulates peroxisome biogenesis and fatty acid oxidation, thereby promoting the immunosuppressive functions of TAMs via the PI3K-AKT-PEX3 signaling pathway. Furthermore, CCL7 inhibits the expression of chemokine CXCL10 by suppressing the AKT2-STAT1 signaling pathway, which reduces the infiltration of activated CD8+ T cells in the tumor. Blocking CCL7 delays CRC progression and enhances the therapeutic efficacy of PD-L1. Conclusion Our study highlights the novel role and regulatory mechanisms of CCL7+ TAMs in ICIs immunotherapy resistance, suggesting that CCL7 may serve as a potential combined therapeutic target for ICIs immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53a194d2240d9d29b67527ded8020c64d8c9fb2a" target='_blank'>
              Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells
              </a>
            </td>
          <td>
            Yijiao Chen, Xudong Liu, Jiongming Chen, Liwen Kuang, Nan Zhang, Danyang Li, Dan Zhao, Dongmei Xue, Juan Lei, Jiangang Zhang, Yongsheng Li, Lei Wu
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Secreted phosphoprotein 1 (SPP1+) macrophages are a recurrent and functionally critical immune cell subset across multiple cancer types. They drive adverse clinical outcomes by promoting immunosuppression, tumor invasion, metastasis, and therapy resistance. Given their prevalence and pivotal role, SPP1+ macrophages have become a major focus in cancer immunology and a promising target for therapeutic development. SPP1+ macrophages have been identified in a wide range of human malignancies through single-cell RNA sequencing and spatial transcriptomics studies. Their differentiation and maintenance are strongly influenced by reciprocal cellular interactions and hypoxic conditions within the tumor microenvironment (TME). Within the tumor microenvironment (TME), SPP1+ macrophages promote tumor progression by interacting with cancer-associated fibroblasts (CAFs) and helping to form a physical barrier that restricts immune cell infiltration into the tumor core. Specifically, they impair the recruitment of CD8+ T cells and promote T cell exhaustion (TEX). In this review, we focus on recent advances in understanding the differentiation of SPP1 macrophages in hypoxic tumor microenvironment and the role of SPP1+ macrophages in immunosuppression and their therapeutic implications in cancer. Targeting this subset of macrophages has emerged as a highly promising therapeutic strategy, with several approaches demonstrating encouraging results in preclinical models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7c7489149a391c5b3e442dad42f10334718f488" target='_blank'>
              SPP1+ macrophages in tumor immunosuppression: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Juanjuan Wang, Ya Wang, Yuqing Liu, Rongcun Yang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ee5dbb33a6a382fa70961ac781d31dc13ae0aa3f" target='_blank'>
              Tumor cell dissemination is facilitated through regulatory T cell-driven extracellular matrix remodeling
              </a>
            </td>
          <td>
            Ailen D. Garcia-Santillan, Jessanne Y. Lichtenberg, He Shen, Jasmine M. Rodriguez, Sandra Makar, Jonathan Barra, Nicholas M. Clark, Wei Du, Leandro M. Martinez, Ashley D. Hadjis, Taylor Calicchia, Mikhail G. Dozmorov, J. Bravo-Cordero, Amy L. Olex, Priscilla Y. Hwang, Paula D. Bos
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Although significant progress has been made in immune-targeted therapy for multiple myeloma (MM), it remains highly recurrent and incurable. Consequently, there is still an urgent need to develop more effective strategies against the recurrent and refractory tumor subsets. LILRB4, which is expressed on MM and Myeloid-Derived Suppressor Cells (MDSC) and plays an important role in promoting tumor progression and regulating the immuno-suppressive microenvironment. Therefore, it is an attractive target for MM treatment. We developed a bispecific natural killer cell engager (BiKE), LILRB4/CD16A, to mediate NK cell-mediated lysis of MM cells. BiKE combined with CD16A strongly activated NK cells derived from human peripheral blood, and at the same time, BiKE bridged tumor cells to NK cells and promoted NK cytotoxicity, showing significant antitumor activity against LILRB4-high MM cells. NK cell cytotoxicity was further enhanced by the combined stimulation of innate immunity using cGAS-STING signaling agonists. In xenograft MM tumor models in immunodeficient mice, NK cells derived from human peripheral blood and expanded in vitro were combined with BiKE and cGAS-STING signaling agonists, demonstrating effective anti-tumor activity and inhibition of MM cell proliferation. Collectively, the combination of cGAS-STING agonists and LILRB4-targeting NK cell engagers offers a promising approach for treating relapsed/refractory MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ca8c9caa017ad4c2d23fdf37525626e42f6b4d1b" target='_blank'>
              The combination of LILRB4-targeting NK cell engagers and cGAS–STING agonists enhances the anti–multiple myeloma immune activity of NK cells
              </a>
            </td>
          <td>
            Meng Li, Yuwei Zhao, Lizhou Zhao, Xue Chen, Jianxun Kang, Aiping Tong, Chen Yang, Ping Wang, Minjun Yang, Kejiang Wang, Jialiang Gao, Ying Li, Xuemei Fu
          </td>
          <td>2025-12-19</td>
          <td>PLOS One</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Despite effective viral suppression with antiretroviral therapy (ART), people living with HIV (PLWH) experience persistent inflammation, immune dysfunction, and premature onset of cardiovascular and aging-related comorbidities. To define the underlying mechanisms, we performed longitudinal transcriptomic profiling in peripheral blood mononuclear cells (PBMCs) from a cohort of simian immunodeficiency virus (SIV)-infected rhesus macaques spanning four key stages: pre-infection, acute infection, short-term ART, and long-term ART. Bulk RNA sequencing revealed dynamic immune remodeling across infection and treatment. Acute SIV infection induced robust antiviral and inflammatory programs, with upregulation of interferon-stimulated genes (ISGs), IL-27, JAK/STAT, and NF-κB signaling, coupled with suppression of T- and B-cell activation pathways. Short-term ART effectively reversed these transcriptional perturbations, restoring adaptive immune gene expression and reducing innate antiviral responses to near-baseline levels. In contrast, chronic SIV infection on long-term ART maintained viral suppression but was characterized by reactivation of innate immune pathways, including TLR2/TLR4/MYD88, NF-κB, and inflammasome (NLRP3/or NLRP12, caspase-1) signaling, along with sustained macrophage activation, platelet/coagulation signaling, and senescence-associated secretory phenotype. Protein analyses confirmed persistent CASPASE-1 and NF-κB activation in spleen tissue. Pathologic evaluation of a carotid artery from an SIV-infected, long-term ART– treated macaque revealed macrophage-rich plaques with p21⁺ senescent cells with intraluminal thrombus formation, recapitulating key features of HIV-associated atherogenesis. Together, these findings demonstrate that while ART normalizes acute infection–induced immune dysregulation, chronic SIV infection sustains a chronic, macrophage- and TLR-driven inflammatory state linked to vascular injury and aging process regardless of long-term suppression of viremia. Targeting inflammasome, NF-κB, and senescence pathways may mitigate non-AIDS comorbidities in PLWH.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7a8f96a2324d1327914a92bba9009e04dbf070e" target='_blank'>
              Persistent Activation of Monocytes/Macrophages and Cell Senescence in SIV-Infected Macaques on ART
              </a>
            </td>
          <td>
            Yilin Chen, Xiaofeng Ding, Sonalika Ray, Siva Thirugnanam, Robert V. Blair, Ahmad Saied, S. Sukhanov, J. Kolls, Woong-ki Kim, P. Delafontaine, Jay Rappaport, Xuebin Qin, Namita Rout
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="Small cell lung cancer (SCLC) is characterized by its highly aggressive phenotype and dismal outcome. Despite the benefit of adding immune checkpoint blockade to standard chemotherapy, tumors acquire the ability to evade immunosurveillance and develop resistance. To investigate these underlying mechanisms, we perform high-dimensional profiling of human and murine SCLC specimens. In matched primary and metastatic human samples, we observe MHC-I loss in metastases, highlighting its role in immune evasion. Correspondingly, silencing MHC-I in SCLC cells drastically reduces immune infiltration and promotes metastasis in mice. Using mass spectrometry and phospho-tyrosine kinase analyses, we identify ERBB2 signaling as a suppressor of MHC-I and driver of immune-modulatory transcripts. Mechanistically, genetic and pharmacologic blockade of ERBB2 induces MHC-I in a STING-dependent manner and prevents immune evasion in autochthonous murine SCLC. Strikingly, combining ERBB2 inhibition with anti-PD-1 elicits profound synergistic responses in preclinical models, suggesting this combination for future clinical trials in SCLC patients. While the emergence of immune checkpoint inhibitors has improved outcomes in patients with small cell lung cancer (SCLC), tumour that develop means of immune evasion become resistant. Here, the authors report that ERBB2 signalling induces loss of MHC Class I expression and subsequently immune evasion in preclinical models of SCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f612388efd2f0a9c1ebc8d3e60e6b396ae989beb" target='_blank'>
              ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer
              </a>
            </td>
          <td>
            L. Meder, C. Orschel, C. Bouchez, R. Gholamipoorfard, C. V. Orschel, David Stahl, Christoph Kreer, Mirjam Koker, Marieke Nill, Ilayda G Kocak, Ka-Won Noh, Xinlei Zhao, Leon Ullrich, B. Häupl, Josefine Jakob, Marie-Lisa Eich, Alexandra Florin, Holger Grüll, J. Wolf, Filippo Beleggia, R. Buettner, T. Oellerich, Florian Klein, J. Brägelmann, H. C. Reinhardt, Nima Abedpour, R. Ullrich
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="Lung mononuclear phagocyte (MNP) subsets differ in their ability to restrict Mycobacterium tuberculosis (Mtb) during chronic infection, yet the mechanisms underlying this difference are not well defined. Here, we show that CD11clo monocyte-derived cells (MNC1), the subset of lung cells that is most permissive for Mtb viability during chronic infection, express lower levels of interferon-gamma (IFNγ) signaling proteins, resulting in reduced responses to IFNγ compared to alveolar macrophages (AM) and CD11chi MNC2. Moreover, type I IFN signaling suppresses IFNγ-mediated MHC-II expression, impairing CD4 T cell activation by MNC1 cells. Importantly, prior immunity conferred by contained Mtb infection enhances IFNγ responsiveness of monocyte-derived cells, reducing bacterial burdens in lungs and within MNC subsets. Our findings indicate that heterogeneous IFNγ responsiveness is exploited by Mtb for persistence in vivo. Overcoming or bypassing impaired IFNγ responsiveness may guide the development of more effective TB vaccines and host-directed therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1185bf27cd38b33e534c27d9aa87381e2cd898fa" target='_blank'>
              Impaired IFNγ responsiveness of monocyte-derived lung cells limits immunity to Mycobacterium tuberculosis
              </a>
            </td>
          <td>
            Weihao Zheng, J. Limberis, Zachary P. Howard, Alexander Mohapatra, E. Takagi, J. Ernst
          </td>
          <td>2025-11-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e312c1a3a9dbed5ee9046577d5060ddafb93654" target='_blank'>
              Identifying the therapeutic potential of Niclosamide in overcoming IFN-gamma dependent cancer immune evasion in the Tumor Microenvironment
              </a>
            </td>
          <td>
            Yue Zhang, Sophia Peng, Hamid Akhbariyoon, Suzi Kim, Ellie Lai, En Cai
          </td>
          <td>2025-10-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="ABSTRACT Staphylococcal enterotoxins (SE) crosslink the MHC‐II on antigen‐presenting cells (APC) with the T‐cell receptor, inducing a polyclonal T‐cell response. Although APCs are the initial targets of SE and are critical in shaping subsequent T‐cell activation, the effects of SE on APC function remain poorly understood. This study investigates the immunomodulatory effects of staphylococcal enterotoxin A (SEA) on monocytes and their differentiation into monocyte‐derived dendritic cells (moDC) or macrophages (MDM). Transcriptomic analyses of human monocytes via RNA sequencing revealed SEA‐induced enrichment of gene pathways associated with inflammation, infection, and dermatitis, effects that were amplified in the presence of T cells. Phenotypic and functional characterization showed that SEA‐primed monocytes differentiated into MDM with an altered polarization, deviating from classical M1/M2 pathways. SEA‐primed MDM exhibited downregulation of key markers, including HLA‐DR, CD80, CD86, and PD‐L1. Functional assays demonstrated that SEA‐primed MDM pushed hyperinflammatory T‐cell responses, with significantly enhanced proliferation and IFN‐γ secretion. In contrast, following SEA‐priming, moDC retained robust antigen‐presenting capabilities and displayed enhanced expression of molecules involved in T‐cell interactions. These findings provide mechanistic insights into SEA‐mediated immune modulation, illustrating how SEA reprograms MDM functions and amplifies proinflammatory T‐cell responses. This advances our understanding of superantigen‐driven immune interactions, offering a foundation for developing therapeutic strategies to mitigate superantigen‐mediated immune conditions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31b8b3bf0438451c3b982c5f615c660d9c3ce361" target='_blank'>
              Staphylococcal Enterotoxin A Shapes Monocyte Transcription and Macrophage Polarization: Implications for Immune Responses in Infection and Inflammation
              </a>
            </td>
          <td>
            C. Arasa, Khaleda Rahman Qazi, David Brodin, Manuel Mata Forsberg, E. Sverremark-Ekström
          </td>
          <td>2025-12-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Background Currently, immune checkpoint inhibitors (ICIs) and other immune-activating strategies represent the main approach to cancer treatment; however, immune resistance in many solid tumors limits the immune therapy response and can cause strong toxic side effects. In solid tumors, the development of effective anti-tumor immune responses is hindered by limited immune cell infiltration and an immunosuppressive tumor microenvironment (TME). To overcome current immunotherapy challenges, we proposed a novel approach providing local and stable treatment levels to activate or revitalize anti-tumor immunity, to achieve the effect of TME infiltration and sustained presence in solid tumors. Methods Using genetic engineering methods to synergistically activate immunity in the TME, we programmed macrophages to express therapeutic payloads, including interleukin (IL)-12 and the signal regulatory protein alpha-Fragment crystallizable fusion protein (SIRPα-Fc), a CD47 ICI. Co-culture studies were performed to evaluate the effects of the genetically engineered macrophages (GEMs) on the T cells and GEMs themselves in vitro. We evaluated the tumor response, cellular response, and cytokine response. The GEMs were administered to a mouse model of tumor-cell transplantation, where they were retained and expressed as lentiviral payloads. Results The IL-12 secreted by the GEMs provided effector signals for T cells, thereby enhancing the tumor resident anti-tumor macrophages and CD8+T-cell populations. In addition, the secretion of SIRPα-Fc enhanced the phagocytic activity of the macrophages toward tumor cells and promoted their antigen presentation function. The combination therapy of dual proteins produced significant synergistic effects in solid tumor models and further enhanced memory immunity. The GEMs also improved the efficacy of ICIs in the ICI-resistant gene engineering tumor models and demonstrated significant anti-tumor efficacy in the metastasis models. Conclusions Our study showed the potential clinical application of GEMs in the treatment of tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e54b7612ca10a019c14cb39b2232584f60b628c0" target='_blank'>
              Engineered macrophages accumulate in solid tumors and locally deliver immune-activating proteins to inhibit tumor progression
              </a>
            </td>
          <td>
            Yan Xu, Yan Zhou, Jiahe Wang
          </td>
          <td>2025-11-01</td>
          <td>Translational Cancer Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/842af96f572eb3d970548668b36cfda84da5efb2" target='_blank'>
              Glucocorticoid Receptor Signaling in Myeloid Cells Orchestrates Inflammation Resolution and Muscle Repair
              </a>
            </td>
          <td>
            Sirine Souali-Crespo, Joe G. Rizk, Emilia Calvano, Rajesh Sahu, Emina Colovic, Imane Chabba, Valentine Gilbart, Erwan Grandgirard, Bastien Morlet, Qingshuang Cai, Daniel Metzger, D. Duteil
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="T-cell exhaustion is a terminal state of immune dysfunction characterized by impaired proliferation and effector functions, diminished cytokine secretion, and sustained expression of inhibitory receptors. In coronavirus disease 2019 (COVID-19), increasing evidence links exhausted T-cell phenotypes with poor clinical outcomes, including severe disease, delayed viral clearance, and persistent symptoms associated with Long COVID. Exhaustion results from prolonged antigenic stimulation and inflammatory signals and is marked by transcriptional reprogramming, metabolic and epigenetic dysregulation, and co-expression of inhibitory receptors such as programmed cell death protein-1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Notably, exhausted phenotypes in COVID-19 frequently coexist with hyperactivation, raising the unresolved question of whether inhibitory receptor expression reflects transient activation or irreversible dysfunction. Emerging therapeutic strategies to reverse these dysfunctional states include immune checkpoint inhibitors, cytokine modulation, metabolic interventions, and epigenetic therapies, although their clinical translation remains at an early stage. Critical research gaps include the scarcity of longitudinal data, incomplete profiling of T-cell subsets across disease stages during COVID-19 and Long COVID-19, and contradictory evidence of vaccine-induced exhaustion with limited understanding of its consequences. This non-systematic literature review synthesizes current advances in COVID-19 immunopathology and therapeutic strategies, underscoring that understanding T-cell exhaustion is crucial to improving outcomes and shaping next-generation immunotherapies and vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fcda848fedb31d45bcaf7a6be07292887c93eed0" target='_blank'>
              T-cell exhaustion in COVID-19: what do we know?
              </a>
            </td>
          <td>
            Roderick Chen-Camaño, Rodrigo DeAntonio, S. López-Vergès
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7685879ea7ac1e20291aff20e7f95411d243860e" target='_blank'>
              Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I–driven cancer immunotherapy
              </a>
            </td>
          <td>
            A. Barinov, Heidy Vera-Peralta, Joëlle S. Nader, V. Najburg, C. Combredet, Atousa Arbabian, Ségolène Gracias, P. Frantz, Roseline Vibert, Eddy Simard, Marie Coateval, Daniel Pouliquen, Tacien Petithomme, M. Prot, E. Simon-Lorière, David Hardy, Sarra Loulizi, B. Brzezicha, Jens Hoffmann, Véronique Riebbels, Jean-François Le Bigot, Marc Grégoire, J. Fonteneau, Anastassia V. Komarova, Nicolas Boisgerault, Frédéric Tangy
          </td>
          <td>2025-11-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Immunotherapy has potential for impactful cancer cures by empowering patients’ own immune cells. We developed a radio-immunotherapy regimen that can cure large immunologically hot and cold murine tumors. Here we explored the divergent role of CD8 T cells during this radio-immunotherapy in contrasting hot colon carcinoma versus cold melanoma models. We introduced an immunocompetent mouse model with mCherry expressing CD8 T cells to provide immune cell tracking in vivo. We investigated single-cell function, metabolism, and gene expression changes with temporal context using flow cytometry, in vivo multiphoton imaging, single-cell RNA sequencing, and multiplexed immunofluorescence to determine the underlying mechanisms. We found that in contrast to the hot colon carcinoma model, CD8 T cells from the cold melanoma model do not drive tumor cures, despite getting activated, possibly due to a static oxidative metabolism and exhausted phenotype as well as down regulation of tumor MHC-I expression. These findings have implications for improving immunotherapy response in immunologically cold cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b84b993daf38493e48753044d461ef43b7961296" target='_blank'>
              Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors
              </a>
            </td>
          <td>
            Alexa R. Heaton, Nathaniel J Burkard, Anqi Gao, A. Hoefges, AS Feils, Samantha K. Burkard, Mildred A. Felder, N. Tsarovsky, Dan V. Spiegelman, Garrett M. Lublin, Alina A. Hampton, Aurora D’Amato, Huy Q. Dinh, A. Rakhmilevich, AK Erbe, Paul M. Sondel, Melissa C. Skala
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>36</td>
        </tr>

        <tr id="Sepsis survivors frequently develop compromised humoral immunity, manifesting as prolonged immunosuppression that increases susceptibility to secondary infections with high associated mortality. While mesenchymal stromal cells (MSCs) have demonstrated efficacy in mitigating initial inflammatory responses and improving early survival rates in murine cecal ligation and puncture (CLP) models, they show limited effectiveness against subsequent secondary infections. Given that lymphopenia represents a primary driver of this infection vulnerability, we sought to investigate whether spleen-targeted MSC therapy could prevent lymphocyte depletion and enhance protection against secondary infections. In this study, we developed CXCR5-overexpressing MSCs (MSCCXCR5) to enhance their targeted migration toward splenic CXCL13. Using a CLP mouse model followed by secondary Staphylococcus aureus (S. aureus) infection, we systematically evaluated the therapeutic potential of MSCCXCR5 in combating post-sepsis immunosuppression. MSCCXCR5 demonstrated enhanced splenic migration, specifically homing to CXCL13-rich B-cell zones, and conferred significant protection against both S. aureus secondary infection and sepsis-induced lymphopenia. Mechanistic investigations revealed that MSCCXCR5 treatment preserved follicular and germinal center B-cell populations, maintaining splenic architecture and potentiating antigen-specific B-cell responses to CLP challenge. These effects collectively contributed to markedly improved survival outcomes in CLP mice following secondary infection. Our findings demonstrate that MSCCXCR5 confers dual-phase protection in sepsis, improving survival during both the initial hyperinflammatory phase and subsequent immunosuppressive period. This comprehensive therapeutic effect stems from MSCCXCR5’s ability to preserve B-cell function and prevent secondary infections in septic mice.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d199c5b8bb6884ae15ffcd0a40ee496c082eb0ec" target='_blank'>
              CXCR5-engineered mesenchymal stromal cells home to spleen and mitigate post-sepsis syndrome by preventing secondary infection
              </a>
            </td>
          <td>
            Jiahao Shi, Lu Zhu, Xin Sui, Xiaomeng Yi, Xiaoyong Chen, Zhishan Li, Minjie Liu, Y. Bao, Dongyan Zhu, Yuantao Li, Heshe Li, Ying Wang, Lin Nie, Rouchen Lin, Yunli Tong, Jing Huang, Jianqi Feng, Rui Fang, Tao Wang, A. P. Xiang, Xiaoran Zhang
          </td>
          <td>2025-11-05</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3443903af73c8ea2603fc42506194395d5951dde" target='_blank'>
              Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
              </a>
            </td>
          <td>
            Chien-Huan Weng, Anais Assouvie, Lauren Dong, JC Beltra, S. Budhu, L. Mangarin, Yacine Marouf, Lucia Morgado-Palacin, Cailian Liu, Sébastien Monette, Jonathan F. Khan, Isabell Schulze, Dmitry Zamarin, Linda Hamadene, Fadi Samaan, Daniel Hirschhorn, S. Pourpe, David Schröder, R. Zappasodi, Pamela M. Holland, N. Anandasabapathy, E. Wherry, J. Wolchok, T. Merghoub
          </td>
          <td>2025-11-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>170</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/73a6affa626cddbc311a72d5431b139dc8c83520" target='_blank'>
              IgD-Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid-Induced Cell Death
              </a>
            </td>
          <td>
            Kais Almohammad, Marc Young, S. Vettorazzi, Franziska Greulich, Mahmoud Alkhatib, J. Tuckermann, H. Jumaa, Corinna S. Setz
          </td>
          <td>2025-10-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="


 Introduction:
 Chronic Lymphocytic Leukemia (CLL) results in the expansion of immunosuppressive B-cells leading to risk for secondary malignancies, infection, and suboptimal T-cell based immunotherapeutic responses. Treatments that restore immune function (e.g. ibrutinib) may improve the efficacy of CD19 CAR T-cell (CART) therapies. We previously demonstrated that venetoclax (Ven) causes complex immunologic changes which broadly improve circulating immune cell (including T-cell) function. While we found that Ven appears to improve CD19 CART cytotoxicity in most patients, some CD19 CAR T-cells manufactured after Ven treatment did not perform as well in ex vivo cytotoxicity assays. We performed a multiomic correlation analysis to elucidate germane molecular features that may help predict and optimize Ven-enhanced CD19 CART cytotoxicity.
 Methods:
 We collected peripheral blood mononuclear cells (PBMCs) and serum from 13 consented CLL patients initiating standard of care Ven-based therapy (Ven-monotherapy N = 9, Ven+ɑCD20 N = 4; BDR-164122). Specimens were collected before treatment (D0) and after 30 days (D30) of therapy. CD19 CART were manufactured for 6 patients at both timepoints using an ɑCD19 construct (scFv/CD28/TCRζ via retroviral transduction). Cytotoxicity was measured against Raji-Luciferase cells. D0 and D30 specimens were analyzed by flow cytometry (including T-cell subsets and exhaustion markers) and RNA-seq (with xCell for cell-type deconvolution, rMATS for splicing, LISA for master regulator analysis). Enrichment analysis identified biological processes linked to cytotoxicity with statistical significance calculated as False Discovery Rate (FDR) adjusted P value. Metabolomics were performed with the Biocrates MxP Quant 500 XL assay. For each multiomic feature, magnitude change from D0 to D30 was calculated. These changes were correlated with changes in CD19 CART ytotoxicity across 7 effector-to-target ratios (1:8 through 8:1) using Spearman's correlation.
 Results:
 Enhanced CD19 CART cytotoxicity correlated with increased NK-cell frequency (CD56+/CD57+, CD56-/CD57+) determined by flow cytometry and cell-type deconvolution. In addition, RNA sequencing studies demonstrated that CD19 CART activity correlated with gene expression changes in interferon-ɑ (IFNA1, FDR<0.001) and interferon-ɣ (IFNG, FDR<0.002) response pathways. Specifically, an increase in key interferon signaling genes (GZMA, STAT1, CASP1) were associated with improved CD19 CART cytotoxicity. Moreover, a decrease in some interferon signaling genes (JAK2, STAT2, IFNAR2) was associated with a decrease in CD19 CART activity. LISA analysis identified POU2F2 and HDAC1 as key transcriptional regulators of genes associated with enhanced post-Ven CD19 CART killing. Elevated anti-inflammatory metabolites (cortisol, cortisone), as well as cysteine and phosphatidyl lipids correlated with improved CD19 CART cytotoxicity. Diminished CD19 CART cytotoxicity correlated with increased CD4+ LAG3+ T-cells coexpressing TIM3/TIGIT, and total CD3+ T-cells. Cell-type deconvolution demonstrated an inverse correlation between regulatory T-cells (T-regs) and CD19 CART cytotoxicity. Increase in NFκB signaling and splicing factor genes (e.g. RELA, RELB, NFKB1, NFKB2, TNF, U2AF1, U2AF2) were associated with a decrease in CD19 CART cytotoxicity (FDR<0.001). Alternative splicing by rMATS analysis identified a MAP3K7 (TAK1) event resulting in a TAK1 variant lacking its negative regulatory domain. This alternative splice form of TAK1 enhances NFκB signaling and impacts CD19 CART activity. Elevated serum triacylglycerols, GABA, spermine, and taurine detected by metabolic studies correlated with diminished CD19 CART cytotoxicity. Conclusion: Using a comprehensive multiomic approach we uncovered signaling pathways associated with improved CD19 CART activity following Ven-based therapy in CLL patients. The activation of the interferon-ɑ, interferon-ɣ and glucocorticoid signaling pathways enhance CART activity. In contrast, NFκB signaling and spliceosome-related pathways contribute to sustained immune activation and negative impacts on CAR T-cell function. Venetoclax treatment appears to alter T-cell (especially T-reg) and NK-cell subtypes, which influence the anti-tumor activity of CD19 CAR T-cells. Our work provides a foundation for further mechanistic inquiry into Ven-related immunologic impacts, which can improve synergistic combination treatments using CART for CLL patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be9262399f1e435c641b61481400c69897fe78fa" target='_blank'>
              Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Jacob P Wright, F. Hernandez-Ilizaliturri, C. Mavis, Joseph Tario, Alex Niu, Taylor K Mandeville, Dorothy C. Pan, Grant Schofield, Dae-Kyum Kim, Joseph Barbi, Hua-Hsin Hsiao, Spencer Rosario, M. Cortese
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 IntroductionChronic lymphocytic leukemia (CLL) is marked by profound immune dysregulation, which compromises both the numerical and functional integrity of the T cell compartment, posing significant challenges for chimeric antigen receptor (CAR) T-cell therapy. CLL patients often exhibit an elevated expression of inhibitory receptors such as PD-1 and CTLA-4 on their T cells. Additionally, the immunosuppressive microenvironment in these patients is marked by the predominance of effector and effector memory T cells, which are less capable of sustaining long-term immune responses. Prior studies, including work from our group (Fraietta JA et al., 2018), have highlighted the importance of early memory T cell subsets in promoting CAR T cell expansion, persistence, and anti-tumor efficacy. However, these subsets are intrinsically rare in CLL, limiting the success of manufacturing strategies that rely on their enrichment or ex-vivo expansion. Studies by Ludwig LM et al. (2021) and van Bruggen JAC et al. (2022) demonstrated that short-term Venetoclax treatment selectively depletes naive T cells, but prolonged therapy led to their numerical recovery along with upregulation of OXPHOS and glycolysis pathways. However, the effects of Venetoclax on T-cell functionality and its implications for CAR T-cell manufacturing remain uncertain. We aimed to study if treatment with Venetoclax could improve the qualitative and quantitative defects in the T cells in CLL patients ensuring better CAR T-cells and identify the ideal timepoint following treatment to collect T cells for CAR T manufacturing.
 MethodsWe analyzed peripheral blood samples from discovery (n=14) and validation (n=23) cohorts of CLL patients, with one or more prior lines of therapy, treated with Venetoclax monotherapy or in combination with the anti-CD20 antibody Obinutuzumab. Deep phenotyping of T cells and their response to activation with PMA and Ionomycin was performed using a spectral flow cytometry panel. CD19-directed CAR T cells (incorporating the 4-1BB costimulatory domain) were manufactured, and their proliferation and anti-tumor efficacy were assessed by flow cytometry and restimulation assays in vitro. Statistical analyses were performed using the Friedman test, 2-way ANOVA or Kruskal Wallis test, as appropriate.
 ResultsTreatment with Venetoclax improved the qualitative and quantitative T cell defects with a significant increase in the proportion of naïve (CD45RA+CD27+CCR7+) T cells (both CD4+ and CD8+) and decrease in the effector memory (CD45RA-CD27-CCR7-) compartment. Both manual gating and unsupervised clustering analysis showed a significant decrease in the frequency of regulatory T cells (Tregs) and T cells expressing markers of effector differentiation (KLRG1, CD244, EOMES) and inhibition/exhaustion markers (PD1, CD39, CTLA4, TIGIT). The differences were more pronounced after 1 year of treatment and the findings were confirmed in an independent validation cohort. Upon activation, the treatment-naive samples showed a significant increase (percentage or absolute) in the expression of activation-exhaustion markers (ICOS, PD1, TIM3, TIGIT, CTLA4) while the increase was more restrained after Venetoclax treatment. CAR T-cells were manufactured and functionally assessed through co-culture and repeated stimulation with the aggressive, MHC-deficient CD19+ leukemia cell line NALM6. CAR T-cells manufactured with samples one year post treatment with Venetoclax exhibited greater fold expansion and population doublings on repeat stimulation with NALM6 cells compared to their paired treatment-naive samples. Cytokine analysis and cytotoxicity assays are currently being performed to strengthen our findings.
 ConclusionOur findings strongly suggest that the BCL2 inhibitor Venetoclax exerts beneficial immunomodulatory effects beyond their primary anti-tumor activity. By reducing tumor burden and potentially directly influencing T cell biology, Venetoclax facilitates not only quantitative T cell recovery but also qualitative improvements. Such improvements include phenotypic shifts away from exhaustion and towards less differentiated states (potentially enriching for early memory precursors) and the restoration of key T cell functions like proliferation and cytokine production - factors that may significantly improve CAR T cell manufacturing and therapeutic efficacy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b0f58a6bf6fe69cb96d274bc1c6f4165ac0c965" target='_blank'>
              Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Arun Arunachalam, Beatriz Coutinho de Oliveira, Céline Grégoire, Ziran Zhao, Lily Simpson-Heavey, John C. Molina, A. Kater, F. Peters, A. Wiestner, J. Woyach, J. Melenhorst
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="Immune checkpoints act like dimmer switches that keep immune responses in balance. In autoimmune disease, problems usually fall into four overlapping types: weak inhibitory signals, too much co-stimulation, metabolic or epigenetic rewiring of checkpoint pathways, and a mismatch between tissue and blood findings. This narrative review focused on human and translational studies from PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (Embase), Web of Science, and Scopus (to 2025), prioritizing tissue-based data, trials of checkpoint agonists or co-stimulation blockade, cell-based tolerance (low-dose interleukin-2 (IL-2), chimeric antigen receptor regulatory T cells (CAR-Tregs), and extracellular vesicle (EV) approaches. Tissue profiling tracks disease activity better than blood alone. Immunometabolic stress, especially lactate-driven protein lactylation and ferroptosis, can blunt programmed cell death protein-1/cytotoxic T-lymphocyte associated protein-4 (PD-1/CTLA-4) braking and destabilize regulatory T cells (Tregs). A practical biomarker panel pairs lesion immunohistochemistry/spatial maps of PD-1/programmed death-ligand-1 (PD-L1) and second-wave checkpoints with soluble PD-1, PD-L1, CTLA-4, and EV cargo under strict pre-analytical control. Therapy should be staged: first, lower the inflammatory and metabolic load, then restore inhibitory tone with checkpoint agonists or co-stimulation blockade, and add Treg support and EV-guided delivery when regulation is fragile. Safety needs vaccine timing, age-/sex-aware dosing, and composite panels that distinguish flare from over-suppression. The next step is endotype-first, spatially informed, biomarker-anchored trials to achieve durable, safer immune rebalancing.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc3b98a9c47abbacb791867bf6e6236a27247d00" target='_blank'>
              Immune Checkpoint Dysregulation in Autoimmune Disorders: A Narrative Review of Therapeutic Implications
              </a>
            </td>
          <td>
            Diwan Mahmood Khan, Rohit Kumar, Mahavadi Sriharsha, Srihita Mahavadi, Arnaw Kishore
          </td>
          <td>2025-11-01</td>
          <td>Cureus</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Radiation-induced skin injury (RISI) is a common and debilitating complication of radiotherapy, characterized by persistent inflammation and delayed wound healing. Macrophages play a central role in this process; however, the molecular mechanisms governing their dysfunction under radiation stress remain poorly understood. To elucidate the role of triggering receptor expressed on myeloid cells 2 (TREM2) in macrophage regulation after irradiation, we combined single-cell RNA sequencing, in vivo mouse models, and in vitro macrophage assays. Conditional knockout mice (LysMCreTrem2flox/flox) were used to selectively delete Trem2 in macrophages. Radiation induced a distinct TREM2+ macrophage subset; however, despite elevated Trem2 mRNA, protein levels declined due to ADAM17-mediated shedding driven by radiation-induced reactive oxygen species (ROS) accumulation and NRF2 activation. Inhibition or small interfering RNA (siRNA)-mediated knockdown of ADAM17 restored TREM2 protein expression, reduced soluble TREM2 release, improved macrophage survival, and promoted anti-inflammatory M2 polarization. Conversely, Trem2 deficiency enhanced apoptosis, sustained inflammation, and delayed wound healing, whereas Trem2 overexpression or local adoptive transfer of TREM2+ macrophages accelerated tissue repair. Mechanistically, TREM2 conferred radioprotection through extracellular signal-regulated kinase (ERK) pathway activation, linking the ROS–NRF2–ADAM17 axis to TREM2–ERK signaling in macrophage survival and polarization. Collectively, these findings identify a novel regulatory cascade, ROS–NRF2–ADAM17–TREM2–ERK, that governs macrophage fate under irradiation. Targeting this pathway or supplementing TREM2+ macrophages may offer promising therapeutic strategies for mitigating RISI.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5e8bb0105bfc306e09e4c0af1d74cb3671e412a" target='_blank'>
              TREM2 Deficiency Regulates Macrophage Apoptosis and Repair in Radiation-Induced Skin Injury
              </a>
            </td>
          <td>
            Zijian Chen, siyuan cai, Pengfei Li, ziyi zhou, zhenxing huang, juntao deng, Linbo Jin, Zucheng Luo, Dongli Fan, Junli Zhou, Fazhi Qi, Yiming Zhang
          </td>
          <td>2025-11-13</td>
          <td>Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Autoimmune diseases represent a broad group of chronic conditions characterized by loss of immune tolerance, autoreactive lymphocyte activation, and pathogenic autoantibody production. CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for hematologic malignancies, has emerged as a promising strategy to directly eliminate autoreactive B cells and reprogram immune function. CD19-CAR T infusion can induce rapid remission, reduce autoantibody levels, and sustain drug-free disease control. Despite these encouraging results, current evidence is limited to small patient cohorts with short follow-up, leaving uncertainties regarding long-term safety, durability of remission, and the stability of immune reconstitution. Most studies implicitly assume that quantitative B-cell recovery equates to restored immune health, yet the functional resilience of the post-CAR-T immune system—its ability to protect against infection, respond to vaccines, and maintain durable tolerance—remains unexplored. To address this gap, we propose an integrated framework for evaluating the functional competence of immune reconstitution following CAR T-cell therapy and for designing next-generation targeting strategies. Functional recovery should be assessed not only by quantitative B-cell repopulation but also by vaccine responsiveness, infection surveillance, and immune repertoire diversity. Vaccine challenge studies and infection monitoring can reveal whether protective immunity is restored, while sequencing-based profiling of B- and T-cell repertoires can clarify whether regulatory balance and clonal diversity are re-established. In parallel, translational innovations such as dual-target CAR constructs (e.g., CD19 + BAFF-R) and chimeric autoantibody receptor (CAAR) T cells offer complementary solutions to broaden target coverage and improve selectivity. Moreover, Epstein–Barr virus (EBV)–mediated immortalization of patient-derived autoreactive B cells provides a feasible ex vivo platform for generating physiologically relevant antigenic stimuli during CAR engineering. This approach could yield T cells that are functionally “educated” to eliminate pathogenic clones while preserving protective immunity, thereby addressing the central challenge of rebuilding a resilient and tolerant immune system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/803ca15907028d5ecd42afcef39a38a8ff458830" target='_blank'>
              Application of CD19-CAR T cell therapy in autoimmune diseases
              </a>
            </td>
          <td>
            Lynn Choi
          </td>
          <td>2025-10-24</td>
          <td>Journal of High School Science</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Despite major advances in immunotherapy, respective treatments often show only limited benefit in patients with chronic lymphocytic leukemia (CLL). Immune checkpoint blockade, which has shown durable responses in multiple malignancies, has yielded inferior efficacy in CLL. Similarly, adoptive CAR-T cell therapy, which has achieved remarkable success in other B cell malignancies, resulted in lower response rates in CLL. The lack of success of these immunotherapies is likely due to the profound T cell dysfunction and immune suppressive microenvironment, typical characteristics of this disease. The so-called “exhaustion” of T cells is marked by impaired effector capacity, sustained inhibitory receptor expression, and loss of progenitor exhausted (TPEX) populations, cell subsets which are critical for responses to PD-1 blockade. This suggests that reversing T cell exhaustion could be key to improving outcomes.
 Emerging evidence implicates the immunoregulatory cytokine interleukin-10 (IL-10) as a context-dependent modulator of T cell exhaustion. While traditionally viewed as an immunosuppressive mediator that limits tissue damage during chronic inflammation and suppresses antiviral immunity, IL-10 may, in cancer, enhance tumor-infiltrating CD8⁺ T cell function, prolong their survival, and delay T cell exhaustion.
 Using the Eµ-TCL1 adoptive transfer (TCL1-AT) mouse model of CLL, we previously identified a role for IL-10 receptor (IL-10R)–STAT3 signaling in sustaining CD8⁺ TPEX cells, preventing terminal exhaustion, with loss of signaling accelerating CLL progression (Hanna et al., Immunity 2021). As IL-10 expression is linked to better outcome in CLL patients and IL-10R loss is associated with DLBCL development early in life, we hypothesize that IL-10 improves the fitness of cytotoxic T cells thereby preventing immune escape in CLL and likely other B cell malignancies.
 To test the potential of IL-10 in modulating T cell responses against CLL, we generated a stabilized IL-10 fusion protein (IL-10-Fc) and demonstrated that treatment of TCL1-AT mice with IL-10-Fc slowed CLL progression, reduced exhausted effector T cells, and preserved TPEX populations.
 To dissect T cell-intrinsic effects, we employed an in vitro exhaustion assay by repetitive antigen-specific stimulation of T cell receptor (TCR)-transgenic murine CD8⁺ T cells with peptide-loaded target cells. IL-10 treatment maintained effector T cells in these cocultures, reduced terminal exhaustion markers TIM-3 and CD39, and promoted a polyfunctional phenotype with robust cytokine production and CD107a expression, demonstrating a direct effect of IL-10 on T cell fitness.
 To gain a broader view of IL-10-mediated immune modulation in the TCL1-AT model, we performed spectral flow cytometry and single-cell RNA-sequencing following short-term IL-10-Fc treatment. Both T cell and myeloid compartments displayed therapy-induced alterations, including shifts in regulatory T cells, CD8⁺ T cells, neutrophils, and monocytes. Notably, IL-10-Fc reduced PD-L1⁺ patrolling monocytes, which were linked to immune suppression in CLL, and increased inflammatory monocytes, which suggests a reversal of pro-tumoral myeloid activity.
 Finally, a pilot combination treatment study revealed that IL-10-Fc synergized with the BTK inhibitor ibrutinib, achieving profound disease control in the TCL1-AT mouse model beyond either agent alone. These findings position IL-10 as a promising immunomodulatory therapy in CLL, capable of restoring T cell function and remodeling the suppressive tumor microenvironment.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/189bf152f9c8c3a59e8922ef6b9ef1ab630e8fe4" target='_blank'>
              IL‑10 limits CLL progression by reprogramming T cell exhaustion and myeloid suppression
              </a>
            </td>
          <td>
            A. Floerchinger, Min Gao, Jan Philipp Schadendorf, Yuliia Borysovych, Nicolas Aubert, Hannah Briesch, L-M Pilger, Mei-Wen Peng, P. Lichter, Stella E. Autenrieth, M. Zapatka, L. Tang, M. Seiffert
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate under pathological conditions such as cancer, where they contribute to immune evasion, tumor progression, and resistance to therapy. These cells exert potent immunosuppressive effects by inhibiting T cell activation, inducing regulatory T cells, modulating antigen-presenting cells, and shaping an immunosuppressive tumor microenvironment (TME). Their suppressive functions involve multiple mechanisms, including amino acid depletion, production of reactive oxygen and nitrogen species, expression of immune checkpoint ligands, and secretion of immunoregulatory cytokines such as IL-10 and TGF-β. Besides these immune-related roles, MDSCs also promote tumor growth through non-immunological mechanisms, including the stimulation of angiogenesis and undergoing metabolic reprogramming. These adaptations support their survival and function in the hostile TME. Given their multifaceted role in cancer, MDSCs represent a promising target for therapeutic intervention. Furthermore, their abundance and dynamic modulation during treatment confer them tremendous potential as biomarkers to monitor therapy efficacy and stratify patients. This review provides a comprehensive overview of MDSC biology, their mechanisms of action, and their emerging clinical relevance as biomarkers and therapeutic targets. We also explore current strategies aimed at targeting MDSCs, including their depletion, inhibition of recruitment, functional blockade, and promotion of their differentiation into mature myeloid cells. Integrating these approaches with existing cancer therapies holds great promise for enhancing antitumor immunity and overcoming resistance in both solid tumors and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d195f524c3054c9a1106fbc8581ac237b69c234e" target='_blank'>
              Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
              </a>
            </td>
          <td>
            S. Silva-Romeiro, Rocio del, Carmen Flores-Campos, M. L. Sánchez-León, V. Sánchez-Margalet, L. Cruz-Merino, María, Luisa Sánchez-León
          </td>
          <td>2025-11-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Background The efficacy of immunotherapy is often hindered by the suppression of immune responses via the tumor microenvironment (TME). The presence of cancer cells forces other proximal non-cancerous cells to support tumor growth and persistence. A clear example of this cancerous-to-non-cancerous communication is represented by the accumulation of myeloid-derived suppressor cells (MDSCs) within the TME. Several studies have convergently shown that the overexpression of DNA-methyl-transferase-1 (DNMT1) in these cells results in protection from necroptosis and enhanced accumulation in vivo. Conversely, targeting DNMT1 through hypo-methylating agents has shown promising therapeutic potential by not only reducing the levels of MDSCs but also enhancing cancer immunogenicity and the efficacy of immune checkpoint inhibitors (ICI). Methods Murine 4T1 (triple-negative breast cancer (TNBC)) and CT26 (colon carcinoma) cell lines were cultured under standard conditions and used to generate tumor models in BALB/c mice. An oncolytic adenovirus expressing a DNMT1-targeting short hairpin RNA (OAd.shDNMT1) was engineered and validated for DNMT1 knockdown and genome-wide methylation reduction. Small extracellular vesicles (sEVs) were isolated from virus-infected cancer cells and characterized for RNA content and uptake by MDSCs. MDSC differentiation and suppressive function were assessed in vitro using flow cytometry and co-culture assays with murine splenocytes. In vivo, tumor-bearing mice received intratumoral OAd.shDNMT1, systemic decitabine, or immune checkpoint inhibitors (anti-Programmed cell Death protein-1), and tumor growth, immune infiltration, and systemic MDSC levels were evaluated. Results In this study, we report that, by using virally infected TNBC murine cells as a source for shDNMT1-loaded sEVs, OAd.shDNMT1 successfully reduced MDSC levels in vitro and in vivo. Furthermore, the co-administration with ICI resulted in a significant tumor growth reduction in mice bearing poorly immunogenic TNBC 4T1 cells. Also, our treatment promoted antitumor immunity, prolonged survival, and complete tumor eradication in modestly immunogenic colon CT26 cancer cells. Conclusion This multifaceted strategy, based on OV-mediated immune stimulation and reduction of MDSC levels via sEVs, may improve clinical outcomes and the success of immuno-based regimens for patients facing MDSC-rich and highly aggressive cancer subtypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/854d707af7ff1d7731b63579e115f89b9c83b43b" target='_blank'>
              Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy
              </a>
            </td>
          <td>
            Salvatore Russo, Yvonne Giannoula, S. Feola, Justin Cerioni, Firas Hamdan, Jacopo Chiaro, Anja Thu Ha Dang, Paolo Bottega, Michaela Feodoroff, M. Fusciello, Virpi Stigzelius, Carmine D'Amico, Carmen Caiazza, Gabriella Antignani, Federica D'Alessio, Milda Sakalauskaite, Julia Petryk, J. Bell, C. Ilkow, M. Grönholm, Vincenzo Cerullo
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood (PB) and bone marrow (BM) monocytes was performed from healthy donors (HDs) and MM patients to generate a comprehensive single-cell transcriptional map. Although PB and BM monocytes displayed comparable cellular compositions, MM monocytes exhibited marked transcriptional alterations, most prominently within the type I interferon (IFN) signaling pathway. Trajectory analyses revealed IFN-driven disruptions in monocyte differentiation and developmental trajectories in both PB and BM compartments. Functional co-culture assays demonstrated that activation of the type I IFN pathway enhanced MM cell proliferation, suggesting that IFN-mediated monocyte reprogramming facilitates tumor progression. In an independent validation cohort, longitudinal sampling before and after induction therapy confirmed that anti-myeloma treatment alleviated the excessive IFN response of BM monocytes. Collectively, these findings uncover a mechanistic link between aberrant IFN activation and monocyte dysregulation in MM, providing new insights into immune dysfunction and highlighting the IFN pathway as a potential therapeutic target to restore anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c95b600545a3e90a13c96978be5b8e9b2126411" target='_blank'>
              Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
              </a>
            </td>
          <td>
            Jian Cui, Jingwei Wang, Xiaoyun Li, Lina Wang, X. Mao, Rui Lyv, Wenqiang Yan, Jingyu Xu, Jieqiong Zhou, C. Du, S. Deng, Mu Hao, Yan Xu, S. Yi, D. Zou, Tao Cheng, Xin Gao, Lugui Qiu, Gang An
          </td>
          <td>2025-11-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Immune checkpoint blockade therapies, particularly targeting PD-1/PD-L1 axis, have shown limited efficacy in glioblastoma (GBM), primarily due to the profoundly immunosuppressive tumor microenvironment dominated by glioma-associated microglia and macrophages (GAMs). While CMTM6 is known to stabilize PD-L1 in tumor cells by preventing its ubiquitin-mediated degradation, its role in microglia remains undefined. We employed a multi-omics approach to evaluate CMTM6 expression and function. By analyzing the bulk RNA-seq data sets from TCGA and CGGA, as well as single-cell data sets (TISCH2 and UCSC), the expression of CMTM6 across different glioma grades and immune cell populations was examined. Immunohistochemistry and immunofluorescence were used to validate CMTM6 expression and co-localization with microglial/macrophage markers in GBM tissues. In vitro, CMTM6 knockdown was performed in HMC3 microglial cells to assess changes in cytokine and immune checkpoint expression. In vivo, a tamoxifen-induced, microglia/macrophage-specific Cmtm6 conditional knockout mouse model was used to investigate tumor growth and survival outcomes. CMTM6 was significantly upregulated in high-grade gliomas and enriched in M2-like microglia/macrophages. Immunostaining confirmed elevated CMTM6 and CD68 expression in GBM samples, with CMTM6 co-localizing with microglial markers (CD68, IBA1, and TMEM119). By knocking down CMTM6 in HMC3 cells, the levels of CD274 (PD-L1) and TGFβ isoforms decreased, while the expression of pro-inflammatory cytokines IL6 and CCL3 increased, suggesting a shift toward an M1-like phenotype. In vivo, microglia/macrophage-specific deletion of Cmtm6 suppressed tumor growth, delayed body weight loss, and extended survival duration. This study identifies CMTM6 as a critical regulator of the immunosuppressive phenotype of microglia/macrophages in GBM. Targeting CMTM6 in microglia/macrophages may represent a novel strategy to reprogram the tumor immune microenvironment and improve the efficacy of immunotherapy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2983570a9c22d4513306860ad1a429e127cd5f00" target='_blank'>
              CMTM6 drives glioblastoma progression by promoting M2 polarization and suppressing antigen presentation in microglia/macrophages
              </a>
            </td>
          <td>
            Xiang Li, Wenbo Han, Wenpei Cai, Ruoxin Yang, Gaojie Bai, Changxiu Sun, Shiyuan Ge, Cheng Zhang, Xinyi Han, Han Yang, Yi Chen, Qiao Shan, Xiaohui Li, Xueli Tian, Yuan Lyu, Junqi Li, Xinjun Wang
          </td>
          <td>2025-10-27</td>
          <td>European Journal of Medical Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Understanding the interplay between oncogenic mutations and the tumor microenvironment could help improve therapy for hematological malignancies. We found that the STAT5-activating oncogenes JAK2 p.V617F, FLT3-ITD, and BCR::ABL1 induce oncostatin M (OSM), which triggers disease progression and immunosuppression. The OSM receptor was predominantly expressed on nonhematopoietic bone marrow (BM) stromal cells. OSM reprogrammed these cells via STAT3 and induced the secretion of cytokines connected to T-cell exhaustion, including IL-6 and MCP-1. Compared with control mice, OSM-overexpressing mice presented reduced T-cell numbers, increased levels of inhibitory receptors on T cells, and elevated lactic acid production by BM stromal cells. OSM induced the expansion of myeloid cells which suppressed T cells. Conversely, genetic deletion of Osm in a JAK2 p.V617F-driven polycythemia vera mouse model reduced polycythemia, BM fibrosis, inflammatory cytokine levels and the expression of inhibitory markers on T cells. Transcriptomic analyses of T cells from OSM-overexpressing mice revealed enrichment of IL6–JAK–STAT3 and inflammatory signaling pathways. Additionally, pharmacological inhibition of OSM reduced disease activity and cytokine production. These findings establish OSM as a key mediator linking oncogenic STAT5 activation to remodeling of the microenvironment and immune suppression. Targeting OSM signaling therefore represents a promising therapeutic strategy to alleviate disease progression in myeloproliferative neoplasms and related malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d49eb0cd9f9aa70be266360e0a4941b4deb7497" target='_blank'>
              Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies
              </a>
            </td>
          <td>
            Michael Rassner, T. Müller, Kirstyn Anne Crossley, G. Andrieux, Sabina Schaberg, Cornelia Endres, Lena Jakob, Teresa Poggio, N. Köhler, J. Kolter, Gerhard Müller-Newen, Katharina Schönberger, N. Cabezas-Wallscheid, I. González-Menéndez, Leticia Quintanilla-Martinez, Melissa Zwick, Driti Ashok, T. N. Hartmann, Olaf Groß, O. Gorka, M. Follo, A. Illert, M. Boerries, R. Zeiser, J. Duyster
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Cancer stem cells (CSCs) represent a small subset of tumor cells populations characterized by their ability to self-renew and differentiate. These cells are often considered resistant to chemotherapy, radiotherapy, and immunotherapy, playing a crucial role in driving tumor progression and metastasis. To evade immune attacks, CSCs utilize various genetic and epigenetic strategies that diminish immune recognition, enhance tolerance to immune-induced cytotoxicity, and foster the development of a protective immunosuppressive microenvironment. This microenvironment is shaped by a group of key immunosuppressive cells, particularly myeloid-derived suppressor cells (MDSCs), which not only directly inhibit effector T cells and natural killer (NK) cells, facilitating the immune escape of CSCs, but also significantly contribute to the maintenance of tumor cell stemness and promote their metastasis. Conversely, the developmental signals of MDSCs are also regulated by CSCs. This complex interplay between MDSCs and CSCs adds layers of complexity to the cancer-immune cycle and the associated tumor treatment strategies. Therefore, understanding the detrimental interdependence between MDSCs and CSCs to effectively impede tumor progression has become heated topic in tumor immunology. In this review, we provide a timely summary of the latest studies on the reported characteristics of CSCs and MDSCs, discuss their interconnection during tumor progression, and evaluate various immunotherapeutic strategies targeting these cell populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f6883e12fe0f725487279c796b8b972017bb7c9" target='_blank'>
              Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy
              </a>
            </td>
          <td>
            Bo Wang, Xiaoguo Zhao, Shuxin Han, Yuekang Xu, Jinyao Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Stem-like CD8⁺ exhausted T cells (Tex) sustain antitumor immunity, whereas TGFβ signaling acts as a major immunosuppressive pathway. In patients with colorectal liver metastases, we observe that elevated TβRI expression in peri-metastatic hepatocytes correlates with poor prognosis. We therefore investigate whether disrupting hepatocytic TGFβ signaling can reinvigorate stem-like CD8⁺ Tex cells to restrict liver metastasis. In support of this hypothesis, mice with hepatocyte-specific TβRI depletion exhibit reduced liver metastatic burden across multiple tumor models. Mechanistically, hepatocytic TβRI blockade suppresses Galectin-9 secretion, which reshapes the transcriptional program of intra-tumoral CD8⁺ T cells. This reprogramming promotes a phenotypic transition from terminal exhaustion toward stem-like and effector states, yielding T cell subsets with enhanced metastasis-control capacity. Importantly, this axis functions independently of macrophages and CD4⁺ T cells. Furthermore, therapeutic delivery of Galunisertib using choline-modified lipid nanoparticles synergizes with αPD-1, fostering the conversion of exhausted CD8⁺ T cells into responsive Ly108⁺CX3CR1⁺ subsets and suppressing liver metastases. Collectively, our results identify hepatocyte TGFβ signaling as a targetable checkpoint against liver metastases. How TGF-β regulates liver metastasis remains further investigation. The authors here find that TβRI blockade in hepatocytes decreases liver metastatic progression via revitalizing stem-like CD8⁺ Tex subsets, and an LNP encapsulated with the TβRI inhibitor Galunisertib synergizes with αPD-1 to ameliorate liver metastasis">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8539be173ace8a0b4d35310e7d3ebf922993bf40" target='_blank'>
              Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8+ Tex subsets
              </a>
            </td>
          <td>
            Hao Wang, Yan Zhou, Yuanyu Tu, Junxiong You, Baogui Gao, Kun Yuan, S. Zhong, Changjie Huang, Q. Han, Yuntao Dai, Ye Ma, Qingyuan Zhang, Xinyi Yan, Junjiang Wang, Xiaorui Wang, Liang Zhao, Xuegang Sun
          </td>
          <td>2025-11-27</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/02d1f577ff573db5c6fa1e5a829b978c4c5a4e28" target='_blank'>
              Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
              </a>
            </td>
          <td>
            Yao Zhang, Yuting Lei, Yanzhao Huang, Yan Gao, Rong Liu, Kaiyun Guo, Chunlian Zhao, Ming Lei
          </td>
          <td>2025-12-03</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Macrophage activation markers, specifically CD163 and CD169, play pivotal roles in the modulation of immune responses within the tumor microenvironment (TME), influencing the outcome of various cancers. These markers delineate the activation states of macrophages, with CD163 associated with the protumoral phenotype and CD169 with activation of tumor immunity. This review comprehensively explores the dualistic roles of these markers in cancer progression and immune suppression, and discusses the mechanisms through which these markers influence macrophage behavior, the impact of their expression on cancer progression, and the therapeutic potential of targeting these pathways to reprogram the TME toward enhancing antitumor immunity. This review aims to underscore the therapeutic potential of macrophage activation markers as targets for cancer treatment, highlighting emerging strategies and future directions in cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53fc1215ec60391859572318c1aaf77d4a3cec5e" target='_blank'>
              Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer
              </a>
            </td>
          <td>
            Yukio Fujiwara, Yoshihiro Komohara
          </td>
          <td>2025-11-01</td>
          <td>Pathology International</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f39864620cfab03542ab6a808667a34fb36a9c78" target='_blank'>
              Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)
              </a>
            </td>
          <td>
            Chuqi Wang, Yuhan Wang, Camillo Benetti, Xiao Xian Lin, Enes Dasdemir, Petra Hyroššová, Jordan Yong Ming Tan, Edward Ayoub, K. Bhatia, Fang Qi Lim, Yun Li, Zihui Zhao, Ahmed M Mamdouh, Shir Ying Lee, Jakub Rohlena, Chad V. Pecot, M. Andreeff, Katerina Rohlenova, Hussein A. Abbas, Shruti Bhatt
          </td>
          <td>2025-11-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Memory T cells endow the mammalian host with an essential form of adaptive immunity that generates durable and rapid protection following re-exposure to an infectious pathogen or a cancerous transformation1–4. How naive CD8⁺ T cells develop into memory T cells that bifurcate into long-lived central (TCM) versus effector (TEM) subsets after such an antigen encounter remains ill-defined at the molecular level. To address this gap, here we dissect the functional T-cell receptor (TCR) repertoire of 242 murine CD8⁺ TCRαβ clonotypes specific for the peptide-major histocompatibility complex molecule (pMHC) comprising an immunodominant influenza A virus (IAV) oligopeptide epitope NP366–374 presented by H-2Db 5,6. Using single-cell transcriptomics with TCR sequencing, biophysical measurements of force-dependent TCR-pMHC interactions, in vivo memory development, and structural analyses, we integrate these data to define relationships between signaling polarity and memory fate. We find that TCM and TEM polarities are reflected in distinct subunit-related mechanotransduction biases: TCM-associated TCRs favor TCRβ-driven pMHC engagement, whereas TEM-associated TCRs preferentially favor TCRα-driven pMHC engagement. Moreover, “bipolar” clonotypes (TBP) capable of generating both memory subsets exhibit more balanced signaling, the largest average clonal expansions, and broadest heterosubtypic crossreactivities. By contrast, variegated TCM TCR sequences foster mostly clonal singlets with the greatest IAV mutant recognition potential within the overall memory repertoire, thus revealing two complementary memory niche crossreactivity strategies. Weak, force-sensitive TCR bonds are pervasive for this entire repertoire, being most conspicuous amongst TCM clonotypes. At the atomic level, highly nuanced variation in TCRαβ bonding to either peptide and/or MHC modulates mechanical load transmission across the holoreceptor’s ectodomains, transmembrane segments, and CD3 cytoplasmic tails to differentially influence downstream tyrosine phosphorylation and memory development. Collectively, TCR diversity anticipates epitope-specific pathogen evolution, whereas divergent TCR signaling regulates memory fate with implications for adoptive T-cell immunotherapies seeking to maximize persistence and minimize functional exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47c5e8a658084ff1675ec010b34b843ae8e69de3" target='_blank'>
              Atomistic TCR-ligand interactions instruct memory T-cell differentiation
              </a>
            </td>
          <td>
            A. Akitsu, Kemin Tan, R. J. Mallis, Matthew A. Booker, J. Duke-Cohan, K. Brazin, Evan H. Kirkpatrick, Andrew N. Parkins, Sarita Aryal, V. Cinella, Jonathan J Lee, Kaveri I. Uberoy, Jenna K. Koenig, Matthew Biddle, Cameron M. Messier, P. Lizotte, M. Tolstorukov, Wonmuk Hwang, Matthew J Lang, Ellis L. Reinherz
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00ed13bb7acb39c5e98a4fa14592f332d5a91492" target='_blank'>
              A narrative review of therapy-induced senescence in cancer: mechanisms, immune interplay, and therapeutic opportunities
              </a>
            </td>
          <td>
            Henry Sutanto, Alfan Ahkami, D. Fetarayani, P. Z. Romadhon
          </td>
          <td>2025-12-01</td>
          <td>Journal of the Egyptian National Cancer Institute</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of naturally developing neoplasms, as well as tumors responding to (immuno)therapy. In this setting, robust, acute but ultimately resolving type I IFN responses appear to support natural and therapy-driven cancer immunosurveillance by a number of mechanisms, including an accrued propensity of malignant cells to arrest their proliferation and undergo apoptotic cell death, as well as broad immunostimulatory effects on CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells (DCs) and tumor-associated macrophages (TAMs). Conversely, weak, indolent and ultimately non-resolving type I IFN responses de facto facilitate tumor progression, not only by promoting stemness in malignant cells (which is associated with increased metastatic dissemination and resistance to therapy), but also by favoring the establishment of a highly immunosuppressive lymphoid and myeloid tumor microenvironment. Here, we provide a critical discussion of the context-dependent impact of type I IFN signaling on cancer progression and response to treatment, focusing on the tumor-intrinsic and extrinsic factors that may account for such a heterogeneity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2e617f9f9711708567426eb2cf65f4ef606f0b6" target='_blank'>
              Context-dependent impact of type I interferon signaling in cancer
              </a>
            </td>
          <td>
            Ainhoa Ruiz-Iglesias, Emma Guilbaud, Lorenzo Galluzzi, Santos Mañes
          </td>
          <td>2025-10-30</td>
          <td>Molecular Cancer</td>
          <td>1</td>
          <td>7</td>
        </tr>

        <tr id="The tumor microenvironment (TME) constitutes a highly complex and dynamic ecosystem wherein diverse leukocyte subsets engage in intricate cross-talk that ultimately dictates the balance between tumor progression and suppression. This review provides a comprehensive analysis of the dualistic functions of key immune cell populations-including natural killer (NK) cells, effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)-within this milieu. Particular emphasis is placed on the Nigerian context, where unique genetic backgrounds, such as the high prevalence of sickle cell trait, and environmental factors, including endemic infections, significantly shape immune phenotypes and cancer pathogenesis. We explore how cutting-edge single-cell technologies are revolutionizing our understanding of the spatial architecture, functional plasticity, and cellular heterogeneity of these leukocytes in patient cohorts, revealing mechanisms of both immune surveillance and tumor-promoting immunosuppression. The paradoxical roles of these cells elucidate the variable clinical outcomes observed with immunotherapies and underscore the critical need for precision medicine strategies that are tailored to individual immune landscapes. Finally, we discuss emerging therapeutic modalities aimed at selectively depleting pro-tumor subsets like Tregs or MDSCs while activating anti-tumor effectors such as NK cells, which hold substantial promise for reshaping the TME and improving oncology outcomes both in Nigeria and across the globe.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85d4138591bf3dda987df758be78f378fdcee1f4" target='_blank'>
              Leukocyte Subset Dynamics in the Tumor Microenvironment: Dual Roles, Single-Cell Insights, and Implications for Cancer Immunotherapy in Nigeria
              </a>
            </td>
          <td>
            Okluchi Hartumu
          </td>
          <td>2025-11-25</td>
          <td>Hematological Disorders in the Single-Cell Era</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Multiple myeloma (MM) remains an incurable disease despite therapeutic advancements extending survival. Relapses driven by drug resistance and minimal residual disease underscore the need for novel treatment strategies. Natural Killer (NK) cells play a key role in MM immunity, yet their function is suppressed by inhibitory cytokines and metabolites from the tumor microenvironment. Developing anticancer drugs with immunomodulatory properties, such as enhancing tumor sensitivity to NK cell recognition, remains a critical challenge. MM cells exhibit high protein synthesis rates, making them vulnerable to proteostasis disruption. Dysregulated ribosome function and aberrant mRNA translation contribute to proteasome inhibitor resistance. RNA Polymerase I (RNA Pol I)-mediated rDNA transcription, the rate-limiting step in ribosome biogenesis (RiBi), is significantly upregulated in MM. Targeting rDNA transcription and inducing nucleolar stress response (NSR) presents a promising therapeutic approach, though its immunomodulatory role is not well understood. Our study examined two “first-in-class” RNA Pol I inhibitors, CX-5461 and BMH-21, which differentially regulate NK cell-activating and inhibitory ligand expression in MM. BMH-21 enhanced NK cell degranulation and increased IFN-γ and TNF-α secretion, demonstrating stronger immunostimulatory effects than CX-5461. Conversely, CX-5461 induced a significant DNA damage response (DDR) and senescence, leading to HLA-E upregulation and suppressing NK cell activity. Mechanistic analyses revealed that HLA-E presentation is governed by ATR/AKT/mTORC1/S6K signaling and Pioneer Round of Translation (PRT), linking its regulation to DDR. This effect was modulated by Lenalidomide and Panobinostat. Moreover, RNA Pol I inhibition enhanced Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC) of NK cells against MM, uncovering novel immuno-mediated antitumor mechanisms.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3eac9f710ed72751582b0e2b38db7a164c640592" target='_blank'>
              Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma
              </a>
            </td>
          <td>
            Elena Sproviero, Eleonora Gnocchini, Tommaso Cipollone, Sara Petillo, Chiara Cassone, R. Molfetta, A. Zingoni, A. Soriani, C. Cerboni, M. Petrucci, F. Fazio, R. Paolini, Gabriella Palmieri, M. Cippitelli
          </td>
          <td>2025-11-28</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Megakaryocytes (MKs) have traditionally been viewed as terminal hematopoietic cells responsible solely for platelet production. However, recent advances in imaging and single-cell transcriptomics have revealed substantial heterogeneity among MK populations and diverse functions beyond thrombopoiesis. MKs actively participate in innate and adaptive immunity, modulate the hematopoietic stem cell (HSC) niche, and adapt to physiological and pathological stimuli. Located in distinct anatomical sites such as bone marrow and lung, MKs exhibit compartment-specific specializations that enable them to serve as critical integrators of hemostatic, immune, and regenerative processes. Experimental models using human pluripotent stem cells and inducible MKs have enhanced mechanistic insights, while innovative bioreactor platforms and xenotransplantation strategies advance translational applications in platelet production and therapy. Furthermore, immune MK subsets derived from pluripotent stem cells show promising therapeutic potential for modulating inflammation and autoimmune diseases. Continued exploration of MK diversity, tissue-specific roles, and intercellular communication will unlock new opportunities for leveraging MK plasticity in regenerative medicine, immunotherapy, and hematologic disorders, repositioning these versatile cells as central players in systemic homeostasis and defense.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a42ed6c49b37f5e87fc8596501cc105433a716fc" target='_blank'>
              Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects
              </a>
            </td>
          <td>
            Seungjun Kim, Kiwon Lee
          </td>
          <td>2025-10-27</td>
          <td>Cells</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Therapy-induced senescence (TIS) generates an immunogenic state in cancer cells by altering how they present antigens, produce cytokines, and organize their surfaceome. TIS can be exploited for therapeutic purposes using “immunosenolytic” strategies, including adoptive cellular therapies such as chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells. A frequently overlooked barrier may limit the success of these living drugs: mitochondrial apoptotic priming in the target TIS cancer cells. Contrary to the prevailing dogma, recent assessments of mitochondrial apoptotic signaling via BH3 profiling (a functional assay measuring proximity to the mitochondrial apoptotic threshold and identifying BCL-2 family dependencies) have revealed that TIS cancer cells are globally less primed for apoptosis than their proliferating precursors. TIS cancer cells exhibit a conserved, druggable dependence on specific members of the BCL-2 family for survival. Interestingly, the pre-existing priming and anti-apoptotic addictions of parental, non-senescent cells, are retained upon induction of senescence. This suggests an “inherited” mitochondrial memory that may predict the (immuno)senolytic responsiveness of TIS cancer cells. BH3 profiling could help to personalize CAR-based immunosenolytic therapy according to apoptotic readiness across pre- and post-TIS states. This companion diagnostic could inform the rational use of BH3 mimetics in combination with CARs and guide the engineering of precision immunosenolytic interventions such as “armored” CAR-T/NK cells neutralizing specific anti-apoptotic dependencies at the effector-target interface. This perspective reframes mitochondria as predictive checkpoints that can be monitored and targeted to enable TIS cancer cells to respond precisely and durably to adoptive CAR-T/NK immunotherapy within “one-two punch” senogenic-immunosenolytic designs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d448509a34a438cbd0714844d26b75b81a37d50" target='_blank'>
              Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy
              </a>
            </td>
          <td>
            Javier A. Menendez, Ruth Lupu, B. Martín-Castillo, Josep Sardanyés, Tomás Alarcón, S. Verdura, E. Cuyás
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20f65e1524ffb4190a28bef066a656c7fa921b4e" target='_blank'>
              B-cell Follicles in the Secondary Lymphatic Tissues Act as a Critical Microanatomical Niche for Sustained Viral Replication, Virus-host Interaction and Damage During Chronic SIV Infection of Rhesus Macaques
              </a>
            </td>
          <td>
            Yilun Cheng, Miaoyun Zhao, Jackson Chen, Subhra Mandal, Mark G. Lewis, Qingsheng Li
          </td>
          <td>2025-11-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 CAR-T cells have emerged as a therapeutic strategy for autoimmune diseases, including systemic lupus erythematosus (SLE). One open question is the impact of preconditioning on therapeutic responses. In preliminary experiments using pre-irradiated lupus-prone New Zealand Black/New Zealand White (NZB/W) mice, second-generation anti-mCD19 CAR-T cells positively impacted many disease features. Significant bone marrow (BM) B-cell depletion and lower proteinuria were observed across irradiated groups, suggesting an immunosuppressive effect. Based on these findings, we aimed to demonstrate the impact of CAR-T cells over irradiation on various immunologic and clinical features by modifying the conditioning regimen in these mice. Twenty two-week-old pre-irradiated mice were treated with PBS or CAR-T cells+IL-2. Lymphocytes were assessed in blood, BM, and spleen 4-weeks post treatment. The engraftment of CAR-T cells was documented in all samples. CAR-T cell-treated mice showed persistent B cell decrease in various subsets (marginal zone/naïve B cells and plasma cells). Furthermore, increases in CD4+ and CD8+ T cells, with a lower percentage of effector/central memory T cells and higher naïve T cells were observed as an outcome of CAR-T treatment. CAR-T treated mice also displayed lower anti-dsDNA antibodies and proteinuria. Thus, CAR-T cells showed a differential impact on lupus beyond irradiation. Other disease features to ascertain CAR-T cell efficacy for SLE are being explored.



 Supported by Kyverna Therapeutics, Inc., Emeryville, CA.



 Therapeutic Approaches to Autoimmunity (THER)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48e017f60a3235e38047b172faeb8b5872f707d" target='_blank'>
              Efficacy and engraftment of anti-CD19 CAR-T cells in murine lupus 4343
              </a>
            </td>
          <td>
            J. Romo-Tena, Shouvonik Sengupta, William Ambler, S. Nakabo, C. Carmona-Rivera, Eduardo Patino Martinez, L. P. Blanco, Shairaz Shah, Jennifer Zeng, Ashley E. Mahne, Joseph K Cheng, T. Van Blarcom, Mariana J. Kaplan
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8+ T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/863d3f6179309aee5c3016baab1955820d8c1527" target='_blank'>
              The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma
              </a>
            </td>
          <td>
            Soyoung Kim, IkJoon Han, Suin Lee, Sujin Park, Jae-Won Jeon, Hyunsu Bae
          </td>
          <td>2025-11-25</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0895fbd19269fbdc4298e324e79791c8a18caebd" target='_blank'>
              CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.
              </a>
            </td>
          <td>
            J. Boldison, P. Leete, E. Robinson, Wendy Powell, Joanne Davies, Conor McMullan, Sophie L Walker, Noel G Morgan, S. Hanna, F. S. Wong
          </td>
          <td>2025-11-22</td>
          <td>Diabetologia</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Background/Objectives: Extracellular vesicles (EVs) are key mediators of intercellular communication and are implicated in the neuropathogenesis of HIV-associated brain injury (HABI). However, their direct effects on glial cells, particularly in the context of antiretroviral therapy (ART), remain incompletely understood. Methods: In this study, we investigated how EVs from naïve, Simian Immunodeficiency Virus (SIV)-infected, and SIV-infected ART-treated rhesus macaques impact primary mixed glial cultures. Results: Through multiple, sequential applications mimicking chronic exposure, we found that EVs from SIV-infected animals significantly reduced glial expansion and induced a simplified, reactive astrocyte morphology indicative of neuroinflammatory stress. In contrast, EVs from naïve animals supported glial health. EVs derived from ART-treated animals provided partial protection from SIV-induced effects, yet still suppressed glial proliferation and failed to fully restore normal morphology. Furthermore, cytokine profiling revealed that both SIV and SIV + ART EVs induced a sustained proinflammatory secretory phenotype, characterized by elevated IL-6, IL-8, and IFN-γ. Conclusions: Our findings demonstrate that systemically circulating EVs in SIV infection are potential drivers of glial dysfunction. The persistence of these pathogenic EV effects despite ART suggests a vesicle-mediated mechanism that may contribute to chronic neuroinflammation and cognitive impairment in virally suppressed individuals.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67fab60169c13d075bcfdc8d7c00be88b51107c6" target='_blank'>
              Simian Immunodeficiency Virus-Derived Extracellular Vesicles Induce a Chronic Inflammatory Phenotype in Healthy Astrocytes Unresolved by Anti-Retroviral Therapy
              </a>
            </td>
          <td>
            Alison R Van Zandt, Miranda D. Horn, Ryan P. McNamara, Tiffany A. Peterson, N. Maness, Blake Schoest, Elise M. Frost, Yijun Zhou, Matilda J. Moström, D. P. Dittmer, Andrew G. MacLean
          </td>
          <td>2025-10-24</td>
          <td>Pharmaceutics</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a clonal malignancy of plasma cells that remains largely incurable despite major advances in proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Chimeric antigen receptor (CAR)-engineered immune cells have transformed the therapeutic landscape, but CAR-T cell therapy faces challenges such as severe cytokine release syndrome (CRS), neurotoxicity, limited persistence, and logistical complexity. In recent years, natural killer (NK) cells have emerged as a promising platform for next-generation cellular immunotherapy, offering innate antitumor activity, a reduced risk of graft-versus-host disease (GvHD), and the feasibility of “off-the-shelf” allogeneic production. This review summarizes current advances in CAR-NK cell therapy for MM, focusing on two major aspects: the diversity of cell sources—including NK-92, peripheral (PB) and cord blood (CB), and induced pluripotent stem cell (iPSC)-derived NK cells—and the expanding repertoire of target antigens such as BCMA (B-cell maturation antigen), NKG2D, CD38, CD70, SLAMF7, CD138, and GPRC5D. We highlight preclinical and early clinical studies demonstrating potent cytotoxicity, favorable safety profiles, and innovative multi-targeting strategies designed to overcome antigen escape and enhance persistence. Emerging clinical data suggest that CAR-NK cell therapy may combine the specificity of CAR recognition with the inherent safety and versatility of NK biology, offering a potential paradigm shift in the treatment of relapsed or refractory MM. Further clinical validation will determine whether CAR-NK cell therapy can achieve durable remission and complement or surpass current CAR-T modalities.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6c564648f2cac8ed7d5dc089469d07120d75f71b" target='_blank'>
              State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens
              </a>
            </td>
          <td>
            Asya Bastrich, Kamilla Vinogradova, D. Mokrousova, Anna Efremova, O. Makhnach, D. Goldshtein
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Ageing is accompanied by a decline in immune function, associated with susceptibility to infections and malignancies, and reduced vaccine efficacy. These immunological changes, affect multiple components of the immune system, particularly T lymphocytes, which exhibit altered subset distributions and accumulate senescent features. CD57, a surface glycoprotein expressed on T cells, has emerged as a potential marker of terminal differentiation and senescence used for immunomonitoring in infection or cancer contexts. However, the use of CD57 as a marker of T cell senescence remains unclear. To investigate this, we analyzed CD57 expression on CD8+ and CD4+ T cells in healthy donors from two independent cohorts, considering cellular differentiation, age, cytomegalovirus status, and other senescence markers. Our findings reinforce the association between CD57 expression, T cell differentiation, and CMV seropositivity, but not with chronological age. Although CD57 is associated with altered proliferation and survival in all T cell differentiation subsets, it does not fully align with a senescent phenotype. Therefore, we propose that CD57 may be better appreciated as a marker of immunological age. Moreover, the interpretation of CD57 expression must account for CMV serostatus to avoid misleading conclusions, especially in oncology and ageing research.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/791c677aa468081272cce86ad911aff7f1cd5dc4" target='_blank'>
              Re-evaluating CD57 as a marker of T cell senescence: implications for immune ageing and differentiation
              </a>
            </td>
          <td>
            Gaëlle Autaa, D. Korenkov, J. van Beek, Isabelle Pellegrin, Béatrice Parfait, Debbie van Baarle, Odile Launay, Eric Tartour, V. Appay
          </td>
          <td>2025-10-31</td>
          <td>Immunity & Ageing : I & A</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="


 Introduction: Aging impairs immune function and leads to increased vulnerability to infection, malignancy, and vaccine failure.Immunosenescence, marked by reduced thymic output, naive T cell attrition, and progenitor exhaustion, undermines vaccine responses and anti-tumor immunity in aged individuals. While cytokine-based and stem cell-modifying therapies have attempted to reverse this decline, they remain limited by toxicity, durability, or translational feasibility. Here, we present an mRNA approach that transiently reconstitutes thymic signaling pathways in an unrelated organ. By expressing Delta-like ligand 1 (DLL1), Fms-like tyrosine kinase 3 ligand (FLT3-L), and interleukin-7 (IL-7) - collectively termed DFI - in the liver, we observed rejuvenated aged immunity via coordinated modulation of thymopoiesis, lymphoid progenitors, and immune function.
 Methods: We identified age-related decline of Notch, IL-7, and FLT3-L signaling in thymic epithelial cells and peripheral T cells using spatial transcriptomics (Slide-seq v2) and single-cell RNA-seq across the human and murine lifespan. Modified mRNAs encoding DFI were encapsulated in SM-102 lipid nanoparticles (LNPs) and administered to aged mice (72 weeks). Hepatic expression, pharmacokinetics, and tissue specificity were assessed via RIBOmap and immunofluorescence. Functional impact on thymopoiesis, hematopoiesis, and immune function was assessed via flow cytometry, V(D)J sequencing, TREC analysis, peptide vaccination, tumor challenge (B16-OVA and MC38-OVA), and immune checkpoint inhibitor (ICI) therapy. Autoimmune safety was evaluated in NOD, Act-mOVA, and EAE models.
 Results: DFI mRNA was selectively translated in hepatocytes, yielding membrane-bound DLL1 and secreted IL-7 and FLT3-L without off-target organ expression. This induced expansion of naïve CD4⁺ and CD8⁺ T cells, increased TRECs, and restored thymic cellularity in aged mice. Mechanistically, DFI did not reprogram hematopoietic stem cell (HSC) fate or reverse myeloid bias but significantly expanded common lymphoid progenitors (CLPs) in the bone marrow. These CLPs exhibited increased CCR9 expression and thymus-homing potential, consistent with peripheral DLL1-mediated Notch signaling and improved thymic seeding. Early thymocyte subsets (DN1-DN3) were selectively enriched, accompanied by rapid induction of Rag2 and Nur77 in thymocytes, supporting enhanced de novo thymopoiesis. Despite HSC aging signatures remaining intact, DFI circumvented upstream deficits by expanding committed lymphoid progenitors and reinvigorating thymic output.
 Beyond the T cell compartment, DFI restored conventional dendritic cell type 1 (cDC1) populations and boosted co-stimulatory molecule expression (CD40, CD83, CD86). In parallel, it decreased dysfunctional age-associated B cells and increased follicular B cells, resulting in more robust antigen-specific IgG responses and IgM-to-IgG class-switching after peptide vaccination.
 Functionally, DFI pre-treatment doubled vaccine-specific CD8⁺ T cells in aged mice and improved antigen recall cytokine production (IFN-γ, IL-2). In tumor models, DFI conditioning enhanced spontaneous rejection of MC38-OVA and B16-OVA tumors and improved survival. It restored intratumoral CD8⁺ T cell infiltration and diversity and reversed age-associated T cell exhaustion signatures. When combined with ICI, DFI synergistically enhanced tumor control and survival in aged mice with established tumors.
 Importantly, DFI did not trigger autoimmune responses. In NOD mice, DFI did not accelerate type 1 diabetes or increase autoreactive TCRs. In Act-mOVA mice, tolerance to endogenous OVA was preserved. In the EAE model, DFI increased peripheral MOG-specific T cells but did not worsen CNS inflammation or clinical scores. DFI's immunostimulatory effects were strictly transient, dissipating 4 weeks post-treatment without long-term adverse effects.
 Conclusions: Transient hepatic expression of DLL1, IL-7, and FLT3-L safely and effectively reactivates thymopoiesis, expands functional T cell pools, and enhances antigen-specific immune responses in aged hosts. By bypassing stem cell-intrinsic defects and rejuvenating the thymic niche via liver-derived trophic cues, DFI overcomes major roadblocks of immune aging. This mRNA-based, non-integrating platform supports scalable, cyclic immunostimulation without autoimmunity, suggesting a viable strategy to enhance vaccine efficacy and cancer immunotherapy in elderly patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ca64b5c3c124926369d482741b8ee751943695e" target='_blank'>
              Transient hepatic reconstitution of thymic factors using mRNA rejuvenates T cell immunity, and improves vaccination and cancer immunotherapy responses in aged hosts
              </a>
            </td>
          <td>
            M. Friedrich, Julie Pham, Jiakun Tian, Hongyu Chen, Jiahao Huang, N. Kehl, Sophia Liu, Blake Lash, Fei Chen, Xiao Wang, Rhiannon K. Macrae, Feng Zhang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="


 Background: Treatment resistance and relapse in myeloma and lymphoma are driven by diverse immunosuppressive mechanisms within the tumor microenvironment (TME), including expansion of myeloid-derived suppressor cells (MDSCs) and regulatory T cells, upregulation of immune checkpoints, and suppression of antigen presentation, which collectively impair cytotoxic T and natural killer (NK) cell function. Heat shock protein 70 (HSP70), highly expressed in many hematologic malignancies, including multiple myeloma and lymphoma, plays a central role in these processes by stabilizing oncoproteins, inhibiting apoptosis, and promoting immune escape. Extracellular HSP70 released from tumor cells, often bound to tumor-derived antigens, can induce pro-tumorigenic inflammation and facilitate recruitment of immunosuppressive cells, and interfere with antigen processing and stress-induced cell death. Prior attempts at HSP70–based vaccination showed limited clinical efficacy due to challenges in purifying material and efficiently targeting APCs, highlighting the need for novel strategies to leverage this pathway in myeloma and lymphoma immunotherapy.
 Methods: We developed a panel of murine monoclonal antibodies to HSP70 by immunizing BALB/c mice with murine fibroblast L-cells expressing human HSP70 fused to green fluorescent protein. This panel was then screened in immune-competent BALB/c mice injected with luciferase (luc)-expressing MOPC315.BM murine myeloma cells, selected due to the 95% homology between murine and human HSP70. Clone 77A was identified from this screen as showing the most robust in vivo anti-tumor activity and subjected to further in vitro and in vivo testing.
 Results: Clone 77A enhanced antigen-presenting cell (APC) uptake of HSP70 tumor antigen complexes, promoted cross-priming of antigen-specific T cells, and engaged FcγRIII on NK cells and antigen presenting cells and thus modulated both innate and adaptive immunity.
 In immunocompetent myeloma models (MPC11 and Vk*MYC), 77A remodeled the immunosuppressive TME by inhibiting myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs). Also, 77A promoted dendritic cell (DC) infiltration and expanded central memory CD4+ and CD8+ T- and NK-cell populations, subsequently generating a potent anti-tumor activity. Bulk RNA-seq and pathway analysis confirmed activation of antigen processing/presentation and NK cell-mediated cytotoxicity pathways.
 In the EG7.OVA (chicken ovalbumin) lymphoma model, 77A reshaped the TME to favor tumor-specific immune activation, including expansion of OVA presenting DCs and proliferation of OVA323–339-specific CD4+ T cells and OVA257-264- specific CD8+ T cells with enhanced effector function. These antigen specific T cells from 77A-treated tumor bearing mice exerted significant ex vivo cytotoxicity against EG7.OVA cells. Moreover, 77A augmented proliferation and effector function of OVA257-264- specific CD8+ T cells administered into the EG7.OVA lymphoma bearing mice, supporting its potential for a combined regimen with adoptive T cell therapy (ACT). We also found that HSP70 subcutaneous co-administration into established lymphoma tumors enhanced 77A's therapeutic efficacy in the EG7.OVA model. Additionally, 77A markedly enhanced anti-tumor activity of proteosome inhibitors (bortezomib and carfilzomib), radiation, and STING agonists (diABZI and IACS-8803) in MPC11 and Vk*MYC models. Its activity extended to solid tumors, including 4T1 breast cancer, and was further potentiated by tumor expression of immunogenic antigen hemagglutinin. or PD-1 immune checkpoint blockade.
 In the MM1.S xenograft model, 77A retained activity under NK cell depletion, likely due to myeloid polarization toward an M1 phenotype. The activity was more modest compared with that seen in more immune competent models, highlighting its long-term efficacy relied on T cell priming and effector function. Finally, 77A directly enhanced human immune function by boosting MART-1 specific CD8+ T cell expansion and enhancing NK cell cytotoxicity in healthy donor samples.
 Conclusion: 77A is a first-in-class anti-HSP70 antibody that uniquely leverages HSP70 neoantigen biology to bridge innate and adaptive immunity. It generates robust and durable anti-tumor activity in hematologic and solid tumor models, and synergizes with multiple immunomodulatory and standard therapies, supporting its clinical translation as a novel immunotherapy platform.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a887ea64b847a742d0e834756a184372d82443b" target='_blank'>
              First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models
              </a>
            </td>
          <td>
            Jun Wei, Richard J. Jones, I. Kuiatse, Hua Wang, R. Orlowski
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>93</td>
        </tr>

        <tr id="


 Tumor-associated myeloid populations contribute significantly to immunosuppression and treatment resistance in glioblastoma (GBM). While the pro-tumorigenic influence of tumor-associated neutrophils (TANs)—including their role in promoting angiogenesis, immunosuppression, and immune checkpoint expression—is well documented, their potential anti-tumoral functions remain insufficiently investigated.



 This study employed CT2A syngeneic murine models of GBM to investigate the immunological and oncological consequences of systemic neutrophil depletion. Anti-Ly6G antibodies were administered intraperitoneally to selectively eliminate circulating neutrophils. Tumor progression was monitored through in vivo bioluminescence imaging (IVIS), while immune profiling was conducted using flow cytometry on samples from the brain, blood, and spleen.



 Over a 21-day period, IVIS imaging revealed signficantly elevated radiance in neutrophil-depleted mice relative to controls, indicating enhanced tumor burden (mean radiance fold-change: 2.7; p = 0.042). Kaplan-Meier analysis showed that neutrophil-depleted animals had significantly shortened survival (median: 19 vs. 24 days; log-rank p = 0.0058). Importantly, this reduction in survival was not observed in neutrophil-depleted mice lacking tumors, suggesting that the neutrophil effect is context-dependent within the GBM tumor microenvironment (TME). Flow cytometric analysis confirmed effective peripheral neutrophil depletion, with CD45⁺Ly6G⁺CD11b⁺ cells reduced from 3.1% to 0.03% (p < 0.001). Additionally, a trend toward reduced brain-infiltrating CD8⁺ T cells was observed in the absence of neutrophils (p = 0.0553).



 Our findings present one of the first reported pre-clinical evidence that TANs may exert protective, anti-tumoral effects within the GBM TME. Neutrophil depletion not only accelerated tumor progression and impaired survival but also disrupted immune equilibrium in the brain. These data support a paradigm shift in which TANs may be leveraged or reprogrammed as therapeutic agents in future GBM immunotherapies. Continued investigation is warranted to delineate the molecular basis of TAN plasticity and their potential role in reshaping anti-GBM immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/225247f6ba2e8abda8f3fd79dd3a30a5922e4a2d" target='_blank'>
              TMIC-43. Tumor-Associated Neutrophils: A Double-Edged Sword in Glioblastoma Progression
              </a>
            </td>
          <td>
            Matthew A Abikenari, John Choi, Ravi Medikonda, Lily H Kim, Rohit Verma, Andrew Tran, Shreyas Annagiri, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Introduction: Emerging evidence suggests that the immunosuppressive tumor microenvironment is a major limiting factor impairing CAR-T cell function. Recent studies have identified immunosuppressive erythroid precursor cells (EPCs) – a novel cell population that accumulates in pathological contexts (including neonates, cancer-bearing hosts, and infected individuals) – which potently suppress immune responses and diminish upon maturation. In this study, we aim to investigate the impact of these immunomodulatory EPCs on CAR-T cell function and explore potential strategies to overcome their suppressive effects, thereby enhancing CAR-T cell efficacy.
 Methods: We established KA539 lymphoma models in irradiated C57BL/6 mice and collected clinical peripheral blood samples from hematologic malignancy patients to quantify EPCs accumulation in extramedullary tissues. Functional profiling was performed via RNA-seq on FACS-sorted CD45⁺ versus CD45⁻ EPCs, validated by scRNA-seq. To assess EPCs-mediated CAR-T cell suppression, CD19 CAR-T cells were co-cultured with EPCs followed by multiparameter analysis including proliferation, cytokine secretion, exhaustion, and tumor-killing capacity of CAR-T cells. Mechanistically, we performed RNA-seq and Cut&Tag with erythroid precursors upon BRD4 inhibition, and genetic validation in erythroid-specific BRD4 cKO mice to demonstrate that BRD4 regulates the immunity of CD45+ EPCs.
 Results: We confirmed that both tumor-bearing mice and patients with hematologic malignancies showed significantly increased EPCs proportions in extramedullary tissues, including peripheral blood, spleen, and liver. RNA-seq analysis revealed that CD45+ EPCs exhibited elevated expression of immunosuppressive genes, including VISTA, PD-L1, LGALS3. Notably, tumor-bearing mice exhibited increased EPCs levels following CAR-T treatment, particularly in the poor-response group, suggesting a potential link between EPCs expansion and therapeutic resistance. Coculture with CD45+ EPCs significantly impaired CAR-T cell function, reducing both TNF-α secretion and proliferative capacity. Consistent with our previous findings on BRD4's role in blocking erythroid maturation, we observed that BRD4 similarly impeded EPCs' maturation in tumor-bearing mice and patient-derived samples. Furthermore, BRD4 inhibition downregulated immune-related genes and pathways in EPCs. Integrated analysis of Cut&Tag and RNA-seq data revealed that BRD4 directly transcriptionally activated immune regulatory genes in EPCs, including PD-L1 and VISTA. Besides, experiments with BRD4conditional knockout mice further confirmed that BRD4 inhibition promoted maturation of CD45+ EPCs and repressed expression of novel immune checkpoint VISTA. Importantly, flow cytometry analysis demonstrated that BRD4 inhibition significantly alleviated EPCs-induced CAR-T cell exhaustion, as evidenced by reduced expression of the exhaustion markers PD-1 and LAG-3, supporting BRD4 inhibition as a viable strategy to potentiate CAR-T cell function by modulating EPCs' immunosuppressive activity.
 Conclusion: Our study establishes that immunosuppressive EPCs directly impair CAR-T cell function. We demonstrate that BRD4 transcriptionally activates VISTA expression in EPCs, and targeting BRD4 reverses EPC-mediated CAR-T suppression. These findings unveil a novel mechanism of the immunosuppressive microenvironment in CAR-T therapy and provide a potential approach to enhance clinical efficacy against hematologic malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c440cfd119e2a331ecd6f4081b0a4605fb549576" target='_blank'>
              BRD4 sustains immunosuppressive erythroid precursors to compromise CAR-T cell function
              </a>
            </td>
          <td>
            Meng Zhang, Mengmeng Huang, Yijin Chen, Haiqiong Zheng, Yanjuan Liu, Dawei Huo, Yong-xian Hu, Pengxu Qian, He Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="


 The neuropathology observed during Venezuelan equine encephalitis virus (VEEV) infection, including blood-brain barrier (BBB) breakdown, is linked to an overwhelming immune response in the brain, but the roles of specific cell types are not fully elucidated. Here we temporally profiled the immune response to VEEV by performing single cell RNA sequencing on brains of infected mice. This data revealed activation of microglia subsets and their sequential decline in abundance concurrent with infiltration of immune cells, including cytotoxic lymphocytes NK cells and CD8+ T cells. Targeting these cells, we found depletion of NK cells and CD8+ T cells synergistically improved BBB integrity and survival. NK cell-depleted brains have fewer CD8+ T cells and both NK cell-depleted and double-depleted brains have increased microglia. NK cell-depleted infected brains had similar levels of elevated cytokines IFN-a, CCL2, CCL5, and IFN-g, chemokines CXCL1 and CXCL10, and interleukins IL-6 and IL-1b, while having higher IFN-b. Double-depleted brains had strikingly higher levels of each of these proteins, in addition to IL-10, IL-12, GM-CSF, and TNF. Through this work, we have begun profiling immune signatures associated with improved outcomes of VEEV infection, underscoring the utility in understanding complex immune responses for the development of immunomodulatory therapies aimed at limiting BBB dysfunction and improving infection outcomes.



 [1] This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory under Contract DEAC52-07NA27344.



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3abebda82cc25e9b9ebfbc8beda7bf7d191a43b9" target='_blank'>
              Depletion of cytotoxic lymphocytes shifts brain immune response, promoting blood-brain barrier integrity and survival in Venezuelan equine encephalitis virus infection 3984
              </a>
            </td>
          <td>
            Margarita V. Rangel, A. Sebastian, N. Leon, Ashlee M. Phillips, D. Murugesh, N. Hum, D. Weilhammer
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="ABSTRACT Trained immunity is a long-term functional reprogramming of innate cells that allows for the formation of immune memory akin to adaptive responses, but with a more rapid nonspecific response. We recently identified an anti-inflammatory trained immunity response, termed trained tolerogenic immunity (TTI), induced by low virulence Candida dubliniensis, that protects against acute lethal polymicrobial sepsis via myeloid-derived suppressor cells (MDSCs). Trained immunity and MDSCs arise following hematopoietic stem and progenitor cell (HSPC) expansion in the bone marrow. Here, we show that C. dubliniensis induces inoculum-dependent protection and HSPC expansion, whereas depletion of HSPCs following C. dubliniensis immunization abrogates protection. We further show that myeloid progenitors and putative MDSCs are increased in the bone marrow following C. dubliniensis immunization, and that HSPC depletion results in reduced MDSC influx into the peritoneal cavity following lethal challenge. Bone marrow cytokine analysis revealed that mediators associated with MDSC development and trafficking, including G-CSF, CXCL2, and CCL2, are upregulated following C. dubliniensis immunization. Finally, we find that the C-type lectin receptor adaptor protein Card9 is required for C. dubliniensis-induced protection and HSPC expansion, but not fungal trafficking to the bone marrow. Taken together, these results suggest that Card9-dependent fungal recognition in the bone marrow drives myelopoiesis and the induction of immunosuppressive MDSCs that are protective against lethal inflammation and sepsis. IMPORTANCE Cells of the innate immune system can be “trained” by inducers to have enhanced memory responses, a phenomenon known as trained immunity. We recently identified an anti-inflammatory training response that is induced by low virulence fungal species (i.e., Candida dubliniensis) and is protective against acute lethal polymicrobial sepsis. Trained immunity inducers, including C. dubliniensis, can access the bone marrow and direct hematopoietic responses. Here, we demonstrate that protection is correlated with C. dubliniensis-induced bone marrow expansion, which directs a myeloid bias in the bone marrow and ultimately results in the expansion of protective myeloid-derived suppressor cells. Involvement of the C-type lectin receptor adaptor protein Card9 in the protective response suggests fungal recognition in the bone marrow drives this response. These findings offer new insights into how trained immunity inducers direct differential outcomes, which will inform the development of novel immunotherapeutics to exploit the full spectrum of trained immune responses. Cells of the innate immune system can be “trained” by inducers to have enhanced memory responses, a phenomenon known as trained immunity. We recently identified an anti-inflammatory training response that is induced by low virulence fungal species (i.e., Candida dubliniensis) and is protective against acute lethal polymicrobial sepsis. Trained immunity inducers, including C. dubliniensis, can access the bone marrow and direct hematopoietic responses. Here, we demonstrate that protection is correlated with C. dubliniensis-induced bone marrow expansion, which directs a myeloid bias in the bone marrow and ultimately results in the expansion of protective myeloid-derived suppressor cells. Involvement of the C-type lectin receptor adaptor protein Card9 in the protective response suggests fungal recognition in the bone marrow drives this response. These findings offer new insights into how trained immunity inducers direct differential outcomes, which will inform the development of novel immunotherapeutics to exploit the full spectrum of trained immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/28ef5d4d2e11b7eea19c57b43a1c7a076c5b6b77" target='_blank'>
              Induction of myelopoiesis by Candida dubliniensis drives protective trained immunity against sepsis in a Card9-dependent manner
              </a>
            </td>
          <td>
            S. Righi, E. Lilly, A. J. Harriett, Patrick W. Daly, MaryJane Jones, Chad Steele, Mairi C. Noverr, Paul L Fidel
          </td>
          <td>2025-10-31</td>
          <td>mBio</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7bcfd3df2c5d1e60c0a8518093894d3b787fd6a7" target='_blank'>
              Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies.
              </a>
            </td>
          <td>
            Limin Jia, Zhaoyang Wang, Jinfa Du, Zhigang Ren, Jiandong Jiang, Pan Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers of medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Glucocorticoid (GC)-resistant, acute graft-versus-host-disease (GVHD) is a major cause of mortality following allogeneic hematopoietic stem cell transplantation. Second line treatment with Ruxolitinib (RUX) can be effective, but only a minority of patients attain durable complete remissions. Biopsies from the gut in patients with refractory GVHD are frequently characterised by large clonal expansions of CD8+ T cells. Experimental models of GVHD have suggested that these T cell effector expansions may be sustained by progenitor-type T cells expressing the transcription factor TCF1, which possess greater inherent proliferative and self-renewal potential than effector cells. We hypothesised that a similar progenitor-type population can be found in humans and is resistant to GC treatment.
 Using clinically relevant concentrations of methylprednisolone and several independent methods for human T cell stimulation, we determined output population architecture and function with a combination of multiparameter flow cytometry, bulk and single cell transcriptional profiling. Under conditions of repetitive anti-CD3/CD28 stimulation over a three-week period, GC-treated CD8+ T cells showed greater proliferation and overall expansion than control cells. GC-treated CD8+ T cells showed greater retention of cell markers (e.g., IL-7RA, CD27) and transcriptional profiles (e.g., KLF2, LTB, BCL2) associated with a 'less-differentiated’ state. In vitro assays indicated intact cytokine-generating function and killing capacity of the GC-resistant CD8+ T cells versus controls. These GC-driven changes to T cell proliferation and phenotype were largely restricted to CD8+T cells and occurred independently of the presence of CD4+ T cells.
 To track the population architecture of GC-treated CD8+ T cells compared to controls, we performed scRNAseq of 3-week expanded cultures. The GC-treated CD8+ T cell population showed a distinct differentiation trajectory composed primarily of two IL7RA-expressing clusters: a major effector memory-like cluster expressing cytotoxic genes (e.g., PRF1) as well as known GC-regulated genes (e.g., GILZ); and a smaller cluster composed of progenitor-like cells, expressing TCF7 (encoding TCF1) and LEF1. To test how this GC-induced shift in population architecture emerged during culture, we tracked cell proliferation and cellular state according to the individual input differentiation status of CD8+ T cells (TN, TCM, and TEM(RA)) prior to activation; these experiments showed that GC-induced changes in proliferation and cell state were primarily derived from the expanding TN-origin cells. To test the clinical relevance of these findings in vivo, we interrogated patient scRNAseq data derived from n=19 biopsies of acute lower gut GVHD, treated with (n=14) or without GC (n=5) at the time of biopsy. We identified strong enrichment for our TCF-1+ progenitor-like cluster in patients with severe GVHD treated with GC (median 35.1% versus 9.5% of CD8+ T cells, p<0.05).
 To address how JAK1/2 inhibition would influence the GC-resistant phenotype, we applied RUX at clinically relevant concentrations and showed that its addition blocked proliferation in GC-treated cultures to a greater extent than control cells. However, RUX simultaneously further enriched for the TCF-1hi IL-7Rahi progenitor-like population which additionally displayed elevated expression of the anti-apoptotic molecule, BCL-2. We reasoned that BCL-2 inhibition would have the potential to separately target the progenitor population. To test this hypothesis, we treated control and GC-treated T cell cultures with clinically relevant concentrations of Venetoclax (VEN), alone or in combination with RUX. VEN treatment alone did not block proliferation but led to reduced frequencies of progenitor-like cells arising in the presence of GC. When combined, VEN and RUX led to both reduced proliferation and reduced progenitor frequency in parallel to increased activated Caspase-3 expression by CD8+ T cells, particularly in the presence of GC.
 Taken together, these data show that treatments used for GVHD including GC and RUX may select for progenitor-like CD8+ T cells with the potential to sustain tissue injury and lead to refractory disease. Strategies combining drug targets which can inhibit T cell proliferation whilst preventing the retention of multipotent and proliferative progenitor populations may be required to overcome the limitations of current GVHD treatment strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5de99b6fdb68f489811020a31ec532757463d4e2" target='_blank'>
              T cell resistance to glucocorticoids in graft-versus-host disease
              </a>
            </td>
          <td>
            Andrew McIntyre, Lisanne Schoutens, Elisa Armbrecht, Andrew Gravett, Nicolas Sanschagrin, Callum Wright, Matthew Collin, R. Chakraverty
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="


 Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of late mortality in allogeneic-hematopoietic stem cell transplantation with bronchiolitis obliterans syndrome (BOS) among the most lethal treatment-resistant complications. Despite approval of ibrutinib, ruxolitinib, belumosidil, and axatilimab, clinical response in moderate and severe BOS patients remains poor, highlighting the need for new therapies. Bromodomain and Extra terminal (BET) proteins are epigenetic readers driving oncogenic and inflammatory transcriptional programs in multiple cell types. We reported that BET inhibition reduced acute GVHD pathogenicity via suppression of the IL23/T helper 17 axis, without impairing the graft-versus-leukemia effect. Thus, we hypothesized that BET inhibition would be a feasible therapeutic option by restraining the direct inflammatory T cells as well as macrophage (mac) polarization to profibrotic (M2) phenotype known to be critical to cGVHD pathophysiology. In a BOS model, pulmonary function tests showed mice treated with BETi improved lung function and decreased collagen deposition. Here, we present our results identifying novel mechanisms driving cGVHD pathogenesis that are targeted by BET inhibition that ameliorates disease.
 Methods: We used an established BOS cGVHD model wherein B.10.BR (H2k) recipients conditioned with chemotherapy (120mg/kg x 2 cytoxan) and total-body irradiation (800cGy) received 7.5e6 T cell depleted bone marrow (TCD-BM) cells from allogeneic donor CD45.2+ C57BL/6 (B6, H2b) mice +/- 7.5e5 CD45.1+ B6 splenocytes (Day 0). TCD-BM only recipients that do not develop disease served as controls. Recipients with established cGVHD/BOS were treated days 28-~55 (study end) with vehicle or the BET inhibitor (BETi, OPN-51107, 10mg/kg 3x/weekly), that also has anti-tumor effects on malignant B cells. Spectral flow cytometry, histopathology, immunofluorescence (IF) and single-cell RNA sequencing (scRNA-seq) of lung tissue were performed to evaluate effector cells associated with BOS pathology.
 Results: BETi decreased circulating CXCR5+ B cells and CD4+ T helper cells (p<0.001) as well as plasma levels of the B cell chemoattractant CXCL13 that binds CXCR5 (p<0.001). BETi treated mice displayed reduced splenic activated CD44+CD62L- T follicular helper (Tfh) cells (p<0.0001) and restored IL10+ T follicular regulatory (Tfr):Tfh ratios (p<0.05). BETi did not impact germinal center B cell numbers (p=0.56) but did reduce alveolar plasma B cells (p<0.05). Plasma ELISA showed mice with cGVHD had increased circulating pathogenic IgG1/IgM, but not IgG2c, which was attenuated under BETi (p<0.01). Lung IF staining confirmed reduced pathogenic IgG1/IgM deposition in BETi mice compared to vehicle controls (p<0.05). Antibodies (Abs) in cGVHD can be both allo- and auto-antigen (Ag) reactive. To test this, we harvested lung tissue sections from B6 Rag2-null mice (lacking Abs) for staining with serum from TCD-BM, cGVHD and BETi mice. cGVHD serum had increased Abs reactive to auto (H-2b)-Ags, that was lower in the BETi cohort (p<0.001). scRNA-seq revealed 22 distinct cell types in the BOS lung. In cGVHD mice, GSEA analysis revealed upregulation of pathways for migration and cell adhesion pathways in alveolar macrophages and those related to bacterial defense response in interstitial macrophages (IM), all downregulated in BETi mice (p<0.05). cGVHD mice had enriched anti-inflammatory Arginase1 and profibrotic Tgfb1 expression (p<0.001) in tissue-resident alveolar macrophages (TRAM) and IMs, which was significantly reduced in BETi treated mice. Spectral flow cytometry confirmed that BETi targeted lung-infiltrating M2 macs, through selective diminishment of CD206+ M2 IMs (p<0.01) but not TRAMs (p=0.66). We found that FcgR expressing M2 IMs were increased in cGVHD, with reduced levels in BETi treated mice (p<0.01). Reduced FcgR-Ab interactions in M2 macs could mechanistically contribute to the observed reduction in TGF-b expression and crosstalk to collagen depositing fibroblasts.
 Conclusion: We identify BET proteins as a key regulator of inflammation in BOS. BETi suppresses Tfh cells, thereby reducing Ab production and deposition. Within the lung, BETi selectively targets M2 IM macs to reduce FcgR and TGF-b expression, thereby regulating collagen deposition and fibrosis. These findings reveal a previously unrecognized mechanistic axis driving cGVHD and highlight BET inhibition as a promising therapeutic strategy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/38c47ec289350015a32c65bd5cc2318bd08f87e3" target='_blank'>
              BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd
              </a>
            </td>
          <td>
            Rathan Kumar, Lotus Neidemire-Colley, E. Garfinkle, Camryn Steere, Simran Surana, Annie Murray, Giorgia Giordano, Olivia Martin, Emerson Woodbury, Kara Corps, M. Karunasiri, Mathew Gorr, Loren STATE Wold, Kenneth Oestreich, N. Grieselhuber, B. Blazar, Ivan Maillard, Katherine Miller, Hannah Choe, Parvarthi Ranganathan
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="
 Although immunotherapy has transformed cancer treatment, glioblastoma (GBM) remains stubbornly resistant due to multiple immunosuppressive mechanisms. Our previous work identified polyamine metabolism as a key driver of this immunosuppression, with difluoromethylornithine (DFMO) improving survival in a T and B cell-dependent manner. However, DFMO alone, or in combination with PD-1/PD-L1 blockade, failed to yield durable benefits. This suggests the emergence of adaptive resistance mechanisms. To investigate this, we performed single-cell RNA sequencing (scRNA-seq) on DFMO-treated tumors, revealing increased T-cell inflammation and IFN-γ-driven gene expression. Surprisingly, the most upregulated gene was apolipoprotein D (ApoD), a lipid transport protein that sequesters arachidonic acid (AA). AA is an inflammatory lipid essential for T-cell-induced IFN-γ-STAT1-dependent ferroptosis of tumor cells during immunotherapy. Notably, this STAT1-ApoD axis was also acutely induced in response to other immunotherapies in murine GBM models. We therefore hypothesized that IFN-γ–induced ApoD expression represents a potential mechanism of tumor immune evasion. Our preliminary findings show that ApoD overexpression protects tumor cells from AA-induced lipotoxicity and ferroptotic cell death, decreasing survival in GBM mouse models, which was dependent on intact adaptive immunity. ApoD-overexpressing tumors displayed a higher myeloid-to-CD8⁺ T cell ratio and increased expression of immune checkpoints and suppressive markers, indicating a more immunosuppressive microenvironment. Collectively, our study demonstrates ApoD as a critical adaptive responder to inflammatory stress in GBM. Ongoing research will further explore ApoD-targeted interventions, including lipid nanoparticle-mediated siRNA delivery. We will investigate the intrinsic role of ApoD in controlling tumor cell susceptibility to ferroptosis, and, in parallel, examine its extrinsic effects as a secreted factor that reshapes the immune microenvironment by suppressing T cell function and promoting myeloid immunosuppression. This may lead to future therapies that enhance immunotherapy efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/002ee8adc2baa74e88b71b10cd71ff6d47d4f268" target='_blank'>
              TMIC-82. Sequestration of inflammatory lipids as an immune evasion mechanism in glioblastoma
              </a>
            </td>
          <td>
            Tzu-yi Chia, Chao Wei, Leah K. Billingham, Suzi Delay, Lauren Boland, Nishanth S. Sadagopan, Jay Subbiah, Si Wang, Hanxiao Wan, Jiawei Huo, J. Duffy, Alina R Murphy, Rebecca Du, Joshua Katz, Aurora Lopez-Rosas, Yu Han, G. Vázquez-Cervantes, Hardik Shah, Peng Zhang, Irina V Balyasnikova, M. Lesniak, Catalina Lee-Chang, J. Miska
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Purpose Cancer immunotherapy aims to enhance the immune system’s ability to recognize and eliminate cancer cells, providing a sustained and effective immune response. However, the tumor microenvironment (TME), characterized by an abundance of tumor-associated M2 macrophages and the presence of exhausted or naïve T cells (non-effector T cells), remains a major barrier to effective immunotherapy. Herein, inflammatory M1 macrophage-derived extracellular vesicles (M1EV) were surface-modified to display interleukin-2 (M1EV_IL2), aiming to develop a multifunctional cancer immunotherapeutic agent capable of modulating both innate and adaptive immune responses. Methods We engineered M1EV to label the surface with azide groups through metabolic glycoengineering and developed M1EV_IL2 that displayed IL-2 via bioorthogonal chemistry. M1EV_IL2 were purified by size-exclusion chromatography (SEC) and characterized through comprehensive analyses, including nanoparticle tracking analysis (NTA). In vitro macrophage repolarization and T cell activation were evaluated at the gene-expression level, followed by ex vivo assays assessing T-cell proliferation, cytokine secretion, and activation marker expression. Results M1EV_IL2 effectively retained the intrinsic physicochemical properties of EVs while displaying IL-2 stably on its surface. It upregulated M1 macrophage markers, IL-1β and CXCL10, while downregulating the M2 macrophage marker CD206, thereby inducing M2-to-M1 macrophage repolarization. In addition, M1EV_IL2 also activated CD4+ T cells and induced the activation of naïve CD8+ T cells to effector T cells, leading to enhanced cell proliferation and secretion of antitumor cytokines. Conclusion These results indicate that M1EV_IL2 has the potential to reshape the tumor immune landscape by simultaneously activating macrophages and T cells, thereby enhancing both innate and adaptive immune responses. Unlike conventional cancer therapies, which directly target tumor cells, M1EV_IL2 is expected to enhance immune responses, potentially mitigating adverse effects while improving therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b118249d7b0665de4875eb1da2d46b5bd10b41f" target='_blank'>
              Interleukin-2 Surface Displayed M1 Macrophage-Derived Extracellular Vesicles for Modulating the Tumor Microenvironment
              </a>
            </td>
          <td>
            Kyeong Tae Kim, Jeong Hyun Lee, S. Kang, W. Rhee
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 Background: While current immune cell engagers have shown therapeutic promise, systemic exposure can lead to cytokine release syndrome (CRS) and on-target off-tumor effects. Their short half-life and the immunosuppressive tumor microenvironment (TME) limit tumor immune infiltration and therapeutic efficacy. Microbial-based cancer therapy utilizing tumor-homing bacteria offers an alternative delivery strategy to overcome challenges such as immune suppression within the TME and limited tumor infiltration.
 Building on our recently developed surface display platform using non-pathogenic E. coli K-12 DH5α for cytokine delivery within the TME (Yang et al., Nat Biotech, 2024), we introduce a new class of Live Immune Modulating Engagers (LIME) that display single-chain variable fragments (scFvs) targeting both tumor-associated antigens (TAAs) and immune cell (T or NK) receptors. We hypothesize that dual surface display of anti-tumor and anti-immune effector scFvs on tumor-homing E. coli will enhance anti-tumor immunity by promoting immune activation and targeted engagement.
 Methods: We engineered E. coli to express scFvs targeting TAAs (e.g., CD19, CD123, Mesothelin (MSLN), HER2, and EGFR) and immune receptors (e.g., CD3, NKG2D, CD16), fused to various scaffold proteins to optimize surface display, confirmed by flow cytometry. In vitro, engineered E. coli were co-cultured with primary human T or NK cells and tumor cells to assess bacterial binding, immune activation (CD25, CD69, Ki67), and cytotoxicity (7-AAD/Annexin V) by flow cytometry. For in vivo studies, syngeneic mouse models bearing subcutaneous tumors, KPC for PDAC MSLN+, A20 for B cell lymphoma CD19+, were treated with intravenous (i.v.) injections of PBS, non-LIME E. coli, engineered LIME E. coli (1-2×10⁸ Colony-Forming Unit (CFU)), intraperitoneal (i.p.) anti PD-1 (8 mg/kg, 2x weekly) and LIME plus anti PD-1. Tumor growth was monitored bi-weekly via caliper measurements. Tumors and organs (liver, spleen, lymph nodes) were harvested for flow cytometry, confocal imaging, multiplex ELISA, and CFU quantification.
 Results: We successfully engineered E. coli to surface-display single and dual scFv constructs using various scaffold proteins, with Intimin Eaea (Neae) demonstrating the highest binding affinity and strongest activation of T and NK cells. Two distinct LIME construct groups were engineered: T-LIME, displaying an anti-CD3 scFv for T cell engagement, and N-LIME, displaying an anti-NKG2D scFv for NK cell activation. Both platforms were able to co-display scFvs targeting TAAs. These dual-display LIME robustly activated (CD25 and CD69 positivity) primary human T and NK cells and significantly enhanced their cytotoxicity (7AAD/AnnexinV positivity) against multiple tumor cell lines. Anti-CD19 and anti-MSLN N-/T-LIME were used for examining in vivo efficacy with or without anti PD-1 blockade treatment. For immunocompetent mice bearing A20 lymphoma, two i.v. injections of T- or N-LIME along with anti PD-1 i.p. was safe, led to dramatic tumor shrinkage (p<0.0001) with 80-100% mice surviving long term (>40 days to date) vs no control in scaffold only E. coli, minimal control in anti-PD1 cohort, and modest control (40% of mice cured) in the LIME cohort. We observed similar results in terms of enhanced tumor control with LIME plus anti PD-1 blockade in the KPC model, though none of these mice were cured. The engineered E. coli enriched up to 1012 CFU/g in the tumor, 107-fold more compared to spleen, liver, and kidney. Multiplex ELISA analysis showed that LIME triggered a strong immune response within the TME and with minimal increase in CRS indicating cytokines in the peripheral blood. Confocal imaging of the tumor tissue showed increased infiltration of T and NK cells in the mice treated with the LIME and confirmed enrichment of engineered E. coli in the necrotic regions of the tumor and infiltration of the engineered E. coli in non-necrotic tumor tissue.Conclusions: Here we describe the development of LIME, a novel platform for targeted cancer immunotherapy, using non-pathogenic E. coli to display bispecific scFvs that activate T and NK cells and drive tumor-specific killing with minimal systemic toxicity. In vivo, LIME synergize with anti PD-1 to induce robust and durable tumor control, highlighting their potential as a safe, modular, and tumor-selective immunotherapy platform.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/760df2da5ca1668d711954b767a4b40d85abeca1" target='_blank'>
              LIME: A first-in-class of live bacterial immune engagers for cancer immunotherapy
              </a>
            </td>
          <td>
            Anna Clara Bader, Shaobo Yang, Ashley Hu, Stephanie Sendker, Daniel Chen, Michal Sheffer, Eden Bobilev, Fuguo Liu, Xingyu Deng, Hetal Nath, Isabel E Kaplan, Maily Nyugen, Mila Stanojevic, Mubin Tarannum, A. Ali, Roman Shapiro, Young Rock Chung, E. Parry, Nathalie Javidi-Sharifi, Julissa Tello, Stephanie Dougan, H. Einsele, Evelyn Ullrich, J. Koreth, Robert J. Soiffer, Catherine J. Wu, Jerome Ritz, R. Romee
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid proliferation, diffuse infiltration, and resistance to conventional therapies. Despite advances in surgery, radiotherapy, and chemotherapy, the prognosis remains dismal, with median survival rarely exceeding 15 months. The immunosuppressive and heterogeneous tumor microenvironment (TME), along with profound tumor-intrinsic resistance mechanisms, contributes significantly to treatment failure. Cardiotonic steroids (CTS), such as ouabain, have recently gained attention for their pleiotropic effects beyond Na+/K+-ATPase inhibition, including modulation of intracellular signaling, induction of cell death, and immune regulation. In GBM, ouabain has been shown to reduce tumor cell viability, impair migration, disrupt angiogenesis, and alter different signaling pathways. Although direct evidence of ouabain’s effects on the GBM immune microenvironment is limited, findings from other models suggest that it can modulate both innate and adaptive immune responses, affecting T cells, regulatory T cells, dendritic cells, monocytes, and NK cells. While previous reviews have explored the anticancer and pharmacological aspects of cardiotonic steroids, the immunological dimension of ouabain’s activity remains underrepresented. This review integrates current evidence on ouabain’s dual actions in tumor biology and immune regulation, emphasizing its emerging therapeutic potential and the need for deeper investigation within high-grade glioma models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c73049935628c7b64bd22cf222eb78736095626" target='_blank'>
              From hormonal immunomodulation to glioblastoma therapy: the emerging role of Ouabain
              </a>
            </td>
          <td>
            Arthur Gomes de Andrade, D. Carvalho, Daniel Wilson Arruda Magalhaes, A. C. de Queiroz, M. S. Alexandre-Moreira, Sandra Rodrigues-Mascarenas, L. H. A. Cavalcante-Silva
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="


 Background: Signal-induced proliferation-associated gene 1 (Sipa1), a RAP1 GTPase-activating protein, is expressed in both hematopoietic cells and stromal cells. It negatively regulates G-protein signaling pathways involving in cell adhesion and proliferation. We have demonstrated that Sipa1loss induces bone marrow (BM) mesenchymal stem and progenitor cells (MSPCs, CD45-TER119-CD31-CD44-CD51+SCA1+ and SCA1- subsets) alterations that drive the development of myeloproliferative neoplasm. Meanwhile, we have observed reduced Sipa1 expression in the BM MSPCs in mice with acute myeloid leukemia (AML) (Blood Adv. 2018, 2(5):534-548). However, the impact of the Sipa1 reduction on AML progression remains unclear.
 Methods: We have here explored the impact of Sipa1 expression in the host BM mesenchymal and immune cell niche by, 1) analyzing AML progression in Sipa1-/- and Sipa1+/+ recipient mice transplanted with MLL-AF9 AML cells with or without prior irradiation; 2) in vivo depletion of specific lymphoid subsets using neutralizing antibodies to determine their contributions; 3) immune and mesenchymal niche characterization using RNA sequencing and flow cytometry; 4) determining clinical correlation between Sipa1 expression in hematopoietic cells and treatment outcomes in patients with AML.
 Results: Remarkably, Sipa1 deficiency in host microenvironment led to delayed or no AML development, reflected in that 30% of the Sipa1-/- recipient mice did not develop AML while all Sipa1+/+ mice did after AML cell injection without prior irradiation. Notably, such a difference in AML development was not observed in lethally irradiated Sipa1-/- and Sipa1+/+ recipient mice where their immune cells were eliminated, indicating the critical involvement of Sipa1-/- immune cells in the AML inhibition. Further, in vivo depletion of NK cells by antibody neutralization could completely reverse the difference in AML development kinetics in the Sipa1-/- mice, suggesting that Sipa1 deficiency may boost NK cells anti-AML immune response. The enhanced anti-AML activity of Sipa1-/- NK cells was consistent with the increased maturation and activation of Sipa1-/- NK cells derived from spleen and blood. Furthermore, RNA sequencing suggested significant enrichment of the inflammatory genes associated with NK cell cytoxicity in Sipa1-/- BM MSCs (CD45-TER119-CD31-CD44-CD51+SCA1+) relative to that in Sipa1+/+ mice, providing another potential mechanism contributing to the increased anti-AML activity of Sipa1-/- NK cells, driven by the inflamed Sipa1-/- BM MSCs. Most importantly and notably, in line with these findings in mice, low SIPA1 expression in bone marrow mononuclear cells is associated with better survival and therapy responses to BET and mTOR inhibitors in AML patients (TCGA LAML dataset, and unpublished data from Prof. Caroline Heckman's lab in Helsinki University).
 Conclusions: Altogether, our study suggests that Sipa1 loss boosts anti-AML response of NK cells, possibly triggered by enhanced inflammatory host microenvironment. These findings along with the clinical correlation between low SIPA1 expression and better survival in AML patients point to the translational potential of these discoveries, meriting further investigation of therapeutic potential of Sipa1 deficient NK cells for AML and the underlying mechanisms.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f8871824fe2ad8aaef916abb388f27c2c0036c5" target='_blank'>
              Sipa1 loss in host niche boosts anti-AML immune response
              </a>
            </td>
          <td>
            Runqing Zhang, L. Sandhow, H. Cai, Hong Qian
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Trained immunity (TI) represented a unique state of innate immune activation, characterized primarily by persistent epigenetic modifications in immune cells. This phenomenon was first observed during pathogen infections and vaccinations, where it manifested as enhanced defensive responses in innate immune effector cells—such as those of the mononuclear phagocyte system and natural killer cells—upon re-stimulation. Cancer was a disease with complex mechanisms, marked by the loss of normal growth regulation in cells due to genetic mutations or epigenetic dysregulation, leading to abnormal proliferation and dissemination. With hundreds of subtypes, cancer could arise in virtually any human tissue or organ. The primary cause of cancer-related mortality was metastasis, which referred to the spread of cancer cells from their original site to distant organs and accounted for approximately 90% of cancer deaths worldwide. The induction of TI involved multiple immune components including myeloid cells, natural killer cells, pattern recognition receptors, and various cytokines. Notably, the enhanced response observed during secondary stimulation remained non-specific to particular pathogens. Compared to conventional therapeutic approaches, TI demonstrated superior systemic immune activation. Simple pharmacological stimuli such as β-glucan or Bacillus Calmette-Guérin (BCG) not only triggered innate immune responses but also conferred benefits to adaptive immunity, resulting in more rapid immune activation and enhanced efficacy. TI enhanced the capacity of immune cells to recognize and eliminate cancer cells, playing a critical role in countering metastasis. In this review, we summarized existing knowledge in the field, focusing on the mechanisms underlying TI induction and its significance in combating cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be50ad019666a2caa18340fc39a316d430799286" target='_blank'>
              The significance of trained immunity in cancer
              </a>
            </td>
          <td>
            Junxing Qu, Xinya Guo, Xinru Wang, Huiwen Meng, Peizhi Li, Zhiheng Sun
          </td>
          <td>2025-12-01</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Activation and exhaustion marker expression have become critical for evaluating the efficacy of immune checkpoint inhibitors in cancer therapy. Exhaustion biomarkers, such as Programmed Death-Ligand 1 (PD-L1) and Lymphocyte-Activation Gene 3 (LAG-3), were analyzed in solid tumors alongside co-expression of T-cell activation markers, such as CD86 and Ki67, to gain insights into the immune cell status. Flow cytometry was used to characterize LAG-3 and PD-L1 expression on cytotoxic and memory T cells from patients with various solid tumors, including melanoma, non-small cell lung cancer (NSCLC), and breast cancer, using cryopreserved peripheral blood mononuclear cell (PBMC) samples. The expression of exhaustion markers, LAG-3 and PD-L1, was variable across patients with solid tumors, with elevated levels observed on CD8+ T cells. This suggests an up-regulation in response to persistent tumor antigenic stimulation. The co-expression of exhaustion markers on CD8+ T cells may indicate a role in T-cell dysfunction and immune evasion. These findings highlight the complexity of exhaustion marker expression in immune cells and their influence on immune responses in patients with solid tumors. By integrating LAG-3 and PD-L1 profiling with other markers of immune activation and exhaustion, this study underscores the potential of these markers as predictive biomarkers for immunotherapy response and provides insights into mechanisms of immune evasion in solid tumor cancers.



 Immune Mechanisms of Human Disease (HUM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5345c8124cfc479e7f2de77345d1f38e458a7f71" target='_blank'>
              Activation and exhaustion marker expression on immune cells from patients with solid tumors 9367
              </a>
            </td>
          <td>
            Angelina Bisconte, Rachel Owen, Jackie Benko, Jorge Pardo, Samantha Splitt, Deborah Phippard
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Upon activation, B cells integrate signals from antigen and T cell help to choose between a rapid extrafollicular (EF) response and entry into the germinal center (GC). EF differentiation produces short‐lived plasmablasts that provide immediate but relatively low‐affinity antibody, whereas GC entry commits B cells to iterative selection, somatic hypermutation, and affinity maturation, ultimately yielding high‐affinity plasma cells and memory B cells. At the B–T cell border, where both responses originate, B cells also undergo class switch recombination (CSR). In this review, we examine the molecular mechanisms of CSR, highlighting the interplay between the DNA deaminase AID, transcription, and noncanonical nucleic acid structures. We further discuss the differential requirement of glycolysis between the EF versus GC response and how the cytokine IL‐21 fine‐tunes B cell entry into the GC. Together, these perspectives integrate genomic alterations, metabolic demands, and cytokine‐mediated signaling at the critical decision point between EF and GC pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ecc034aac7cb165cdbc5d307ab3c3ccca1cecfd1" target='_blank'>
              Mechanisms Promoting Stability of B Cells
              </a>
            </td>
          <td>
            Vivian L S Kuan, Jayanta Chaudhuri
          </td>
          <td>2025-10-29</td>
          <td>Immunological Reviews</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="


 Immunotherapy combinations can improve patient outcomes, yet the interactions within the tumor microenvironment (TME) that drive therapeutic synergy are poorly understood. Tumor establishment drives monocyte recruitment and differentiation into tumor-associated macrophages (TAMs), which have essential roles in coordinating immune responses and are thus attractive targets for therapeutic modulation. In a murine model of combination anti-PD-1 and anti-PD-L1 checkpoint blockade, tumor control was associated with increased infiltration of CD8+ T cells and M1-like repolarization of TAMs. Live-cell imaging of the tumor microenvironment revealed stable contacts between tumor-infiltrating CD8+ T cells and TAMs, in which the extent of the contact interfaces increased with combination immunotherapy. Treatment with anti-PD-L1 was able to increase macrophage expression of pro-inflammatory factors and phagocytic activity, suggesting a role for TAMs to reactivate CD8+ T cells in the TME. However, co-treatment with anti-PD-1 was ultimately necessary for tumor control, indicating the need for combination targeting of the TME.



 Mayo Clinic David and Margaret Grohne Cancer Immunotherapy Pilot Award



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b4b5c68bd11e510478b663ba12c5b0fe316f16" target='_blank'>
              Macrophage repolarization by immune checkpoint blockade drives T-cell engagement in the tumor microenvironment 2076
              </a>
            </td>
          <td>
            Tina Kwok, Jessica N Lancaster, Haidong Dong, Ildefonso Silva
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 CD19 CAR T-effector (CAR19Teff) therapy is promising in autoimmunity but limited by the inability to modulate pathogenic T cells and safety concerns like cytokine release syndrome and neurotoxicity. To address these limitations, we developed CD19 CAR engineered regulatory T cells (CAR19 EngTregs), which offer B cell depletion with the crucial capacity to suppress pathogenic T cells via bystander suppression and lower inflammatory cytokine secretion. We engineered human CAR19 EngTregs with stable FOXP3 and CAR expression and enriched edited cells to high purity using a chemically induced IL-2 signaling complex (CISC). CAR19 EngTregs exhibited stable core Treg markers upon CAR or TCR stimulation and mediated robust T cell suppression. In a human plasma B cell generation assay, CAR19 EngTregs showed antigen-dependent activation, and prevented B cell proliferation, differentiation to plasmablasts and long-lived plasma cells, and immunoglobulin (Ig) production. In both in vitro killing assays and adoptive transfer studies in humanized mice, CAR19 EngTregs mediated B cell depletion with lower cytotoxic and inflammatory cytokine levels than CAR19Teff. In pristane-treated humanized mice, human CAR19 EngTregs depleted B cells in vivo, elicited lower serum inflammatory cytokines, lower Ig titers, and reduced pathology versus CAR19Teff. These data demonstrate CAR19 EngTreg therapy could treat B and T cell-mediated autoimmunity with superior efficacy and safety than CAR19Teff therapy.



 Therapeutic Approaches to Autoimmunity (THER)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc68595cac5ee9c5c77d06a22d75ddf391cd903c" target='_blank'>
              CAR19 EngTregs offer broad capacity to modulate immune tolerance and improve safety in B and T cell mediated autoimmune disorders 3850
              </a>
            </td>
          <td>
            Victoria L. DeVault, M. Doglio, Annaiz Grimm, Jennifer Mellen Mellen, Pierluigi Carulli, Peter J. Cook, P. Zarin, M. Hoover, Tingxi Guo, Chris Moore, B. Camisa, Clara Bercher, A. Ugolini, F. Sanvito, Patrizia Cristofori, Travis Drow, Brock McKinney, Noelle P. Dahl, Aesha Vakil, Brian Christin, Gene I. Uenishi, Chandra Patel, Tiffany F. Chen, David J. Rawlings, C. Bonini, T. Wickham, A. D. Río-Espínola
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy, despite revolutionizing hematological malignancies, remains limited in solid tumors due to immunosuppressive microenvironments and systemic toxicities from combination immunotherapies. Recent engineering innovations demonstrate that physically linking anti-PD-L1 antibodies to interleukin-12 within CAR-T cells creates tumor-localized immunomodulation, concentrating therapeutic activity at PD-L1-positive sites while minimizing systemic exposure. In preclinical models, PD-L1-binding IL-12 fusion proteins achieved superior antitumor responses (100 vs. 50% complete responses) compared to non-binding controls, with significantly reduced inflammatory toxicity. Spatial proteomic analysis revealed comprehensive tumor microenvironment remodeling including enhanced CD8+ T cell infiltration and reduced immunosuppressive myeloid populations. Validation in human CAR-T cells targeting TAG72-positive ovarian cancer confirmed appropriate PD-L1 binding and enhanced cytotoxicity. This rational engineering strategy addresses multiple barriers simultaneously through molecular sequestration, offering a promising platform applicable to alternative checkpoint-cytokine combinations and other cellular therapeutics. Clinical translation represents a critical next step for extending CAR-T efficacy to solid malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7a6546fc7d661b815d3d60a952bbd89932e2713" target='_blank'>
              Tumor-localized immunomodulation: a critical advance in engineering CAR-t cells for solid malignancies
              </a>
            </td>
          <td>
            Maryam Abid, Ursula Abu Nahla, Muhammad Nabeel Saddique
          </td>
          <td>2025-11-04</td>
          <td>Annals of Medicine and Surgery</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 CD74 is a transmembrane protein and cognate receptor with high-affinity binding for macrophage migration inhibitor factor (MIF). The CD74-MIF interaction potentiates numerous oncogenic effects, of which stimulation of immunosuppressive pathways and angiogenic properties potentiates tumor progression. Within the tumor microenvironment (TME), glioma cells release MIF promoting immunosuppressive myeloid recruitment to the TME via CD74 signaling. This tumor-immune crosstalk potentiates the development of immunosuppressive bone-marrow derived macrophages and abrogates the CD8+ T- and NK-cell anti-tumor effector response which is also associated with poor survival in adolescent and young adult patients with glioma (AYA).



 We hypothesize targeting CD74/MIF signaling within bone marrow-derived myeloid cell-associated immunosuppression may mitigate glioma malignant progression.



 We challenged an immunocompetent, PDGF-β driven RCAS/Ntv-a preclinical model of glioma malignant progression with CD74-knockout bone marrow transplant (BMT) following cranium-sparing, whole body irradiation (IR). Three cohorts were compared: IR+CD74KO-BMT, IR+CD74WT-BMT, and control RCAS/N-tva. Bulk RNA sequencing was performed on immune cells isolated from the brain TME from both experimental conditions at the point of observed clinical decline in control animals. Pharmacological disruption of MIF-CD74 in vivo with ibudilast and its impact on TME immune infiltrates was analyzed by spatial proteomics. Overall survival (OS) was analyzed using Kaplan-Meier methodology.



 Bulk RNA sequencing of TME immune cells showed significant upregulation of multiple inflammatory pathways in the IR+CD74KO-BMT group compared to the control group, including IL2-STAT5, IFNγ, and TNFα-NFkβ signaling pathways, and downregulation of oncogenic signaling pathways, like PI3k-AKT-mTOR. IR+CD74KO-BMT OS was significantly longer compared to IR+CD74WT-BMT (68d vs 48d; p<0.0001) and the control group (36d; p<0.0001). CD74-MIF axis disruption in vivo with ibudilast increased CD8+ T-cell infiltration, proliferation and Granzyme B cytotoxicity, while reducing PD-1 and increasing GITR expression.



 Disruption of the CD74/MIF-axis following CD74KO-BMT enhances survival and delays glioma malignant progression via pro-inflammatory reprogramming of the brain TME.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aa971e486ace05d1b76319ded486c4c03adbab2c" target='_blank'>
              TMIC-50. Targeting MHCII invariant chain transmembrane protein CD74 confers a survival advantage in a preclinical model of glioma malignant progression
              </a>
            </td>
          <td>
            Mark A. Damante, Alessandro Canella, B. Bhinder, Matthew Nazzaro, Robert Mitchell, O. Elemento, Justin D. Lathia, Richard Bucala, P. Rajappa
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="


 Introduction Immunotherapy has shown clinical promise in multiple myeloma (MM), but relapse remains common, largely due to the immunosuppressive bone marrow (BM) microenvironment, characterized by T cell exhaustion and the accumulation of myeloid-derived suppressor cells (MDSCs). Recent advances highlight the therapeutic promise of 4-1BB (CD137) agonist antibodies in enhancing T cell–mediated anti-tumor responses, though their efficacy in MM remains poorly defined. Investigating 4-1BB expression dynamics in a preclinical MM model informed our rationale for targeting this pathway. Tasquinimod (TasQ), a small-molecule immunomodulatory agent, currently evaluated in a phase Ib/IIa clinical trial in MM patients (NCT04405167), offers a complementary strategy. By inhibiting the S100A9 signaling pathway, TasQ interferes with the recruitment and function of MDSCs, resulting in a less suppressive tumor microenvironment (TME) which reestablishes the anti -tumor immunity. In this study, we assessed the therapeutic potential of two distinct 4-1BB agonist antibody clones in an immunocompetent preclinical MM model. Building on these findings, we further explored the combination of the most effective 4-1BB agonist with TasQ, aiming to overcome the immunosuppressive tumor microenvironment, and strengthen anti-myeloma immune activity.
 Methods 4-1BB expression was analyzed during disease progression in 5T33MM mice using single-cell RNA sequencing of spleen and BM, 2 myeloma-infiltrating organs. These findings were validated by flow cytometry in both 5T33MM and 5TGM1 models. Therapeutic potential was assessed by treating 5TGM1 tumor-bearing mice with two 4-1BB agonist clones—LOB12.3 (IgG1κ; n=7/group) and 3H3 (IgG2a; n=5/group), using clone-specific isotype controls. Beginning on day 3 post-tumor inoculation, mice received 100µg of antibody intraperitoneally twice weekly until end stage. In a follow-up experiment, the lead 4-1BB agonist was combined with TasQ, administered at 30mg/kg in drinking water, to evaluate the impact of dual targeting the immunosuppressive TME (n=11/group). Tumor burden was assessed by determining the percentage of plasmacytosis in BM and spleen through cytospin stainings, together with M-protein measurement by serum electrophoresis. Immunomodulating effects were investigated using multi-parameter flow cytometry. Statistical significance was determined using the Mann–Whitney U test or one-way ANOVA, with p<0.05 considered significant.
 Results 4-1BB was predominantly detected on T cells and natural killer (NK) cells, with its expression further increasing as the disease progressed. Treatment of 5TGM1 mice with 4-1BB agonists significantly increased the percentage of CD4+ and CD8+ T cells in the BM and spleen. Interestingly, treatment with clone LOB12.3 resulted in a significant reduction in NK cell percentages in both the BM and spleen, while clone 3H3 selectively reduced splenic NK cells. Therapeutically, clone 3H3 significantly decreased M-protein levels and BM plasmacytosis (p<0.01), while no significant effects were observed for clone LOB12.3.
 Treatment with the IgG2a-formatted 4-1BB agonist combined with TasQ led to a significant reduction in M-protein levels and BM plasmacytosis (p<0001). Plasmacytosis was 62.50% in the isotype control group, decreased to 36.18% with 4-1BB agonist, 37.64% with TasQ, and further reduced to 14.09% in the combination therapy group, highlighting the enhanced efficacy of dual treatment. These effects were mediated by increased granzyme B–mediated T and NK-cell activation and enhanced differentiation of effector T cells (CD44⁺CD62L⁻). While this therapy did not alter the frequency of dendritic cells (DCs) in the BM, it enhanced their maturation, as evidenced by increased CD86 expression—particularly on type 1 and type 2 conventional DC subsets.
 Conclusion In conclusion, our findings demonstrate that 4-1BB activation can enhance anti-tumor immunity in MM; however, the therapeutic efficacy is dependent on the specific agonist used. Notably, the IgG2a-formatted 4-1BB agonist showed superior activity, underscoring the importance of isotype selection in achieving optimal immunotherapeutic outcomes. Moreover, co-administration with TasQ enhanced therapeutic efficacy, supporting the potential benefit of a combinatorial approach. Further investigation is warranted to elucidate the mechanisms driving these responses and to refine 4-1BB-targeted strategies for effective clinical translation.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/588054f9d7bef7f7dc4607713845e8f0a14c731a" target='_blank'>
              IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
              </a>
            </td>
          <td>
            Hatice Satilmis, Adrien Denis, Emma Verheye, E. De Bruyne, E. Menu, M. Törngren, H. Eriksson, K. Vanderkerken, K. De Veirman
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="


 Long-lived plasma cells (LLPCs) sustain lifelong antibody secretion, forming the foundation of durable immune memory. However, the molecular mechanisms underpinning LLPC survival within the bone marrow (BM) remain incompletely understood. Using single-nucleus RNA-seq and ATAC-seq (10X Multiome) from matched blood and BM antibody-secreting cells (ASCs) of healthy adults, we profiled 8,059 nuclei, generating an integrated transcriptional and epigenetic map of ASCs across their developmental continuum with unparalleled resolution. In the BM LLPC cluster, Gene Set Enrichment Analysis (GSEA) validated the enrichment of the TNF/NF-κB signaling pathway and TLR cascades, emphasizing their anti-apoptotic roles. These clusters also demonstrate increased chromatin accessibility at key loci such as RELA, TLR1, TLR6, TLR10, NFKBIA, and TAB1, underscoring the central roles of TLR and TNF-α signaling pathways in activating the NF-κB pathway. Upregulated genes such as BCL2, NFKBIZ, TNFAIP3, and BIRC3 highlighted key survival mechanisms, while motif enrichment analysis revealed significant enrichment for REL and NF-κB binding motifs, supporting chromatin-level regulation of LLPC longevity. Together, these findings advance our understanding of LLPC survival and resilience and provide a framework for improving vaccine strategies and targeted immunotherapies.



 Computational and Systems Immunology (COMP)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e86cf15dec942c9c651d1f78f13be792e4e03baf" target='_blank'>
              Dissecting the transcriptional and epigenetic landscape of human antibody-secreting cells in blood and bone marrow long-lived plasma cells 4589
              </a>
            </td>
          <td>
            Hira Anis, Monica Cabrera-Mora, Christopher Scharer, Ignacio Sanz, Greg Gibson, F. Eun‐Hyung Lee
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15−/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15−/− BMDCs. Isg15−/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15−/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05fa00535a2acdc99ae44733e69601b7e28b4dad" target='_blank'>
              ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells
              </a>
            </td>
          <td>
            P. Martínez-Fleta, Clara Pertusa, Irene Fernández-Delgado, R. Izquierdo-Serrano, M. Ramírez-Huesca, Nieves Fernández-Gallego, D. Calzada-Fraile, Elena Moya-Ruiz, Raquel Castillo-González, Susana Guerra, E. Martín-Gayo, F. Sánchez-Madrid
          </td>
          <td>2025-10-24</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="


 Systemic lupus erythematosus (SLE) is an autoimmune disease involving immune and non-immune cells, with complex pathogenesis and limited therapies. Dysregulated B cells, particularly double-negative 2 (DN2) B cells (CD19?, CD27?, IgD?, CD21?, CD11c?), are central to SLE by driving autoimmune processes. However, the origins and development of DN2 B cells remain poorly understood. B lymphopoiesis occurs in the bone marrow and is strongly regulated by mesenchymal stromal cells (MSCs). MSCs are non-hematopoietic immunosuppressive cells, which regulate immunity, including promoting regulatory B cells over plasma cells. In SLE, MSCs fail to suppress B cell activation into plasma blasts, but their immunomodulatory properties remain underexplored. We hypothesize that pathogenic DN2 B cells partly originate from a dysregulated bone marrow niche due to impaired stromal cell function. Single-cell transcriptomics and proteomics of healthy bone marrow identified resident DN B cells (∼30% of total B cells), with a small percentage being DN2. SLE plasma-primed MSCs while maintaining their phenotype, showed reduced PGE2 and TGF-β production and promoted naïve B cell differentiation into DN2 B cells, unlike healthy plasma-primed MSCs. These findings suggest that SLE MSCs exhibit impaired immunomodulatory capacity, contributing to the expansion of pathogenic DN2 B cells. This study provides new insights into DN2 biology and MSC dysfunction, highlighting potential therapeutic targets for SLE.



 LRA and Boston Children’s Hospital Cell Discovery Network



 Hematopoiesis and Immune System Development (HEM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5523d5b604cb369018cf0d5d4d7bd4c741b26f91" target='_blank'>
              Functional genomics deciphers pathogenic B cell dynamics in lupus bone marrow 3662
              </a>
            </td>
          <td>
            Mariasilvia Colantuoni, Nada Abdel Aziz, Marcos Chiñas, Holly Wobma, P. Nigrovic, Lauren A. Henderson, Diana Gomez Martin, Maria Gutierrez-Arcelus
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is characterized by an immunosuppressive tumor microenvironment (TME), largely orchestrated by anti-inflammatory glioma-associated macrophages/microglia (GAMs). Tumor hypoxia exacerbates this immunosuppression by activating the hypoxia-inducible factor (HIF) pathway in GAMs, promoting their polarization toward an anti-inflammatory phenotype that sustains a T cell–excluded, immune “cold” TME. This hypoxia-driven reprogramming severely impairs CD8⁺ T cell infiltration and effector function through metabolic suppression, contributing to resistance against chemotherapy and immune checkpoint blockade (ICB). We demonstrate that targeting tumor hypoxia with the hypoxia-activated prodrug evofosfamide (evo; TH-302; IMGS-101) markedly improves survival in both GL261 and CT2A murine GBM models (p<0.0001). Evo treatment significantly enhances CD8⁺ T cell infiltration (p<0.01) and restores effector function, as evidenced by increased granzyme B expression (p<0.001) and decreased expression of exhaustion markers TIM-3 and LAG-3 (p<0.001). CD8⁺ T cells isolated from evo-treated tumors display robust cytotoxicity against both antigen-specific (GL261-OVA) (p<0.001) and antigen-independent (CT2A) targets (p<0.0001), underpinned by enhanced metabolic fitness, including increased ATP production via both glycolysis and oxidative phosphorylation. Evo also reconfigures the myeloid compartment by disrupting microglial clustering within hypoxic niches, promoting a phenotypic shift toward pro-inflammatory GAMs (upregulation of CD80, MHC II; p<0.001) while suppressing M2-like markers (Arginase-1, PD-L1; p<0.01). These reprogrammed GAMs support greater CD8⁺ T cell proliferation (p<0.01) and survival (p<0.001) in co-culture systems. Notably, evo-mediated hypoxia alleviation sensitizes tumors to ICB and enables durable, curative responses when combined with intracranial anti–CTLA–4—, but not anti–PD-1—in ICB-refractory CT2A tumors. Together, these findings establish hypoxia as a central regulator of immune suppression in GBM and validate hypoxia-targeting strategies as powerful adjuncts to immunotherapy. Evofosfamide emerges as a potent immunomodulatory agent capable of reprogramming the GBM TME and unlocking new avenues for therapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b941e6c02c788c35cba71fb7f448d1313c0744c7" target='_blank'>
              TMIC-84. Hypoxia reduction remodels the glioblastoma immune microenvironment to enhance therapeutic sensitivity
              </a>
            </td>
          <td>
            Ivana William, Broderick Turner, Guillaume J Trusz, Spencer T Lea, Michael A Curran
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Tumor necrosis factor receptor 2-positive regulatory T (TNFR2+ Treg) cells, the most suppressive subset of Treg cells, are enriched in malignant pleural effusion (MPE), contributing to disease progression. However, the underlying mechanisms responsible for their accumulation remain unclear. Here we demonstrate that the C–X–C motif chemokine ligand 16 (CXCL16)/C–X–C chemokine receptor type 6 (CXCR6) axis plays a critical role in recruiting TNFR2+ Treg cells to MPE, with cancer-associated fibroblasts serving as the primary source of CXCL16. Mechanistically, under the hypoxic conditions prevailing in the pleural cavity, cancer-associated fibroblasts in MPE undergo glycolysis, which in turn leads to an increase in the production of endogenous lactate. This elevated lactate induces histone H3 lysine 18 lactylation (H3K18la) at the promoter regions of both the CXCL16 gene and its transcription factor forkhead box O3 (FOXO3), which may contribute to CXCL16 transcription. TNFR2+ Treg cells that express high levels of CXCR6, the only receptor for CXCL16, are subsequently recruited into MPE. The infiltration of TNFR2+ Treg cells may reinforce the immunosuppressive milieu of MPE, facilitating disease progression. Collectively, these findings uncover a novel mechanism governing immunosuppression in MPE, providing new insights into potential therapeutic strategies to disrupt this process. Malignant pleural effusion (MPE) is a severe condition often seen in advanced lung cancer, characterized by the accumulation of fluid around the lungs due to the presence of cancer cells. Researchers explored why the immune system struggles to fight MPE. They focused on a type of immune cell known as TNFR2+ Treg cells, which suppress the body’s ability to attack cancer. The study involved analyzing samples from patients and mice to understand how these cells are drawn to MPE. The researchers found that cancer-associated fibroblasts in MPE produce a protein called CXCL16, which attracts TNFR2+ Treg cells. This process is driven by lactate, which regulates genes expression in a way that increases CXCL16 production. Blocking CXCL16 reduced the recruitment of these suppressive cells and slowed disease progression. The study suggests that targeting lactate production or CXCL16 could improve treatment outcomes for MPE. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/91a71b2ab5cf300257fc0c85581cf1150ec21a51" target='_blank'>
              H3K18 lactylation in cancer-associated fibroblasts drives malignant pleural effusion progression via TNFR2+ Treg recruitment
              </a>
            </td>
          <td>
            L. Ye, Xuan Xiang, Zi-Hao Wang, Siyu Zhang, Q. Xue, Xiao-Shan Wei, Yao Liu, Haolei Wang, Jiaqi Ai, Bohan Yang, Long Chen, Yiran Niu, W. Peng, Qiong Zhou
          </td>
          <td>2025-11-01</td>
          <td>Experimental & Molecular Medicine</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="
 Despite responses in other malignancies, immune checkpoint inhibitor immunotherapy does not significantly improve outcomes for most glioblastoma (GBM) patients. Our group previously showed that anti-PD-1 therapy extended survival in CD8-knockout (CD8-KO) mice, implicating that another immune population may mediate the therapeutic effect. Now, depleting the CD4 T-cell in the CD8-KO mice significantly extended survival (medOS=66) in syngeneic gliomas compared to CD8-WT mice treated with IgG (med OS=39.5, p-val=0.0256) or anti-CD4 alone (medOS=35.5, p-val=0.0008). Immune-enriched single-cell RNA sequencing from the gliomas during the therapeutic window (P45) revealed a previously underappreciated CD3⁺CD4⁻CD8⁻ double-negative T-cell (DNTs) population expanded in the tumor of the CD4-depleted CD8-KO mice. These DNTs exhibited upregulation of pro-inflammatory cytokines (Tnf, Ccl12), activation markers (Cd40lg, Il7r, Cd69, Cd226), and reduced expression of exhaustion markers (Pdcd1, Ctla4, Tox), distinguishing them transcriptionally from conventional T-cells. The DNT population lacks markers consistent with NK-cells, NK T-cells, or gamma-delta T-cells. In vitro, DNTs secrete TNF-α at baseline and in response to glioma stem cells (GSCs). DNT–GSC co-culture suppresses GSC proliferation by 20-36%. The DNTs co-cultured with M0 macrophages increased macrophage phagocytosis by 44%, as assessed by fluorescent E. coli uptake assays. Glioma-associated myeloid cells from DNT-enriched mice showed upregulated gene ontologies related to inflammation, antigen presentation, and phagocytic activation, contrasting with the immune tolerance signatures in the CD8-WT background mice. Moreover, anti-PD-1 treatment in the CD4-depleted CD8-WT background and the CD8-KO only mice blunted the survival difference, suggesting that global T-cell elimination is a prerequisite for the emergence of antitumor DNT function. In summary, our findings identify a novel immunoregulatory and antitumor role for DNTs in glioma, characterized by TNFα-driven inflammatory signaling and myeloid activation. These data uncover a previously unrecognized immune axis that may be leveraged to overcome immunotherapy resistance in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/928ff08c6367893a7a75add253009e2dfc2d8104" target='_blank'>
              IMMU-35. CD3⁺CD4⁻CD8⁻ (Double-Negative) T-cells Provide Inflammatory Signals That Influence Myeloid Cells and Enhance Survival in Glioblastoma
              </a>
            </td>
          <td>
            Malcolm F. McDonald, Yuhui Yang, Ashley Puentes, H. Najem, Khatri Latha, Eric A. Goethe, Yeunjung Ko, A. Heimberger, A. Harmanci, Ganesh Rao
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non-AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8+ T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8+ T cell-dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1+PD-1+Tim-3- stem-like memory CD8+ T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8+ T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8+ T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8+ T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c80f585d4308a75bf3227e6815a7fdd66bafcb" target='_blank'>
              Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8+ T cells during chronic HIV-1 infection.
              </a>
            </td>
          <td>
            Guangming Li, Yaoxian Lou, Jianping Ma, Liang Cheng, Haisheng Yu, Ourania Tsahouridis, Xiu-yuan He, Masaya Funaki, James Ahodantin, Wenwen Bi, Jianwen Chen, Xiaoxuan Fan, Salma Sharaf, N. Goonetilleke, R. B. Jones, Shyamasundaran Kottilil, Poonam Mathur, Lishan Su
          </td>
          <td>2025-11-05</td>
          <td>Science translational medicine</td>
          <td>1</td>
          <td>40</td>
        </tr>

        <tr id="


 Melanoma patients treated with anti-PD1 or anti-PD1/anti-CTLA4 present intrinsic or acquired resistance to these immune checkpoint blockade (ICB) treatments. However, the interactions between tumor-stromal-immune cells in the microenvironment (TME) underlying these resistances remain unclear. In this study, we used a cohort of melanoma patients (n = 61) treated with ICB, pre-treatment (n = 33) and post-progression (n = 28), for whole-exome sequencing, single-nucleus RNA sequencing and high-resolution spatial imaging. We developed a framework to analyze response and resistance (intrinsic and acquired) via tumor-intrinsic programs, immune features, and tumor-stromal-immune interactions. Patients with low immune infiltration exhibited enrichment of macrophages associated with hypoxia and angiogenesis phenotypes. Samples with high immune infiltrates displayed an enrichment in lymphocytes, particularly TCF7+ CD8+ T cells. Pre-treatment samples from patients experiencing durable clinical benefit are encriched in memory B cells and plasmablast-like B cells.The presence of Bcells and of follicular dendritic cells in non-lymph node biopsies support the presence of tertiary lymphoid structures within the TME. Lastly, the presence of a TIMD4-expressing macrophage subset correlates with lymphocyte infiltration, indicating its potential role in promoting anti-tumor immunity. Our work defines TME immune profile interaction with tumor-stromal cells associated with clinical outcomes in melanoma.



 NCI HTAN



 Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2a8d3010e6c8bda33a8b18473b82b46e0a2ceaea" target='_blank'>
              Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125
              </a>
            </td>
          <td>
            Giuseppe Tarantino, Yiwen He, Priyanka Solanky, Xinyu Cui, K. Pfaff, A.R. Thorner, Timothy R. Blosser, Elliot Boblitt, Allison Frangieh, Tyler J. Aprati, Boyang Zhang, Jiajia Chen, H. Faulkner, Aleigha R Lawless, M. Manos, K. Helvie, T. Sharova, Dennie T. Frederick, Sachi Krishna, Chanell Mangum, Domenic Abbondanza, Cai McCann, Bruce Johnson, Alex K. Shalek, Eliezer M. Van Allen, Xiaowei Zhuang, Ryan J. Sullivan, Barbara Engelhardt, Sami Farhi, S. Rodig, F. S. Hodi, Genevieve M. Boland, David R. Liu
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Introduction Glioblastoma (GBM) is a highly invasive brain tumor with limited treatment options and poor prognosis. Natural killer (NK) cells are key effectors of antitumor immunity, capable of eliminating cancer stem-like cells. However, GBM creates an immunosuppressive microenvironment that limits NK cell function. Here, we identify cystatin F as an immunosuppressive factor involved in regulating NK cell granule-mediated cytotoxicity. Methods We analyzed cystatin F expression in GBM and its correlation with immune exhaustion markers. NK cell activity was compared between GBM patients and healthy donors. In vitro co-cultures of cystatin F-expressing microglial cells and glioblastoma stem-like cells were used to assess NK cell function. To block cystatin F activation from dimeric to active monomeric form, a small-molecule inhibitor of cathepsin V, the activating protease, was applied. Results Cystatin F expression correlated with immune exhaustion and suppression markers in GBM. NK cells from patients showed reduced cytotoxicity compared to healthy donors. Co-cultures confirmed that cystatin F-expressing microglia impaired NK cell cytotoxicity, while inhibition of cathepsin V restored NK cell function in standard cytotoxicity assays, 3D spheroids, and microfluidic perfused models. Discussion These results indicate that cystatin F mediates NK cell suppression in GBM. Targeting its activation enhances NK cell cytotoxicity, offering a potential strategy to improve NK-based immunotherapy for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3bb3c49f85522c7de4609841eca5e88d65fb2178" target='_blank'>
              Targeting cystatin F activation enhances NK cell cytotoxicity in glioblastoma models
              </a>
            </td>
          <td>
            E. Senjor, A. Habič, U. Švajger, Ana Mitrović, M. Proj, A. Porčnik, Borut Prestor, Miha Jerala, Matic Bošnjak, Stanislav Gobec, B. Breznik, Janko Kos, Milica Perišić Nanut
          </td>
          <td>2025-10-28</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="
 Glioblastomas (GBM) are the most common and aggressive primary adult brain tumors, and advances in immunotherapy have failed to significantly improve patient outcomes. The presence of the blood brain barrier (BBB), abundance of immunosuppressive myeloid cells, and relative paucity of cytotoxic lymphocytes are major challenges preventing immunotherapy success in GBM. We previously identified the small calcium-binding protein S100A4 as a major regulator of GBM immune suppression. Targeting S100a4 via genetic depletion in tumor or stromal cells is sufficient to reprogram the tumor immune-landscape and extend survival of GBM-bearing mice. We recently developed an S100A4 blocking monoclonal antibody to target S100A4 signaling in the tumor microenvironment; however, this antibody has limited BBB penetrance. To overcome this challenge, we generated a bispecific S100A4-Transferrin-Receptor (TFR) antibody (BsA) that utilizes TFR-mediated transcytosis to cross the BBB. We assessed efficacy of BsA treatment in the preclinical syngeneic S100ß-vErbB;p53 (SVP) GBM mouse model. Using ELISA, confocal immunofluorescent microscopy, and bulk RNA-sequencing, we report that the BsA treatment accumulates in the CNS at nearly twenty-fold the concentration of the monoclonal antibody and reprograms the tumor immune microenvironment to promote immune cell infiltration and pro-inflammatory activation. BsA monotherapy modestly extends survival in the SVP model in an immune-cell dependent manner, as treatment in SVP-tumor bearing NSG mice abolishes this survival benefit. We further assessed if BsA treatment sensitizes immune cold GBMs to immune checkpoint blockade. Combination with αPD-1 checkpoint-blockade nearly doubled median overall survival in the SVP mouse model, with increased tumor infiltrating reactive CD4 and cytotoxic CD8 T cells. Single cell RNA-sequencing revealed an enhanced interferon-γ response signature in GBM cells and macrophages from combination therapy treated-tumors, with an accompanying upregulation of MHC-I and MHC-II associated genes, respectively. These results indicate that the BsA is a promising agent to reprogram the GBM immune-landscape and reactivate anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b268ed87c481994ebeaa18e8a1d19b3140eec028" target='_blank'>
              EXTH-122. A novel S100A4/TFR bispecific antibody to reprogram the GBM tumor microenvironment and reactivate anti-tumor immunity
              </a>
            </td>
          <td>
            Thomas Wong, Xue-Mo Fan, M. Faisal, Fransisca Leonard, Nourhan Abdelfattah, Jia-Shiun Leu, Yaqoob Ali, Reece Kang, Ningyan Zhang, Kyuson Yun
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a349f447081e148334ada4b0e5ec3e64399cf656" target='_blank'>
              Trophoblast stem cells and syncytiotrophoblasts lack inflammatory responses to LPS but retain robust interferon-mediated antiviral immunity
              </a>
            </td>
          <td>
            Cristine R. Camp, Joshua Baskaran, Matthew Brown, Carly Parker, Paige Drotos, Rachel C. West
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="
 Myeloid-rich microenvironment is a hallmark of glioblastoma (GBM), the most aggressive and lethal brain malignancies in adults, leading to profound immunosuppression and therapy resistance. Metabolic dysregulation in tumor-associated myeloid cells (TAMCs) has been recognized as a key player driving immune evasion and supporting their pro-tumorigenic roles. Our single-cell RNA sequencing analysis and multiplex immunofluorescence have demonstrated high overexpression of monocarboxylate transporter 4 (MCT4), a key lactate transporter, in TAMCs in both murine and human GBMs, which may greatly contribute to TAMC-mediated GBM immunosuppression. To enable a myeloid-specific targeting of MCT4 in GBM, we have developed MCT4 nano-therapeutics using our antibody-directed immune targeting (ADIT) nano-platform. Lipid nanoparticles were surface functionalized with anti-PD-L1 antibody and encapsulated with small interfering RNA (siRNA) that targets MCT4. Our data indicated a robust and durable MCT4 inhibition, achieving over 90% gene knockdown efficiency. In vitro, MCT4 nano-therapeutics effectively targeted and reprogrammed immunosuppressive TAMCs, and restored CD8+ T cell proliferation and activation. In vivo, MCT4 nano-therapeutics through intracranial administration significantly improved the anti-glioma effectiveness of radiotherapy in CT-2A glioma-bearing C57 mice, leading to enhanced brain tumor infiltration of effector CD8+ T cells and CD103+ dendritic cells as well as much prolonged animal survival. When further combined with anti-CTLA-4 immune checkpoint therapy, over 60% of mice were cured from CT-2A glioma, and the long-term survivor animals developed anti-glioma immunological memory. Besides intracranial injections, we have also demonstrated the effectiveness of MCT4 nano-therapeutics through a systemic intranasal delivery route. These findings altogether may highlight a great potential of targeting lactate transport for modulating myeloid-mediated GBM immunosuppression and create a new immunotherapeutic approach to improve the existing standard treatments and immunotherapies for GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3cbe44139c87ecba179bf8e865f8c5ead1c37390" target='_blank'>
              DDEL-27. Nano-therapeutic modulation of lactate transport in myeloid cells potentiates anti-tumor immunity and radiotherapy for glioblastoma
              </a>
            </td>
          <td>
            Hanchen Lin, Jiawei Huo, Xiaoyang Chen, Leah K. Billingham, H. Najem, Jingqi Sun, Caylee Silvers, Jianzhong Zhang, Rafał Chojak, Yu Han, Aurora Lopez-Rosas, Si Wang, Atique U. Ahmed, Catalina Lee-Chang, A. Heimberger, M. Lesniak, Pavithra Viswanath, J. Miska, Peng Zhang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Recent advancements in the treatment of multiple myeloma (MM), including immunomodulatory agents, monoclonal antibodies, and T cell-redirecting therapies, have significantly improved patient outcomes. However, MM remains incurable. The interaction between MM cells and non-malignant cells within the immunosuppressive tumor immune microenvironment (TiME) plays a critical role in disease progression, but it has not been fully elucidated.
 Our previous study reported that myeloid-derived suppressor cells (MDSCs), dysfunctional dendritic cells (DCs), and tumor-promoting osteoclasts (OCs) are enriched in the bone marrow of myeloma patients and play critical roles in T cell dysfunction. However, the underlying mechanisms remain incompletely understood (Front Immunol. 2022). A myeloid inhibitory receptor, LILRB4, was identified as highly expressed in a super high-risk subgroup of MM cells by single-cell RNA sequencing of patient samples. LILRB4 expression facilitated the generation of monocytic MDSCs and was associated with poor outcomes in MM patients (Haematologica 2024 & 2025). These findings suggest a potential mechanism by which LILRB4 drives an immunosuppressive microenvironment through the induction of immunosuppressive myeloid cells.
 Here, we further observed a significant reduction in erythroid-lineage commitment in MM patients with high LILRB4 expression, and we explored its molecular and cellular impact on the interaction between myeloma cells and the tumor microenvironment (TME). We report that LILRB4 is highly expressed in MM and activates the SHP2/ERK/AP-1 signaling cascade, thereby enhancing the expression of AP-1-associated chemokines and promoting the transdifferentiation of erythroid cells into immunosuppressive erythroid-derived myeloid cells (EDMCs). Through in vivo and in vitro analyses, we demonstrate that CD45⁺ erythroid progenitor cells (EPCs) in the MM microenvironment lose their erythroid differentiation potential and instead transdifferentiate into EDMCs. This reprogramming is driven by elevated levels of CCL3 secreted by LILRB4⁺ MM cells. Compared with the control group, deletion of CCL3 significantly inhibited myeloma cell growth, increased peripheral blood hemoglobin levels, reduced EDMC proportions in the bone marrow, enhanced IFN-γ secretion by CD8⁺ T cells, decreased the frequency of regulatory T cells (Tregs), and reduced the proportion of macrophages. Additionally, the ratio of monocytic MDSCs (M-MDSCs), which preferentially differentiate into tumor-associated macrophages (TAMs), to granulocytic MDSCs (G-MDSCs) was also decreased. EDMCs emerged as another major source of tumor-associated myeloid cells, further contributing to the suppressive TiME.
 These results provide a novel model of hematopoietic diversion in which myeloma “hijacks” CD45⁺ erythroid progenitor cells, redirecting them toward a myeloid fate to evade immune surveillance. EDMCs, as potent immunosuppressive players, strongly inhibit CD8⁺ T cell function and accelerate disease progression. Additionally, our findings establish a mechanistic link between LILRB4 and MM-associated anemia, a well-known poor prognostic factor.Our study therefore suggests that LILRB4 overexpression induces key molecular changes that enable macrophage inflammatory protein-1 alpha (MIP-1α/CCL3)-mediated formation of an immunosuppressive myeloid tumor microenvironment, thereby promoting MM cell growth and survival.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1316f08649414674d11974365803ce69ba88ff10" target='_blank'>
              LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells
              </a>
            </td>
          <td>
            Lanting Liu, Hao Sun, Yijie Wang, Xiyue Sun, Gang An, Lugui Qiu, Mu Hao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="


 Introduction: Chronic lymphocytic leukemia (CLL) is characterized by profound immune dysregulations. Venetoclax (Ven), a selective BCL-2 protein inhibitor, has shown robust clinical activity in both treatment-naïve and relapsed/refractory (R/R) CLL. In Ven-treated patients with CLL, a reduction in the number of non-malignant lymphocytes and a decline in tumor-supportive T-cell subsets were reported. However, the effects of Ven treatment on the patients' immunological profile remain incompletely characterized.
 Aims: This study aims to characterize the immunological effects of Ven-based therapies in CLL by tracking longitudinal changes in T-cell and NK-cell phenotypic and functional profiles.
 Methods:In this multicenter, observational study 68 patients with R/R CLL, eligible for therapy with Ven-based regimens, were enrolled. Forty-six patients received Ven + rituximab and 22 Ven monotherapy. Peripheral blood (PB) samples were collected at the time of treatment start (n=68), and after 1 (n=60), 6 (n=56) and 12 (n=57) months of therapy. The percentage and the phenotype of T and NK cells were assessed by multicolor flow cytometry.
 Results: Data of 58 enrolled patients have been analyzed to date. In parallel with the reduction of circulating leukemic cells, Ven treatment induced a significant decline in absolute CD3⁺, CD4⁺ and CD8⁺ T-cell counts, which was already evident after one month and persisted at the 6- and 12-month timepoints. During treatment, in the CD4⁺ T-cell compartment, the frequency of naïve (TN) and central memory (TCM) subsets remained stable over time, while within the cytotoxic subsets we observed a decrease in the effector memory (TEM) T cells and a parallel, significant increase of the terminally differentiated (TEMRA) T cells compared to the pre-treatment distribution. In the CD8+ T-cell compartment we observed a similar rise in the proportion of TEMRA, which was paralleled by a decrease in the proportion of TCM and TEM subsets. The evaluation of immune checkpoint expression on CD4⁺ T cells revealed a downmodulation of PD-1 that was already evident after one month of treatment and a reduction of BTLA, TIM-3 and LAG-3 levels that became evident at the later 6- and 12-month timings. Interestingly, a more detailed analysis performed in a subgroup of patients showed that the observed reduction in immune checkpoint expression was mostly restricted to the less differentiated (i.e. TN, TCM) CD4+ subpopulations. Concerning the CD8⁺ T-cell compartment, Ven treatment significantly lowered BTLA expression - particularly within the TN and TCM subsets - across all timepoints, whereas the levels of the other immune checkpoints remained largely unaltered. Of note, an expansion of the immunosenescent CD57⁺PD-1⁻ subset was persistently detected within the CD8⁺ TEMRA subset already after one month of treatment and within the CD4⁺ TEM and TEMRA subsets at the later 12-month timepoint. T-cell homing capacity was also evaluated, based on CXCR3 and CD62L expression. Interestingly, both CD4⁺ and CD8⁺ T cells showed increased CD62L expression after 12 months of treatment, indicating enhanced migration capacity to lymph nodes. In the context of innate immunity, Ven administration resulted in an overall decrease in the absolute number of NK cells, detectable as early as one month after treatment initiation. Notably, the frequency of the CD56dimCD16⁺ NK-cell subset, mostly responsible for cytotoxic activity and ADCC, increased significantly at the 6- and 12-month timepoints. By contrast, the proportion of the less represented CD56bright NK-cell subset remained stable in the PB of Ven-treated patients. We did not detect any relevant difference in the modulation of T-cell and NK-cell phenotype between patients treated with Ven plus rituximab and those receiving Ven monotherapy.
 Conclusion: This study provides a longitudinal evaluation of the immunomodulatory effects of Ven treatment in the largest cohort of patients with CLL analyzed to date. Our results indicate that Ven therapy reshapes both the T-cell and NK-cell compartments by alleviating features of exhaustion, enhancing lymph node homing potential and promoting the expansion of cytotoxic subsets. At the time of data presentation, conclusive results from additional phenotypic analyses and functional assays will be available. These immunological modulations may be harnessed to elucidate Ven off-tumor effects and to refine optimal therapeutic sequencing strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ba4e66f3d5a0eec4a163635c182e19c61aaa3c7e" target='_blank'>
              Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia
              </a>
            </td>
          <td>
            Giorgia Mancin, V. Griggio, Rebecca Jones, Giulia Bondielli, A. Visentin, R. Moia, A. Frustaci, A. Bosi, M. Varettoni, Francesca Perutelli, M. C. Montalbano, G. Catania, P. Sportoletti, L. Laurenti, F. Mauro, L. Orsucci, Luca Arcaini, Francesco Passamonti, M. Deodato, G. Gaidano, L. Trentin, B. Bruno, C. Vitale, M. Coscia
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="


 Immunosenescence leads to impaired immunity against infections in the elderly. As a key component of adaptive immunity, T cells are crucial for immunity against infection and cancer and exhibit distinct phenotypic changes with age. Characterizing these age-related alterations in T cells is essential for developing strategies to address immune dysregulation in the elderly. In vitro activation model showed that aged mice have a higher frequency of PD1+ exhausted-like CD8 T cells at baseline and higher TCR-induced cell death upon activation. Inhibiting both apoptosis and necrosis rescues TCR activation-induced cell death. Using a murine hepatitis virus (MHV) intranasal infection model, we observed that aged mice had greater weight loss, higher mortality, and impaired CD8 T cell responses during MHV infection. Infected aged mice exhibited increased expression of inhibitory receptors on antiviral CD8 T cells and a decrease in the population of CD8 T cells producing IFN-γ. Single-cell RNA sequencing showed that aging altered the transcriptional profile of antiviral CD8 T cells and reduced T-Bet and ZEB2 expression, key factors for effector CD8 T cell differentiation. Aging also upregulated T cell exhaustion gene signature mediated by the transcription factor TOX. Overall, our findings demonstrate that aging reshapes the molecular program of antiviral CD8 T cells and compromised antiviral T cell immunity in the aged.



 Supported by NIH/ NIA AG-083398; NIAID AI-158294



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/80e47c0f1fb034ad0cc56d0aad4b1018f719c06e" target='_blank'>
              Aging compromises effector differentiation and induces exhaustion-like phenotype in CD8 T cells 2511
              </a>
            </td>
          <td>
            Ziang Zhu, Tuoqi Wu, Chen Yao
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e-4). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e08f1dd96dd018add58f7a79b8066098738fcfe" target='_blank'>
              Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
              </a>
            </td>
          <td>
            Denis J Ohlstrom, William C. Pilcher, Marina E. Michaud, Chaitanya R. Acharya, Sarthak Satpathy, Edgar Gonzalez-Kozlova, R. Jayasinghe, Katherine E. Ferguson, Hope L. Mumme, Shivani Nanda, Yizhe Song, Sowmitri Mantrala, Dimitra Karagkouni, Jessica Schulman, Nick Pabustan, Junia Vieira Dos Santos, Daniel W. Sherbenou, J. Keats, Alex Gout, Steven Foltz, A. Laganà, T. Kourelis, Ravi Vij, M. Dhodapkar, D. Avigan, H. Cho, L. Baughn, Ajay K Nooka, S. Lonial, Shaji K. Kumar, Mehmet K Samur, Ioannis S Vlachos, Li Ding, Sacha Gnjatic, George Mulligan, Manoj K. Bhasin
          </td>
          <td>2025-12-09</td>
          <td>Blood cancer discovery</td>
          <td>0</td>
          <td>110</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b6398ddc5edaa94a066851abec2558753a9728" target='_blank'>
              NLRP1 Shapes Immune and Inflammatory Signatures in Human Melanoma but Not in Mouse Models
              </a>
            </td>
          <td>
            V. P. Targhetta, Raquel de Souza Vieira, Hedden Ranfley, C. N. de Souza Breda, N. O. Câmara
          </td>
          <td>2025-11-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Extramedullary acute myeloid leukemia (eAML) relapse is frequent after allogeneic hematopoietic cell transplantation (HCT), suggesting the emergence of immune escape from graft-versus-leukemia (GvL) responses. The previous observation of complete responses of post-HCT leukemia cutis (LC) to CTLA-4 blockade points towards opportunities to restore GvL through immunomodulation. However, mechanisms of extramedullary tropism and associated immune populations remain unknown, limiting rational therapy development. We therefore dissected the immune microenvironment and leukemia features of eAML using single-cell RNA sequencing (scRNA-seq) on prospectively collected biopsies from 7 individuals.
 We performed scRNA-seq on 16 eAML biopsies and 6 peripheral blood (PB) samples prior to and following immune checkpoint blockade (ICB). For comparison, we included publicly available external scRNA-seq datasets of post-HCT AML relapse bone marrow (BM) (n=7) and healthy donor skin (n=6), yielding 150,475 cells. Targeted genotyping (nanoranger) revealed leukemic involvement in progenitor cells of recipient origin (souporcell). In contrast to BM, LC was enriched for regulatory T cells (Tregs) (1.8% vs 12.9%; p < 0.001), despite similar number of T cells. T cells in LC were donor-derived (median chimerism 99%, range 33-100%), confirming the potential for GvL to be active in extramedullary sites.
 To explore programs driving extramedullary tropism, we performed differential gene expression analyses (DGEA) of leukemia cells from LC versus BM. 4 of 7 extramedullary and 1 of 7 medullary AML cases displayed reduced HLA class II expression, indicating immune escape. We found increased expression of the adhesion molecule ICAM1 (encoding CD54) and decreased PECAM1 (encoding CD31) expression in LC. Further, integrin genes were differentially expressed with higher levels in medullary (ITGA4, ITGA6, ITGAL, and ITGB4) or extramedullary AML (ITGA5 and ITGAV). These differences were directly detectable in two cases with concomitant circulating and extramedullary disease, supporting tissue-dependent expression of AML. Thus, extramedullary tropism associates with immune escape and altered homing receptor expression.
 To define how T cell gene expression profiles differed between LC and BM, we performed DGEA and found CD4+ and CD8+ T cells to differentially express genes associated with T cell homing such as CD44 (higher in LC) or SELL (encoding CD62L), ITGB2, ITGB7, ITGA4 and ITGAL (higher in BM). Further, LC-associated T cells showed increased expression of immune checkpoint molecules (PDCD1, LAG-3 or CTLA-4), suggesting higher levels of T cell exhaustion. Comparison of T cell states across BM, PB, eAML and healthy skin tissues revealed the number of T cells with high expression of an exhaustion signature and reduced levels of a memory score was most frequent in LC. TCR repertoire analysis with matched BM showed that T cell clonotypes unique to LC had a higher expression of an exhaustion signature than those shared (10.3% vs 2.3%), consistent with local antigen recognition. Together, LC associates with an exhausted T cell infiltrate, suggesting a potential mechanistic basis for clinical activity of ICB.
 Finally, we performed immune monitoring prior to and during consecutive PD-1 and CTLA-4 blockade in one post-HCT LC case. We tracked circulating WT1 (HLA-A*01:01)-specific CD8+ T cells (flow cytometry) in 11 PB samples over 32 months. Onset of LC associated with reduced WT1-specific T cells (1.7% vs 0.8%), while nivolumab led to re-expansion (1.2%). Following ipilimumab and until further LC progression, WT1-specific T cells contracted once again (0.8%), demonstrating associations with the clinical course. ICB also induced changes in tissue-resident T cells: CXCL13+ CD4+ T cells with high expression of PDCD1 contracted post PD-1 blockade, while Tregs expanded. Throughout, overlap of local and circulating TCRs remained high (~50%), suggesting a minority of T cells to be leukemia specific. Overall, ICB reshaped circulating and local T cell repertoires, illustrating that immunomodulation may overcome immune escape in eAML.
 In sum, we provide a comprehensive single-cell characterization of LC, uncovering immune evasion, altered homing, and T cell exhaustion, highlighting fundamental differences between medullary and extramedullary AML. This sets the stage for future studies to dissect tissue-specific leukemic niches and informs rational design of immunotherapies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e6dd3b9066608d20229412f45edd909b0b787cc8" target='_blank'>
              Mechanisms of immune escape and altered tissue homing in leukemia cutis
              </a>
            </td>
          <td>
            L. Penter, Alexandria Maurer, Nicoletta Cieri, Wesley S Lu, Haoxiang Lyu, Shuqiang Li, K. Livak, Lars Bullinger, Jerome Ritz, Pavan Bachireddy, M. Davids, Jacqueline Garcia, Robert J. Soiffer, Catherine J. Wu
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="


 Multiple myeloma (MM), the second most common hematologic malignancy, presents significant clinical challenges due to its relapsing/refractory nature and incurability, primarily attributed to the high complexity of the bone marrow (BM) microenvironment. Emerging evidence suggests that metabolic reprogramming within the tumor microenvironment (TME) plays a pivotal role in tumor progression and the anti-tumor function of CD8+ T cells. However, the limited understanding of the metabolic landscape of the MM BM microenvironment has hindered the identification of potential therapeutic targets. In this study, we demonstrate that although CD8+ T cells from MM patients exhibit elevated expression of immune checkpoint molecules, they do not enter a canonical exhausted state. Instead, their dysfunction is reversibly suppressed by microenvironmental alterations. Metabolomic profiling revealed a significant remodeling of the tryptophan metabolic pathway in the MM BM microenvironment, characterized by the accumulation of nitrogen-containing metabolites and indole derivatives, which directly impair CD8+ T cell-mediated anti-tumor activity. Further investigation identified indole-related metabolites as key metabolic regulators in the MM BM niche, promoting immune evasion by functionally suppressing CD8+ T cells. These findings not only uncover a novel mechanism of immune suppression in MM but also provide potential therapeutic targets for developing metabolism-focused immunomodulatory strategies.
 In multiple myeloma (MM) patients, bone marrow CD8+ T cells exhibit elevated PD-1 expression but comparable TIM-3 levels to non-myeloma controls. Notably, no significant differences were observed in cytokine secretion capacity or exhaustion-related transcription factor expression between PD-1+/TIM-3+ and PD-1-/TIM-3- T cell subsets. Thus, while a substantial population of CD8+ T cells persists in the MM microenvironment, they do not exhibit the canonical exhausted phenotype traditionally defined in chronic viral infections or other malignancies.
 Unexpectedly, fresh myeloma BM CD8+ T cells show blunted cytokine responses, reversible by overnight culture but inhibited by autologous BM supernatant. This suppression is BM-specific, as peripheral T cells remain unaffected by plasma.
 The <3 kDa hydrophilic fraction of bone marrow (BM) supernatant significantly impaired the cytotoxic capacity of BCMA CAR T cells. Untargeted metabolomic profiling revealed that the inhibitory BM supernatant exhibited distinct metabolic alterations, primarily enriched in the following pathways：Amino acid metabolism; Energy metabolism ; Nucleotide metabolism. Notably, multiple indole derivatives were upregulated in the tryptophan metabolic pathway.
 Metabolomic analysis revealed significant upregulation of indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), and kynurenine in the inhibitory bone marrow supernatant. Functional validation demonstrated that indole, indoleacrylic acid, IPA, and IAA all exhibited dose-dependent suppression of CAR T cell-mediated tumor cytotoxicity. Notably, IAA displayed potent immunosuppressive activity even at low concentrations, suggesting enhanced immunomodulatory potential. Mechanistically, both IAA and IPA significantly upregulated aryl hydrocarbon receptor (AHR) expression， indicating that indole-related metabolites may impair antitumor T cell function through AHR-mediated signaling pathways.
 Overall, we have come to the following conclusions：flow cytometric and transcriptional analyses revealed that CD8+ T cells in the multiple myeloma (MM) bone marrow microenvironment exhibit an activated phenotype rather than classical exhaustion markers, despite their functional impairment. Ultrafiltration and functional assays demonstrated that the <3 kDa hydrophilic fraction of MM bone marrow supernatant significantly inhibits CD8+ T cell effector functions. Indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) are significantly elevated in the bone marrow of a subset of multiple myeloma (MM) patients, where they potently inhibit the anti-tumor function of CD8+ T cells, likely through activation of the aryl hydrocarbon receptor (AhR) signaling pathway on T cell surfaces.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1c2fdacb0730e5456a357462f821514cc752968" target='_blank'>
              Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma
              </a>
            </td>
          <td>
            Yueyi An, Huixing Zhou, Xiaoyun Jin, Shengdian Wang, Wen Gao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="
 Besides its robust antiviral activity, type I interferon (IFN-I) also exerts immunomodulatory effects and can even drive pathology during chronic viral infections. Mechanisms that regulate IFN-I induction during virus infection, thus strongly affecting the outcome of disease, remain to be defined. Here, using the lymphocytic choriomeningitis virus (LCMV) Docile strain, we identified acid ceramidase (aCDase,
 Asah1
 ) as a critical lipid-metabolic regulator of endosomal, nucleic acid-driven IFN-I responses and disease outcome during chronic virus infection. aCDase is highly expressed in plasmacytoid dendritic cells (pDCs) and required for robust early IFN-I production. aCDase deficiency resulted in ceramide accumulation, blunting IFN-α/β induction, impairing IFN-I-dependent upregulation of programmed death-ligand 1 (PD-L1) on antigen-presenting cells and preventing the exhaustion of virus-specific CD8
 +
 T cells, leading to severe immunopathology. This pathology is abrogated by CD8
 +
 T-cell depletion or by adoptive transfer of IFN-I-induced PD-L1-expressing macrophages. Conversely, limiting ceramide production in acid sphingomyelinase (Asm)-deficient mice prevented ceramide accumulation, and pDCs showed accelerated IFN-I induction. Mechanistically, ceramide abundance regulated IFN-I production by altering endosomal signaling microdomains. Collectively, our findings reveal ceramide homeostasis as a key determinant of IFN-I-driven CD8
 +
 T-cell exhaustion and immunopathology during chronic viral infection and highlight aCDase as a potential therapeutic target.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3347a83451be199ba4cf611d6ba58e4cec09e11d" target='_blank'>
              Acid ceramidase regulates CD8+ T-cell exhaustion via type I interferon-mediated upregulation of PD-L1
              </a>
            </td>
          <td>
            Zhongwen Hu, Hossam Abdelrahman, Abdelrahman Elwy, F. Kuang, Swati Dhiman, Shafaqat Ali, Marcel Marson, Lisa Holnsteiner, Thamer A Hamdan, Justa Friebus-Kardash, Elisa Wiebeck, Wiebke Hansen, S. Scheu, Erich Gulbins, P. Lang, K. Lang, Judith Lang
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Extracellular vesicles (EVs) are central mediators of intercellular communication in both healthy and malignant states. In normal B lymphocyte (cell) biology, EVs derived from B cells, mast cells, T cells, and mesenchymal stromal cells regulate maturation, antigen presentation, and activation. B cell-derived EVs can either suppress excessive activation to maintain immune homeostasis or amplify responses during an active immune response. Modulation of these responses often occurs via phosphoinositide 3-kinase signaling pathways in recipient cells. In B cell malignancies, such as leukemias, lymphomas, and multiple myeloma, EVs play pivotal roles in disease progression and therapy resistance. Tumor- and stromal-derived EVs can transfer pro-survival proteins, regulatory RNAs, and drug-resistance factors to directly promote tumor progression. In addition, EVs can shape the tumor microenvironment to indirectly promote tumor progression through macrophage polarization, stromal cell reprogramming, and suppression of anti-tumor immunity. Conversely, under certain conditions, B cell EVs can enhance immune surveillance by stimulating T cells and presenting antigen, highlighting their dual potential in cancer biology. Clinically, B cell-derived EVs represent promising liquid biopsy biomarkers: increases in EV abundance, expression of surface antigens, altered protein cargo, and distinct RNA signatures have been associated with disease stage, treatment response, and patient outcomes. Despite this potential, variability in EV isolation and analysis methods remains a barrier to clinical translation. Moving forward, identifying robust biomarker signatures across platforms and clarifying mechanisms of cargo selection and EV uptake will be critical for advancing diagnostic and therapeutic applications. Overall, B cell-derived EVs act as contextual regulators of immune function and malignancy, positioning them as both modulators of disease progression and promising clinical tools.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62930a7e9c707674957a1f9402a815a0e545b47b" target='_blank'>
              Extracellular vesicles in malignant and normal B lymphocyte growth and development
              </a>
            </td>
          <td>
            Kaitlyn E. Mayne, Rashid Jafardoust, Hong-Dien Phan, S. L. Christian
          </td>
          <td>2025-12-10</td>
          <td>Extracellular Vesicles and Circulating Nucleic Acids</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="


 Background:
 Autoimmune phenomena occur in 20-50% of patients with myelodysplastic syndromes (MDS), exacerbating hematopoietic suppression and increasing cardiovascular/infection/bleeding risks. Recent data from our group suggest that the canonical model of stem cell intrinsic failure in MDS is incomplete in that a major fraction of MDS patients present with a large-granular-lymphocyte (LGL) phenotype, comprised of clonal-like expansions of CD57+ T-cells and NK cells in the bone marrow (BM) that strongly correlate with autoimmune cytopenias in lower-risk (LR)-MDS. We hypothesized that CD57+LGLs contribute to BM failure (BMF) through three key mechanisms: (i) enhanced expression of the Fc receptor, CD16A and associated reactivity in response to IgG1 and IgG3 autoantibodies; (ii) ability to recognize loss of HLA class I expression on hematopoietic progenitors; and (iii) activation and proliferation in response to cytokines and chemokines. Targeting these cells has the potential to restore effective hematopoiesis.
 Methods:
 Clinical flow cytometry was used to profile presence and abundance of cells across >20 immune subsets in matching BM and blood samples (N=279 MDS). We then performed scRNA-seq, including matched TCR as well as single-nucleotide ATAC seq on BM mononuclear cells (BMMCs) from a separate cohort of six LR-MDS pts and three healthy individuals. Further, we performed mass cytometry (CyTOF) for ex-vivo profiling of BM from 19 MDS patients (N=10 LR/IR-MDS, N=9 high-risk-MDS) and age-matched controls. From this same cohort, we also performed in vitro killing assays by incucyte using isolated BM-derived LGLs. Retrospective analysis of 22 MDS patients treated with intravenous immunoglobulin (IVIG) for autoimmune cytopenias and LGL expansion was performed. TCR clonality was assessed via TCR-seq in a subset.
 Results:
 Clinical flow analysis reveal a strong association with BMF with expanded BM NK cells (>20% of lymphocytes) and/or circulating NK-LGL or CD8-LGLs (p<0.00001). Strikingly, their abundance was inversely correlated with myeloblast burden (p<0.05). In parallel, we show a major fraction of MDS patients have high abundance of BM-derived CD57+CD8 T cells and NK cells by CyTOF analysis. Further characterization by scRNA-seq and TCR-seq reveal expansion of conventional T cells or CD57+LGLs that bear a profound phenotypic relation to innate-like cells (e.g., expression of NKG2A and/or KIR receptors, CD16A, NKG2D, etc). We compared innate-like CD8 T cells between age-matched controls and LR-MDS patients, and observed a clear qualitative difference in their functional status, where LGL CD8 T cells from LR-MDS patients were strongly activated and expressed significantly higher levels of perforin, granzymes, cytokines and chemokines compared to the same subsets of cells from controls (p<0.0001). Finally, we co-cultured patient BM-derived LGLs with autologous BM cells and demonstrated in vitro killing uniquely in the presence of autologous BM-derived IgG, revealing antibody-dependent cellular cytotoxicity (ADCC) reactivity and an unappreciated axis of autoantibodies engaging LGLs as a clear mechanism of BMF.
 To test the hypothesis that LGL-mediated ADCC might drive BMF, we conducted a retrospective clinical study of IVIG treated MDS patients with severe BMF and abundance of LGLs (N=22) and observed an ORR=73% (16/22). In a subset of nine patients (n=7 with lower-risk MDS) who had serial blood samples available for TCR-Seq, those with confirmed clonality via TCR-Seq had an 80% hematologic and 60% hemolytic response, whereas patients without detectable clonality had only 25% response.
 Conclusion:
 Although the dataset is small and retrospective, it strongly suggests a beneficial effect of IVIG on BMF in patients with expanded NK cells and T cell clones. This clinical response to IVIG is further evidence of the importance of ADCC reactivity and underlying autoimmune signatures in driving BMF, where BM LGLs, comprised of terminally mature CD57+ NK and CD8 T cells, have capacity to kill autologous developing hematopoietic cells. Based on all of our preclinical data, we predict IVIG has a ‘diluting’ effect on the overall abundance of endogenous autoantibodies and their ability to bind antigen and induce ADCC. This strategy to target these cells has the potential to improve peripheral blood counts, patients' quality of life and improved capacity for response to immunotherapies targeting the MDS clone(s).
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/487a001efb78fcaad4458104694c8d2635056e0b" target='_blank'>
              Bone marrow CD57+ LGL cells comprised of NK and CD8 T cells drive bone marrow failure in Myelodysplastic Syndromes
              </a>
            </td>
          <td>
            J. Feld, R. Rai, Kyle Wiatrowski, Richard Sheppard, Haocheng Yu, E. Demakos, Diego Chowell, Jane Houldsworth, Shafinaz Hussein, A. Horowitz, Lewis R Silverman
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Dendritic cells (DCs) are essential regulators of adaptive immunity, functioning as professional antigen‐presenting cells that bridge innate sensing with the induction of adaptive immunity and immune memory. The DC population is heterogeneous, encompassing numerous phenotypic subsets depending on the tissue, pathophysiological condition and species studied, which historically complicated their classification. Advances in bulk or single‐cell transcriptomics and ontogenetic studies have clarified DC heterogeneity and highlighted type 1 conventional DCs (cDC1s) for their unique ability to induce protective CD8+ T cell responses against cancer and intracellular pathogens. Beyond immunity, DCs also maintain tolerance to self and harmless antigens. Contrary to earlier assumptions that tolerogenic DCs are simply immature, recent evidence shows that both immunogenic and tolerogenic maturation involve an extensive and convergent reprogramming of cDC1s during the activation process licensing them for shaping T cell responses, a process referred to as DC maturation. This evolving understanding is reshaping how we study DCs, including the necessity to integrate the timing of DC maturation and their microanatomical redistribution during this process. The novel insights these studies are bringing carry significant implications for vaccines or immunotherapies against intracellular pathogens or cancers, and treatments against allergy or autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4f0236bce193fec556b42698afce4c36c4c5719f" target='_blank'>
              Identity, Functions, and the Spatiotemporal Maturation of Type 1 Conventional Dendritic Cells
              </a>
            </td>
          <td>
            Ramazan Akyol, Marc Dalod
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Neutrophils foster a pro-tumorigenic microenvironment in multiple myeloma (MM) by releasing inflammatory cytokines, immunosuppressive factors, and reactive oxygen species (ROS), contributing to immune evasion and disease progression. Elevated neutrophil-to-lymphocyte ratio serves as a poor prognostic marker, yet neutrophil-targeted therapies remain underexplored. Our prior work identified three novel drug combinations that disrupt both epigenetic regulation and cell cycle control—particularly effective in transcriptionally active, treatment-resistant MM. These combinations also upregulate Smad signaling, indicating potential to reprogram the immune microenvironment and enhance anti-myeloma immunity.
 The CDKi/HDACi combination of dinaciclib and entinostat was identified as a potent combinatorial therapy, as it showed the greatest synergy in treatment-resistant myeloma subtypes and presented higher survival in a murine Vk*MYC; Nras LSL Q61R/+; IgG1-Cre (VQ) allograft mouse model. We investigated the CDKi/HDACi combination for further preclinical development. We explored the targets, mechanism of action, and efficacy of combined CDK/HDAC inhibition in vitro (cell lines) and in vivo (NSG xenografts and Bcl-xL transgenic spontaneous tumors) and confirmed that the combination leads to MYC suppression, upregulation of tumor suppressors like p16, anddelayed tumor progression. Freshly obtained smoldering myeloma patient bone marrow biopsy cells were utilized to evaluate the efficacy of the combination compared to single-agent treatment. The CDKi/HDACi combination was effective at selectively reducing the viability of human CD138+ MM cells ex vivo.Finally, a genetic signature of combined CDK/HDAC inhibition emerged for MM cells. RNA-seq and gene set enrichment analysis revealed downregulation of DNA replication, protein folding, and, importantly,immune pathways, including those related to leukocyte migration and pro-inflammatory chemokines (e.g., CXCL1, CXCL2, IL1A, IL23A). These changes align with the suppression of inflammatory and neutrophil-recruiting signals, suggesting that CDK/HDAC inhibition may indirectly suppress neutrophil activation and trafficking in the MM microenvironment.
 To overcome translational barriers associated with dinaciclib and entinostat, we evaluated next-generation agents: KB0742, a selective and orally bioavailable CDK9 inhibitor, in combination with quisinostat or zabadinostat, two potent HDAC inhibitors with more favorable pharmacokinetic and safety profiles. We validated their synergistic action in limiting proliferation and alteration of biomarker expression. Our next steps are to use co-culture conditions of MM cells with neutrophils, to observe the effects of CDKi/HDAi combination treatment by monitoring neutrophil activation markers, including CD11b and ROS production, compared to single agents. We will further investigate pro-inflammatory cytokines and chemokines involved in neutrophil recruitment and activation (e.g., CXCL1, CXCL2, CXCL8, IL1A, IL23A). These transcriptional changes, accompanied by increased re-expression of tumor suppressors (e.g.,p16) and TGFβ/SMAD signaling components, would predict reprogramming of an anti-inflammatory microenvironment by these combination treatments in myeloma.
 These findings point to a promising but underdeveloped therapeutic avenue whereby suppressing neutrophil-driven inflammation enhances anti-myeloma immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9784fe983e1a8413d51f126d5fbd75b2e2cf4b86" target='_blank'>
              HDAC and CDK inhibitor combinations suppress neutrophil activation in myeloma
              </a>
            </td>
          <td>
            Snehal M Gaikwad, Tyler J. Peat, Wendy Du Bois, Shuling Zhang, Nana Gyabaah-Kessie, Jing Zhang, Dickran Kazandijian, Aleksandra Michalowska, Beverly Mock
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="


 Background: Immunotherapy has transformed cancer care, inducing durable responses in both hematologic and solid tumors. Despite these advances, many patients derive limited benefit, potentially secondary to an immunosuppressive tumor microenvironment (TME), defined by defective antigen presentation, immunosuppressive cell infiltration, and stromal barriers that restrict T-cell trafficking.
 Our group has established the use of mesenchymal stem cells (MSCs) as modifiers of the tumor microenvironment (TME) (Studeny M…Andreeff, Cancer Res 2002; JNCI 2004). We demonstrated in solid tumors that intravenously injected MSCs have the innate capacity to migrate into the TME and contribute to the generation of tumor-associated fibroblasts at the invasive edge of the tumor and their metastases. While MSCs are believed to be immunosuppressive, we hypothesized that they could be modified into immunostimulatory cells and convert a “cold” TME into a pro-inflammatoryTME. In a clinical pilot trial, we demonstrated proof-of-concept that IFNβ-secreting MSCs homed to ovarian tumors and mediated intratumoral IFNβ delivery (NCT02530047)(Andreeff M et al. Cancer Res (2018)78:75).
 Results: We developed an immunotherapeutic strategy using induced pluripotent stem cell–derived mesenchymal stem cells (iMSCs) engineered to secrete IL-7 and IL-15, two potent cytokines selected for their robust immunostimulatory properties. iMSCs, clonally derived from iPSCs, offer superior expansion and scalable production compared to BM-MSCs. These iMSCs retained classical MSC morphology and proteogenomic profiles, supporting their identity and functionality. Telomere length and CyTOF-based cell cycle analysis revealed high proliferative capacity, far superior to BM-MSCs. Stable transgene expression was validated using GFP-tracked clones throughout differentiation and expansion. These iMSCs enhanced bone marrow regeneration following radiation therapy (Okeleji, O et al ASH2025).
 Proprietary gene editing ensured efficient and consistent integration of IL7 and IL15 transgenes, providing a robust platform for cytokine delivery. IL-7/IL-15-iMSCs produced supraphysiological cytokine levels (2,000–4,000 pg/mL), representing a nearly 20-fold increase over levels seen in previously engineered T cells. This enhanced cytokine output drove proliferation of resting and CD3/CD28-activated T cells, as confirmed via CFSE assays. CyTOF profiling revealed robust downstream STAT5 phosphorylation, pS6 activation, and BCL2 upregulation, indicative of efficient IL-7/IL-15 receptor downstream signaling. Hence, immunosuppressive iMSCs were modified to be potent immunostimulatory cells. We applied this concept to high-grade serous ovarian carcinomas (HGSOC). PBMCs conditioned with IL-7/IL-15-iMSCs significantly reduced the number of both platinum-sensitive and platinum-resistant ovarian cancer cells in vitro. To evaluate therapeutic efficacy in vivo, we administered IL-7/IL-15-iMSCs i.p. into the ID8 murine ovarian cancer model in immunocompetent mice. Multiplex immunofluorescence demonstrated that iMSCs home to tumors, secrete cytokines locally, and promote intratumoral T-cell, NK-cell, and macrophage infiltration, collectively leading to prolonged survival. This outcome was associated with a shift from an immune-excluded to an inflamed, immune-infiltrated TME. The ovarian TME was enriched in CD163⁺Arg1⁺PD-L1⁺M2-like macrophages, which exhibited a phenotypic shift toward an M1-like state, marked by Arginase-1 downregulation, in the IL-7/IL-15 treatment group. Experiments investigating activity of IL-7/IL-15-iMSCs in carboplatin-resistant ID8 models are ongoing and will be reported. Results in triple-negative breast cancer will be reported separately (Singh, S et al. ASH2025).
 Conclusion: We demonstrate that IL-7/IL-15-iMSCs display potent in vitro immunostimulatory activity, inducing robust T cell proliferation and activation. IL-7/IL-15-secreting iMSCs convert an immunosuppressive TME into a “hot” milieu, defined by massive T-cell and macrophage infiltration, M1 polarization, and restoration of T-cell functionality. Gene-modified iMSC-induced reprogramming of ovarian TME resulted in reduced tumor burden and improved survival in a murine ovarian cancer model. Results support the potential of IL-7/IL-15-iMSCs as a novel immunotherapeutic platform for overcoming immune resistance in cancer, including hematological malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9ab550875609985f12d7a0a7eb4312645f47adc" target='_blank'>
              Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct  Pro-inflammatory tmes
              </a>
            </td>
          <td>
            M. Muftuoglu, Sandeep Singh, Andrea D Bedoy, Li Li, Mahesh Basyal, Nath Dipmoy, Lauren B. Ostermann, Ivo Veletic, Christopher D. Pacheco, Poo Yee Mak, Edward Ayoub, Taeyun Kim, Kyle M. Garland, Robert Pierce, Mathew Angel, Sanjeev Luther, Christopher B. Rohde, M. Andreeff
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is widely considered unresponsive to immunotherapy due to its immunosuppressive microenvironment and limited immune cell infiltration. However, recent single-cell transcriptomic studies reveal the presence of exhausted, potentially antigen-specific T cells in human GBM. We have developed a locally administered, brain-confined cytokine therapy with minimal systemic exposure using an engineered, neonatal Fc receptor (FcRn)-silenced, Compartment-Locked (CL) IL-12Fc fusion protein. This approach thus relies on presence and reactivation of tumor-resident, IL-12-responsive cells. In syngeneic, preclinical GBM models, intratumorally administered CL IL-12Fc induces robust antitumor efficacy, also under conditions of peripheral lymphopenia (induced via systemic temozolomide) or when T cell influx was pharmacologically inhibited. In 3D-perfused, patient-derived GBM explant cultures—with a largely preserved native tumor microenvironment and without addition of autologous peripheral immune cells—CL IL-12Fc triggered pro-inflammatory reprogramming. Proteomics-based secretome analysis revealed significant upregulation of interferon-gamma (IFNγ) pathway signatures. Single-cell RNA sequencing of GBM tissues prior to culture setup confirmed the presence of resident memory T cells in most patients. Notably, single cell transcriptome analysis of post-treatment explants demonstrated a robust IFNγ response in both tumor-associated macrophages, microglia and tumor cells. Our findings demonstrate that CL IL-12Fc can activate local immune responses within human GBM samples, independent of peripheral immune cell recruitment. This localized immune activation is an important prerequisite for the clinical translation of locally confined cytokine therapy. We aim to validate these findings using spatially resolved multiplex immunofluorescence histology. In summary we provide evidence that CL IL-12Fc can facilitate local immune activation without peripheral immune cell requirement.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/060cb1db812334f914a22c2a53795e6b0d1cdc11" target='_blank'>
              IMMU-51. Treatment efficacy in murine and human glioma models with brain Compartment-Locked IL-12 does not per se rely on influx of peripheral immune cells and induces distinct transcriptome and secretome changes
              </a>
            </td>
          <td>
            Sabine Spath, L. Le Large, Michal Beffinger, N. Tatari, M. Ritz, B. Taskoparan, U. Salazar, Sereina Deplazes, Felix Behr, C. Zinner, W. Vader, Carlo Bertozzi, D. van der Meer, G. Hutter, J. vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 Introduction: The bone marrow (BM) microenvironment supports survival of the malignant multiple myeloma (MM) cells and is composed of cellular components that foster MM development and progression by suppression of immune responses. Despite major progresses in understanding the MM biology and pathophysiology, it is still incurable. Myeloid cells are well-described to suppress antitumor immunity (Barry et al., 2023; De Sanctis et al., 2023). However, the molecular mechanisms to achieve immunosuppressive myeloid cell states are unknown. Cytokine IL-4 is the primary driver of tumor infiltrating monocyte-derived macrophage (MO-MAC) phenotype as reported by LaMarche that deletion of IL-4Rα alone within early myeloid progenitors in BM reduced tumor burden; while deletion in downstream mature myeloid cells had no effect (LaMarche et al., 2024). Mechanistically, IL-4 derived from BM basophils and eosinophils acted on granulocyte-monocyte progenitors (GMPs) to transcriptionally program the development of immunosuppressive tumor-promoting myeloid cell.Hematopoietic Adaptor-Containing SH3 and SAM domains (HACS1) maps to a region on chromosome 21 that is frequently disrupted in hematopoietic malignancies, suggesting its involvement in these diseases (Claudio et al., 2001). Previously, we showed that Hacs1 is involved in MM development through changes of its microenvironment. It regulates IL4 signaling in B cell, T cell, macrophages and dendritic cells and affects their function (Wang et al., 2010). Hacs1-/- bone marrow derived macrophages (BMDMs) are hyper-responsive to IL-4 stimulation and display an alternative activation M2 phenotype. We found CD11b+/Gr-1+/ CD31+/Siglec F myeloid progenitors as well as immature myeloid progenitors and eosinophils were significantly increased in Hacs1-/- mouse bone marrow.
 Method: In the current study, we investigated the role of Hacs1 in MM immunosuppressive microenvironment utilizing Hacs1-/-mouse BM-myeloid derived suppressor cells (MDSCs) as well as MM tumor-bearing mice to study MM progression and therapeutic resistance.
 Results: Our results showed Hacs1-/-mouse bone marrow in MM tumor-bearing mice has upregulated PD-L1 expression in MDSCs, suppressing T cell function. Overexpression of Hacs1 or stimulation Hacs1 reduces MDSC accumulation, resulting in elevated T cell activity and reduced tumor load. Our data suggest that Hacs1 plays a key role in regulation of the immunosuppressive microenvironment in MM. Furthermore, myeloid cells from Hacs1-/-mouse BM have increased expression of MS4A3 gene, a key gene regulating cell differentiation to monocytic/granulocytic-myeloid-derived suppressor cells (M-MDSCs and G-MDSCs, respectively) (Liu et al., 2019). At the mechanistic level, MS4A3 enhances IL-3 and GM-CSF signaling in Hacs1-/-BM CD34+ cells, compared to Hacs1+/+cells.Conclusion: These data suggest that Hacs1 negatively regulate IL-4 signalling axis in bone marrow and drives pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling. Hacs1 is a key player in cellular signaling within the immune system with roles in immune regulation, cancer development, and potential serves as a MM therapeutic target.
 Keywords: Hacs1-/-, Multiple Myeloma, myeloid derived suppressor cells (MDSCs), bone marrow microenvironment, chemo resistance
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f2d0467e47b26436ae5260ef710bda44c102442" target='_blank'>
              Title: Hacs1 is a myeloma immunosuppressor driving pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling
              </a>
            </td>
          <td>
            Dingyan Wang, Xiao-Yan Wen, Jamie Li, Raymond Qu, Wiiliam JiaYi Wu, Xinmiao Andrew Yang, Derek Shiqi Xu, Jingdong Wu, Leqi Shen, Jeremy Dai, Yuan Gao, Jinyi Zhang, Anthony Gramolini Gramolini, Xiaoyuan Liu, K. Siminovitch, Keith Stewart
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Immunosuppression within the tumor microenvironment (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This immunomodulatory vaccine was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8fef4f03c94eaba07eeff2c05c0e60c396891042" target='_blank'>
              Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
              </a>
            </td>
          <td>
            Tiyun Han, Guilai Liu, Chenyi Bao, Jian Zong, Caiyi Fei, Jing Li, Shi Xu, Qingbo Ma, Yingjuan Qian
          </td>
          <td>2025-10-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 Some cancers trigger a response that resembles a viral infection, called viral mimicry, which can stimulate the immune system. This process has been linked to better responses to certain drugs in solid tumors, but its role in Acute Myeloid Leukemia (AML) is not well understood. In this study, we explore whether viral mimicry in AML is associated with immune activation and its response to BCL2 inhibition
 RNA-sequencing data from 707 AML samples from the BeatAML2 dataset was analyzed. Each patient was assigned a viral mimicry score based on the expression of interferon-stimulated genes. Immune infiltration was estimated using established gene signatures for T cells, monocytes, dendritic cells, and other immune populations. The expression of immune checkpoint genes such as PD-1, PD-L1, CTLA4, and TIM-3 were also measured. Drug sensitivity was assessed using ex-vivo area under the curve (AUC) values for azacytidine, venetoclax, and ABT-737. Spearman correlation (ρ) and FDR-adjusted p-values were used for statistical analysis.
 Expression of 1,442 genes were significantly linked to viral mimicry scores (p<0.05, |ρ|>0.3). The strongest association was with IFI44L, an interferon-stimulated gene (ρ=0.91, p<0.005). Other top genes included OAS3, MX1, and RSAD2, all tied to interferon signaling. Viral mimicry was moderate to strongly correlated with immune cell markers, including monocytes (ρ=0.47), dendritic cells (ρ=0.37), cytotoxic lymphocytes (ρ=0.36), CD8+ T cells (ρ=0.31), and NK cells (ρ=0.29), all with p<0.005. These findings suggest that higher mimicry is associated with broader immune activation. Immune checkpoint gene expression increased alongside viral mimicry scores. The highest correlation was with PD-L1 (CD274) (ρ=0.46), followed by TIGIT, CTLA4, and HAVCR2, each with ρ>0.30 and p<0.005. Viral mimicry scores were not associated with ABT-737 response, and most immune checkpoints lacked predictive value. Modest correlations with azacytidine (ρ=-0.31) and venetoclax (ρ=-0.24) suggest partial enrichment for HMA and BCL2 sensitivity (both p<0.005), but not enough for clinical prediction.
 This is the first study showing that viral mimicry in AML is linked to immune activation and higher expression of immune checkpoint genes, but it does not help predict response to BCL2 inhibitors. Although the clinical impact is not yet clear, these findings highlight a unique immune-related signature that could help guide future studies of immunotherapy or hypomethylating agents in AML. Further clinical validation is needed.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f628c14fb62d4b292b806619aec4afa5af2e330" target='_blank'>
              Viral mimicry in AML is linked to immune activation but not BCL2 inhibitor sensitivity
              </a>
            </td>
          <td>
            Mobina Shrestha
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Inflammatory bowel diseases (IBD), including Crohn´s disease (CD) and ulcerative colitis (UC) remain highly prevalent and are associated with a reduced quality of life in affected patients. The pathophysiology of IBD is multifactorial since genetic predisposition, altered immune function, changes in intestinal microbiota, environmental factors, and loss of intestinal barrier function together induce disease manifestation. A critical key factor is the dysregulation of the immune system which explains that all medical therapeutic approaches target the immune response. However, the success of these therapies is limited and associated with severe side effects which demonstrates the need for novel therapeutic approaches. Previous research demonstrated that CD4+ regulatory T (Treg) cells are important regulators of intestinal homeostasis but are reduced in number and function relative to effector T cells in IBD. This led to the concept that genetically engineered, antigen-specific Tregs may represent a promising strategy to address immune dysregulation in IBD. Due to their antigen specificity, chimeric antigen receptors (CARs) enable additional target-dependent activation and migration of Tregs at disease sites. While CARs are increasingly established for the generation of antigen-specificity for T cell therapies in cancer, the implementation of CARs for IBD is in a preliminary state. Nonetheless, CAR constructs specific to circulating carcinoembryonic antigen (CEA), flagellin, or IL23R have been developed recently for potential application in IBD. Based on these novel developments, this review will discuss the role of Tregs in IBD disorders and present the current state of CAR Treg models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ca608e891981776bd2aa9079f1b66c12af72c13e" target='_blank'>
              Opportunities and challenges harnessing antigen-specific CD4+ regulatory T cells in inflammatory bowel disease
              </a>
            </td>
          <td>
            Jessica Kümmel, Nicolas Schlegel, Johanna C. Wagner
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Waldenström Macroglobulinemia (WM) is an incurable lymphoid malignancy characterized by a spectrum of differentiation states from clonal B lymphocytes (Ly) to IgM-expressing plasma cells (Pc). Activation of mitochondrial apoptosis by Bcl-2 antagonists is already under clinical investigation for treatment-naïve (TN) and relapsed/refractory (R/R) patients. However, the biological mechanisms whereby WM cells evade mitochondrial apoptosis remain undefined. In this work, we leveraged functional and single-cell transcriptomic approaches to unravel fundamental principles of apoptosis evasion in WM.
 We collected viable WM cells from the bone marrow of 27 WM patients (25 MYD88L265P and 2 MYD88WT; 25 patients were TN, 2 were R/R). Samples were subjected to intracellular BH3 profiling (iBH3), a functional assay that derives the apoptotic priming and the anti-apoptotic dependencies based on the pattern of cytochrome c release in response to pro-apoptotic stimuli. Surface staining with anti-CD19 and anti-CD138 antibodies was included to discriminate Ly and Pc in each sample. We found that the apoptotic profile differed considerably between malignant Ly (CD19+CD138-) and Pc (CD19+CD138+). WM Pc displayed lower apoptotic priming (P=0.002) and lower Bcl-2 dependency (P=0.03) than WM Ly. In contrast, non-Bcl-2 anti-apoptotic dependencies, particularly Mcl-1 dependency, were higher in Pc than Ly (Mcl-1 dependency: 93.0 and 42.8%, respectively, P<0.001).
 Despite being predominantly Bcl-2 dependent, Ly showed remarkable heterogeneity across samples. Integrating Ly apoptotic profiles with patient clinical data, we found a positive correlation between the amount of serum monoclonal component (MC) and co-dependency upon Mcl-1 specifically detected in Ly (Pearson r=0.68, P<0.001). We also observed an increasing gradient of Mcl-1 dependency (P<0.001) when comparing Ly from patients affected by chronic lymphocytic leukemia (a prototypical Bcl-2 dependent malignancy, N=17), hyposecretive (MC<30 g/L, N=20), and hypersecretive WM (MC<30 g/L, N=7).
 To assess whether Ly and Pc express different sets of pro- and anti-apoptotic genes, we performed single-cell RNA sequencing coupled with BCR sequencing on 8 WM bone marrow samples, 3 of which were hypersecretive. As expected, BCL2 was upregulated in WM Ly compared to residual normal memory B-cells. With respect to normal Pc, WM Pc expressed a higher level of the MCL1/PMAIP1 couple and a lower level of the pro-apoptotic BCL2L11 (encoding Bim). Focusing on tumor cells only, we identified 9 clusters with different transcriptional profiles. Five of them (Clusters 1-5) covered the Ly population, two harbored features of intermediate lymphoplasmacytic states, one corresponded to canonical JCHAINhighPRDM1high Pc, and an additional minor cluster was composed of atypical JCHAINhighPRDM1neg Pc. Consistent with iBH3 results, there was a clear-cut progressive increase of MCL1 expression during the differentiation of WM Ly towards canonical WM Pc. In contrast, BCL2, as well as BIRC3 and BIRC6, remained high up until the intermediate clusters and then dropped down at the Pc end of the differentiation trajectory. Interestingly, PMAIP1 followed a wave-like pattern with very high expression in intermediate states and low levels on the two ends of the differentiation process. BCL2A1, an anti-apoptotic gene often involved in therapy resistance, was highly expressed in a fraction of WM Ly belonging to Cluster 5. More importantly, within the WM Ly population, the highest expression of MCL1, at levels comparable to those observed in intermediate states,was detected in Cluster 4. This Ly cluster was particularly enriched in hypersecretive patients and may underpin the functional Mcl-1 dependency associated with this clinical phenotype.
 Lastly, we searched for targetable signaling pathways transcriptionally upregulated in clusters with high MCL1expression. While B-cell receptor signaling and NF-kB activity were comparable across clusters, IRE1/XBP1 pathway and, to a lesser extent, STAT3 activity were increased in JCHAINhighPRDM1high Pc and may represent actionable targets to suppress Mcl-1 addicted cells.
 In sum, cell differentiation stage coordinates the expression of Bcl-2 family genes and modulates anti-apoptotic dependencies in WM. Such transcriptional and functional intratumor heterogeneity may underlie the relatively low rate of deep responses to Bcl-2 antagonism in WM and suggest novel combination strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a9fe24492d9101d3917015b59b6d5449cccef431" target='_blank'>
              Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia
              </a>
            </td>
          <td>
            Cristina Frusteri, A. Real, F. Nadeu, Laura Fumagalli, Valentina Manconi, Ali Jafari Kia, Eleonora Terrabuio, A. Montresor, Maria Pia Manto, Eleonora Gugole, Angela Mercuri, L. Bonaldi, Gabriela Constantin, M. Krampera, C. Visco, M. Scupoli, Carlo Laudanna, Isacco Ferrarini
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Mucosal-associated invariant T (MAIT) cells are unique unconventional T cells with diverse roles in immunity, yet how their context informs their function is not well known. This contextual regulation is particularly relevant in cancer, where MAIT cells have an enigmatic role. We performed a systematic review and meta-analysis to identify MAIT cell transcriptomic signatures under different environmental conditions. We identified four bulk-RNA-sequencing studies that compared multiple activation stimuli. We found a stimulus-specific transcriptional signature for immune checkpoint genes, that we confirmed in a single-cell RNA-sequencing dataset. We used flow cytometry to examine in vitro human MAIT cells across four activation stimuli and confirmed that stimulus drives unique checkpoint signatures upon MAIT activation for Lag3, PD-L1, PD-1, NKG2A and Tigit. Strikingly, PD-L1 was more highly induced in vitro than PD-1 in MAIT cells up to 72 hours. Our data suggest that human MAIT cell regulation is context-dependent. These findings have the potential to critically inform efforts targeting MAIT cells for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ecf762a805ede9d94ba29010a5a748ff3406109" target='_blank'>
              Immune Checkpoint Expression in Mucosal-Associated Invariant T (MAIT) Cells is Stimulus-Dependent.
              </a>
            </td>
          <td>
            C. Clutter, Audrey Re, Kenadee Jacobson, Kendell Clement, Jeffrey Aubé, Ryan M O'Connell, D. Leung
          </td>
          <td>2025-12-06</td>
          <td>Journal of leukocyte biology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="
 The tumor microenvironment of glioblastoma is dominated by immunosuppressive microglia/macrophages that dampen anti-tumor immunity, comprising a major barrier to effective immunotherapy. Developing strategies to reprogram these macrophages is essential to overcome treatment resistance. Bacterial extracellular vesicles (bEVs) are secreted nano-sized (~25–100 nm) particles that modulate myeloid cell activity in a species-dependent manner. We developed a scalable strategy to purify bEVs from the human commensal Escherichia coli Nissle strain consisting of: tangential-flow filtration, Benzonase depletion of free nucleic acids, and size-exclusion chromatography, yielding ~3.5 mg of bEV-associated protein per liter of culture. E. coli Nissle bEVs activated NF-κB and IRF pathways in THP-1 dual-reporter monocyte-derived cells in a dose-dependent manner, with an ED50 approximately seven-fold lower than that of purified LPS or heat-killed bacteria, indicating a distinctly higher potency. We further depleted free LPS that may co-isolate with bEVs, and noted a ~3000-fold reduction in LPS content, with less than 10% protein loss. LPS-depleted bEV bioactivity surpassed LPS amount-matched crude bEVs, supporting that bEV, not residual copurifying LPS, drove the observed in vitro bioactivity. bEVs activated peripheral-blood mononuclear cell-derived CD11b⁺CD68⁺ macrophage-like cells at concentrations as low as 1 ng/mL, while lymphocyte populations experienced minimal effects, in line with bEVs acting primarily on myeloid cells. We next treated M-CSF, IFNγ, and IL-4 polarized human monocyte-derived macrophages with bEVs. In IL-4 polarized (M2-like) macrophages, bEVs induced a more pronounced M1-like reprogramming compared to IFN-γ treatment, increasing CD38, CD80, and CD86 while decreasing CD47 and CD206. This reprogramming persisted even at sub-ED50 concentrations, as low as 0.6 ng/mL. Collectively, this workflow consistently yielded bioactive bEVs that robustly reprogram macrophages. Future work will test the ability of bEVs to reprogram GBM-associated microglia/macrophages, with the ultimate goal of combination with immunotherapies to overcome treatment resistance in the immunosuppressive GBM microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/314efedf3ab7696248eb4216de5020641b87b2b2" target='_blank'>
              IMMU-16. Development of high-purity bacterial extracellular vesicles for suppressive myeloid cell reprogramming in glioblastoma immunotherapy
              </a>
            </td>
          <td>
            Irem Karaman, Justin Ruiz, O. T. Pumar, Asmita Pathak, Jonathan Mitchell, B. León, Selma Maacha, Wael El-Rifai, Defne Bayik, Dionysios C. Watson
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet resistance and immune-related adverse events (irAEs) remain significant challenges. γδ T cells and B cells are recognized as critical players in the tumor microenvironment (TME), but their roles in shaping T cell phenotypes and contributing to ICI resistance are not fully understood. Using syngeneic tumor models in autoimmune-prone NOD mice, which enable simultaneous profiling of tumor immunity and autoimmunity, we investigated mechanisms underlying ICI sensitivity and resistance. In the resistant tumor model, CD8+ T cells exhibit a naïve phenotype, with elevated TCF-1 expression and reduced activation markers such as PD-1 and CTLA-4. In contrast, activated CD8+ T cells dominate the sensitive tumor model, highlighting T cell phenotypes as key drivers of ICI responses. Further analyses implicated γδ T cells and B cells in these divergent responses. Depleting γδ T cells in the resistant model significantly improved tumor control, underscoring their role in mediating resistance. Conversely, CD8+ T cell activation was enhanced in B cell-deficient mice, suggesting B cells may restrict antitumor immunity. Together, these findings provide critical insights into the interplay between T cells, γδ T cells, and B cells within the TME and highlight potential therapeutic strategies to overcome ICI resistance without inducing irAEs.



 National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number: T32AI138945



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a88c64fd65f389029580f6961ad4a61916ee0e46" target='_blank'>
              The Interplay Between γδ T cells and B cells Contributes to Immune Checkpoint Inhibitor Resistance 3426
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Persistent antigen exposure, a hallmark of chronic infections and tumors, drives the formation of a distinct population of CD8+ T cells, known as exhausted CD8+ T (TEX) cells, with increased expression of immune checkpoint molecules and reduced effector function. Immune checkpoint inhibition (ICI) therapy has emerged as a powerful tool to reinvigorate the function of TEX cells. However, despite the immunostimulatory effects of radiotherapy (RT), combining RT with ICI has yielded modest clinical benefits in cancer patients. While the success of ICI therapy largely depends on the presence of progenitor TEX cells, the impact of high-dose ionizing radiation (IR) on the TEX population, particularly enriched within the treatment field, remains understudied. Here, we show that chronically infected mice with LCMV-Clone 13 subjected to sublethal whole-body irradiation (WBI) exhibited a lasting numerical decline and impaired antigen-specific function in their TEX cells. Using single-cell RNA sequencing and multiparameter flow cytometry, we observed that WBI gradually altered the subset composition of surviving TEX cells, highlighted by the loss of progenitor and effector-like TEX cells while terminally-exhausted TEX cells were enriched. Lastly, WBI rendered ICI therapy less effective in rescuing TEX cells and decreasing viral burden. These findings provide important insights into how high-dose IR alters the fate of TEX cells, potentially impairing their responsiveness to ICI therapy.



 Supported by NIH Grants GM134880, AI114543



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ef55b305a83cb203c9064f70e6ab8c59e03b2320" target='_blank'>
              Ionizing radiation impairs the efficacy of immune checkpoint inhibition by driving terminal exhaustion of progenitor exhausted CD8+ T cells 4054
              </a>
            </td>
          <td>
            Mohammad Heidarian, S. Kannan, Xin Zhao, M. Mix, Hai-Hui (Howard) Xue, John T. Harty, V. Badovinac
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="


 Pediatric high-grade gliomas (pHGG) are characterized by an immunologically cold and highly immunosuppressive tumor microenvironment (TME). It is dominated by M2-like tumor-associated macrophages (TAMs), which impair CAR T-cell function and persistence. However, broad myeloid targeting can be detrimental, as recent evidence shows that inflammatory macrophages are essential to support CAR T-cell activity. We therefore identified CD123 as selectively expressed on immunosuppressive TAMs, making it a promising target to remodel the TME. Meanwhile, B7-H3 is a tumor-associated antigen that is broadly expressed in pHGGs, making it an ideal target for CAR T-cell therapy. We now hypothesize that dual targeting of CD123+ TAMs and B7-H3+ tumor cells would synergistically deplete suppressive myeloid populations, restore T-cell function, and enhance anti-tumor efficacy.



 To evaluate the therapeutic potential of CD123 and B7-H3 dual CAR T-cell therapy in modulating the TME, preserving supportive myeloid subsets, and enhancing anti-tumor efficacy in pHGG.



 Using immunocompetent pHGG models, we tested CD123 and B7-H3 CAR T-cells through in vitro cytotoxicity, antigen stimulation, and co-cultures with bone marrow–derived M1 or M2 macrophages. In vivo, CD123 CAR T-cells were administered intratumorally as monotherapy or in combination with B7-H3 CAR T-cells. Endpoints included TAM depletion, phenotypic and transcriptomic TME remodeling, tumor progression, and survival.



 CD123 CAR T-cells exhibited minimal cytotoxicity against B7-H3+ glioma cells but selectively depleted M2-like TAMs in vitro and in vivo. M2 macrophages suppressed B7-H3 CAR T-cell persistence in vitro; this suppression was reversed by co-treatment with CD123 CAR T-cells. Dual CAR T-cell therapy significantly enhanced anti-tumor activity, reduced myeloid and microglial infiltration, and extended survival in vivo.



 Targeted depletion of CD123+ TAMs enhances B7-H3 CAR T-cell efficacy by mitigating immunosuppressive signaling while preserving beneficial myeloid support. This dual-targeting strategy offers a mechanistically guided approach to overcoming TME-driven resistance in DIPG and other pHGG.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43e9945f878d4e3f16528ee181777513363175aa" target='_blank'>
              EXTH-114. Dual CD123 and B7-H3 CAR T Cells Potentiate Immune Responses and Remodel the Tumor Microenvironment in Pediatric Gliomas
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem L Coleman, Paulina Velsquez, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Introduction: Relapsed and refractory hematologic malignancies remain a significant clinical challenge despite integration of newer therapeutic strategies engaging the immune system as standard of care. As such, identifying and characterizing specific defects in the anti-tumor immune response will be key to the development of newer therapies that improve survival. We have previously reported that the immune checkpoint Siglec-15, a member of the sialic acid binding immunoglobulin-like lectin family of proteins, is overexpressed in hematologic malignancies and circulates at high levels in the plasma of children in leukemia. Importantly, inhibition of Siglec-15 restored local anti-tumor immune responses and abrogated tumor progression highlighting a crucial role for Siglec-15 in immune evasion in murine models of leukemia and lymphoma. However, the mechanism(s) by which Siglec-15 promotes immune escape and leukemogenesis has not yet been defined. Here we investigate how Siglec-15 creates an immunosuppressive immune microenvironment through aberrant hematopoiesis in a murine model of leukemia.
 Methods: Using a well-established model of murine B-cell acute lymphoblastic leukemia (B-ALL), control (Cas9) or CRISPR knockout Siglec-15 BCR-ABL1+cells wereinjected into un-irradiated, immune competent (wild type, WT) or immune deficient (Rag1-/-) C57BL/6 mice and single cell RNA sequencing (scRNA seq) performed on paired bone marrow (N=4/group) and spleen (N=4/group) samples. To validate scRNA findings, multiparameter flow cytometry was performed to determine impact of knockout of Siglec-15 on hematopoiesis and innate immune subsets.
 Results: scRNA seq suggests that knockout of Siglec-15 in B-ALL restores circulation of mature neutrophils that are associated with an anti-tumoral, pro-inflammatory phenotype as compared to control where there are predominantly more immature neutrophils that have a pro-tumoral and immunosuppressive gene signature. With Siglec-15 KO, there is increased expression of genes such as Egr1, Ccl6, Klf6 that are known to promote neutrophil differentiation, pro-inflammatory cytokine production and recruitment to tumor sites. By flow cytometry, there is an increase in pluripotent stem cells in the bone marrow of Siglec-15 knockout mice (p<0.01, one-way ANOVA, n=10 mice/group) compared to control. Further, there is increased skewing to myeloid primed multipotent progenitors, MPP2/3 and FCyR+ MPP3, with Siglec-15 knockout (p<0.01, one-way ANOVA, n=10 mice/group). Interestingly, there is no expansion of the immediate myeloid precursors, common myeloid precursors and granulocyte -monocyte precursors, in control mice, there is a significant decrease with knockout of Siglec-15 (p<0.001). However, we observe an increase in innate and adaptive effector immune cells, including neutrophils, B and T cells, in the bone marrow and spleen of knockout mice.
 Conclusions: We have found that there are significant Siglec-15 dependent changes in the bone marrow and spleen in B-ALL by scRNA sequencing. Preliminary data suggests that Siglec-15 may promote aberrant myelopoiesis in murine model of B-ALL at early time points. Ongoing experiments aim to examine the extent to which B-ALL promotes aberrant myelopoiesis in children. Together, these data implicate Sig-15 as an immune checkpoint that may be inhibited therapeutically to promote an immune response to leukemia cells.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/da7888656dfb2e3a70892bf153bf689cc4183854" target='_blank'>
              Siglec-15 dependent alteration of the leukemia immune microenvironment
              </a>
            </td>
          <td>
            Dailia B. Francis, Marina E. Michaud, Jodi Dougan, Miyoung Lee, Manoj K. Bhasin, Christopher Porter
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="
 Introduction:
 Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate immune cells against tumor cells but can cause immune related adverse events such as myocarditis, a serious side effect with up to 40% case fatality rate. We hypothesize that cardiac fibroblasts and cytotoxic T-Cells work in tandem to direct inflammation in the setting of ICI treatment, resulting in myocarditis.


 Methods:
 To study the role of CFBs in ICIM, we first examined fibroblast behavior
 in vivo
 through picrosirius red staining for cardiac fibrosis. We then cultured C57BL/6 murine CFBs and treated them with cardiac serum acquired from a genetic mouse model of ICIM and analyzed
 Cxcl9
 expression by qPCR. Additionally, we stimulated CFBs with media or IFNγ for 24 hours (uCFBs and sCFBs respectively) before co-culturing them with CD8 CXCR3hi T-Cells for 6 hours, after which we analyzed
 Cxcl9
 and
 Cxcl10
 CFB expression by qPCR (Fig 1C) and T-Cell cytotoxicity by flow cytometry (Fig 1D/E). We next examined CD8 T-Cells harvested from C57BL/6 mice treated with combination immunotherapy to induce ICIM via single-cell sequencing to investigate potential axes of T-Cell/CFB crosstalk
 in vivo
 .


 Results:
 Our picrosirius red staining revealed a significant increase in cardiac interstitial and perivascular fibrosis, suggesting that CFBs are inflammatorily active and fibrotic in the context of ICIM (Fig 1A). We demonstrated that treating CFBs with ICIM cardiac serum results in a significant upregulation of CXCL9 by qPCR (Fig 1B). Utilizing our co-culture system, we demonstrated that the presence of CD8 CXCR3hi cytotoxic T-cells significantly increases CXCL9/10 expression compared to both control and IFNγ stimulation, underscoring the importance of T-cell presence in CFB activation (Fig 1C). We also used flow cytometry to confirm the cytotoxic quality of the T-Cells used in our co-culture system (Fig 1D/E). Using single-cell sequencing, we identified a cluster of CXCR3hiVLA4hi CD8 T-Cells from ICI-treated myocarditis mice (Fig 1F.) which are highly cytotoxic compared to other clusters (Fig 1G.), demonstrating that VLA-4:VCAM-1 signaling between T-cells and CFBs may act as a critical driver of cytotoxicity in the heart.


 Conclusions:
 Our findings position cardiac fibroblasts as potentially critical drivers of T-Cell migration and increased cytotoxicity in the context of ICIM, rendering this crosstalk an important direction of study in future of understanding and treating ICIM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f55ccb863bc3d94fa9ccdf7c648353cb039d3ca" target='_blank'>
              Abstract 4369397:
 Uncovering the Role of T-Cell and Fibroblast Crosstalk in Immunotherapy-Induced Myocarditis
              </a>
            </td>
          <td>
            Noah Wagner, Maria Rosaria Vitale, Yin Sun, Maria Zambrano, Abraham L. Bayer, Pilar Alcaide, Javid Moslehi, Han Zhu
          </td>
          <td>2025-11-04</td>
          <td>Circulation</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="
 Glioblastoma (GB) is recalcitrant to immunotherapy due to severe CD8⁺ T cell exclusion and abundance of immunosuppressive tumor-associated macrophages (TAMs). Defining the mechanisms of immune evasion in GB is essential for identifying therapeutic vulnerabilities. Here, we unveil dural nociceptors—pain-sensing sensory neurons—as critical, noncanonical drivers of immune evasion in GB. We demonstrate that dural nociceptors are activated and reprogrammed by soluble factors present in GB-associated cerebrospinal fluid. In syngeneic orthotopic GB murine models, ablation of nociceptors significantly improves survival, enhances anti-tumor immune responses, and sensitizes otherwise unresponsive tumors to immune checkpoint blockade therapy (ICBT). Mechanistically, GB-associated dural nociceptors secrete elevated levels of the immunomodulatory neuropeptide calcitonin gene-related peptide (CGRP). Single-cell RNA-sequencing analyses of human GB samples show that RAMP1, the receptor subunit for CGRP, is selectively expressed on TAM subsets with pronounced immunosuppressive features. Using macrophage-specific RAMP1 conditional knockout (cKO) mice, we found that RAMP1 deletion in TAMs significantly prolongs survival of GB-bearing mice, reduces TAM immunosuppression, and enhances CD8⁺ T cell infiltration and effector function while limiting exhaustion. This survival benefit is lost with CD8⁺ T cell depletion, highlighting the key role of CGRP-driven TAM–T cell crosstalk in shaping anti-tumor immunity. Importantly, GB-bearing cKO mice exhibit markedly improved responsiveness to ICBT. At the molecular level, we uncover a strong reciprocal antagonism between CGRP and interferon-gamma (IFN-γ) signaling that dictates TAM fate. CGRP inhibits IFN-γ–induced STAT1 activation, while IFN-γ blocks CGRP-driven cAMP levels and downregulates RAMP1 expression. CGRP acts as a neural cue that imprints immunosuppressive features in TAMs by blocking their sensitivity to IFN-γ, a critical pro-inflammatory cytokine required for anti-tumor immunity, at transcriptional and epigenetic levels. Thus, the CGRP–RAMP1 axis represents a hijacked neural circuit driving immune evasion in GB and offers a translatable strategy to restore immunotherapy response by repurposing FDA-approved CGRP antagonists.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9270ae1ee1b759973548b67c05e73c8236d6b169" target='_blank'>
              IMMU-68. Glioblastoma co-opts dural nociceptors to drive immune evasion and immunotherapy resistance
              </a>
            </td>
          <td>
            Suman Asalla, Omar Santiagonunez Ahumada, Jordan E. Krull, Yan Wang, Disha Patel, Tom Liu, Samiksha Prasanna, Andrew Jerome, Shuo Chen, Andreas Wieland, Pierre Giglio, Benjamin M. Segal, Qin Ma, Nandini Acharya
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Activation of the stimulator of interferon genes (STING) modulates cellular responses in a cell-context-dependent manner. Intrinsic IFN-stimulated gene (ISG) expression enhances cellular responses to STING activation. We previously demonstrated that chronic myelomonocytic leukemia (CMML) is characterized by cell-intrinsic ISG upregulation. While STING-activation can mediate hematopoietic stem-cell (HSC) self-renewal or exhaustion and CD14+-monocyte depletion, the distinct effects of acute, short-term and long-term STING activation in distinct clonal hematopoietic populations remains unclear.
 Therefore, we sought to evaluate the effects of STING activation dynamics in normal and CMML HSC and monocyte populations. To do so we first treated BM mononuclear cells (MNCs) from patients (pts) with CMML (n=11) or healthy donors (HDs, n=6) in co-culture with mesenchymal stromal cells with a STING agonist (dazostinag). Given that monocytic lineage is characterized by high expression of cysteine-cysteine chemokine receptor 2 (CCR2), MNCs were also treated with TAK-500, an IgG1 anti-CCR2 antibody linked to a STING agonist payload, to evaluate the specific effects of STING activation in monocyte populations. Dazostinag or TAK-500 depleted total and CCR2+ MNCs from CMML pts but not from HDs Accordingly, STING activation with dazostinag or TAK-500 induced a dose-dependent depletion of monocytic cell lines (MOLM13, THP1) through IRF3 phosphorylation and caspase 3 cleavage. To evaluate if acute STING activation impairs CMML's HSPCs repopulation potential we performed colony-formation studies in BM CD34+ cells from CMML pts (n=8) and observed that TAK-500 and dazostinag impaired myeloid, but not erythroid, colony-formation.
 We previously reported that Vav-KDM6B/Tet2f/f/Vav-Cre (KDM6B/Tet2)mice recapitulate features of CMML. Single-cell RNA-sequencing (scRNA-seq) of MNCs from these mice and control (Vav-cre) mice confirmed myeloid bias and expansion of CCR2+ monocytes that upregulate IFN response genes and inflammatory signals in KDM6B/Tet2 mice. BM CCR2+ monocyte expansion in KDM6B/Tet2 mice was confirmed by flow cytometry. Therefore, to evaluate the effects of acute STING activation in vivo, we treated KDM6B/Tet2 mice with a single dose of TAK-500. TAK-500 enhanced CCR2+ BM cell apoptosis and reduced LSK colony formation capacity. In vivo depletion of MOLM-13 and human CD45+ cells was also observed after acute TAK-500 treatment in xenograft models and in a CMML patient-derived xenograft model, respectively.
 To dissect the effects of short-term STING activation, we then treated KDM6B/Tet2 mice with vehicle or TAK-500 weekly for 3 consecutive weeks. Therapy was associated with peripheral blood monocyte depletion, BM CCR2+ cell depletion, and apoptosis. TAK-500 also induced LSK expansion and depletion of granulomonocytic, common-myeloid, and megakaryocytic/erythroid progenitors. LSK expansion with reduced colony-forming capacity and CD14+ monocyte differentiation was sustained in colony-formation assays. Bulk RNA-sequencing of sorted LSKs demonstrated downregulation of genes involved in RNA metabolism and translation, G1/S transition and neutrophil degranulation, suggesting reduced cell activity and differentiation. scRNA-seq of BM MNCs after 3 weeks of therapy confirmed depletion of CCR2+ cells, myelomonocytic precursors and monocyte populations with TAK-500 but not with vehicle. STING activation induced type I IFN gene expression (e.g Irf7) in monocytes and splenic extramedullary hematopoiesis. Analysis of cell-cell communication networks revealed increased number of interactions involved in cell migration, inflammation and immune interactions between monocyte and other cell types.
 To compare the effects of short vs long-term STING activation, we treated control and KDM6B/Tet2 mice with TAK-500 over a period of 14 weeks. In contrast to short-term STING activation, long-term TAK-500 exposure was not associated with CCR2+ cell depletion, changes in LSK or progenitor populations or transformation in KDM6B/Tet2 mice. scRNA-seq of MNCs revealed decreased expression of inflammatory genes on monocyte and progenitor populations compared to short-term exposure which suggests cell-adaptive responses to overcome inflammatory and cell death programs associated with acute STING activation.Together, these data highlight the complex effects of STING activation dynamics in distinct hematopoietic populations and their role in CMML pathophysiology.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14d404567ac411e598fe7813e54939096a5ebec9" target='_blank'>
              Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia
              </a>
            </td>
          <td>
            Yue Wei, Xiaoping Su, Ziyi Li, S. Loghavi, Hui Yang, Hong Zheng, Kirbie Linthicum, Vicky A. Appleman, Tiquella Hatten, Harry Huang, Jeffrey Raizer, Alexander Parent, N. Lineberry, Siddha Kasar, G. Garcia-Manero, G. Montalban-Bravo
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>141</td>
        </tr>

        <tr id="The tumor microenvironment (TME) plays a critical role at all stages of tumor progression. Cancer-associated fibroblasts (CAFs), as the main components of this environment, display diversities in origin, phenotype, and function, which contribute to cancer progression by regulating the tumor cell biology via cell–cell contact, releasing numerous regulatory elements such as growth factors (GFs), cytokines, and chemokines, and even remodeling the extracellular matrix (ECM). In this Review, we discuss the current understanding of CAFs’ pro- or anti-tumor functions in various hematological malignancies, including acute and chronic leukemia, lymphoma, and multiple myeloma (MM). The accumulating evidence highlighted that CAFs not only are implicated in these neoplasms’ initiation, development, and metastasis but also are involved in chemoresistance to various chemotherapy drugs such as daunorubicin and bortezomib. Intriguingly, cell culture-based methods’ results outlined that targeting signaling pathways that are used by CAFs to exert their pro-tumorigenic effects could be exploited in favor of tumor inhibition, which requires more investigation. Therefore, this therapeutic approach should be considered in future studies to develop a novel targeted therapy in hematological malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9c626fb73b1c7437edf3b7ee6bad0590c30c6a7c" target='_blank'>
              The emerging role of cancer-associated fibroblasts in hematological malignancies: from their influence on tumor progression and drug resistance to novel therapeutic opportunities
              </a>
            </td>
          <td>
            Sahar Jalilivand, Somayeh Yazdanparast, Mehdi Bakhtiyaridovvombaygi, Mehrdad Izadirad, Fatemeh Mikanik, Ahmad Gharehbaghian
          </td>
          <td>2025-11-11</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 CD8 T cells are a critical component of the immune response to infections as well as in prevention and restriction of cancer growth. Across multiple solid cancer types, tumor infiltration of CD8 T cells is associated with improved patient survival. CD8 T cell cytotoxicity and cytokine production have been characterized as the primary mechanisms by which these cells execute their immune function. However, basal cell motility, defined as random walk and exploratory spread, is an essential and underappreciated aspect of the CD8 T cell-mediated antitumor response. Cell motility enables effector CD8 T cells to search for and reach their cell targets within a solid tumor microenvironment. Here, we investigate the impact of IL-21 on effector CD8 T cell motility. We show that compared to effector CD8 T cells expanded in the presence of IL-2 alone, those expanded in IL-2 and IL-21 exhibit increased cell motility in vitro and in vivo. We also show that IL-21 enhances mitochondrial respiration and mitochondrial calcium in effector CD8 T cells. Our data suggests that increased mitochondrial calcium and mitochondrial ATP promote CD8 T cell motility through IL-21-mediated STAT3 activity. Therefore, IL-21 plays an important role in effector CD8 T cell mitochondrial fitness, cytoskeleton stiffness, and cell motility, which can be leveraged in the design of adoptive T cell therapies for the treatment of solid tumors.



 Supported by NIH R01 CA260909; T32AI007405.



 Cytokines and Chemokines and Their Receptors (CCR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c85e17d7c962d1daada79818491cc536bfb732e9" target='_blank'>
              Enhancement of effector CD8 T cell motility by IL-21 through STAT3 4131
              </a>
            </td>
          <td>
            Maureen Hoen Rauhut, Fahiima Abdullahi, Felipe Valença-Pereira, Mercedes Rincon
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 The treatment landscape of diffuse large B-cell lymphoma (DLBCL) has progressed with the emergence of immune-cell therapies (ICTs), such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. However, many patients still remain incurable despite these innovative options. Treatment resistance in DLBCL is associated with the immunosuppressive tumor microenvironment (TME), and myeloid-derived suppressor cells (MDSCs) play a crucial role in contributing to it. Furthermore, an increase in MDSCs has been linked to disease progression, poor prognosis, and reduced effectiveness of ICTs. Therefore, understanding how DLBCL cells promote MDSC development is essential for overcoming treatment resistance to ICTs. To address this issue, in this study, we investigated how DLBCL cells induce monocytic (M)-MDSCs from normal peripheral blood mononuclear cells (PBMCs) using an indirect co-culture system and traced the molecular changes involved. Four human DLBCL-derived cell lines (HDBCLs), including two double-expressor HDBCLs (KPUM-UH1 and KPUM-MS3) (Sasaki N, Exp Hematol 2011) and two activated B-cell-like HDBCLs (HBL1 and DLBCL2), were used. PBMCs from healthy donors were indirectly co-cultured with HDBCLs for 96 hours, and flow cytometry was used to analyze PBMCs for the induction of M-MDSCs displaying the CD14+/HLA-DR-/low phenotype. Total RNA was extracted from the CD33+ myeloid fraction of PBMCs after co-culture, and gene expression profiles (GEP) were analyzed using microarray analysis. Consequently, we first demonstrated that all four HDBCLs tested were effective in inducing CD14+/HLA-DR-/low myeloid cells from normal PBMCs within 96 hours of co-culture. The induced CD14+/HLA-DR-/low myeloid cells were also shown to be potent in inhibiting T cell proliferation, confirming these cells as M-MDSCs both phenotypically and functionally. The ability to induce M-MDSCs was highest in DLBCL2, followed by HBL1, while KPUM-UH1 and KPUM-MS3 showed modest M-MDSC-inducing capabilities. Based on the finding that M-MDSCs were induced through indirect co-culture with HDBCLs, we screened soluble factors in the conditioned medium (CM) of HDBCLs secreted by these cells using cytokine arrays, and found that all four HDBCLs secreted MIF. Additionally, the results showed that DLBCL2 cells produced high levels of interleukin-10 (IL-10), while HBL1 cells secreted IL-10 at low levels, and KPUM-UH1 and KPUM-MS3 cells did not produce detectable IL-10. We then examined the functional roles of MIF and IL-10 in the induction of M-MDSCs by HDBCLs. Interestingly, the MIF inhibitor 4-IPP greatly reduced M-MDSC induction by all four HDBCLs, and exposure to recombinant (r) MIF alone had minimal ability to induce M-MDSCs from normal PBMCs, indicating that MIF plays an essential but preparatory role in M-MDSC induction. Conversely, blocking IL-10 with a neutralizing antibody significantly decreased M-MDSC induction from PBMCs by IL-10-secreting HDBCLs, and adding rIL-10 increased the M-MDSC-inducing effect of IL-10-non-secreting HDBCLs, indicating that IL-10 plays a more facilitative role in inducing M-MDSCs. To understand the molecular regulation in PBMCs during the induction of M-MDSC by the co-existence with HDBCLs, we examined gene expression changes in CD33+ myeloid cells at 24, 48, and 96 hours after co-culturing with HDBCLs. We also examined the molecular dynamics in co-culture with non-IL-10-secreting cell lines that occurred after 96 hours of rIL-10 treatment. Results from gene set enrichment analysis revealed that gene sets associated with inflammatory response and tumor necrosis factor-alpha (TNF-α) signaling, as well as inflammatory molecules such as IL-1α, were upregulated 24 hours after co-culture. However, these upregulated gene sets became less expressed after 48 hours and eventually were downregulated after 96 hours. Additionally, the downregulation of inflammatory response and TNF-α signaling was further amplified by rIL-10. In conclusion, our study demonstrated that the multistep process of M-MDSC induction from PBMCs, triggered by HDBCLs, begins with an initial transient hyper-inflammatory phase induced by MIF and transitions into a post-inflammatory immunosuppressive phase accelerated by IL-10. Our findings suggest that targeting phase-specific cytokines and related molecules could reduce the induction, maturation, and proliferation of M-MDSCs, ultimately enhancing therapeutic outcomes, especially in ICTs.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ebe1659b4ff0741b0dd9144d5311758dfae1768" target='_blank'>
              Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells
              </a>
            </td>
          <td>
            Yu Inoue, Y. Shimura, Yui Niiyama-Uchibori, Shotaro Chinen, Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino, T. Tsukamoto, S. Mizutani, Junya Kuroda
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Immune Aplastic Anemia (AA) is an autoimmune disease where hematopoietic stem and progenitor cells (HSPC) are destroyed by cytotoxic CD8+ T cells, resulting in peripheral cytopenias, i.e. anemia, thrombocytopenia and neutropenia. Most compelling evidence that HSPC destruction is immune-mediated is that two-thirds of severe AA patients demonstrate hematologic improvement in response to immunosuppressive therapy consisting of anti-thymocyte globulin and cyclosporin A. Interferon γ (IFNγ) and tumor necrosis factor α (TNFα) have both been implicated as critical effector molecules involved in the destruction of bone marrow HSPCs in AA. Furthermore, mRNA expression of the inflammatory chemokine receptor CXCR3 and the chemokine CCL20, a ligand of CCR6, has been shown to be elevated in peripheral blood and bone marrow mononuclear cells, suggesting a role for T helper/cytotoxic (Th/c) 1 and Th/c17 cells in the pathobiology of AA.



 To further elucidate the pathobiology of AA, we conducted a comprehensive multiproteomic analysis of adult AA patients eligible for bone marrow transplant ([BMT]; n=20; samples pre-BMT) and matched healthy controls (n=20). We performed plasma proteomic analyses using Olink and conducted high-dimensional immunophenotyping by flow cytometry using peripheral blood mononuclear cells (PBMCs).



 Using Olink proteomic analysis, we observed that, relative to healthy controls, plasma from AA patients exhibited significantly higher levels of several hematopoietic growth factors, including thrombopoietin (TPO), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) and Fms-like tyrosine kinase 3 ligand (FLT3LG), indicating that an AA disease signature is reflected in circulation. Furthermore, we observed that AA patients had significant (Bonferroni corrected) elevations in interleukin 15 (IL15), a cytokine that plays a crucial role in T cell activation and effector functions. Thus, we looked at other T cell-associated molecules and observed trends towards elevations in several other cytokines in plasma of AA patients, including IFNγ, IL17A, IL17F, and interleukin 2 receptor α (IL2Rα). Interestingly, there was also a trend towards an increase in plasma CCL20 in AA patients, as previously reported.
 Using high-dimensional flow cytometry immunophenotyping on PBMCs, we observed an increase in the percentage of circulating T cells, both CD4+ and CD8+ T cells, in PBMCs from AA patients. These T cells exhibited an activated phenotype with increased surface expression of the costimulatory receptor 4-1BB. Profiling of both CD4+ and CD8+ T cell subsets revealed a T helper 17 (Th17) and T cytotoxic 1 (Tc1) cell enrichment with increased proportions in overall Th17 (both Th1.17 and Th17.22 cells) and Tc1 cells (both Tc1 and Tc1.17 cells).
 While antigen presentation plays a critical role in initiating immune responses in autoimmune diseases, little is known about the role of antigen presenting cells (APCs) in AA pathobiology. Here, we showed that, while the percentage of professional APCs, i.e., B cells, monocytes and dendritic cells, was reduced in blood of AA patients, these cells presented an activated phenotype characterized by significant upregulation of the costimulatory receptor 4-1BB at their surface. In addition, B cells from AA patients exhibited higher surface expression of the inflammatory chemokine receptor CCR6 and the antigen presentation molecule HLA-DR, while monocytes expressed higher level of CCR7, a chemokine receptor essential for cell migration to lymph nodes.Conclusion: In this study, we confirmed that AA is characterized by significant increases in several hematopoietic growth factors in the periphery, which may reflect compensatory mechanisms that counterbalance the lack of blood cell production in the bone marrow. Furthermore, we demonstrated that AA is an autoimmune disease characterized by an inflammatory phenotype biased towards a Th/c1.17 immune response and increased circulating Th1 and Th17 cytokines (e.g. IFNγ and IL17A/F). Finally, we showed that multiple APCs may participate in antigen presentation in AA, as both B cells and monocytes/DCs exhibit an activated phenotype with increased expression of chemokine receptors and major histocompatibility complex class II molecules. Overall, our data suggest that broad APC activation and pathogenic Th/c1.17 immune responses contribute to AA pathobiology.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc62d3214c4189d70d8471303aff50affc5b9a9f" target='_blank'>
              Comprehensive multiproteomic analysis reveals an inflammatory phenotype in immune aplastic anemia characterized by broad activation of antigen presenting cells and t helper/cytotoxic 1.17 immune responses
              </a>
            </td>
          <td>
            audrey le floch-ramondou, Julie Horowitz, Kirsten Nagashima, Maria Matthaiakaki Panagiotaki, Erica Chio, Shane McCarthy, Kerry Casey, S. Hamon, Thomas Norton, L. Perlee, Andrea T Hooper, J. Orengo
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 We are witnessing a significant increase in complex T cell-mediated immune disorders, such as food allergies and autoimmune disease. This trend suggests that the activation threshold for T cells may be altered, and understanding how to modulate this threshold has profound implications for disease treatment. In this study, we demonstrate that the effector program of CD8? T cells (including naïve, circulating memory, and tissue-resident cells) induced by TCR and cytokine stimulation is regulated by the class II histone deacetylase, HDAC5. HDAC5 exhibits little to no deacetylase activity against histone tails, but can function in the cytoplasm as a scaffolding protein or to directly deacetylate protein targets. Using small interfering RNA (siRNA) in cell lines of primary human CD8+ cytotoxic intraepithelial lymphocytes (IE-CTLs), we show that the loss of HDAC5 decreases their activation. Furthermore, inhibiting HDAC5 activity with the HDAC4/5 inhibitor LMK235 reduces the activation potential of ex vivo isolated human intestinal IE-CTLs following stimulation, suggesting that HDAC5 enzymatic activity is required for this effect. Finally, our data indicate that HDAC5 inhibition broadly impacts CD8? T cell activation, including in circulating memory and naïve subsets. This work identifies HDAC5 as a critical enzyme regulating the activation of CD8? T cells and highlights the potential of targeting HDAC5 to modulate CD8? T cell activation thresholds in inflammatory disorders.



 Supported by NIH BIBIB 2 T32 EB 9412; NSF Graduate Research Fellowship Program; University of Chicago Celiac Disease Research Center.



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3f63a425ec70d967412fb047c150bfd3ab601d0" target='_blank'>
              HDAC5 regulates the activation of cytotoxic CD8+ T cells 4190
              </a>
            </td>
          <td>
            Megan Borregard, C. Ciszewski, Yandong Zhang, Hening Lin, B. Jabri
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>70</td>
        </tr>

        <tr id="


 T cell-engaging bispecific antibodies (TCBs) depleting B cell subsets are promising therapeutics for cancer and autoimmune diseases, with several approved or in development. However, an unavoidable consequence is immunosuppression in already vulnerable patients. Depleting B cells compromises the ability to fight infections and vaccine efficacy. These risks vary with underlying disease, effects on off-target cell populations and the TCB target. Differentiating drug candidates’ secondary TCB effects is key in drug development, but preclinical models may not fully capture complex B cell biology. We employed a multimodal systems immunology approach of two human in-vitro systems: immune organoids capturing productive germinal center responses, and an immunocompetent bone marrow model with B precursor- and differentiated plasma cells. We integrated data from high-dimensional flow cytometry, single cell RNA- and CITE-sequencing, to assess the consequences of TCB-mediated immune responses across different tissues. This allowed us to capture a differential off-tumor B cell subset toxicity of TCBs directed against two therapeutically validated TCB targets, in line with the reported clinical infection risk and B cell depletion that diverge between both. Overall, this translational work shows the value of human in-vitro approaches as a preclinical evaluation for immunosuppression, by accurately capturing complex human immune biology and therapeutic activity of candidate molecules.



 Translational and Interventional Immunology (TI)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ab71e60522c5a275a95f316de0a2c67184842200" target='_blank'>
              Translating immunosuppressive risks of T-cell bispecifics using human in vitro models and systems immunology 9247
              </a>
            </td>
          <td>
            Lea Schroer, Jenna M. Kastenschmidt, Michael Bscheider, Nick Corr, Susanne Fischer
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the accumulation of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB). Several alterations in the BM microenvironment have been linked to AML onset and progression, some of which affect the immune system and promote tumor evasion. Genetic alterations also contribute to these processes, including overexpression of the MN1 gene, which is addressed in this study. MN1 overexpression is associated with a more aggressive leukemic phenotype and therapeutic resistance. Among the pathological findings in the leukemic BM microenvironment, the relative increase in AML-associated macrophages (AAMs) appears to support AML progression. AAMs display a phenotype similar to that of healthy M2-like macrophages and are thus linked to anti-inflammatory and immunosuppressive activity. In this context, therapeutic approaches aimed at reprogramming AAMs toward a more inflammatory and antitumoral profile, resembling M1-like macrophages, have been investigated. This study aimed to evaluate the immunomodulatory effects of BPI-2358, a tubulin polymerization inhibitor and JNK pathway activator, on AAMs in AML models driven by MN1 overexpression. Human PB-derived M2 macrophages were treated with BPI-2358 (0.125–0.5 µM) for 48 hours. Immunophenotyping (CD80, CD86, CD206, CD163) and cytokine analysis (TNF-α, IL-1β, TGF-β) revealed a shift toward a pro-inflammatory profile. Our findings showed that BPI-2358 treatment had a significant impact on marker expression, leading to an upregulation of CD86 and a downregulation of CD163 in human samples. Additionally, we detected elevated levels of pro-inflammatory cytokines, including IL-1β and TNF-α, along with a reduction in TGF-β secretion. Similarly, murine BM-derived M2 macrophages treated under the same conditions showed increased expression of M1-related genes (Cd80, Tnf-α, Nos2) and downregulation of Arg1, a classical M2 marker, by qRT-PCR. A phagocytosis assay was performed using M2-polarized murine macrophages treated with BPI-2358 (0.5 μM) and MN1-GFP⁺ murine AML cells. Treated macrophages exhibited an increased phagocytic capacity compared to untreated controls. A cell proliferation assay was performed by co-culturing BM-derived M2 murine macrophages, pre-treated with BPI-2358 (0.5 μM), with MN1-GFP⁺ murine AML cells at a 1:1 ratio. Cell growth was monitored over a 10-day period by performing regular cell counts. Notably, a significant decrease in MN1 cell proliferation was observed on days 3 and 4 in co-cultures with BPI-2358-treated macrophages, indicating that the treatment impaired leukemic cell expansion. Moreover, exposure to an AML-conditioned microenvironment induced a tolerogenic macrophage profile in vitro, which was partially reversed by treatment, highlighting the functional plasticity of these cells. Transcriptomic analysis by RNA-seq revealed differential gene expression and pathway enrichment consistent with macrophage reprogramming. Transcriptomic analysis showed that BPI-2358 upregulated 4,829 genes, including those involved in tissue damage response, tissue remodelling, and the pro-inflammatory cytokine Il1b. The treatment also significantly suppressed the IL-6/JAK/STAT3 pathway, a key driver of the immunosuppressive M2 phenotype and tumor immune evasion. Ex vivo cytotoxicity was assessed in a panel of primary AML samples (n=25) treated with BPI-2358 (0.125–0.5 µM) for 72 hours. Flow cytometry was used to evaluate viability of leukemic blasts (CD34⁺ or CD117⁺ for CD34⁻ AMLs) and macrophages (CD34⁻ or CD117⁻ HLA-DR⁺ CD14⁺) using Annexin V/DAPI staining and TMRE for mitochondrial membrane potential. Finally, the in vivo efficacy of BPI-2358 was assessed in an MN1-driven AML mouse model (MN1-GFP⁺). Mice received BPI-2358 (7.5 mg/kg IP, daily), and flow cytometry analysis of the BM showed a reduction in leukemic engraftment. The treatment did not impact the animals' body weight, suggesting minimal systemic toxicity. A significant decrease in the frequency of circulating MN1⁺ cells was observed, along with a marked reduction in MN1⁺ cell infiltration in the spleen. This was further supported by a significant decrease in spleen weight in the BPI-2358-treated group. These findings reinforce the potential of macrophage reprogramming as a complementary strategy in AML treatment, especially in molecularly high-risk subtypes such as those associated with MN1 overexpression.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7341436505bbad9e3856fea1f022bb194207dcdb" target='_blank'>
              BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo
              </a>
            </td>
          <td>
            L. Pinheiro, I. Weinhäuser, D. Pereira-Martins, Katherine Hampton, Annalisa Altera, D. Fowler-Shorten, Matthew Markham, A. Polski-Delve, Tabitha Bartlett, C. Hellmich, Luíse A A Simões, Cleide Lúcia Araujo, Rita De Cássia Cavaglieri Medeiros, L. Quek, G. Huls, J. Schuringa, S. Rushworth, E. Rego
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="
 Brain metastases (BM) from lung adenocarcinoma represent a formidable clinical challenge due to limited therapeutic efficacy. To gain insight into complex tumor microenvironment (TME) of BM, we analyzed single-cell RNA-sequencing data comprising 66,769 cells from primary tumors (PTs; 44,355 cells) and matched BM lesions (22,414 cells). Our analysis revealed a profound shift in cellular composition during metastasis: while T cells predominated PT (44.12%), tumor cells became the most abundant population in BM (55.17%), with corresponding reductions in T cells (27.57%) and macrophages (19.3%). Cell–cell communication analysis identified fibroblasts as central mediators in both PT and BM, with a transition from collagen signaling in PT to thrombospondin signaling in BM, facilitating interactions with tumor cells, B cells, and oligodendrocytes. Ingenuity Pathway Analysis revealed enrichment of collagen-related genes in fibroblasts (MFAP4, COL15A1, FBLN1, FBLN2) and Th1/Th2 pathway genes in T cells (IKZF1, SH2D1A, RASGRP1, SKAP1). Subclustering uncovered seven distinct fibroblasts subpopulations and a notable shift from PT-enriched C0 to BM-enriched C1, suggesting dynamic phenotypic adaptation. Pseudotime trajectory analysis further clarified fibroblasts differentiation states. T-cell subclustering revealed a significant increase in immunosuppressive regulatory T cells (84.1%) and proliferating CD4+ T cells (10.5%) in BM, highlighting mechanisms of immune evasion. COL15A1 expression correlated with poor patient survival and emerged as a promising therapeutic candidate, showing increased sensitivity to Dabrafenib, Trametinib, Piperlongumine, Cabozantinib, Staurosporine, and Vemurafenib. Additional gene drug associations were observed, with FBLN1, RASGRP1, MFAP4, SH2D1A, and IKZF1 linked to potential sensitivity to Erlotinib, Afatinib, Fluorouracil, and Brefeldin A. These findings provide a high-resolution map of the BM TME and highlight COL15A1 and related pathways as potential targets for precision therapy in patients with BM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc3a5b204d80d9cd5d66d31480f9cf9dd3274795" target='_blank'>
              TMIC-44. Fibroblast reprogramming and immune evasion define the tumor niche in brain metastases
              </a>
            </td>
          <td>
            Sanskriti Dey, J. Chuang, Chih-Yang Wang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains one of the most lethal primary brain tumors, characterized by profound immunosuppression and resistance to conventional immunotherapy. A hallmark of the GBM microenvironment is the prevalence of functionally exhausted T cells, marked by sustained expression of inhibitory receptors such as PD-1 and impaired effector function. These exhausted T cells represent a major barrier to durable anti-tumor immunity and effective immunotherapeutic intervention. To address this, we explored PD1-IL2v, an engineered immunocytokine designed to selectively stimulate PD-1⁺ cells with IL-2 signaling while minimizing activation of regulatory T cells. Using both the immunogenic GL261 and the immune checkpoint-resistant SB28 murine models of GBM, we administered PD1-IL2v either systemically or directly into the tumor. Flow cytometry was employed to assess changes in tumor-infiltrating lymphocytes, with particular focus on exhaustion and effector phenotypes. Notably, local administration of PD1-IL2v, but not systemic delivery, effectively reactivated CD8⁺ T cells within the tumor microenvironment. PD1-IL2v treated mice exhibited enhanced cytokine production, increased proliferation, and restoration of cytotoxic activity in T cells. Phenotypic profiling of tumor infiltrating lymphocytes (TILs) revealed an expansion of a stem-like subset of exhausted T cells (PD-1⁺TCF1⁺), alongside the emergence of a novel, differentiated population with superior effector functions, termed “better-effector” T cells. Therapeutic intervention with PD1-IL2v led to complete tumor rejection in a subset of animals, and increased infiltration of functional T cells into the tumor core. Our findings underscore T cell exhaustion as an untapped reservoir of tumor-reactive T cells that can be therapeutically reinvigorated using PD1-IL2v. This approach not only restores anti-tumor immunity but also induces superior effector populations capable of driving tumor regression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d2a360e4ecb23a3988292b555a7155b5788a697" target='_blank'>
              IMMU-26. Reinvigorating exhausted T cells in glioblastoma via PD1-IL2v immunocytokine therapy
              </a>
            </td>
          <td>
            U. Salazar, B. Taskoparan, Sereina Deplazes, V. Nicolini, Laura Codarri-Deak, H. Okada, C. Klein, Johannes vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Clonal hematopoiesis (CH), defined as an expanded hematopoietic stem cell (HSC) clone with somatic mutations in the absence of blood malignancy, is common in aging and associated with increased severity of inflammatory non-hematologic disorders. The co-occurrence of CH in patients with solid tumors correlates with poor prognosis and a more aggressive phenotype of the malignancy. This leads to the notion that CH mutations alter anti-cancer immunity, and that CH-derived monocytes and macrophages may contribute to a proinflammatory tissue microenvironment. Being innate immune cells, monocytes and macrophages can mount a heightened inflammatory and defense responses to secondary challenges (“trained immunity”) that are known to accentuate tumor control. On the other hand, excessive or prolonged stress stimulus may lead to its suppression (“immune tolerance”). The effect of DNMT3A mutations found in CH on innate immune responses has not been explored.
 Using colitis-associated colon cancer (CAC) as a model, we previously reported that CH driven by heterozygous loss of Dnmt3a, mimicking the most common genetic alteration in human CH, promoted initiation and progression of solid tumors in the context of severe chronic inflammation. We hypothesized that Dnmt3a-CH tilts myeloid responses toward immune tolerance rather than trained immunity, compromising tumor control.
 To assess the impact of Dnmt3a-CH to tumor immune microenvironment (TME), we created a mouse model with 10% test BM cells (Dnmt3a+/– or WT control) marked with CD45.2 mixed with 90% CD45.1+CD45.2+ WT competitor and engrafted into pre-conditioned CD45.1+ recipients prior to CAC induction by the azoxymethane (AOM)/dextran sulfate sodium (DSS) method. Mice with Dnmt3a+/– BM developed more numerous, larger CAC tumors, solidifying the prooncogenic role of Dnmt3a-CH. Flow cytometry revealed preferential infiltration of Dnmt3a+/– BM-derived cells in the TME, particularly immune-suppressive M2-like macrophages. Increased abundance of Dnmt3a+/– anti-inflammatory M2-like macrophages was confirmed by scRNA-seq on FACS-sorted tumor-infiltrating donor-derived CD45.2 cells from mice non-competitively transplanted with Dnmt3a+/– compared to WT control BM. Cytokine profiling in whole tumor lysates revealed reduced pro-inflammatory IL-1β and TNF-α indicating a switch to a tolerogenic immune state in Dnmt3a+/– BM chimerae.
 Repeated inflammatory insults can cause a switch to immune tolerance. To test this, mice transplanted with Dnmt3a+/– and WT control BM were subjected to 3 bouts of DSS-induced bacterial colitis or kept untreated. Despite developing more pronounced colitis as evidenced by greater shortening of the colon and increased weight loss, Dnmt3a+/–-engrafted recipients showed decreased pro-inflammatory cytokine levels in serum and elevated levels of immunosuppressive IL-10. Strikingly, although in vitro differentiated BM-derived macrophages (BMDMs) from untreated Dnmt3a+/– mice showed higher phagocytic activity compared to WT controls, this function was dramatically impaired after DSS challenge in alignment with an immune tolerance phenotype. Similar results were observed in human THP-1 cells CRISPR-edited to disrupt one DNMT3A allele. After stimulation with high-dose lipopolysaccharide (LPS) to mimic an inflammatory challenge associated with endotoxemia secondary to colitis, DNMT3A-disrupted THP-1 macrophages exhibited significantly dampened phagocytosis compared to WT controls. RNA-seq analysis revealed the DNMT3A+/- THP-1 showed reduced expression of gene sets and pathways related to inflammation and innate immune defense.
 These observations demonstrate that tolerogenic reprogramming of Dnmt3a-CH macrophages after an inflammatory insult establishes a tumor-permissive immune microenvironment in CAC. Indeed, myeloid-specific heterozygous Dnmt3a loss (by LysM-Cre) was sufficient to promote tumor initiation, while depletion of phagocytes in vivo using clodronate liposomes during CAC induction reversed Dnmt3a-CH-induced increase in colon tumor burden.
 In conclusion, DNMT3A-driven CH enables colitis-associated tumorigenesis by priming myelopoiesis towards innate immune tolerance under excessive inflammation, creating an immunosuppressive TME and corrupting tumor control. Targeting innate immune tolerance in individuals with DNMT3A-CH may represent a strategy to mitigate the risk of inflammation-associated cancers.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e59f93632128a080292d7ca72e60726d86ccb977" target='_blank'>
              DNMT3A-driven clonal hematopoiesis permits colitis-associated tumorigenesis by promoting innate immune tolerance
              </a>
            </td>
          <td>
            Qingchen Yuan, Yang Feng, Christopher Thai, Andrey Smirnov, Eric Helm, Bowen Yan, Prabhjot Kaur, Annalisse R. Mckee, Cassandra Berntsen, Daniil E. Shabashvili, Jixiu Shan, Jason Brant, Dorina Avram, Hossein Khiabanian, Jonathan Licht, Olga A. Guryanova
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Background Cellular immunotherapy has revolutionized cancer treatment. Yet its efficacy in acute myeloid leukemia (AML) remains limited due to an immunosuppressive tumor microenvironment (TME) often characterized by deficient immune-stimulatory cytokines and elevated immunosuppressive metabolites. Adenosine (Ado), a key inhibitor is degraded by the non-redundant enzyme adenosine deaminase (ADA), which converts Ado into the immune-stimulatory inosine (Ino). IL-12 is a potent cytokine that strongly boosts immune cells, but its systemic toxicity limits clinical use. To address this, we engineered tumor-homing, non-pathogenic Escherichia coli (E. coli) to co-display surface-tethered IL-12 and ADA, enabling localized cytokine delivery and metabolic reprogramming. We hypothesized that this dual strategy efficiently reprograms the immunosuppressive niche in AML, thereby unlocking robust local NK (and T cell) anti-leukemic immunity.
 Method Non-pathogenic E. coli K12 DH5α were engineered to surface-display murine and human IL-12, ADA, or IL-12+ADA fusion using optimized outer membrane scaffolds with FLAG tags using an approach in our recently published paper (Yang et al, Nature Biotechnology 2024). Expression was induced with rhamnose and confirmed by flow cytometry. IL-12 bioactivity was validated via HEK-Blue reporter assay. ADA kinetics and activity were assessed via LC-MS and colorimetric assays. NK cells were co-cultured for 24h with E. coli displaying ADA, IL-12, ADA+IL-12, or scaffold control followed by multicolor flow cytometry to assess Ado-signaling (A2AR, CD73, CD39, CD26), surface markers (i.e., CD25, NKG2D, NKp30), and AML-directed cytotoxicity (Zombie-NIR, IFNg, TNFα) against the AML targets NOMO1 and OCI-AML3. To model TME metabolism, cells were treated with 1mM Ado, Ino or PBS. In-vivo efficacy was tested in a immunocompetent B16-F10 melanoma model and BALB/c mice bearing GFP⁺/NanoLuc⁺ WEHI-3 AML cells. Leukemic burden (bioluminescence imaging, blood), weight, and survival were monitored. Bacterial distribution was assessed by CFU assays in relevant organs.
 Results Engineered E. coli co-displaying IL-12 and ADA showed robust FLAG-tagged surface expression (>80%) with significant IL-12 bioactivity (OD650, 0.9 vs. 0.2, p<.001). Murine ADA displayed by YiaT181 showed highest enzymatic activity (Km=0.05, Vmax=53µmol/min), fully converting Ado to Ino within 4h. NK cells cocultured with IL-12 displaying E. coli showed strong upregulation of key activation markers compared to scaffold control (CD25, 56 vs. 25% and NKp30, 68 vs. 35%, p<.001), leading to a ≥3.4-fold greater AML-directed cytotoxicity and IFNγ production. Importantly, rhIL-12 (50ng/ml) increased expression of the Ado-generating metabolic checkpoint CD73 (2 to 9%, p=.003) and Ado receptor A2AR on NK cells (31 to 51%, p=.001), indicating increased Ado susceptibility. Ado exposure reduced AML-directed killing by ~50% (p<.001) and NK cell activation (NKp30 expression was 33 vs. 18%, p=.003). ADA-expressing E. coli restored NK cell immunity and AML lysis in-vitro (55 vs. 15%, p<.001). Co-display of IL-12 and murine ADA maintained full NK effector function under Ado-rich conditions and enhanced AML-targeted lysis (15 vs. 56%, p<0.01). In-vivo, i.v. delivery of E. coli expressing ADA, IL-12, or ADA+IL12 fusion was well-tolerated and demonstrated potent antileukemic activity in immunocompetent WEHI-3 AML models. Substantial tumor control led to prolonged survival in the IL-12+ADA group (2 of 3 alive at d29, median survival not reached) vs a median of 10 days in control mice. Robust tumor control was reached in the IL-12 (26d) and ADA (17d) group. Post-mortem analysis of mice revealed unprecedented tumor-guided bacterial migration to the bone marrow, a phenomenon not previously reported. ADA-engineered bacteria accumulated up to 4x105 CFU and IL-12 displaying bacteria up to 3x104 CFU in the bone marrow. Intratumoral delivery of IL12+ADA-engineered E. coli induced complete tumor regression and 100% survival in a B16-F10 melanoma model, with tumor rechallenge confirming durable antitumor immunity, suggesting immune memory and long-term immune protection.
 Conclusion Engineered nonpathogenic E. coli co-displaying IL-12 and ADA effectively reprogram the AML TME, enhance NK cell activation, and drive sustained anti-tumor responses. This live microbial platform offers a safe, localized, and versatile immunotherapy strategy applicable to both hematologic and solid tumors.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/04c11cfcf5a3539fa2c39d0839134cb7fc2116bd" target='_blank'>
              Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity
              </a>
            </td>
          <td>
            Stephanie Sendker, Shaobo Yang, Anna Clara Bader, Alice Chen, Eden Bobilev, Ashley Hu, Xingyu Deng, Fuguo Liu, Veronica Hui, Maily Nguyen, Andreia Maia, Sara Piccinelli, Kerim Berkay Aslan, Fabian Göllner, A. Ali, Rémy Duléry, Hetal Nath, Daniel Chen, Mounica Vallurupalli, Andrew Lu, Stephanie Chamberlain, Tereza Kochs, Nathalie Javidi-Sharifi, Michal Sheffer, Roman Shapiro, Andrew Lane, Robert J. Soiffer, Mubin Tarannum, Jerome Ritz, R. Romee
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="


 A durable T cell immunity against cancer is dependent on a continually refilling of effector CD8+ T cells. Thymic output has been correlated with favorable prognosis in cancer patients of advanced ages, suggesting thymus is an important source for refilling T cells that are capable of controlling cancer progression in the periphery. However, it remains unclear how PD-1 signals regulate the cytotoxic potential of CD8+ T cells in thymus before they egress to the periphery to establish durable anti-tumor immunity. Here we report PD-1 signaling prelimits thymic single positive (SP) CD8+ T cells to acquire cytotoxic potential by downregulating Gzmb and Nkg7, which are required for CD8+ T cell-mediated cytotoxicity. Unexpectedly, we found the absence of Pdcd1 also led to upregulation of Tox and Tim3 in thymic SP CD8+ T cells, thereby pre-programming these cells for exhaustion within the tumor. Thus, the absence of PD-1 signals in CD8+ T cells only partially delayed tumor growth in peripheral tissues. To improve therapeutic effects of PD-1 inhibition, we observed that tumor growth in CD8-specific Pdcd1 conditional knockout mice was further suppressed by treatment with a PD-L1 antibody that blocks PD-L1 and CD80 interaction. Our results imply that PD-1 inhibition promotes the expansion of effector cytotoxic CD8+ T cells but also retains T cell exhaustion potential, which can be mitigated by PD-L1 blockade that allows more CD80 to provide costimulatory signals to T cells via CD28.



 NCI R01CA256927 NCI R01CA261932 NCI P30CA15083



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb1a412c0952a008bc31b083b4dec69b7fbe6657" target='_blank'>
              PD-1 prelimits both cytotoxic and exhaustion potential in thymic CD8+ T cells and affects sustaining peripheral tumor immunity 2875
              </a>
            </td>
          <td>
            Zhiming Mao, Jacob B Hirdler, Cindy Liu, M. Maynes, Joanina K. Gicobi, Michelle A Hsu, Emilia R Dellacecca, Wenjing Zhang, Fabrice Lucien-Matteoni, Haidong Dong
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Despite significant advancements in targeted therapies and immunotherapies, a substantial proportion of non-small cell lung cancer (NSCLC) patients remain unresponsive to treatment. One contributing factor is tumor-induced immunosuppression, which impairs effective T cell responses. Natural killer (NK) cells, while playing a pivotal role in antitumor immunity, have been shown to negatively regulate adaptive immune responses in various contexts. In this study, we characterized the phenotype of NK cells within the NSCLC microenvironment and investigated their potential contribution to immune suppression. CD3- CD56+ NK cells were isolated from tumor resection specimens and profiled using single-cell RNA sequencing and CITE-seq. Identified NK cell clusters were subsequently quantified in tumor-infiltrating lymphocyte (TIL) cultures exhibiting different expansion rates. Our analyses identified a tumor-specific NK cell subset associated with reduced recurrence-free survival (RFS). This subset was preferentially enriched in TIL cultures with low expansion rates compared to those with high expansion rates, suggesting a potential role in limiting T cell proliferation. Future investigations will focus on confirming the regulatory role of this NK cell subset and elucidating the mechanisms underlying its suppressive function.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96876b361473daba1aa036fd63568ae3002f5c55" target='_blank'>
              Immunoregulatory NK cells in non small cell lung cancer (NSCLC) 3221
              </a>
            </td>
          <td>
            Jules Sotty, D. Chung, Nicolas Jacquelot, Jehan Vakharia, Azin Sayad, Ben X Wang, P. Ohashi
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Post-Acute Sequelae of COVID-19 (PASC) are rapidly evolving into a major public health concern. However, the link between acute infection and chronic disease remains unclear. With insights from 3 PASC patient cohorts, we established a clinically relevant mouse model and identified an aberrant immune-epithelial progenitor niche unique to the fibroproliferation in respiratory PASC. Using spatial transcriptomics and imaging, we found that lung-resident CD8+ T-cell (TRM)-derived IFN-γ and TNF stimulated local macrophages to chronically release IL-1β, promoting the accumulation of dysplastic epithelial progenitors to drive fibrosis. Neutralization of IFN-γ and TNF, or IL-1β activity improved alveolar regeneration and pulmonary function, presenting a therapeutic strategy to rescue post-viral disease in the aftermath of infection. We believe that the accumulation of CD8+ TRMs occurs due to an evolutionary need of the epithelium to maintain memory of injury and ensure rapid protection at these vulnerable sites in case of subsequent viral exposures. Dysregulation of this immune-epithelial crosstalk however, results in pathological remodelling of the lungs as observed in PASC. Thus, we are exploring the role of epithelium and the molecular basis of this crosstalk to identify key mediators to ultimately uncouple the protective and pathological functions of CD8+ TRMs post-infection to promote functional lung recovery without compromising immunity to future infections.



 Harish Narasimhan: F31HL170746 and T32AI007496 Jie Sun: AI147394, AG069264, AI112844, HL170961, AI176171 and AI154598



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/543188223d45038e3c98aeb834d328a6cf25d7e3" target='_blank'>
              An aberrant immune-epithelial progenitor niche drives post-viral sequelae 3466
              </a>
            </td>
          <td>
            H. Narasimhan, Jie Sun
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="


 Introduction: Although BCMA-targeted CAR-T therapies and CD3×BCMA bispecifics (e.g., teclistamab) have shown clinical promise, most r/r MM patients eventually relapse due to tumor-intrinsic resistance and T-cell dysfunction. Emerging evidence implicates epigenetic regulators promote immune evasion, tumor cell stemness, and therapeutic resistance in MM. We previously demonstrated that the catalytic subunits of the polycomb repressive complex 2, EZH1 and EZH2, contribute to immune escape and resistance to immunotherapies in germinal center–derived B-cell lymphomas, thus influencing the efficacy of anti-CD19 CAR-T therapy. In MM, EZH2 is frequently overexpressed in cytogenetically high-risk disease and at relapse. We, therefore, hypothesized that inhibition of EZH1 and EZH2 could enhance T cell–based immunotherapy for MM by both directly impairing tumor growth and survival, and by boosting T cell–mediated cytotoxicity.Methods and Results: We first demonstrated a strong tumor-intrinsic anti-clonogenic effect of the EZH2 inhibitor (tazemetostat) and the dual EZH1/2 inhibitor (valemetostat) on the MM cell line RPMI-8226. Colony formation assays revealed a significant, progressive reduction in clonogenic growth following treatment with tazemetostat and valemetostat, with the most pronounced effect observed with dual inhibition (day 10, number of colonies, RPMI-8226: DMSO vs EZH1/2i, 622.5 vs 292.5; p=0.0046).
 We next employed clinically relevant anti-BCMA CAR-T constructs and performed long-term killing assays combining MM cell lines with EZH1/2 inhibitors, with or without CAR-T cells. Notably, EZH1/2 inhibitors significantly enhanced cytotoxicity against MM cell lines (e.g., RPMI-8226; day 5; CAR-T-BCMA+EZH1/2 inhibitor vs CAR-T-BCMA+DMSO, p<0.001). Similarly, in assays using the FDA-approved anti-CD3/anti-BCMA bispecific antibody teclistamab and human T cells, we observed an additive tumor-killing effect (48 hrs; teclistamab+T cells+EZH1/2 inhibitor vs teclistamab+T cells+DMSO, p<0.01).
 Importantly, EZH1/2 inhibition did not impair T-cell viability or effector function. ELISA of co-culture supernatants showed dose-dependent increases in IL-2 and TNF following teclistamab dose escalation, with no significant impact from the inclusion of EZH1/2 inhibitor, confirming intact T-cell cytokine production (24 hrs; teclistamab 1 nM; IL-2 [pg/mL]: DMSO vs EZH1/2 inhibitor, 29 vs 23.7, p=ns; TNF: 503 vs 528, p=ns).
 Finally, we developed an intraosseous orthotopic xenograft model of MM using RPMI-8226 cells. Three days after tumor implantation, mice were administered valemetostat (100 mg/kg, orally, once daily for five weeks) or a vehicle control. One week after the RPMI-8226 injection, the mice were randomized to receive CART-BCMA therapy (0.8 × 10⁶ cells per mouse, intravenously). In this model, continuous valemetostat treatment enhanced the tumor-suppressive effect of CART-BCMA, supported T cell expansion in peripheral blood, and was not associated with any notable toxicities such as weight loss or GVHD. Of note, valemetostat/CART-BCMA combination doubled complete response rate (80% vs 40%) and showed increased serum levels of IFN-γ, a key cytotoxic cytokine, indicating heightened T cell activation and cytolytic function.
 Mechanistically, EZH1/2 inhibition did not alter BCMA expression at either the RNA or protein level, indicating that target antigen expression was preserved. However, RNA-seq analysis of RPMI-8226 and MM1.S cells treated with EZH1/2 inhibitors revealed upregulation of genes involved in cell adhesion (e.g., LAMA1, LAMA2, VCAN, PECAM1), immunogenic signaling (e.g., CXCL9, CXCL10, CXCL14, CD70, TNFSF9), and differentiation (SDC2), along with downregulation of cell cycle–associated genes. These results suggest that EZH1/2 inhibitors reprogram MM cells to a more immunogenic and less proliferative state, enhancing their susceptibility to immune-mediated attack.
 Conclusions: These findings support a dual mechanism of action EZH1/2 inhibitors directly suppress MM clonogenicity and immune evasion, while concurrently enhancing the function and cytotoxicity of T cell–based immunotherapies. By preserving T-cell activity and reprogramming tumor cells, EZH1/2 inhibition represents a promising strategy to improve the durability and depth of response to both CAR-T and bispecific antibody therapies in MM. These data support the development of clinical trials combining EZH1/2 inhibitors with CART and bispecific antibodies in r/r MM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/afe0fbed1d1da929c31f9300e345f697fc861014" target='_blank'>
              Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma
              </a>
            </td>
          <td>
            P. Porazzi, Martina Pucillo, Anushka Anant Padmanabhan, Siena Nason, Zhixuan Zheng, L. Paruzzo, Matthew Ho, Peter Michener, Federico Stella, Antonio Imparato, S. Susanibar-Adaniya, Alfred Garfall, J. Fraietta, M. Ruella
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="


 Immune checkpoint inhibition (ICI) has dramatically advanced cancer treatment but is associated with adverse outcomes including ICI-induced myocarditis. Recent work demonstrated that T cells restricted to cardiac antigens are indispensable, yet how these cells provoke fatal cardiac damage remains poorly defined. To interrogate the mechanisms underlying myocarditis, we derived a transgenic mouse line with cardiomyocyte-restricted ovalbumin expression. Transfer of naïve OTI T cells into transgenic recipients did not induce pathology, but the addition of ICI led to myocarditis. Critically, PD-1 blockade alone proved sufficient. Our findings suggest that PD-1 blockade facilitates de novo CD8 T cell priming, independent of conventional microbial stimuli. Current work aims to determine if ICI obviates the need for classical 2nd and 3rd priming signals. Additionally, we characterized diseased hearts following CD8 T cell priming and subsequent cardiac infiltration. T cells constitute half of the infiltrating immune cells, while inflammatory monocytes/macrophages and DCs dominate the non-lymphocyte population. Elevations in innate cytokines IL-1β and IL-6 were also identified. We then targeted T cell-mediated innate inflammation to ameliorate disease. Thus, these studies use a novel mouse model to 1) underscore the role for CD8 T cells, 2) reveal a noncanonical activation pathway of CD8 T cells during PD-1 blockade, and 3) posit a role for innate inflammation as a driver of pathology.



 Supported by AHA predoctoral fellowship (24PRE1198808); NIH/NIAID AI123176; NIH/NHLBI HL156852



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3a81d81333df1541d1c40b6e6fdc183b42d1e5e" target='_blank'>
              Immune checkpoint blockade induces de novo CD8 T cell priming and innate inflammation leading to myocarditis 3714
              </a>
            </td>
          <td>
            Kathrynne A. Warrick, Jeffery D. Molkentin, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Tumor-immune infiltration is an important predictor of immunotherapy response in undifferentiated pleomorphic sarcoma (UPS). However, most patients respond poorly to immunotherapy due to a lack of tumor infiltrating T cells and an enrichment of tumor-promoting macrophages. Increasing tumor-immune infiltration is therefore critical to improve survival and treatment response in UPS patients. Our goal is to determine why some tumors recruit more immune cells than others. We are investigating how Vgll3, a frequently overexpressed gene in UPS, regulates tumor immune infiltration. In a mouse model of UPS, recent work showed increased immune infiltration into Vgll3-overexpressing tumors (Vgll3+) and a robust response to chemotherapy compared to immune-excluded sarcomas. We are now defining the cellular and molecular mechanisms by which Vgll3 drives immune infiltration to identify pathways that could potentially be targeted therapeutically in genetically distinct, immune-excluded tumors. We observed stronger type I IFN production by Vgll3+ sarcoma cells than sarcoma cells with normal levels of Vgll3, and that Vgll3+ tumors are enriched in a subset of immunostimulatory IFN-responsive classical monocytes. Our studies will reveal new insights into the mechanisms of sarcoma-immune cell infiltration, highlight differential responses of immune subsets to tumor-derived factors, and uncover therapeutic targets to enhance treatment response and survival outcome in UPS patients.



 Supported by funds from the Board of Governors Regenerative Medicine Institute at Cedars-Sinai (to HSG).



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20e44e54d02e13d3da3880c3c66228daf1821c74" target='_blank'>
              Role of Vgll3-driven Type I IFN in Shaping the Sarcoma Immune Landscape 9365
              </a>
            </td>
          <td>
            Basia Gala, E. Ko, Karina Nance, Helen S. Goodridge, Jlenia Guarnerio
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Background/Objectives: In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms. Methods and Results: Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis, but, in the absence of PD-1, tumor cells express NK cell inhibitory receptors, highlighting the necessity for leukemic cells to evade the host’s NK immune response in order to exit the bone marrow. PD-1 expression reduces natural antitumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. Conclusions: These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b41b3b2aebacf7f7340a2020174ac633c1537ec" target='_blank'>
              PD-1 Expression Promotes Immune Evasion in B-ALL
              </a>
            </td>
          <td>
            Ana Casado-García, Gonzalo García-Aguilera, Julio Pozo, Ninad Oak, S. Barrena, Belén Ruiz-Corzo, Jaanam Lalchandani, Ana Chamorro-Vera, Ana Castillo-Robleda, Beatriz Soriano, Silvia Alemán-Arteaga, Elena G. Sánchez, Jorge Martínez-Cano, Andrea López-Álvarez de Neyra, Paula Somoza-Cotillas, Oscar Blanco, Susana Riesco, Pablo Prieto-Matos, Francisco Javier García Criado, M. B. García Cenador, C. Cobaleda, Carolina Vicente-Dueñas, Kim E. Nichols, Alberto Orfao, Manuel Ramírez-Orellana, I. Sánchez-García
          </td>
          <td>2025-11-12</td>
          <td>Hematology Reports</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="


 Cancer immunotherapies have shown significant promise in multiple myeloma (MM). However, their long-term efficacy is limited by immune evasion, and MM remains incurable. A key evasion strategy involves upregulating inhibitory phagocytosis checkpoints (IPCs), which prevent antigen-presenting cells (APCs) from phagocytosing cancer cells. This pathway is critical for the immune effects of standard anti-MM agents, including bortezomib (BTZ), an inducer of immunogenic cell death (ICD), and the monoclonal antibody daratumumab (DARA). Yet, the mechanisms regulating IPCs in MM remain poorly understood.
 To address this gap, we screened IPC axes in MM cells and APCs using bone marrow (BM) aspirates from MM patients (n=39) and healthy donors (n=5) via multiparametric flow cytometry. Immunophenotyping included 9 parameters for MM cells and 16 for APCs, covering IPC and lineage markers. We identified the B2 microglobulin (B2M) / leukocyte immunoglobulin-like receptor B1 (LILRB1) axis as the dominantly expressed IPC in MM. B2M, expressed on MM cells, binds LILRB1 on APCs. Notably, B2M is a known adverse prognostic factor in MM.
 Computational analysis of flow-cytometry data using a semi-automated pipeline allowed us to define 8 distinct myeloid cell clusters, with consistently high LILRB1 abundance, especially in conventional type 1 dendritic cells (DCs). Single-cell RNA-seq data from 90 MM BM samples confirmed LILRB1 expression in DCs, monocytes (Mo) and macrophages (MΦ). qRT-PCR of BM Mo-derived DCs found that LILRB1 mRNA levels increased from healthy donor to smoldering MM to overt MM, suggesting a link to disease progression.
 To functionally assess the B2M/LILRB1 axis, we knocked out B2M in MM cell lines (n=3) and re-expressed a chimeric B2M mutant (B2MMUT) lacking functional LILRB1-binding site by introducing 16 missense mutations. B2M functions as an MHC-I subunit, so this mutant allowed us to isolate its checkpoint role without the confounding effects from complete B2M loss. Yeast 2-hybrid assays confirmed a direct interaction between B2M and LILRB1, but not for B2MMUT. Phagocytosis assays found that B2MKO and B2MMUT cells were more susceptible (more than 2-fold) than WT to phagocytosis by DCs and MΦ after BTZ or DARA treatment (p<0.01). LILRB1 knockdown (KD) in APCs, using an antisense oligonucleotide, similarly enhanced the phagocytic potential after BTZ treatment (p<0.05).
 Since MM cells actively secrete B2M (s-B2M), we analyzed the media from MM cell lines with different B2M statuses: B2M WT, B2MKO, and B2MMUT. We found s-B2M in the media from B2M WT cells, but no B2M in the KO cells and s-B2MMUT in the B2MMUT. Exposure of DCs to the conditioned media of WT s-B2M, but not s-B2MMUT, reduced phagocytosis after BTZ or DARA (p<0.05) of B2MKO cells, suggesting that s-B2M impairs APC function in a LILRB1-dependent manner. Treatment of APCs with His-tagged recombinant B2M (rB2M) confirmed activation of downstream LILRB1 signaling, assessed by modulation of p-SHP1.
 Interestingly, APCs internalized rB2M in a LILRB1-dependent manner, as both LILRB1 KD and treatment with rB2MMUT resulted in reduced internalization. Correlative light and electron microscopy (CLEM) and TEM revealed that internalized rB2M localized to perinuclear vesicles near the microtubule-organizing center (MTOC). Confocal imaging found that rB2M uptake increased microtubule stability, as assessed by a higher acetylated-to-tyrosinated tubulin ratio. Functionally, this correlated with impaired APC maturation following lipopolysaccharide stimulation (assessed by phalloidin staining) and a reduced ability to activate T cells after ICD, as measured shown by reduced T cell-mediated MM cell lysis.
 To evaluate the in vivo relevance, we generated a murine MM cell line (5TGM1) expressing a chimeric B2M (B2Mmut), which cannot bind the murine LILRB1 ortholog. Mice injected with B2Mmut cells exhibited reduced tumor engraftment and growth compared to those injected with WT cells, accompanied by increased infiltration of CD3⁺ and CD8⁺ T cells.Ongoing studies are assessing the effect of the B2M/LILRB1 axis on BTZ or DARA efficacy in vivo and will be presented at the meeting.
 This work provides fundamental insight into the immune role of B2M in MM, revealing the B2M/LILRB1 axis as a novel immune checkpoint in MM driven by impaired APC function. Targeting this axis represents a new therapeutic vulnerability to restore immune competence and improve MM outcomes.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92134e520cb60136119f8590dc507a1192c1b610" target='_blank'>
              The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma
              </a>
            </td>
          <td>
            M. Turi, Pietro Folino, Francesca Barello, Tallya Maciel, Selma Cifric, Paola Rampa, Mehmet K Samur, Giovanni de Nola, Rita Starace, Vanessa Favasuli, Alessandro Salatino, Sofia Pasparaki, Carlo Campa, Delaney Vinaixa, Cole Clericuzio, Priya Thurman, Megan E Johnstone, F. Bonello, Abigail Lytton-Jean, Cirino Botta, Eugenio Morelli, Nikhil C Munshi, Kenneth Anderson, Annamaria Gullà
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 Background Myeloid-derived suppressor cells (MDSCs), which include polymorphonuclear-MDSCs and monocytic MDSCs (M-MDSCs), play key roles in disease progression, resistance to immune-cell therapies, and poor clinical outcomes in multiple myeloma (MM). Among them, M-MDSCs are especially potent in suppressing anti-tumor immune responses, making them an attractive therapeutic target. Previous studies have shown that certain human myeloma cell lines (HMCLs) can induce M-MDSC differentiation through the secretion of important mediators like CCL5 and macrophage migration inhibitory factor (MIF), and that blocking these molecules significantly reduces M-MDSC induction. We have previously demonstrated that immunomodulatory drugs (IMiDs), such as lenalidomide (LEN) and pomalidomide (POM), are effective at inhibiting M-MDSC induction by decreasing CCL5 and MIF expression (Kuwahara-Ota S, Br J Haematol 2020); however, the effects of cereblon E3 ligase modulators (CELMoDs) such as iberdomide (IBER) and mezigdomide (MEZI)—which exhibit anti-tumor activity even in LEN- and POM-resistant MM—on M-MDSC induction remain unknown. This study aims to examine the cellular and molecular effects of CELMoDs on M-MDSC induction in the presence of myeloma cells.
 Methods To evaluate how CELMoDs influence M-MDSC induction, we conducted 96-hour co-culture experiments with two HMCLs and peripheral blood mononuclear cells (PBMCs) from healthy donors. IBER, MEZI, and POM were added at the start of co-culture at concentrations known to be non-cytotoxic from MTT viability tests. We identified M-MDSC populations phenotypically and functionally, and analyzed subsequent molecular changes using RNA microarray gene expression profiling and cytokine assays.
 Results While all three agents promoted degradation of Aiolos and Ikaros in HMCLs, IBER (7.5 nM), MEZI (2.5 nM), and POM (1 μM) maintained over 70% viability in HMCLs after 96 hours of treatment. Despite this, IBER (7.5 nM), MEZI (2.5 nM), and POM (1 μM) significantly decreased M-MDSC induction from PBMCs in a dose-dependent manner. Notably, IBER and MEZI inhibited M-MDSC induction at concentrations 150–1000 times lower than those required for POM, indicating their higher potency. Transcriptomic profiling revealed that co-culture with HMCLs significantly upregulated inflammatory response genes, including TNFα/NFκB and IL6–JAK–STAT pathways, in myeloma cells. Conversely, CD33⁺ PBMCs showed downregulation of interferon-α and -γ response gene sets, consistent with the development of an immunosuppressive phenotype. Interestingly, CELMoDs and POM had opposing effects on inflammation-related gene expression in the two cell populations: they suppressed proinflammatory signals in HMCLs, as shown by decreased CCL5 expression, but simultaneously increased the expression of inflammatory and interferon-related genes in CD33⁺ PBMCs, including those involved in TNFα/NFκB signaling. These findings suggest that CELMoDs modulate immune responses in a cell-type-specific manner within the tumor microenvironment. Further analyses demonstrated that all agents suppressed MIF expression in CD33⁺ PBMCs. Consistent with this, pharmacological inhibition of MIF abrogated M-MDSC induction, confirming its mechanistic involvement. Additionally, we observed that CELMoDs and POM reduced IL-10 secretion from HMCLs, a cytokine previously implicated in M-MDSC generation. Neutralization of IL-10 with a specific antibody significantly inhibited M-MDSC induction in co-cultures with IL-10–producing HMCLs but had no effect in IL-10–non-producing HMCLs, underscoring the central role of IL-10 in this process.
 Conclusion This study demonstrates that CELMoDs and POM suppress M-MDSC induction by targeting key immunosuppressive mediators such as IL-10 and MIF. Notably, these agents exert opposing transcriptional effects in tumor and immune cells, attenuating proinflammatory signals in myeloma cells while enhancing immune activation in PBMCs. These dual effects likely contribute to remodeling the tumor microenvironment toward an immune-permissive state. Collectively, our findings provide a mechanistic rationale for using CELMoDs to target MDSCs and enhance anti-tumor immunity in MM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e86ed67fc256c70ceb145554908eb67444703e4f" target='_blank'>
              Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma
              </a>
            </td>
          <td>
            Yui Niiyama-Uchibori, Yu Inoue, Shotaro Chinen, Takahisa Nakamura, Hiroaki Nagata, Haruya Okamoto, Takahiro Fujino, T. Tsukamoto, S. Mizutani, Y. Shimura, Junya Kuroda
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 CD8+ T cells have the unique capacity to efficiently detect and eliminate intracellular pathogen-infected cells and tumors. One important functional feature of memory CD8+ T (Tm) cells that we and other characterized in prior works, is their ability to provide early protection during reactivation prior to clonal expansion, by enabling the rapid activation and mobilization of innate immune defenses. However, the molecular transcriptional and epigenetic mechanisms underlying CD8+ Tm cell rapid cognate antigen (Ag) dependent reactivation in vivo are poorly understood. Through single cell transcriptomic and chromatin accessibility analyses of Tm cells early post cognate Ag reactivation, we discovered that a small set of transcription factors (TF) are differentially regulated and have enriched binding sites in newly accessible promoters. We hypothesize that these TF drive the early protective effector program that mediate CD8+ Tm cell-dependent host protection. We are using high dimensional flow cytometry and multiplex assays to explore the kinetic of expression of cognate Ag-dependent TF expression, how they regulate each other and how they control distinct effector functions of the Tm cells. We are also testing the roles of these TF using in vitro and in vivo gain and loss of function approaches. We will present data offering new insights into the transcriptional regulation required for an effective CD8+ Tm cell response.



 Supported by NIH R01 AI103338



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fb5ea1846a9c481b19e3f99101f2b081fd4d0b9c" target='_blank'>
              Molecular mechanisms of early memory CD8+ T cell reactivation in vaccinated hosts 4399
              </a>
            </td>
          <td>
            Richard Garcia Betancourt, Marie Boutet, G. Lauvau
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="


 Aging profoundly impacts the immune system, yet the underlying mechanisms driving age-related immunopathologies remain poorly understood. Previous studies have demonstrated that CD8 T cells undergo significant remodeling with age, where memory CD8 T cells largely replace the naïve cells and form two distinct subsets defined by PD1 expression. However, the data connecting these cells to physiological outcomes remained scarce. In this study, we report striking functional differences between young and aged PD1- memory CD8 T cells. We found that aged PD1- memory CD8 T cells lose antigen specificity upon activation and engage in MHC I-independent killing. Despite lacking canonical surface markers of activated or effector T cells, aged PD1- memory CD8 T cells exhibit a transcriptional profile and surface markers resembling pathogenic CXCR6+ CD8 T cells, known mediators of liver damage in the NASH model. In aged mice, these pathogenic cells accumulate systemically and drive widespread tissue damage. Mechanistically, this process is mediated by Fas-FasL interactions and regulated by IL-15 in an antigen-independent manner. This novel cellular mechanism offers a potential explanation for the extensive tissue damage observed in elderly individuals during inflammatory conditions and underscores the therapeutic potential of targeting CD8 T cells to mitigate age-associated diseases.



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7ea1e9bf0ad0a553f67bfe65bf772b9feed2510" target='_blank'>
              Non-specific cytotoxicity of aged memory CD8 T cells drives excessive tissue damage 3669
              </a>
            </td>
          <td>
            I. Shchukina, Patrick Rodrigues, Veronika Vachova, Jan Kossl, Maxim N. Artyomov
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Introduction While autologous CD19-directed CAR-T cell therapy has been highly efficacious in certain B cell malignancies, its efficacy in chronic lymphocytic leukemia (CLL) has been limited by toxicity and T cell dysfunction characteristic of CLL pathophysiology. CAR natural killer (CAR-NK) therapy holds promise as a possible alternative due to a favorable toxicity profile and off-the-shelf allogeneic sourcing potential. A potential challenge for CAR-NK therapy in CLL is the emergence of compensatory pro-survival signaling in tumor cells which may inhibit tumor cell apoptosis. Receptor tyrosine kinase-like orphan receptor (ROR1) is ubiquitously expressed on CLL cells, and signaling via its ligand Wnt5a has been associated with both ibrutinib and venetoclax resistance; however, its connection to cell therapy resistance remains underexplored. Here, we studied Wnt5a-induced ROR1 signaling as an underlying CAR-NK resistance mechanism in CLL and leveraged our findings to develop a novel dual CAR-NK construct designed to overcome apoptotic resistance in CLL.
 Methods ROR1 expression on peripheral blood-derived primary CLL cells was measured via flow cytometry. CLL cells were incubated with 200ng/mL of recombinant Wnt5a and were assessed for their apoptotic priming via BH3 profiling, a functional assay that measures the proximity of tumor cells to the apoptotic threshold and cellular dependence on specific anti-apoptotic proteins. Resistance to NK-mediated killing was evaluated by treating CLL cells with 1ug/mL Wnt5a and exposing them to either CD19-CAR-NK or untransduced primary NK cells, with Annexin V and propidium iodide (PI) staining used to assess CLL cell apoptosis. The ROR1 inhibiting monoclonal antibody (mAb) zilovertamab was used to investigate attenuation of Wnt5a/ROR1-associated survival. Tandem, 2nd generation anti-CD19/ROR1 (dual) CAR constructs were designed by joining an anti-CD19 scFv with an anti-ROR1 scFv via a (G4S)4 linker, followed by a 4-1BB costimulatory domain and a CD3Z signaling domain. CAR constructs were transduced into Jurkat and peripheral blood-derived primary NK cells via an optimized baboon lentivirus protocol. Effector cell activation and cytotoxicity against primary CLL cells, a CD19+ CLL-derived cell line MEC-1, and the ROR1+ NCCIT cell line were evaluated via flow cytometry-based readouts of NK activation marker expression and Annexin/PI staining.
 Results ROR1 expression was confirmed as present in primary CLL cells in all samples (n=33, ΔMFI [ROR1-Isotype] range: 346–2199). Stimulation of the cells with Wnt5a led to reduced apoptotic priming by 11–18% at 4h and 14–42% at 24h (BIM 0.1 µM), with greater reductions observed in high-ROR1 samples. Correspondingly, high-ROR1+ CLL samples incubated with Wnt5a exhibited up to 20% reduction in cell death compared to untreated conditions when co-cultured with either CD19 CAR-NK or untransduced primary NK cells. In venetoclax-treated CLL cells, zilovertamab reversed Wnt5a-induced resistance to NK-mediated killing, restoring cell death levels from 7.6% to 13.9% and restored apoptotic priming by increasing BIM-induced cytochrome C release from 5% to 18%.
 Dual CAR-Jurkat cells showed increased expression of CD69 in the presence of either CD19+ MEC1 or ROR1+ NCCIT cell lines, while single-directed CARs exhibited no increase in activation against nonspecific targets. Dual CAR-NK cells similarly demonstrated higher CD69 expression in primary CLL patient cells (n=6) compared to single-targeting and untransduced NK cells at 16h. Cytotoxicity assays also showed that the dual CAR-NK kills at least as well as CD19-CAR-NK, and outperformed ROR1-CAR-NK and untransduced NK cells across high- and low-ROR1 patients.
 Conclusion We demonstrated that Wnt5a-induced ROR1 signaling is a key pathway that reduces CLL cell priming for apoptosis and enhances CLL cell survival against NK cells, a process reversible ex vivo by zilovertamab. We subsequently developed a novel tandem CD19/ROR1 CAR-NK product with enhanced activation against CLL cells compared to single-directed CARs. This dual CAR-NK also has the potential to subvert single antigen escape. In vivo studies are underway using NSG mice engrafted with HG3 CLL cells engineered to express both ROR1 and constitutive Wnt5a to assess whether a novel dual CAR-NK product expressing the D10-derived anti-ROR1 scFv (derived from zilovertamab) more effectively reduces tumor burden compared to non-ROR1-inhibiting CAR constructs.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e744636b917a48416c5a21d06b1eaab753958a65" target='_blank'>
              A tandem CD19/ROR1 CAR-NK to overcome Wnt5a-mediated apoptotic resistance in chronic lymphocytic leukemia
              </a>
            </td>
          <td>
            Salem Elias, Andrew Lu, Fuguo Liu, Xingyu Deng, Olivia Stringham, Jeremy Zhang, Nathalie Javidi-Sharifi, Lara Bencsics, Stephanie Chamberlain, R. Romee, M. Davids
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="


 Suppressive immune cells and their associated cytokines and chemokines promote vascular endothelial proliferation and malformation, hindering immune cell penetration into the tumor core. In a phase II trial combining bevacizumab with atezolizumab in metastatic NSCLC patients (with a disease control rate of 87.5%) whose disease progressed after atezolizumab monotherapy, we analyzed blood biomarker changes collected at baseline, one week post-therapy, and at disease progression. Myeloid cells, including neutrophils, PMN-MDSCs, and M-MDSCs, were significantly correlated with responses to therapy. Durable responders exhibited high CXCL5 levels (p = 0.005) in blood. Additionally, lower neutrophil-to-lymphocyte ratios (p = 0.022), PMN-MDSCs (p = 0.036), and PD1+CD8+ T cells (p > 0.001) were associated with improved overall survival. Lower levels of suppressive proteins, including TCTP (p = 0.013), IL-6 (p < 0.001), IL-18 (p = 0.03), VEGF-A (p < 0.001), TIE-2 (p = 0.06), PD-L2 (p = 0.041), and CD147 (p = 0.008), were associated with better survival outcomes, highlighting their roles in therapy resistance. In vivo, vascular malformation and immune cell exclusion were prominent, with differential immune cell distribution between the tumor core and edge depending on hypoxia and vascular abnormalities. Combination therapy reduced suppressive and exhausted immune cells. These findings underscore the role of myeloid cells and factors such as IL-6, TCTP, and VEGF-A in resistance to therapy.



 This research was supported by NRF (National Research Foundation of Korea) funded by the Korean Government (RS-2022-NR075028)



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b83f651a43406b89a53faee6059bef8047e5b3f" target='_blank'>
              Immune exclusion driven by myeloid cells contributes to resistance to checkpoint inhibitor and anti-angiogenic therapy in NSCLC 4771
              </a>
            </td>
          <td>
            J. Koh, Young Kyoung Lee, Mi Soon Kim, B. Ku, Sehhoon Park, Myung-Ju Ahn
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains a paradigm of immunotherapy resistance, characterized by minimal effector T cell infiltration and failure to respond to immune checkpoint blockade (ICB) therapies such as anti-PD-1. In contrast, autoimmune states such as experimental autoimmune encephalomyelitis (EAE)—a murine model of multiple sclerosis—elicit robust, antigen-specific T cell responses within the central nervous system. We hypothesized that proinflammatory mechanisms sustaining autoimmunity in EAE could be co-opted to overcome immune tolerance in GBM. Single-cell RNA sequencing was used to profile T cell phenotypes from EAE and syngeneic GBM (CT-2A) models. EAE was induced in tumor-bearing mice, and tumor-specific EAE variants were generated using tumor cell lysate immunization. Cytokine expression was profiled via Luminex and white matter changes were visualized with diffusion tensor imaging and T2 mapping. Functional studies included adoptive transfer of CD3+ T cells or regulatory T cells, and hydrogel-based delivery of IL-6, IL-23, and anti-TGF-β to tumor-draining lymph nodes (TDLNs). T cell bioenergetics were assessed via Seahorse metabolic profiling and flow cytometry. EAE induction in GBM-bearing mice significantly improved survival and increased intratumoral Th1 and Th17 T cell infiltration. Tumor lysate immunization reproduced these effects and sensitized tumors to anti-PD-1 therapy. IL-6, IL-23, and IL-1β were identified as shared inflammatory mediators in both EAE and tumor-immunized states. Targeted lymphoid conditioning via hydrogels loaded with recombinant IL-6, IL-23, and anti-TGF-β reprogrammed TDLNs, enhanced T cell activation and oxidative phosphorylation, and extended survival (P<0.0001). Therefore, autoimmune inflammatory circuits can be repurposed to recondition the immunosuppressive GBM TME. Lymphoid niche modulation using a combination of IL-6, IL-23, and TGF-β blockade offers a novel strategy to sensitize GBM to currently available immunotherapeutic strategies such as anti-PD-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec557fff3154e9f6980a04bed886b991ce663c85" target='_blank'>
              IMMU-13. Leveraging the immune milieu of experimental autoimmune encephalomyelitis to perpetuate an anti-tumor T cell response in glioblastoma
              </a>
            </td>
          <td>
            John Choi, Lily H Kim, John Klich, Andrew Tran, Peggy Ho, Rohit Verma, Kwang Bog Cho, Si Yeon Lee, Gordon Li, Lawrence Steinman, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Glioblastoma (GBM), the most common and malignant primary brain tumor, exhibits profound immune suppression, hindering immunotherapy efficacy. GBM-derived extracellular vesicles (EVs) play a major role through the immunosuppressive polarization of myeloid cells. Inhibition of EV-myeloid cell interactions thus represents a novel target to mitigate GBM-mediated immune suppression. However, there are multiple mechanisms of EV-target interaction, and downstream pathways of GBM-EV signaling are poorly understood. We explored two pharmacological agents targeting different mechanisms of EV uptake: Methyl-B-cyclodextrin (MBCD), which disrupts lipid rafts, and cytochalasin D, which inhibits actin polymerization. Our results showed immunosuppressive myeloid cell (CD11b+/ CD15-/ HLA-DRlow/ CD14high) populations increased upon GBM-EV treatment. Following cytochalasin D treatment, fewer immunosuppressive myeloid cells were observed (7.40%±1.01 vs. untreated 9.66%±2.86), with rescuing T cell proliferation. Conversely, MBCD treatment increased immunosuppressive myeloid cell levels (10.42%±2.38 vs. untreated 8.87%±3.97) without impacting T cell proliferation. This study demonstrates the feasibility of pharmacologically targeting EV-myeloid cell interactions to rescue tumor mediated immune suppression by inhibiting actin-dependent endocytosis with cytochalasin D. The converse results using MBCD treatment indicate differential importance of different EV uptake pathways in monocyte regulation.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c83aad2ce4bc7312164a625b88f12016523ef26e" target='_blank'>
              Selective Targeting of EV Uptake Pathways in Glioblastoma to Combat Tumor-Induced Immune Suppression 4324
              </a>
            </td>
          <td>
            Minori Aoki, Mohammad Asad, Julio Inocencio, Stefan Mitrasinovic, C. Crisman, Ian Parney, Patrick Lasala, Vijay Agarwal, Emad Eskandar, B. Himes
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is the deadliest primary brain tumor, characterized by immunosuppression, low infiltration of lymphocytes, and lack of response to immune checkpoint blockade (ICB) therapies. In other solid tumors, the presence of functional B cells is predictive of response to ICB. However, in GBM, although B cells are antigen-experienced, they do not differentiate to functional plasma cells. B cell activation is opposed by inhibitory signaling, especially mediated through the key inhibitory receptor CD22, which must be halted for differentiation to proceed. We hypothesized that GBM-infiltrating B cells are functionally arrested via CD22 and the immunosuppressive GBM microenvironment, which is characterized by high numbers of tumor-associated myeloid cells (TAMs). Using patient GBM samples and GBM single-cell RNA sequencing data, we showed that TAMs such as microglia strongly express the CD22 ligand α2,6 sialic acid and the α2,6 sialic acid-synthesizing enzyme ST6GAL1. We created an in vitro model of TAMs by treating murine bone-marrow-derived myeloid cells (BMDMs) with supernatant from the murine glioma cell line CT2A. Tumor cell supernatant doubled the expression of α2,6 sialic acid on the TAMs compared to BMDMs, driven by increased expression of St6gal1, showing that secreted factors from tumor cells may remodel TAMs toward a more immunosuppressive state. To elucidate the direct impact of myeloid cells on B cells, we cocultured B cells with TAMs or the microglial cell line BV2. B cells cocultured with TAMs and BV2 cells showed increased phosphorylation of repressive signaling molecules downstream of CD22, including p-SHP-2 and p-SHIP1. This study suggests that myeloid cells are reprogrammed in the context of the tumor microenvironment to become more suppressive to B cells. In future work, we aim to develop a therapeutic targeting α2,6 sialic acid on TAMs in vivo to restore B cell function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c16dc7ca0407ae61b2e9c308129f9a72d793423" target='_blank'>
              TMIC-72. Glioma-associated myeloid cells promote B cell inhibition
              </a>
            </td>
          <td>
            Alina R Murphy, Si Wang, G. Vázquez-Cervantes, Hanxiao Wan, Joshua Katz, Rebecca Du, Jiawei Huo, Tzu-yi Chia, Leah K. Billingham, Suzi Delay, M. Lesniak, Peng Zhang, J. Miska, Catalina Lee-Chang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Respiratory syncytial virus (RSV) infection causes significant morbidity in elderly adults. To determine how advanced age impacts myeloid cell (MC) antiviral responses, we developed a 3D human lung model (HLM) to recapitulate the small airway. The HLM is composed of layered primary differentiated small airway epithelial cells at air-liquid interface, fibroblasts embedded in collagen, and endothelial cells. Introduced blood MC (monocytes and dendritic cells) from 36-40yo (Adult) or 69-88yo (Elderly) donors migrated throughout the HLM. Recovered MC were assessed using flow cytometry, microscopy, and transcriptional profiling. MC acquired phenotypes and morphology of tissue-resident cells, indicating adaptation to the airway environment and differentiation into tissue-resident macrophages. However, prior to infection, sorted Elderly MCs showed reduced expression of genes promoting macrophage differentiation and function, e.g. PPARG, MARCO, INHBA, yet showed higher basal expression of pro-inflammatory genes, e.g. IL18, CDKN1A, TLR9, compared to sorted Adult MCs. After RSV challenge, HLM built with Elderly MC harbored significantly more RSV RNA, consistent with poor induction of genes in IFN signaling, viral sensing, and macrophage activation pathways. Thus, diminished expression of canonical macrophage genes, increased baseline inflammation, and reduced ability to build up antiviral IFN responses contribute to the impaired viral clearance in HLM bearing Elderly MC.



 Funded by NIH R01 EB025596



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/23985d18f4cdd665e0b30abb7a4851c7e3a9795d" target='_blank'>
              Age shapes the myeloid cell antiviral response to RSV infection in a human airway tissue model 4051
              </a>
            </td>
          <td>
            S. Kovats, Mandi M. Roe, Taylor Do, Magdalena Chlebicz, Sean Turner, Laura Mejia, Antonius Oomens, H. Gappa-Fahlenkamp
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="


 Background: Acute Myeloid Leukemia (AML) is characterized by a profoundly dysregulated bone marrow microenvironment (BME) that fosters disease progression and immune escape. While inflammatory cytokines are pivotal in shaping immune responses, a comprehensive understanding of their complex interplay, prognostic significance, and mechanistic roles in AML, particularly across different FAB subtypes, remains a critical unmet need.
 Aims: This study aimed to: 1) comprehensively profile inflammatory cytokines in AML patient BME and identify those with prognostic significance; 2) delineate the cellular sources and inter-cytokine regulatory mechanisms within the AML BME using cutting-edge single-cell transcriptomics; and 3) investigate the functional impact of key inflammatory axes on immune cell function and explore their potential as novel therapeutic targets.
 Methods: We analyzed bone marrow supernatant from46 AML patients and 20 healthy controls for 20 inflammatory cytokines. Clinical correlations, including 5-year overall survival (OS), genetic risk stratification, and FAB subtype, were assessed using ROC analysis, univariate and multivariate Cox regression. For mechanistic insights, single-cell RNA sequencing (scRNA-seq) was performed on bone marrow samples from AML patients and healthy individuals. We employed an innovative CNV, tumor score, classification score methods for robust tumor cell clustering. Subsequent analysis involved mapping cytokine expression to specific cell types, performing ligand-receptor pairing, immune cell communication analysis, and signaling pathway enrichment. Inflammatory cytokine interaction networks were constructed using Cytoscape and STRING. Functional studies utilized in vitro co-culture systems with AML cell lines and primary patient cells, assessing T cell chemotaxis and cytotoxicity, followed by rescue experiments with cytokine modulation.
 Results: Our initial profiling identified 7 significantly dysregulated inflammatory cytokines in AML patient BME. Among these, 5 were significantly associated with 5-year OS, and 2, including IL-1A, emerged as independent prognostic factors for adverse OS. Cytokine expression also varied significantly across FAB subtypes, with M1 and M2 exhibiting distinct inflammatory profiles compared to M5 AML, suggesting an influence of tumor cell origin. ScRNA-seq revealed CCL3 and CCL4 were primarily expressed by healthy T cells, whose numbers and functional capacity were notably reduced in AML patients, with increased naive T cells and decreased CCL3/4 expression. Ligand-receptor and cell communication analyses confirmed reduced CCL3/4 impaired immune cell recruitment and tumor-killing. Network analysis highlighted IL-1A as a central regulator that significantly influenced CCL3/4 expression on T cells. Elevated BME IL-1A was found to suppress T cell CCL3/4 expression, directly contributing to impaired T cell chemotaxis and cytotoxicity. In vitro functional assays demonstrated IL-1A inhibition (using antagonists) restored T cell CCL3/4 expression and anti-leukemic activity. Importantly, exogenous CCL3/4 supplementation synergized with IL-1A inhibition, leading to robust recovery of T cell function and enhanced tumor suppression.
 Conclusion: Our study provides a comprehensive systems-level inflammatory cytokine atlas in AML, identifying IL-1A as a critical independent prognostic factor and a central player in AML immune evasion. We innovatively demonstrate that IL-1A orchestrates the suppression of the CCL3/4-T cell chemotaxis axis, leading to impaired T cell function and compromised anti-tumor immunity. This finding, particularly pronounced in specific FAB subtypes like M5 AML, highlights a novel mechanism by which the AML microenvironment promotes disease progression. Our preclinical data suggest that targeting IL-1A, either alone or in combination with CCL3/4 supplementation, represents a promising immunomodulatory strategy to restore T cell function and improve therapeutic outcomes in AML. These insights open new avenues for refining prognostic models and developing precision immunotherapies for AML patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a819f457cfa0e8527729fec197131b12c0dfcd4f" target='_blank'>
              Deciphering the bone marrow inflammatory cytokine network in AML prognosis and immune evasion: A focus on the IL-1A-CCL3/4 axis as a novel therapeutic target
              </a>
            </td>
          <td>
            Shuqing Wang, Jian Li
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Background: Autologous stem cell transplantation (ASCT) remains the standard of care consolidation in eligible patients with multiple myeloma. Typically, this is followed by lenalidomide maintenance therapy until progression or intolerance. This combinatorial approach results in improved progression-free survival compared to drug-based consolidation. However, the majority of patients ultimately relapse, consistent with myeloma progression and immune escape. Increasing evidence suggests that myeloma may invoke a suppressive tumor microenvironment (TME), principally in the bone marrow (BM), which may impair endogenous T cells and/or therapeutic T cell engagers or chimeric antigen receptor T cells targeting tumor antigen. Immunosuppressive myeloid cells are known to be abundant in the TME, and we and others have previously implicated macrophages in this process.
 To examine potential cellular sources of immunosuppression in the TME, we used flow cytometry to analyze myeloid cells in the BM from patients undergoing ASCT for myeloma. BM mononuclear cells were isolated from aspirates drawn at approximately 2-6 weeks prior to ASCT (n=13), 90 days post-transplant, and at relapse or 1-year post transplant. Post-transplant samples were categorized as relapsed (n=12) or controlled for >1 year (n=8). BM from patients with progressive myeloma was characterized by a population of CD64+CD172+ macrophages that express CD169, putatively marking BM residency, and exhibiting a highly immunosuppressive phenotype evidenced by expression of CD163, CD155, PD-L1, and CSF-1R. Notably, the frequency of CD169+CD163+ macrophages (within CD64+ cells) but not the CD64+CD172+ macrophage population as a whole were expanded in patients at the time of relapse (mean frequency pre-ASCT: 3.46%, D+90: 2.96%, controlled: 4.02%, relapse: 13.83%; P<0.05 relapse vs. controlled; P<0.01 relapse vs. pre-ASCT or D+90), and correlated with multiple myeloma burden in the BM (r2 = 0.477, P=0.0103).
 Using a preclinical system of ASCT in mice bearing VK*MYC myeloma, we identified a similar macrophage subset in the BM, characterized as CD11b+Ly6GnegCD11c+CD64+ with high expression of CSF-1R, PD-L1, and F4/80. We sought to target these putatively immunosuppressive macrophages, using antibody-based CSF-1R inhibition, to determine whether we could augment lenalidomide maintenance after ASCT. We used a suboptimal T cell dose wherein endogenous anti-myeloma immunity is limited and assessed each therapy alone and in combination. We used cereblon (CRBN)-transgenic mice that are genetically modified to allow engagement of thalidomide and its derivatives (including lenalidomide), resulting in degradation of the IMiD targets, Aiolos and Ikaros. As expected, CSF-1R inhibition efficiently ablated the CX3RC1+Ly6Clo monocyte population in the blood and BM (mean frequency in lineage negative in blood: 2.9% vs. 18.1% in isotype-treated; in BM: 0.4% vs. 5.8% in isotype-treated; p<0.001 for both sites). While single agent CSF-1R inhibition or lenalidomide had no significant effect on disease progression, the combination of the two agents had a synergistic effect in attenuating myeloma relapse after ASCT. At 108 days follow-up, median overall survival for mice receiving CSF-1R inhibition and lenalidomide was not reached, while median survival was 65 days for either isotype- or lenalidomide-treated mice, and 77 days for mice receiving only CSF-1R inhibition (P<0.05). Myeloma M band progression was also significantly reduced with combination therapy (p<0.001).
 Conclusion: The ability of CSF-1R inhibition to deplete CSF-1R+ macrophages and prevent tissue fibrosis has previously been demonstrated in preclinical models of chronic graft-versus-host disease (GVHD). Subsequent clinical trials have proven axatilimab, a human anti-CSF-1R antibody, to be well tolerated and effective for the treatment of chronic GVHD, leading to FDA approval. Given lenalidomide is already a standard maintenance therapy, combination therapy with axatilimab represents a readily testable clinical strategy for augmenting progression-free survival in patients with multiple myeloma after ASCT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93ee7098bb14373b537fde66a2a31ad8ddc75d5f" target='_blank'>
              CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation
              </a>
            </td>
          <td>
            Simone A. Minnie, Rachael Adams, Kathleen S. Ensbey, Christine R. Schmidt, Melissa Comstock, Justina Lyons, Samuel R. W. Legg, Tomoko Sekiguchi, Nicole S. Nemychenkov, Julie R. Boiko, M. Koyama, Andrew Spencer, Damian Green, Geoff Hill
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 Background: Despite recent advancements in the treatment of chronic lymphocytic leukemia (CLL), Richter's transformation (RT) into diffuse large B-cell lymphoma (DLBCL) remains a therapeutic challenge with poor outcomes (Coombs et al., 2023). While CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) has shown efficacy in de novo DLBCL, its effectiveness in RT is less well defined (Kittai et al., 2024). Factors such as prior treatment, T cell exhaustion, and distinct immune microenvironments may contribute to limited efficacy in DLBCL (Fraietta et al., 2018; Jain et al., 2023). We evaluated clinical outcomes and immune correlates of CD19 CAR-T in patients with RT at our institution.
 Methods: We retrospectively analyzed 15 patients with RT-DLBCL treated with CD19 CAR-T between 2017 and 2024. A comparator cohort of 19 patients with de novo DLBCL treated with CD19 CAR-T was also analyzed. Pre-infusion peripheral blood mononuclear cells (PBMCs) were analyzed using multiparametric flow cytometric profiling. RNA expression from tumor biopsies was analyzed using NanoString transcriptomic profiling with the IO360 panel, which includes 770 genes found in the tumor microenvironment.
 Results: Fifteen patients with RT-DLBCL were included, 47% male with a median age at infusion of 69 years (range 47-77). The median interval from CLL to RT diagnosis was 41 months (range: 7-210), and from RT diagnosis to CAR-T was 20 months (range: 2-50). CAR-T products used were tisagenlecleucel (tisa-cel, 53%), lisocabtagene maraleucel (liso-cel, 27%), and axicabtagene ciloleucel (Axi-cel, 20%). One patient had received an allogeneic CAR-T product 7 months prior to Tisa-cel. Three patients received hematopoietic stem cell transplant before CAR-T (2 autologous, 1 allogeneic). Leading up to CAR-T, 93% had received RT-directed therapy (median 4 lines) and 66% had received prior CLL therapy. Cytokine release syndrome (CRS) occurred in 67% (7% grade ≥3) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 40% (13% grade ≥3). Overall response rates (ORR) were 80% at day 30 and 47% at 3 months. The median follow-up was 9 months.
 In the comparator de novo DLBCL cohort, median age at CAR-T was 68 (25–76), with 68% male. Most (74%) had received 1–2 prior lines of therapy before CAR-T. The majority (18/19) received axi-cel, and one patient received tisa-cel. Three patients received an autologous stem cell transplant before CAR-T. CRS of any grade occurred in 79% (11% grade ≥3), and ICANS in 74% (42% grade ≥3). The ORR was 88% at day 30 and 82% at 3 months. The median follow-up period was 26 months (range: 1-67).
 Flow cytometry revealed significantly higher frequencies of exhausted T cells in RT patients compared to de novo DLBCL (p=0.0329). RT patients had significantly higher frequencies of TCF1⁺ PD1⁺ (p=0.0217) and TCF1⁺ TIGIT⁺ (p=0.0158) CD8+ T cells, indicating a predominance of dysfunctional precursor-exhausted populations in circulation prior to CAR-T infusion. Moreover, there was an increase in central memory (CM, CD45RO⁺ CCR7⁺) CD8+ T cells in RT samples compared to de novo DLBCL (p=0.0436). Notably, these CM cells exhibited a significantly more exhausted phenotype in RT patients than in de novo cases (PD-1+ p=0.0266, TIGIT+ p=0.0490). Supporting the exhaustion phenotype found by flow cytometry, Nanostring analysis confirmed a significant increase in ENTPD1 expression, a gene that encodes the ectonucleotidase CD39, in tumors from RT patients compared to de novo DLBCL (p=0.02), as well as an increase in DUSP2 expression (p<0.0001), a phosphatase associated with exhaustion on tumor-infiltrating T cells and poor outcomes (Lu 2020; Dong 2018).
 Conclusions: CD19 CAR-T therapy shows promising initial responses in RT, though durability remains limited. Compared to de novo DLBCL, RT patients exhibit higher pre-treatment T cell exhaustion and more immunosuppressive tumor gene expression profiles, which may underlie poorer CAR-T durability. Ongoing transcriptomic analyses will further elucidate tumor-intrinsic and microenvironmental mechanisms of CAR-T resistance in RT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8898e13acca4c0791f3ab6eeb2b41de76671fe10" target='_blank'>
              Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation
              </a>
            </td>
          <td>
            M. B. Hammami, C. Savid-Frontera, Sean Haney, Douglas Marachion, Sean Yoder, Mohammad Hussaini, Michael D. Jain, Frederick L Locke
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 The immunosuppressive tumor microenvironment is a major challenge in GBM. We are developing oncolytic Zika virus (ZIKV) as a treatment that targets treatment-resistant glioma stem cells and ignites CD8+ T-cell dependent anti-tumor immune response. We previously demonstrated that ZIKV infection significantly improves survival in multiple mouse models of GBM (Nair et al, JCI insight, 2021). However, myeloid driven immunosuppression remains a critical barrier. While Siglec-15 has recently been described as a myeloid immune checkpoint in other cancers (Wang et al, Nat Med, 2019), it is relatively unexplored in GBM. An antibody against Siglec-15 is in a phase II clinical trial for metastatic solid tumors (NCT04699123), but not tumors of the central nervous system. In human GBM specimens, we observed that Siglec-15 is highly expressed on myeloid (16-23%) and tumor cells (18-19%). Here, we use therapeutic and genetic approaches to target Siglec-15, as well as immunotherapy-resistant mouse models of GBM. In CT2A-bearing mice, long-term survival (90 days) increased from 40% (only ZIKV) to 60% (anti-Siglec-15+ZIKV). Adding antibody against PD-1 further improves the long-term survival (83%). In the immunotherapy-resistant SB28 model, triple therapy (anti-Siglec-15+ZIKV+anti-PD-1) led to 76% long-term survivors and greater CD8+ T-cell activation (1.7-fold). Upon re-challenge of cured mice, we detected an increase in CD8+ brain resident memory T-cells (11-fold) and CD8+ effector memory T-cells (11-fold), and 80% of mice survived. These findings with antibody against Siglec-15 were further confirmed using Siglec-15 knockout mice. Mechanistically, using bone marrow derived myeloid cells and T-cell proliferation assays, we determined that depletion of Siglec-15 improves phagocytosis of tumor cells (CT2A; 25.2% and SB28; 6.9%) and significantly improves T-cell activation (81%) and T-cell proliferation (86.8%), and these findings may explain why we observed improved outcomes. These results suggest the potential of this triple therapy in overcoming the problem of the immunosuppressive tumor microenvironment in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a95001b5599103be9128f5ed56fc151095bff75" target='_blank'>
              TMIC-21. Dual blockade of Siglec-15 and PD-1, combined with oncolytic Zika virus therapy, confers protection against immune-resistant gliomas
              </a>
            </td>
          <td>
            Ashwani Kesarwani, Sonam Verma, Amber Neil Griffith, Tong Hu, Fei Shu, Amanda Andrade de Costa, Y. Li, Mridu Kanga, Brett H Herzog, D. DeNardo, Mai Dang, Jingqin Luo, Pei-Yong Shi, Xuping Xie, Jun Wang, Lieping Chen, Albert Kim, Peggy L. Kendall, Michael S Diamond, Milan G Chheda
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="


 Acute myeloid leukemia (AML) remains a clinical challenge due to high relapse rates, primarily driven by therapy-resistant leukemic stem and progenitor cells (LSCs). We proposed that intrinsic inflammatory signaling events serve as a survival mechanism in leukemic cells, but that the balance between beneficial and deleterious inflammatory signaling is finely regulated and context-dependent. Indeed, we have previously shown that TNF receptor 1 (TNFR1)-dependent signaling readily kills AML in vivo by activating Receptor-interacting protein kinase 3 (RIPK3) (PMID: 27411587). Hence, we speculated that disruption of critical pro-survival signaling nodes downstream of TNFR1 can be leveraged therapeutically.
 In this study, we describe a novel cytokine-based therapeutic strategy that selectively kills LSCs while simultaneously preserving and even supporting normal hematopoiesis. Using syngeneic murine FLT3-ITD-driven AML models, we found that genetic deletion of the specific TNF superfamily cytokine lymphotoxin alpha (LTA) disrupts cell death pathways and accelerates leukemogenesis, underscoring its role as an intrinsic tumor suppressor. Importantly, therapeutic administration of lymphotoxin alpha as recombinant cytokine reactivated a suppressed RIPK3-dependent signaling cascade, leading to cell death of leukemic progenitor cells and, in parallel, to myeloid differentiation of the leukemic clone. In both syngeneic and patient-derived xenograft (PDX) models representing common oncogenic driver mutations, cytokine monotherapy induced deep and sustained remissions (>300 days), highlighting its efficacy as single agent.
 Mechanistically, the anti-leukemic activity is mediated through depletion of the pro-survival adaptor molecule TNF Receptor-Associated Factor 2 (TRAF2) in the TNFR1 complex I. Notably, this approach spares normal hematopoietic cells due to the presence of a robust pool of TRAF2. Resembling the physiological process of cytokine-mediated emergency granulopoiesis, we even observed propagation of hematopoietic progenitor populations thereby offering a distinct advantage over conventional cytotoxic treatments, which often suppress bone marrow function. These findings reveal a potentially actionable immune mechanism that could shift AML treatment paradigm by uncoupling therapeutic efficacy from toxicity on the healthy hematopoeisis, and provide a rationale for further clinical development of cytokine-based therapies in AML.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3b6686a9b7d1ec600f893083d7517e863079cdd" target='_blank'>
              Unleashing intrinsic inflammation in AML using therapeutic cytokines overcomes pro-survival pathways and induces deep and durable remission In Vivo.
              </a>
            </td>
          <td>
            Ulrike Hoeckendorf, S. Dutta, A. Kloos, Marah Runtsch, Carina Zoetsch, Yongjie Wang, B. Perfler, Sebastian Vosberg, T. Haferlach, Konstanze Döhner, Katharina S. S. Götze, Florian Bassermann, M. Heikenwälder, Johannes Schmoellerl, Johannes Zuber, A. Wahida, Ann-Cathrin Burk, R. Zeiser, H. Sill, A. K. Jayavelu, Armin Zebisch, M. Heuser, Michael Dengler, Philipp Jost
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="The role of the tumor immune microenvironment (TIME) in modulating responses to antiestrogen therapy in hormone receptor-positive (HR+) breast cancers remains unclear. We analyzed pre- and on-treatment biopsies from patients with HR+ breast cancer treated with letrozole to induce estrogen deprivation (ED). Stromal tumor-infiltrating lymphocytes, assessed by H&E-staining, and immune-related gene sets, including IFNɣ signaling, measured by RNA sequencing, were increased in ED-resistant tumors. Cyclic immunofluorescence and spatial transcriptomics revealed an abundance of CD8+ T cells and enhanced antigen processing and immune gene signatures in ED-resistant tumors. In this group, the expression of CXCL9, CXCL10, and CXCL11 - chemokine genes involved in CD8+ T cell recruitment - and the CXCR3 receptor were upregulated both before and after letrozole. CXCL11 levels were higher in conditioned media from HR+ breast cancer cells co-cultured with CD8+ T cells. Both recombinant CXCL11 and co-culture with CD8+ T cells promoted MCF7 and T47D cell growth in estrogen-free conditions. Finally, deletion combined with silencing of the CXCL11 receptors CXCR3 and CXCR7 in MCF7 cells impaired proliferation in response to exogenous CXCL11 and to co-culture with CD8+ T cells in estrogen-free conditions. These findings suggest that CD8+ T cell-associated CXCL11 in the TIME modulates the response of HR+ breast cancer cells to estrogen suppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/415bbace3afb02abd0c993c7111f884259b3be03" target='_blank'>
              CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer.
              </a>
            </td>
          <td>
            Fabiana Napolitano, Yunguan Wang, D. Sudhan, Paula I. Gonzalez-Ericsson, Luigi Formisano, N. Unni, Shahbano Shakeel, James Z Zhu, Khushi Ahuja, Lei Guo, M. R. Chica-Parrado, Yuki Matsunaga, Pamela Luna, Chang-Ching A Lin, Yasuaki Uemoto, Kyung-min Lee, Hongli Ma, Nathaniel J. Evans, A. Servetto, Saurabh Mendiratta, Spencer Barnes, Roberto Bianco, Yi Fang, Lin Xu, Jeon Lee, Tao Wang, J. Balko, Gordon B. Mills, Marilyne Labrie, A. Hanker, Carlos L. Arteaga
          </td>
          <td>2025-12-09</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>68</td>
        </tr>

        <tr id="
 Glioblastoma multiforme (GBM) is a highly aggressive brain tumor marked by resistance to standard therapies, largely due to a profoundly immunosuppressive tumor microenvironment (TME). The nuclear orphan receptors NR4A1 and NR4A2 are overexpressed in GBM and act as key drivers of immune dysfunction and epithelial–mesenchymal transition (EMT). Novel dual NR4A1/2 inverse agonists, termed CDIMs, have been shown to inhibit PD-L1 and TWIST1 while reactivating S1PR1, restoring T cell trafficking to the tumor. Three CDIM compounds (DIM-3,5-Cl₂, DIM-3-Cl-5-CF₃, and DIM-4-OH-3,5-(tBu)₂) were administered at low (8-10 mg/kg) and high (20-25 mg/kg) dose for 12 consecutive days in healthy immunocompetent mice to evaluate tolerability and effects on immune cell distribution. Splenocytes, bone marrow, and peripheral blood mononuclear cells (PBMCs) were then isolated and analyzed via FACS. Notably, DIM-3,5-Cl₂ and DIM-3-Cl-5-CF₃ reduced CD4⁺ and CD8⁺ T cells in the bone marrow, with a corresponding increase in PBMCs, supporting reversal of T cell sequestration. To assess therapeutic relevance, the same regimen was applied in a syngeneic orthotopic CT2A glioma model. DIM-3,5-Cl₂ maintained elevated CD4⁺ and CD8⁺ T cells in PBMCs, further supporting its role in restoring systemic T cell circulation and availability for tumor infiltration. In contrast, DIM-3-Cl-5-CF₃ and DIM-4-OH-3,5-(tBu)₂ induced pronounced immune remodeling, including reduced CD19⁺ B cells and expansion of CD11b⁺ and triple-negative (CD11b⁻CD4⁻CD8⁻) populations, thus reshaping adaptive immunity. Ongoing studies will evaluate survival benefit, systemic cytokine responses, and local immune changes within the tumor microenvironment. Brains from treated animals will be analyzed by immunohistochemistry to assess changes in key immune markers to clarify the impact of CDIMs on intratumoral immune composition. Overall, the presented findings position DIM-3,5-Cl₂ as a promising candidate for reversing immune suppression in GBM and enhancing response to immune checkpoint therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e4ee11f3a994d6e3a11769fbefb1d349f6c5b72d" target='_blank'>
              TMIC-108. Therapeutic immune reprogramming in Glioblastoma using novel dual NR4A1/2 inverse agonists
              </a>
            </td>
          <td>
            Ana Gutierrez, Andrei Mikheev, Chu-Hsia Chen, Zheng Yin, Svetlana Mikheev, Stephen Safe, Robert C. Rostomily
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="major obstacle is the immunosuppressive liver microenvironment, characterized by the presence of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and a high proportion of tumor-associated macrophages (TAMs). Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors such as nivolumab and pembrolizumab have shown limited clinical efficacy in HCC, with only a subset of patients responding to treatment. Conversely, CAR-T cell therapies targeting tumor antigens such as glypican-3 (GPC3) and alpha-fetoprotein (AFP) have shown promise but face limitations due to the difficulty of generating effective T cell responses within the immunosuppressive liver milieu (11). Organoids provide an excellent platform for investigating T cell interactions in hepatobiliary cancers. These 3D models enable the study of immune responses in an environment that closely resembles the in vivo tumor microenvironment (12). Researchers have successfully">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a1b0e2f8ddf3d5e1eaebd7db8f530b03067bdcc" target='_blank'>
              Organoid models for T cell-based immunotherapy in hepatobiliary cancers
              </a>
            </td>
          <td>
            Liwei Du, Jiaxun Dong, Shunda Du
          </td>
          <td>2025-11-25</td>
          <td>Hepatobiliary Surgery and Nutrition</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Objective: Diffuse Large B-cell Lymphoma (DLBCL) is a hematologic malignancy characterized by the clonal expansion of myeloid progenitor cells and a highly immunosuppressive tumor microenvironment (TME). Among the key contributors to this immunosuppression are tumor-associated macrophages (TAMs), particularly those polarized toward an M2-like phenotype. These M2 macrophages support leukemia progression by suppressing anti-tumor immunity, promoting angiogenesis, and enhancing resistance to chemotherapy. Heme oxygenase-1 (HO-1), a stress-inducible enzyme known for its antioxidant and anti-inflammatory functions, has been reported to be upregulated in various cancers, including DLBCL. However, the immunological consequences of HO-1 overexpression in DLBCL, especially its impact on TAM polarization and immune evasion, remain poorly understood. This study aimed to investigate the molecular mechanism by which HO-1 modulates macrophage polarization and shapes the immune microenvironment in DLBCL. The ultimate goal is to provide a theoretical basis for targeting HO-1 or TAM phenotypes as a therapeutic strategy to improve clinical outcomes in DLBCL.
 Methods: A combined bioinformatic and experimental approach was employed. Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) DLBCL cohort and multiple GEO datasets were analyzed. Patients were divided into HO-1^high and HO-1^low groups based on expression levels. Immune cell infiltration was estimated using CIBERSORT and xCell algorithms. Differentially expressed genes (DEGs) between the two groups were identified using DESeq2 and further analyzed through GO and KEGG enrichment to explore biological pathways associated with HO-1. Weighted gene co-expression network analysis (WGCNA) was applied to identify gene modules related to HO-1 and immune infiltration. Protein-protein interaction (PPI) networks were constructed using STRING, and key hub genes were identified using Cytoscape's CytoHubba plugin.
 For in vitro validation, DLBCL cell lines were transduced with HO-1-overexpressing or control lentiviral vectors. Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated and induced to differentiate into M0 macrophages with M-CSF. Co-culture assays were performed using transwell systems, exposing macrophages to HO-1-overexpressing DLBCL cells. Macrophage polarization was assessed by qPCR for M1 (TNF-α, IL-12) and M2 (CD163, IL1RN, ARG1) markers, ELISA for cytokine secretion, and flow cytometry for CD86/CD206 surface markers.
 Results: Patients in the HO-1^high group displayed significantly higher levels of M2 macrophage infiltration and reduced NK cell activation, suggesting a link between HO-1 expression and immunosuppression in DLBCL. DEG analysis revealed enrichment in immune regulatory and vesicle transport pathways. WGCNA and PPI analyses identified HO-1 as closely associated with M2 markers such as CD163 and IL1RN.
 In vitro co-culture experiments confirmed that HO-1-overexpressing DLBCL cells promoted M2 polarization of macrophages. Macrophages exposed to HO-1^high DLBCL cells exhibited increased CD206, CD163, and IL1RN expression, and decreased IL-12 and TNF-α. Flow cytometry analysis corroborated these findings, showing an elevated proportion of CD206⁺ macrophages.
 Through qPCR and WB detection, it was found that the expression levels of IL-4 and IL-10 in DLBCL cells in the HO-1 upregulated group increased, and the levels of IL-4 and IL-10 in the supernatant also increased accordingly. Overexpression of HO-1 upregulated the production of interleukin-4 and interleukin-10 in leukemia cells. IL-4 alone could induce similar M2 polarization in macrophages. Neutralizing IL-4 could partially reverse the M2 polarization induced by HO-1, indicating that IL-4 at least partially mediates the immunomodulatory effect of HO-1.
 Conclusion: This study demonstrates that HO-1 is a critical driver of TAM polarization and immune microenvironment remodeling in DLBCL. Through upregulation of IL-4, HO-1 enhances M2 macrophage polarization, contributing to immune evasion and potentially to treatment resistance. These findings highlight HO-1 as both a biomarker and a promising therapeutic target. Inhibiting HO-1 or reprogramming TAMs from an M2 to an M1 phenotype may improve anti-leukemic immune responses and enhance the efficacy of current DLBCL therapies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fd5c0c36b45197dd9125d511c8e92c3765a6546c" target='_blank'>
              Heme oxygenase-1 facilitates immune evasion in diffuse large B-cell lymphoma by reprogramming tumor-associated macrophage polarization
              </a>
            </td>
          <td>
            Wenbin Lei, Jishi Wang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Group 3 medulloblastoma (G3MB) is the most aggressive medulloblastoma subtype. Although CAR T-cell therapy is promising, it has shown limited efficacy in G3MB due to poor T-cell persistence, largely driven by the immunosuppressive tumor microenvironment (TME) and an intact blood–brain barrier (BBB). M2-like tumor-associated macrophages (TAMs) are major contributors to this immunosuppression, whereas inflammatory TAMs can support CAR T-cell function. We identified Resiquimod, a Toll-like receptor (TLR) 7/8 agonist, as a potent immunomodulator capable of reprogramming TAMs toward a pro-inflammatory phenotype. In parallel, low-intensity focused ultrasound (LIFU) provides a noninvasive method to transiently disrupt the BBB, potentially enhancing both immunomodulatory effects and CAR T-cell infiltration.



 To improve the efficacy of B7-H3-directed CAR T-cell therapy in G3MB by optimizing CAR design, reprogramming the TME using POx-encapsulated Resiquimod (POx-R), and enhancing tumor accessibility with LIFU.



 We engineered B7-H3 CARs with CD28, 4-1BB, or dual costimulatory domains and tested their efficacy in vitro and in vivo. POx-R was administered systemically to enable brain penetration and TAM repolarization. LIFU was applied with microbubbles to transiently open the BBB and facilitate delivery of CAR T-cells. Immune profiling included flow cytometry and RNA sequencing.



 In vitro, CAR T-cells with dual CD28 and 4-1BB costimulatory domains demonstrated superior cytotoxicity and persistence. In vivo, systemically administered POx-R effectively crossed the BBB and induced pro-inflammatory TAM repolarization, as evidenced by upregulation of M1 markers and inflammatory cytokines detected by bulk RNA sequencing and flow cytometry. Preliminary data also indicate enhanced CAR T-cell infiltration and TME remodeling when combined with LIFU-mediated BBB disruption. Ongoing studies aim to elucidate the underlying mechanisms and optimize treatment scheduling to maximize therapeutic synergy.



 This multimodal strategy of integrating CAR engineering, myeloid reprogramming, and BBB modulation offers a promising path to overcome the key barriers limiting CAR T-cell therapy in G3MB.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/504746b3e43fabadaa7dc965df28e142fde180fd" target='_blank'>
              EXTH-71. Optimizing CAR T-Cell therapy in group 3 medulloblastoma through tumor microenvironment modulation and blood-brain barrier disruption
              </a>
            </td>
          <td>
            Serge Yaacoub, Stefanyda Maslova, Ying-ting Hsu, Zhongzhen Yi, Kaleem L Coleman, Martine F. Roussel, T. Gershon, Marina Sokolsky-Papkov, Cheng-Chia Wu, Natasha Sheybani, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Resident memory CD8+ T cells (Trms) are essential for protecting barrier nonlymphoid tissues (NLTs) against reinfection, yet the involvement of dendritic cells (DCs) in this process and the nature of Trm-DC interactions within these tissues remain poorly understood. Our study demonstrates that upon reactivation, memory CD8+ T cells located in the skin-independently of circulating memory counterparts-initiate the infiltration and maturation of plasmacytoid DCs (pDCs) in the tissue. This, in turn, promotes the maturation of conventional type 1 DCs (cDC1s) through type I IFN (IFN-I) signaling in a pDC-dependent manner. Depletion of pDCs or blocking IFN-I signaling disrupts this axis, severely impairing Trm-driven protection against secondary infections with vaccinia virus (VACV) in the skin. Notably, this pDC-dependent, IFN-I-mediated pathway is also essential for Trm-mediated protection against secondary respiratory infections with influenza A virus (IAV). Our findings uncover a crucial collaboration between Trm, pDCs, and cDC1s, offering new insights for enhancing vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fe1fd70d582b73456d2a4754cfa0b98111080ee7" target='_blank'>
              pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection.
              </a>
            </td>
          <td>
            Elena Hernández-García, Miguel Galán, Sofía C Khouili, Elena Moya-Ruiz, Ana Redondo-Urzainqui, F. J. Cueto, Saraí Martínez-Cano, Manuel Rodrigo-Tapias, E. Tomasello, Santos Mañes, Marc Dalod, D. Sancho, S. Iborra
          </td>
          <td>2025-11-25</td>
          <td>The Journal of experimental medicine</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="


 Lupus is a complex autoimmune disease that involves dysregulation of the B cell compartment. Potential mechanisms for this dysregulation include abnormalities in immune dampening pathways, such as the programmed cell death 1 receptor (PD-1). Though PD-1 functions as a negative regulator in T cells, its role in B cells is not clear. We used comprehensive flow and mass cytometry to examine the expression of PD-1 on peripheral blood B cells from lupus and healthy controls in two large patient cohorts. PD-1 was increased on antigen experienced B cells including double negative, memory, and CD11c+ age-associated B cells. Heterogeneity in patient PD-1+ B cells was uncovered, including an enriched PD-1+CD11c+CXCR3+ B cell subset which we speculate may be pathogenic due to their potential to migrate to sites of inflammation, and a diminished PD-1+PD-L1+ B cell subset which we expect is an immunosuppressive phenotype. PD-1 expression was higher in patients with elevated anti-dsDNA, high disease activity and increased with in vitro stimulation (anti-BCR and TLR9). Surprisingly, PD-1+ B cells proliferated more than PD-1- B cells, and PD-1 blockade with an anti-PD-1 antibody further increased proliferation. Our results suggest that PD-1 function in B cells is different than its inhibitory signaling role in T cells. Further, the expansion of PD-1 expressing B cells in lupus, especially in patients with high disease activity, highlights a new potential pathogenic B cell population.



 Supported by T32ES007026; Public Health Sciences Pilot Award; NIH Accelerating Medicines Partnership (RA/SLE Network)



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5935df81b4ecf4492f3d3f23ff65634bbec5dc4d" target='_blank'>
              PD-1 expressing B cells are expanded in lupus 4452
              </a>
            </td>
          <td>
            Melanie Perkins, Nida Meednu, Daria Krenitsky, Alice Horisberger, A. Griffith, Joshua Keegan, Fan Zhang, James A. Lederer, Deepak A. Rao, Lisa A. DeLouise, J. Anolik
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="


 Despite transformative impact of immunotherapy in cancer care, patients with acute myeloid leukemia (AML) continue to experience limited clinical benefits. This inefficacy is partly due to an incomplete understanding of the AML microenvironment (ME), including the role of innate immune cells. Among these, macrophages, which are highly plastic cells and comprise a substantial proportion of tumor-infiltrating immune cells, are key players in this context. In the AML ME, macrophages frequently adopt an anti-inflammatory, pro-tumorigenic (M2-like) phenotype rather than a pro-inflammatory, anti-tumorigenic (M1-like) state. Although their critical role in AML progression and therapy resistance is increasingly recognised, the nature of their interaction with AML blasts remains poorly defined.
 Our previous work demonstrated that the bone marrow of pediatric AML patients is dominated by M2-like macrophages. Building on this, we investigated how macrophages and leukemic blasts from pediatric AML bone marrow influence each other's phenotype and function.
 Using co-culture systems, we found that AML blasts reprogram both undifferentiated and pro-inflammatory macrophages into an anti-inflammatory, immunosuppressive phenotype. By day 6 of co-culture, these reprogrammed macrophages lost their ability to inhibit the growth of t(8;21) and KMT2A-rearranged patient-derived xenograft (PDX) and primary AML cells. Flow cytometry and immunofluorescence analyses revealed a phenotypic shift characterized by downregulation of immune-stimulatory markers (CD80, HLA-DR) and upregulation of immune-suppressive markers (CD206, CD163) along with reduced secretion of pro-inflammatory cytokines (TNF, IFNγ, and IL-1β). Transcriptomic profiling confirmed this immunosuppressive reprogramming, showing significant downregulation of key genes in the NF-κB signaling pathway (NFKB1, IRF1, TRAF1, and IL1B), all associated with M1 polarization.
 Notably, transwell assays showed direct cell–cell contact is required for macrophage reprogramming, as physical separation prevented the M2-like transition. Confocal microscopy revealed the formation of tunnelling nanotubes (TNTs) between AML PDX cells and macrophages, suggesting a route for direct intercellular communication. Mitochondrial labelling demonstrated predominant transfer of mitochondria from AML cells to macrophages. Inhibition of TNT formation reduced expression of M2-associated markers, implicating mitochondrial transfer as a driver of macrophage reprogramming. Transcriptomic and Seahorse metabolic analyses further demonstrated a shift in macrophage metabolism toward increased oxidative phosphorylation (OXPHOS) following co-culture with AML cells.
 To assess functional consequences, we evaluated macrophage-mediated T cell responses. A bioluminescence-based T cell activation assay showed that pro-inflammatory macrophages lost their ability to stimulate T cells after co-culture with AML cells. In cytotoxicity assays, they failed to support T cell–mediated killing of AML cells and suppressed the cytotoxic activity of the bispecific T cell engager blinatumomab against t(8;21) AML cells. Consistent with an immunosuppressive phenotype, reprogrammed macrophages also upregulated expression of the immune checkpoint molecules TIM-3 and LAG-3.
 In conclusion, our study highlights the plasticity of macrophages in the pediatric AML bone marrow microenvironment and their critical role in shaping immune responses. We propose that mitochondrial transfer via TNTs is a key mechanism through which AML blasts reprogram macrophages, fostering immune suppression. Disrupting this AML-macrophage interaction may restore immune surveillance and improve the efficacy of immunotherapies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/063433271ef79c990645540d837dcfbed6e0cc36" target='_blank'>
              Pediatric AML blasts drive immunosuppressive reprogramming and metabolic adaptation in macrophages, impairing T cell activation and anti-leukemic immunity
              </a>
            </td>
          <td>
            A. Perzolli, Farah Massaoudi, J. Koedijk, Elizabeth K. Schweighart, L. Kester, B. Goemans, C. Zwaan, Olaf Heidenreich
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="


 Background: Natural Killer (NK) cells are critical components of the innate immune system, providing rapid responses against virally infected and tumor cells. A specialized subset of these cells, characterized by the expression of the activating receptor NKG2C, plays an essential role in controlling human cytomegalovirus (HCMV) infections. The NKG2C/CD94 receptor complex specifically recognizes HLA-E molecules presenting viral peptides derived from the HCMV-encoded gpUL40 antigen, triggering NK cell activation. Upon engagement with these antigen-loaded HLA-E complexes, NKG2C+ NK cells acquire features reminiscent of adaptive immune cells, including enhanced functionality and the capacity for long-term persistence. As a result, HCMV-seropositive (HCMV+) individuals often harbor elevated levels of long-lived, memory NK cells. Despite growing recognition of their adaptive-like behavior, the signals that govern the development, differentiation, and long-term maintenance of Memory NK cells remain poorly understood. In this study, we identify a transcriptionally distinct subset of Memory NKG2C+ NK cells residing within secondary lymphoid organs. Through predictive cell fate trajectory analyses, we reveal that this memory population likely originates from a transitional NKG2C+ NKG2A+ subset.
 Methods & Results: Human spleen and matched lymph node samples were obtained from eight healthy adult donors, including four HCMV+ and four HCMV-seronegative (HCMV-) individuals. All donors tested positive for Epstein-Barr virus IgG, and the HCMV+ group included an equal distribution of male and female donors (n = 2 each). Nucleic acid testing confirmed the absence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus in all samples. Tissue specimens were obtained through the Versiti Organ Donor Center of Wisconsin and processed into single-cell suspensions. NK cells were isolated and subjected to droplet-based single-cell RNA sequencing (scRNA-seq). Transcriptomic data were analyzed using the Seurat R package, with filtering and clustering based on the number of uniquely expressed genes per cell. Single-cell trajectory analyses were performed using Monocle3 and RNA velocity to infer developmental dynamics.
 To identify and define the transcriptomic profile of Memory NKG2C+ NK cells, we first isolated all NKG2C-expressing NK cells by subsetting cells with a log₂-transformed expression level of KLRC2 greater than 0.3. Unbiased clustering analysis of these filtered cells revealed four transcriptionally distinct NKG2C+ NK cell subsets within the spleen and lymph node. Specifically, we identified 2,792 splenic and 1,843 lymph node NKG2C+ NK cells, which were integrated and clustered to define shared and tissue-specific populations. Among these, one subset found in both tissues exhibited elevated expression of memory-associated genes such as CD52, CD2, CD16, and TCF7, along with significantly reduced expression of FCER1G, NCR1, NCR3, and ZBTB16—features consistent with a memory-like phenotype. Notably, HCMV+ donors had significantly higher frequencies of this Memory NKG2C+ subset in both the spleen and lymph node. These findings suggest that secondary lymphoid organs contain a transcriptionally distinct population of Memory NKG2C+ NK cells, potentially shaped by prior HCMV exposure.
 To investigate the developmental trajectory of Memory NKG2C+ NK cells, we applied Monocle3 and RNA velocity analyses. Monocle3 revealed a clear progression from early to late differentiation states, which was mapped onto the UMAP plot. Notably, the NKG2A+NKG2C+ subset consistently emerged as the developmental origin, suggesting it may serve as a transitional precursor to the Memory NKG2C+ population. To further validate, we employed scVelo's dynamical RNA velocity modeling on NKG2C+ cells from individual donors. In HCMV+ donors, the analysis consistently demonstrated that NKG2A+NKG2C+ cells marked the starting point for all downstream NKG2C+ subsets and progressed toward the Memory NKG2C+ state. Collectively, these findings support a model in which HCMV exposure actively shapes NK cell fate by driving the differentiation of transitional NKG2A+NKG2C+ cells into long-lived, memory-like NKG2C+ NK cells.
 Conclusion: These findings uncover a potential developmental pathway underlying memory NK cell differentiation and establish a foundation for future strategies aimed at leveraging these cells in antiviral immunity and NK cell–based immunotherapies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c1566a7dce238e71dce7e3d25a47ed9d17e34c4" target='_blank'>
              Memory NKG2C+ NK cells develop from NKG2C+ transitional precursors and persist within secondary lymphoid organs
              </a>
            </td>
          <td>
            Mohamed Khalil, Subramaniam Malarkannan
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="
 Despite groundbreaking advances in Oncology over the past decade including the advent of immunotherapy, Glioblastoma (GBM), is still a therapeutic challenge with poor patient outcomes and an urgent need for effective therapies. SLIT2 is a secreted polypeptide that guides migration of cells expressing ROBO1&2 receptors and is key for axonal guidance and angiogenesis. In primary brain tumors, SLIT2 expression increases with malignant progression with highest levels observed in Grade IV GBM patients when compared to Low Grade Gliomas, where it also correlates with poor prognosis. Mechanistically, SLIT2-ROBO1/2 signaling promotes the recruitment and polarization of tumor-associated microglia/macrophages (TAMs) to the tumor microenvironment (TME) via PI3Kgamma, leading to dysmorphic angiogenesis, T cell exclusion and immunosuppression. Despite key functions in the TME, targeting SLIT2 in Oncology has been limited by the lack of validated blocking reagents with proper penetration and signaling inhibition potential. We have developed high-affinity human monoclonal antibodies recognizing both human and murine ROBO1&2 (Anti-Robo1/2 mAbs) which are capable of inhibiting microglia and macrophage migration and polarization in vitro. Treatment of immunocompetent preclinical GBM models with Anti-Robo1/2 mAbs leads to reduced TAM infiltration and tumor-supportive polarization, with profound changes in the GBM microenvironment. We observed vascular normalization, reduced hypoxia and increased infiltration and anti-tumor effective function of CD8+ T cells. Furthermore, inhibiting SLIT2-ROBO1/2 signaling also acted in the meningeal compartment, normalizing the meningeal lymphatic vasculature of GBM-bearing mice, improving antigen and immune cell drainage to deep cervical lymph nodes and improving anti-tumor immune responses. By modifying the tumor immune micro- and macroenvironment, Anti-Robo1/2 mAbs prolong tumor bearing-mice survival and renders immunotherapy-resistant tumors sensitive to checkpoint inhibition therapy. Altogether, our data suggest that Anti-Robo1/2 mAbs are a potential novel immunotherapeutic agent for GBM by simultaneously targeting TAMs and meningeal lymphatics, allowing for improved efficacy of currently available T cell-based immunotherapies in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/24418a1c70ccbfe4767c318dc6a36b731f7649c6" target='_blank'>
              TMIC-41. Anti-Robo1/2 monoclonal antibodies as a novel macrophage-based immunotherapy for glioblastoma
              </a>
            </td>
          <td>
            Luiz Henrique Medeiros Geraldo, Maria de Lourdes Lopes de Oliveira, Levi Blazer, E. Sulman, Jose Ricardo McFaline Figueroa, Sachdev Sidhu, Amanda Lund
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Inducing robust mucosal memory T cells in the lung is critical for developing vaccines against respiratory pathogens like Influenza A virus (IAV). Lung tissue-resident memory (TRM) cells serve as the first defense against IAV but undergo rapid attrition, challenging T cell-based mucosal vaccine strategies for durable immunity. This study examined the impact of combination adjuvants targeting distinct innate receptors on CD8 T cell differentiation and TRM persistence. Intranasal delivery of Adjuplex (ADJ) combined with either TLR4 agonist GLA or STING agonist CDN induced strong expansion of mucosally-imprinted CD8 T cells in lungs and airways. ADJ+GLA predominantly generated Type III T cells, while ADJ+CDN favored Type I T cells. ADJ+GLA vaccination led to the persistence of greater number of lung TRMs, correlated with sustained IL-7R expression and lower viral titers (180d p.v.). Also, ADJ+GLA but not IAV induced stem-like, functionally plastic Type III TRMs provided durable immunity to IAV. In Tbx21 conditional KO mice, ADJ+GLA increased IL-17A+, RORγt+, ICOS+, and CD127+ CD8 T cells, suggesting the roles of RORγT and T-bet in vaccine-induced TRM development. Ongoing studies aim to elucidate the precise role of T-bet and RORγT in durable TRM formation. In summary, innate receptor engagement shapes T cell differentiation and lung TRM durability. Our findings highlight Type III programming as a promising avenue for mucosal vaccine design against respiratory viral pathogens.



 This work was supported by Public Health Service Grants UO1AI12499 and R21AI173757 from the National Institutes of Health and the John E. Butler Professorship to MS.



 Vaccines and Immunotherapy (VAC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/38455ec87f8c161d0e6405c997dadf4ef1b047d7" target='_blank'>
              Innate immune receptor engagement governs functional differentiation of effectors and persistence of tissue-resident memory T cells 4002
              </a>
            </td>
          <td>
            Hongtae Park, Brock Kingstad-Bakke, Thomas Cleven, Hailey E. Bussan, Cynthia Pryde-Aguilar, Myunghwan Jung, M. Suresh
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="


 Glioblastoma (GBM) is the most lethal primary brain tumor, characterized by rapid progression, treatment resistance, and an immunosuppressive tumor microenvironment (TME). The cGAS-STING pathway is a key sensor of cytosolic DNA that plays a critical role in innate immunity by inducing type I interferons and pro-inflammatory cytokines. In GBM, STING expression is frequently downregulated in GBM, resulting in impaired immune activation and facilitating tumor immune escape. Restoring STING activity is a promising immunotherapeutic strategy to stimulate innate immune recruitment and reprogram the TME.



 We evaluated cGAS-STING signaling in a panel of murine GBM stem cell lines (005, NF53, C3, RIG) that closely recapitulate patient GBM heterogeneity while allowing immunocompetent in vivo experimentation. STING was activated using synthetic agonists (e.g., ADU-S100), alone or in combination with autophagy inhibitors or G47Δ oncolytic herpes simplex virus (oHSV) therapy.



 RNA sequencing and western blot analyses revealed diverse basal expression profiles of cGAS-STING components across mGSCs: C3 and RIG expressed higher levels of cGAS, while 005 and NF53 showed greater STING expression. Despite this variability, all lines responded robustly to STING agonists, with transient IRF3 phosphorylation and significant upregulation of type I interferons (e.g., IFN-β) and inflammatory chemokines (e.g., CXCL10, CCL5). Notably, STING activation reduced oHSV replication, while viral exposure dampened STING-induced signaling, suggesting viral interference with host immunity. Conversely, pharmacological inhibition of autophagy enhanced STING-driven cytokine responses, revealing a synergistic avenue for immune activation.



 Our data highlight the therapeutic promise of cGAS-STING modulation in GBM. While oHSV therapy may antagonize STING signaling, combining STING activation with autophagy inhibition can potentiate innate immune responses. Ongoing in vivo studies aim to define how these therapies reshape the TME and improve treatment efficacy. Targeting the cGAS-STING axis represents a promising strategy to overcome immune suppression in GBM and enhance immunotherapy outcomes.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a969dbc289265c92ca99a8c5013566a818dc1b68" target='_blank'>
              EXTH-91. Leveraging the cGAS-STING pathway to modulate the tumor microenvironment and enhance immunotherapies in glioblastoma
              </a>
            </td>
          <td>
            Louise Leparc, J. Gil, Catherine Sadzot-Delvaux, B. Rogister, S. Rabkin, Virginie Neirinckx, Hiroaki Wakimoto
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="


 Our adoptive cellular therapy (ACT) enhances dendritic cell (DC) and T cell infiltration into tumors, improving survival in murine brain tumor models. However, tumors employ mechanisms to restrict immune surveillance and efficacy of immunotherapy. We hypothesize that tumor-induced DC dysfunction facilitates immune evasion during ACT. This study investigates the mechanisms of DC dysfunction in ACT-escaped gliomas.



 T cell phenotypes were characterized using flowcytometry, and DC function was assessed through T cell activation assays. Gene set enrichment analysis (GSEA) was performed on transcriptomic data to identify enriched pathways. The impact of hypoxia and factors secreted from tumor-T cell interactions on DC tolerance was evaluated using RT-qPCR. In vivo correlations between hypoxia and DC tolerance were analyzed using GeoMx spatial transcriptomics.



 ACT-escaped tumors retained adoptively transferred cytotoxic but non-exhausted T cells that failed to recognize antigen-shifted tumors. DCs from both untreated primary and ACT-escaped tumors showed impaired T cell activation and reduced expression of antigen-presentation genes. DCs from ACT-escaped tumors exhibited increased expression of tolerance-associated genes, with significant enrichment in hypoxia pathway genes. Hypoxia induced the expression of DC tolerance genes in a HIF1α-dependent manner, impairing T cell activation. Spatial transcriptomics confirmed a strong correlation between HIF1α and ARG1 in tumor-bearing brains. Increased immune infiltration in ACT-treated gliomas exacerbated hypoxia, as shown by HIF1α and CD45 co-expression, further driving DC dysfunction. Inflammatory factors secreted during tumor-T cell interactions activated hypoxia pathways and induced DC tolerance genes.



 Hypoxia-driven DC tolerance is a key driver of immune escape under ACT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6e9caf76d495a58d49e11136e34904db71176f32" target='_blank'>
              TMIC-38. Dendritic cell dysfunction driven by hypoxia pathway activated DC tolerance as an immune evasion mechanism in adoptive cellular therapy
              </a>
            </td>
          <td>
            D. Jin, A. Reid, John Figg, C. Francis, L. Font, C. Love, Kaytora Long-James, David Hilferty, Sofia Stansbury, Norman Morikawa, Mathew Sebastian, Steeve Boulant, D. Mitchell, C. Flores
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 CD8+ T cells play a pivotal role in protective immune responses against intracellular pathogens and tumors. Most CD8+ T cells activated during a primary immune response will contract and die, however, a small percentage persist to form long-lived memory populations (CD8+ Tmem). CD8+ Tmem rapidly deploy their effector functions (i.e., cytotoxicity, cytokine secretion) to respond to subsequent antigen challenges. While these canonical roles are critical, previous studies have suggested that CD8+ T cells can confer protection in the absence of their cytotoxic machinery. The underlying mechanisms for such non-canonical roles remain ill-defined. Our studies have discovered that CD8+ Tmem engage myeloid cells, namely dendritic cells (DCs), in a cognate fashion to drive robust innate inflammatory responses indicative of both NF-kB and IRF activation. These responses appear to be driven by TNFSF ligand-receptor interactions between CD8+ Tmem and DCs, respectively. The ability to induce innate inflammation is directly correlated with the expression of certain TNFSF ligands, and lack of inhibitory molecules, on CD8+ Tmem. These data suggest an evolutionary adaptation wherein CD8+ Tmem facilitate protective responses not only through direct effector functions, but also by inducing broad innate inflammation. Thus, we propose memory CD8+ T cells as surrogate microbes that can initiate proinflammatory and anti-viral responses through previously unexplored mechanisms.



 Cincinnati Children’s Research Foundation



 Immune Response Regulation: Cellular Mechanisms (IRC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf8f9321a00c72bc1594dfeaba5a6a038af8275a" target='_blank'>
              Memory CD8+ T cell-induced activation of the innate immune system drives inflammation and anti-viral immunity 3109
              </a>
            </td>
          <td>
            Charles N. Vallez, Satomi Ando, Koichi Araki, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Background: Recently, emerging evidence indicated that inflammation-induced epigenetic remodeling in tissue stem cells enhances either degenerative or regenerative responses of epithelial cells to subsequent inflammatory stimuli, a concept recently termed “inflammatory memory” (Zhao D: Blood 2025). We have previously demonstrated that GVHD induces epigenetic remodeling in intestinal stem cells (ISCs) in an IFN-γ-dependent manner, leading to enhanced antigen presentation, particularly via MHC class II (MHC-II), and increased susceptibility to apoptosis in intestinal epithelial cells (IECs) upon subsequent inflammatory stimulation (Miyajima T: 66th ASH annual meeting). In the current study, we investigated the mechanisms by which GVHD induces inflammatory memory in intestinal stem cells (ISCs) and evaluated strategies to suppress this process, using a mouse allogeneic hematopoietic cell transplantation (HCT) model, high-dose IFN-γ administration in naive mice, and an intestinal organoid culture system.
 Methods: Lethally irradiated BDF1 (H-2b/d) recipient mice were transplanted from allogeneic B6 (H-2b/b) or syngeneic BDF1 donors. Intestinal organoids were generated from the small intestines on day 21 post-transplant, cultured for 6 days, and subjected to RNA sequencing (RNA-seq), ATAC sequencing (ATAC-seq), and chromatin immunoprecipitation with quantitative PCR (ChIP-qPCR). We performed QIAGEN Ingenuity Pathway Analysis (IPA) of differentially expressed genes obtained from our RNA-seq data. Additionally, small intestines isolated on day 21 post-transplant were subjected to immunofluorescence staining for histopathological assessment.
 Results: IPA of RNA-seq data from intestinal organoids generated 21 days after mouse allogeneic or syngeneic HCT, focusing on epigenetic modifiers, identified histone acetyltransferase E1A-binding protein (p300) and its paralogue, CREB-binding protein (CBP), as candidate upstream regulators of GVHD-induced transcriptional modifications in IECs. Moreover, ATAC-seq of intestinal organoids revealed enrichment of ATF-3-binding motifs, a transcription factor that interacts with p300 and CBP, in chromatin regions that became significantly more accessible in GVHD compared to syngeneic controls. Consistent with the role of p300/CBP in promoting transcription through histone 3 lysine 27 acetylation (H3K27ac), immunofluorescence staining of the small intestine showed an increased number of H3K27ac+ IECs in GVHD mice. ChIP-qPCR analysis demonstrated that H3K27ac was enriched at the promoters of MHC-II genes (e.g., H2-Aa and H2-Eb1) in IECs from GVHD mice. High-dose IFN-γ also promoted H3K27ac enrichment at the promoters of IFN-γ-responsive genes in IECs, leading to enhanced antigen presentation and increased susceptibility to apoptosis upon subsequent exposure to low-dose IFN-γ. To assess whether p300/CBP is essential for inflammation-induced epigenetic modification, we knocked down (KD) Ep300 (encoding p300) and Cbp in intestinal organoids generated from naïve mice using lentiviral transduction of short hairpin RNA (shRNA). Ep300- or Cbp-KD organoids were treated with a high concentration of IFN-γ to induce epigenetic remodeling and subsequently rechallenged with a low level of IFN-γ. Compared with organoids transduced with nontargeting control shRNA, Ep300- or Cbp-KD organoids exhibited significantly attenuated enhancements of MHC-II upregulation and apoptosis induction following low-dose IFN-γ rechallenge, with Cbp-KD organoids exhibiting particularly strong suppression of inflammatory memory. This was further supported by experiments demonstrating that treatment of IFN-γ-stimulated intestinal organoids with inobrodib, a p300/CBP inhibitor, abrogated IEC hyperresponsiveness to IFN-γ rechallenge, whereas p300-specific inhibitors C646 and curcumin only partially suppressed this response.
 Conclusions: We found that GVHD induces epigenetic remodeling in ISCs through a p300/CBP-dependent manner, in which IFN-γ activates p300/CBP, leading to H3K27ac enrichment at target genes involved in IFN-γ responses. Given the emerging efficacy of p300/CBP inhibitors in various hematological malignancies (Nicosia L: Cancer Cell 2023, Welsh SJ: Blood Cancer Discov 2024), these agents represent promising therapeutic candidates for GVHD by suppressing inflammatory memory in ISCs, while potentially preserving GVL effects and additionally exerting direct anti-tumor activity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/882ab44caa862512ed803885d99907ad37117460" target='_blank'>
              Histone acetyltransferase p300/CBP as a therapeutic target to ameliorate gvhd-induced inflammatory memory
              </a>
            </td>
          <td>
            Toru Miyajima, D. Hashimoto, Asako Moriki, Keisuke Kojima, Shihori Tsukamoto, Tomoe Ichiki, Yumika Saito, Wenyu Li, Zixuan Zhang, S. Harada, H. Senjo, Yuki Yokoi, Y. Hasegawa, H. Ohigashi, Takahide Ara, Kiminori Nakamura, Koji Taniguchi, Takanori Teshima
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="


 Introduction:Cd39 expression in TIB-49 cells enhances the stemness and aggressiveness of AML blasts in vivo (PMID: 39157874, EHA2024-1113) via the Cd39-P2rx7-Wnt signaling axis. However, the impact of Cd39 overexpression in leukemic blasts within the bone marrow (BM) microenvironment still needs to be elucidated.
 Methods: Wild-type (WT) C57BL/6 mice were bred and maintained at Shandong Cancer Hospital and Institute. The syngeneic murine AML cell line TIB-49 from American Type Culture Collection was transduced with a lentiviral vector to overexpress Cd39 and labeled with TdTomato (hereafter referred to as TIB-Cd39high). WT mice were injected intravenously with 1×10⁶ TIB-49 or TIB-Cd39high cells, respectively. BM cells were harvested from leukemic mice for single-cell RNA sequencing (scRNA-seq, CapitalBio Technology, Beijing, China) and flow cytometry (FACS) analysis when showing leukemic symptoms.
 Results: Transcriptomic profiling analysis showed a significant increase in neutrophil proportions in the BM of TIB-Cd39high-bearing mice (BMC2) when compared to TIB-49-bearing mice (BMC1), which was also confirmed by FACS analysis. Neutrophils were then classified into five major subpopulations based on the expression of known marker genes: G1 (Prtn3, Elane), G2 (Ltf, Camp, Ngp, Chil3, Fcnb), G3 (Ltf, Camp, Ngp), G4 (Mmp8, Retnlg), and G5c (Fgl2, Gm2a, Gngt2), corresponding to progressive stages of neutrophil development and maturation (PMID: 32719519). G3 and G4 were found to the predominant populations in BM. Gm26917, G6pdx, Clec2d, and Ifi27l2a were identified as upregulated differentially expressed genes (DEGs) in G3/G4 subsets from the BMC2 compared to the cells from BMC1. Notably, Clec2d has been found to be associated with immunosuppression, directly inhibiting CD4⁺ T cell activity and proliferation via interaction with the Cd161 receptor (PMID: 38153903). We next investigated interactions between AML cells and neutrophils. Cytokine-receptor pair analysis revealed reduced Spp1-Cd44 signaling in the BMC2. Given the critical role of Spp1-Cd44 in neutrophil recruitment and differentiation, its downregulation in the BMC2 may impair neutrophil maturation or promote a pro-tumorigenic, immunosuppressive phenotype.
 Additionally, a higher proportion of Cd4⁺ T cells (Th1 subset) was observed in the BMC2 than that in the BMC1, which was also validated by FACS analysis. GO and KEGG enrichment analyses of these cells showed enhanced leukocyte degranulation but attenuated responses to external stimuli and chemical stress. KEGG pathways associated with neutrophil extracellular trap formation were upregulated, while immune-related pathways (e.g., IL-17 and TNF signaling) were downregulated, suggesting suppressed T cell proinflammatory functions. Our prior work (EHA2025-2202) highlighted the functions of Spp1-Cd44 axis in the interactions between TIB-Cd39high cells and Th1 cells in the BMC2, suggesting its role in AML-mediated immune modulation.
 Beyond AML-immune cell interactions, we analyzed neutrophil-Cd4⁺ T cell crosstalk. The Lgals9-Cd44 signaling from neutrophils to T cells was significantly upregulated in the BMC2. Lgals9 (Galectin-9) was found to regulate T cell functions, including Th1 expansion and apoptosis, further implicating this axis in BM immunosuppression.
 Conclusion: Our findings demonstrated that Cd39 overexpression in AML blasts elicited an immunosuppressive BM microenvironment through the expansion of G3/G4 neutrophils and Th1 cells, which was mediated by three key mechanisms: (1) the Spp1-Cd44 axis, which drive AML-induced effects on neutrophils and Th1 cells; (2) Clec2d-Cd161 signaling, facilitating neutrophil-mediated suppression of CD4⁺ T cells; and (3) Lgals9-Cd44 crosstalk, connecting neutrophil dysfunction to impaired T cell activity. These results suggested that targeting Cd39 could disrupt the immunosuppressive BM microenvironment mediated by leukemic blasts, neutrophils and CD4⁺ T cells, thereby enhancing anti-leukemic efficacy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cde55e438575718386905fd8130a85f6e94ae0f1" target='_blank'>
              Cd39 overexpression in AML blasts elicits an immune suppressive bone barrow microenvironment via G3/G4 neutrophils and Th1 cells
              </a>
            </td>
          <td>
            Hanheng Mai, Hui Yuan, Yunqing Liu, Tan Sang, Zonghong Li, Xiuyan Chen, Jinming Yu, Y. L. Wang, Lili Feng
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Dendritic cells (DCs) and monocytes (Mo) are key components of the innate immune system, playing essential roles in initiating, polarizing, and regulating adaptive immune responses, maintaining inflammatory homeostasis, and surveilling peripheral vasculature. These cells can be activated and adopt an inflammatory phenotype upon recognizing damage-associated molecular patterns (DAMPs), which are commonly released during tissue necrosis or intravascular hemolysis—frequent events in individuals with sickle cell anemia (SCA), one of the most prevalent hemoglobinopathies worldwide. Given the heterogeneity of DC populations, an in-depth analysis is necessary to identify which subsets and phenotypes are associated with inflammatory and clinical parameters of the disease.
 We performed multiparametric flow cytometry to analyze DC and Mo subpopulations and their activation status in PBMCs from SCA patients (HbSS, n = 23) and healthy controls (HbAA, n = 22). Flow cytometry of T lymphocytes, complete blood counts, biochemical parameters, and inflammatory cytokines were also assessed in the same individuals and correlated with DC and Mo data. Unsupervised analysis using X-shift (FlowJo, BD) divided the DC population (Lineage− CD14− HLA-DR+) into nine distinct clusters. Circulating type 1 conventional DCs (cDC1s: Clec9a+ CD141+) were significantly less frequent (p = 0.019) in SCA patients compared to controls. Conversely, one of four clusters of plasmacytoid DCs (pDCs: CD123+ Axl−), characterized by high Sirp-α expression, was significantly increased among patients (p = 0.027), suggesting activation of a specific pDC subset in SCA. Type 2 conventional DCs (cDC2s: CD1c+ CD141−) also showed heterogeneity, being divided into three clusters, one of which was significantly more frequent in SCA patients than in controls (p = 0.010). This cDC2 cluster expressed the lowest levels of Sirp-α and the highest levels of CD40, indicating a more activated/inflammatory phenotype.
 Unsupervised analysis of Mo and inflammatory DCs (iDCs) (Lineage− CD14+ HLA-DR+) revealed two iDC clusters and seven Mo clusters. One classical monocyte (C-Mo: CD14+ CD16−) cluster, characterized by high Sirp-α and low HO-1 expression, was significantly reduced in SCA patients (p = 0.032). A trend toward increased frequency of one iDC cluster (CD1c+) in SCA patients was observed (p = 0.06); this cluster showed low Sirp-α expression. Expression of HO-1 was elevated in all Mo subsets (classical: CD14+ CD16−; non-classical: CD14intCD16−; intermediate: CD14+ CD16+) as well as in three DC subsets (cDC1, cDC2, and pDC), suggesting that DCs are not only activated but may also participate in heme metabolism following hemolysis. Expression of Sirp-α, the inhibitory receptor that also impairs RBCs clearance, was reduced in all Mo subsets and in cDC2, suggesting their activation and possible role in clearance of circulating RBCs in SCA. Classical and non-classical Mo from SCA patients also increased CD71 expression, suggesting higher iron uptake by these cell subsets.
 Initial correlation analyses showed that PD-L1 expression by cDC1 was associated with CD4+ T cell exhaustion (PD-1 expression) in SCA patients (p = 0.05). Additionally, IL-17 production by CD4+ and CD8+ T cells correlated with specific clusters of cDC1, cDC2, and iDCs (p < 0.05). Notably, the frequency of regulatory T cells (Foxp3+) was correlated with a specific pDC cluster (p = 0.006), indicating subset-specific roles of DCs in modulating the adaptive immune response in SCA. Bilirubin levels correlated with both iDC frequency (p = 0.031) and CD86 expression (p = 0.047), suggesting a link between iDC activation and disease severity. In contrast, bilirubin was inversely correlated with pDC frequency (p = 0.044) and HO-1 expression by pDCs (p = 0.039), implying a potential regulatory role of pDCs in SCA.
 Future analyses will further explore correlations across all evaluated parameters. Together, these findings enhance our understanding of DC subset heterogeneity, their activation profiles, and impact on T cell dysfunction in SCA. They also highlight the association between heme/iron handling by DCs and Mos and clinical indicators of disease severity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f853c7b69d60c4e41402d26389f7d72e38722d32" target='_blank'>
              Multidimensional profiling of dendritic cell and monocyte subsets in sickle cell anemia: Correlation with clinical and inflammatory parameters
              </a>
            </td>
          <td>
            M. Souza, I. Paes, S. Saad, F. Costa, Renata Sesti-Costa
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fea79c501094b78a2a882d8896d8f73b9ed30dad" target='_blank'>
              Ovarian Cancer Drives TLR5-Dependent Expansion of Myeloid Progenitors Through Systemic Ligand Dissemination.
              </a>
            </td>
          <td>
            Sree H Kolli, Mitchell T McGinty, Mirna Perusina Lanfranca, Cara N Hatzinger, Audrey M Putelo, Mika K Poblete, Simona Bajgai, Brandon Thompson, Tzu-Yu Feng, Francessca N. Azar, Akshita Mirani, William A. Petri, Stacey L. Burgess, Melanie R. Rutkowski
          </td>
          <td>2025-12-08</td>
          <td>Journal of leukocyte biology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="
 Myeloid-derived suppressor cells (MDSCs) contribute to an immunosuppressive tumor microenvironment that facilitates cancer progression, particularly in patients with high-grade gliomas. We previously reported that increased MDSCs during chemoradiotherapy (chemoRT) is associated with poor outcomes. This study investigates the effect of radiotherapy on immune checkpoint expression on MDSC subsets in patients with recurrent high-grade glioma receiving a second course of RT. Peripheral blood samples were collected on the first and last day of RT. Peripheral blood mononuclear cells (PBMCs) were isolated and subsequently stained with immunofluorescent antibodies to identify and analyze MDSC subsets (HLA-DR, CD33, CD14, CD15) and expression of checkpoint molecules (TIM-3, TIGIT, PD-1, PD-L1, CTLA-4) by flow cytometry. Because MDSCs secrete TGF-β1 and it is a potent immune cell regulator, plasma TGF-β1 concentration was quantified using ELISA in both recurrent and naïve glioma patients. A Kolmogorov-Smirnov assessed normality while paired T-test was used to compare groups, with significance set at p<0.05. Five of 20 and 19 of 25 planned patients have enrolled in our IRB-approved PBMC and plasma protocols at the University of Minnesota Medical Center, respectively. Increased frequency of total MDSCs (12.8%;p< 0.05) and the monocytic(m)-MDSC subset (10.8%;p< 0.05) was measured. Within the total MDSC and mMDSC populations, increased PD-L1 (14.5%, 18.8%, respectively;p< 0.05)) TIM-3 (23.6%, 18.0%, respectively) expression was measured after reirradiation. Increased plasma TGF-β1 was measured in patients with recurrent glioma (+0.143 fold change) compared to patients with naïve glioma (-0.300 fold change) after RT (p<0.05). Preliminary data supports that radiation may negatively influence systemic MDSC-associated immunosuppressive signaling, particularly with recurrent disease. Further understanding of immunodynamic changes secondary to RT will inform personalized immunotherapy strategies for patients with recurrent high-grade glioma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1a5342f3bdc18c1c758e867cebf661ba52ef1fdb" target='_blank'>
              RBIO-19. Radiation-Mediated MDSC Immunodynamics in Recurrent High-Grade Glioma
              </a>
            </td>
          <td>
            Marissa Kaufman, Marnelle Anderson, L. Golden, N. Sando, K. B. Bergerud, Suzanne Coleman, Caryn Martin, Elizabeth Bowser, David Sterling, Marie DiBona, Lawrence Kleinberg, David Largaespada, Jessica Lawrence, Mark Folkertsma, Garrett Fitzpatrick, Sara Alcorn, Jianling Yuan, Mayur Sharma, Matthew Hunt, Elizabeth Neil, Stephanie A. Terezakis, Lindsey Sloan
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, and causes profound immune suppression both locally and systemically, hindering immunotherapy efficacy. Myeloid-derived suppressor cells (MDSCs) are among the most abundant immune cells in the GBM tumor microenvironment (TME), which exert immune suppression primarily by dampening functional cytotoxic T cells. Extracellular vesicles (EVs) are key mediators of GBM immunosuppression and have been shown to polarize myeloid cells toward immunosuppressive phenotypes, including MDSCs. Inhibition of EV-myeloid cell interactions thus represents a novel strategy to mitigate GBM-mediated immunosuppression. However, the mechanisms of GBM-EVs uptake by myeloid cells are poorly understood. Here, we explored two pharmacological EV uptake inhibitors: Methyl-β-cyclodextrin (MβCD), which disrupts caveolin-mediated endocytosis by depleting membrane cholesterol, and cytochalasin D (CytoD), which impedes phagocytosis via actin depolymerization. Our results showed immunosuppressive myeloid cells (CD11b+/HLA-DRlow/-) and their subset, monocytic MDSCs (mMDSCs) (CD11b+/HLA-DRlow/-/CD14high/CD15-), were induced upon GBM-EV treatment of healthy donor CD11b+ cells. Both inhibitors reduced these populations, with CytoD showing a more pronounced effect (CytoD: 15.01%, MBCD: 16.24% vs. untreated 23.77%) along with partial restoration of T cell proliferation. To validate these findings in vivo, we retro-orbitally injected EVs isolated from the syngeneic murine glioma cell lines GL261 and CT2A into immunocompetent C57BL/6 mice, followed by treatment with either CytoD, MBCD, or vehicle. We observed thymic involution following EV treatment, accompanied by an increase in systemic immunosuppressive myeloid cells in PBMCs and spleen. Both pharmacological inhibitors attenuated these effects, reducing systemic MDSC populations and their suppressive profiles. Our findings highlight that GBM-EVs as key drivers of tumor-mediated immune suppression and demonstrate that targeting EV uptake in myeloid cells is a viable strategy to counteract GBM-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a705570b9b3d6eb035bb5c25c78b5cc0aa8687a3" target='_blank'>
              IMMU-64. Pharmacologic inhibition of extracellular vesicle uptake prevents induction of immunosuppressive myeloid cells in glioblastoma
              </a>
            </td>
          <td>
            Minori Aoki, Julio Inocencio, Mohammad Asad, Carolyn Baker, B. Himes
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Despite immunotherapy revolutionizing cancer treatment, myeloid malignancies have remained largely refractory to T cell-based strategies, necessitating an in-depth analysis of the mechanisms inhibiting the therapeutic efficacy and raising the question of whether extrinsic factors in the tumor microenvironment could induce T cell dysfunction. To better understand the components limiting T cell function in myeloid settings, we performed phenotypic analyses and genome-wide DNA methylation profiling of T cells isolated from pediatric acute myeloid leukemia (AML) patients. We observed that AML-derived T cells contain a more differentiated methylation signature and are enriched for the more terminally differentiated TemRA population compared to acute lymphoblastic leukemia (ALL) patient-derived T cells. To identify putative mechanisms of T cell immune suppression in AML patients, we mined St. Jude's comprehensive multi-omic datasets for known immunosuppressive factors; S100A9 was among the most elevated inflammatory transcripts in AML blasts and was confirmed in the plasma protein using diagnostic samples (AML AUC, 0.770; T-ALL AUC, 0.729; B-ALL AUC, 0.561; AML < 13 years AUC, 0.538; AML ≥ 13 years AUC, 0.975).
 We have defined epigenetic regulation of T cell stemness disrupted by loss of DNA methylation genes known to drive myeloid malignancies (Kang et. al., Science, 2024; Prinzing et. al., STM, 2021; Ghoneim el. al., Cell, 2017). Thus, we applied the established exhaustion programs to interrogate the available patient T cell samples and found a significant decrease in cell stemness and multipotency in AML T cells compared to ALL T cells. Additionally, increased methylation was observed in genes associated with naïve T cells, cytotoxicity, and TLR activation in T cells. Decreased methylation was observed in genes related to T cell differentiation, changes in the mitochondria, and cellular metabolism.
 Analyzing the functional and transcriptional impact of S100A9 on healthy donor T cells revealed that both S100A9 protein and AML plasma induced in vitro T cell dysfunction, as demonstrated by the induction of a terminal effector phenotype, blunted cytotoxicity, and proliferation in response to TCR stimulation. S100A9 had a significant metabolic impact on treated T cells by Seahorse Metabolic Flux assay, as well as significant changes in mitochondrial membrane potential and increased total cellular ROS.
 These results suggest that S100A9 released from the AML patient's myeloid tumor drives inflammatory microenvironmental changes, which feed into T cell dysfunction on phenotypic, metabolic, RNA, and epigenetic levels, contributing to decreased T cell efficacy. These results provide mechanistic insight into the suppressive myeloid tumor microenvironment limiting T cell-based immunotherapy and highlight the need to better characterize the crosstalk between the innate and adaptive immune systems. Collectively, these data suggest that the decreased efficacy of T cell-based immunotherapies in pediatric AML is due to dysfunction in the patient-derived T cell, further exacerbated by the inflammatory myeloid microenvironment.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bff646e4fce6d74202b06f7c0808d245d5e0c322" target='_blank'>
              Pediatric Acute Myeloid Leukemia associated S100A9 promotes T cell dysfunction
              </a>
            </td>
          <td>
            Grace A Ward, Tyler G. Bruno, Tian Mi, Zhiyuan You, Shanta Alli, Anoop Babu Vasandan, Tae Gun Kang, Matthew Lear, Stephen Gottschalk, Hongbo Chi, T. Kanneganti, Caitlin C. Zebley, Ben Youngblood
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>132</td>
        </tr>

        <tr id="
 Eradicating glioblastoma (GBM) using immuno-oncology agents would be transformative, but GBM is typically devoid of tumor-infiltrating lymphocytes, limiting the efficacy of immune checkpoint inhibitors (ICIs). Combining ICIs with radiotherapy is an attractive strategy, as standard-of-care radiation not only reduces tumor burden that can enhance antigen presentation, potentially priming the immune system. However, radiation induces activation of transforming growth factor β (TGFβ), which mediates effective DNA repair and immunosuppression that are major barriers to treatment benefit. Based on the hypothesis that activating immunity in GBM requires targeting both the tumor cells and the immunosuppressive tumor microenvironment, we evaluated TGFβ inhibition (TGFβi) in two syngeneic mouse models of GBM: immunogenic GL261 and refractory SB28. GL261 tumors were inherently responsive to anti–PD-L1 therapy, exhibiting durable tumor rejection and long-term survival, including immune memory evidence by rejection upon orthotopic or subcutaneous tumor rechallenge. Notably, the combination of TGFβi and irradiation recapitulated this effect, suggesting that TGFβ suppresses radiation-induced anti-tumor immunity. In contrast, in SB28 tumors, which did not respond to either ICI or TGFβi monotherapies, the combination of TGFβi and 10 Gy only modestly extended survival from 21 to 31 days but did not result in long-term survival. Hypofractionated radiotherapy (5 × 6 Gy) in both models yielded durable responses (defined as twice the survival of controls), though only 25% of survivors exhibited immune memory. In GL261, adding TGFβi increased the proportion of long term survivors with immune memory to 66%, but did not do so in SB28. However, the triple combination of TGFβi, ICI, and fractionated radiotherapy effectively induced long-term survival in SB28 tumor bearing mice, and most mice rejected subsequent tumor rechallenge. These studies indicating that TGFβ is a critical immunosuppressive barrier in GBM demonstrate that its inhibition can unlock effective immune responses when combined with radiotherapy and ICI.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b462116997ba4bb24213670fa0c599defa84f99a" target='_blank'>
              IMMU-22. TGFβ inhibition and radiotherapy synergize to enable immune memory response to PD-L1 immune checkpoint inhibition in syngeneic glioblastoma mouse models
              </a>
            </td>
          <td>
            M. Barcellos-Hoff, Oliver Reiners, Alba Gonzàlez-Juncà, Ann A. Lazar, William Chou
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="


 Introduction:
 Although prior exposure to mutagenic agents like melphalan and lenalidomide is a known risk factor for post-cytotoxic therapy myeloid neoplasms (MN-pCT) in multiple myeloma (MM), the increased rate of MN-pCTs reported in clinical CAR-T trials suggests that CAR T cell-mediated inflammation may further contribute to this risk, possibly by promoting the progression of pre-existing clonal hematopoiesis (CH) to overt leukemia.
 Methods and Results: To better dissect the pathogenetic mechanisms leading to CAR T-cell associated MN-pCT in MM, we developed in vitroTP53-knockout (KO) THP-1 cell line models using CRISPR-Cas9. TP53-KO clones showed resistance to melphalan compared to wild type (WT) with an IC50 shift of 1.4-2.1 µM and had a baseline survival disadvantage in drug-free co-culture, which was reversed upon melphalan exposure, with KO rapidly outcompeting WT clones and reaching a clonal dominance of >95% after 14 days of treatment, irrespective of initial seeding ratios. Upon melphalan withdrawal, recovery of WT cells was observed, while a re-introduction of melphalan again selected for KO clones. These data suggest that clonal selection is a key mechanism by which melphalan contributes to MN-pCT pathogenesis. It is clinically supported by prior whole genome sequencing data from our group which detected SBS99, a mutational signature previously linked to melphalan exposure, in bone marrow mononuclear cells of 4/4 patients diagnosed with a MN-pCT at a median latency of 2.9 (0-7.8) months post-CAR T infusion. To simulate cytokine release syndrome ex vivo, we next determined relevant baseline secretion of inflammatory cytokines by CD4⁺ CAR T-cells (cilta-cel, in-house BCMA-directed CAR-Ts) cultured with OPM-2 cells in vitro. These CAR T-secreted cytokines (IL-2, TNF-α, IFN-γ) were added to competition assays and conferred an additional survival benefit to TP53-KO clones which resulted in dominance of KO clones after 30 days of incubation. This indicates that an inflammatory environment acts as a secondary driver to promote CH expansion subsequently to cytotoxic therapy. To expand our findings beyond TP53, peripheral blood mononuclear cells from three CH-positive patients (DNMT3A vs. TP53-mutated) were subsequently seeded in the CoSeedis® 3D ex vivo platform using two different cytokine supplements, either combined IL-2, TNF-α and IFN-γ (1 ng/ml and 10 ng/ml) or single-agent IL-6 (10 ng/ml). Clonal expansion was determined by targeted sequencing and serial variant allele frequency (VAF) estimation complemented by bulk RNA-seq and proteomic analyses. While VAFs showed only modest increase with IL-2, TNF-α and IFN-γ, consistent expansion was noted with IL-6 with an up to ~6-fold clonal expansion relative to baseline after 14 days of ex vivo cultivation. Further analyses are currently ongoing to confirm the differential impact of cytokines on promoting CH expansion after CAR-T, including potential mitigation by the selective anti-IL-6 monoclonal antibody tocilizumab. These analyses will be presented at the meeting together with correlative RNA and proteome data.
 Discussion and Outlook: Our data indicate a two-step leukemogenic model in which mutagenic and inflammatory stressors act synergistically to drive CH progression to MN-pCT. These findings support the potential of prospective CH screening and advocate for earlier use of CAR T-cells to mitigate the risk of CH-related secondary leukemia in MM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7f1530452b1c4056c433ea70060aef1b2ff341dc" target='_blank'>
              Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma
              </a>
            </td>
          <td>
            Max Köppel, U. Munawar, Shilpa Kurian, M. Meggendorfer, M. Truger, S. Nerreter, Seungbin Han, Christina Verbruggen, Emma Besant, Nina Rein, Johanna Lehmann, Ann-Sohpie Hainold, Torsten Steinbrunn, Jennifer Wing Lam Cheung, Dominic Grün, M. Hudecek, S. Mustjoki, Mikko Myllymäki, Konstantin Matjusinski, H. Einsele, L. Rasche, K. M. Kortüm, J. Waldschmidt
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Abstract Immune cells play diverse roles in cancer development. Myeloid cells are key drivers of tumor-escape mechanisms as they suppress immune responses, facilitate metastasis, and contribute to therapy resistance. In particular, macrophages can be polarized into an inflammatory M1 (anti-tumor) or anti-inflammatory M2 (pro-tumor) phenotype. M2 macrophages are associated with tumor progression, as they secrete factors that promote tumor angiogenesis, suppress T-cell activity, and correlate with poor clinical outcomes in squamous cell carcinoma (SCC). Given this context, this study aims to demonstrate the biological effects of monocytes and both M1 and M2 macrophages in squamous cell carcinoma. Our data indicate higher CD163 immunoreactivity in biopsies from SCC patients. Furthermore, we found that a conditioned medium (CM) containing bioactive compound generated by M2 macrophages enhances the proliferation and invasion of the SCC-25 cell line in vitro. Surprisingly, CM derived from blood CD14+ monocytes increased SCC-25 proliferation at the same rate of M2 macrophages-CM. M1 macrophages conditioned medium significantly enhanced the motility and decreased proliferation in Detroit 562 cells. The analysis of tumor-associated transcripts showed that both M1 and M2 conditioned medium induced high levels of EPCAM mRNA and significantly decreased the expression of MYC, an epithelial-to-mesenchymal transition marker, in SCC cell lines. Detroit cells exposed to conditioned medium from monocytes and macrophage also showed elevated SOX2 mRNA levels. The findings suggest that monocytes and macrophage mediators exert distinct biological effects on SCC cell lines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b95b6b5ca87ce80dd8d38420f26d000da294964a" target='_blank'>
              Monocytes and Macrophage-derived mediators influence the behavior of squamous cell carcinoma cell lines
              </a>
            </td>
          <td>
            G. Perri, Raíssa Gabrieli Candido, Luiz Henrique Camargo Soares, Rafael Carneiro Ortiz, Izabel de Camargo, M. R. S. Nogueira, Edgard José Franco Mello Júnior, Ana Lucia Coelho, Edwin M Posadas, Cory M. Hogaboam, K. Cavassani, A. Campanelli
          </td>
          <td>2025-11-17</td>
          <td>Journal of Applied Oral Science</td>
          <td>0</td>
          <td>40</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025'],
    y: [4],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>